cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	beta	r	Traits	SNP_position	Gene_position
LGG	cis	rs6841433	0.948	rs35736852	MIMAT0003242	hsa-miR-577	31.55	1.27e-118	0.87	0.82	Hemoglobin concentration;	chr4:114687255	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs34115976	MIMAT0003242	hsa-miR-577	31.28	2.02e-117	0.87	0.82	Hemoglobin concentration;	chr4:114656841	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs13133899	MIMAT0003242	hsa-miR-577	31.28	2.02e-117	0.87	0.82	Hemoglobin concentration;	chr4:114661153	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs34546485	MIMAT0003242	hsa-miR-577	31.22	3.5e-117	0.87	0.82	Hemoglobin concentration;	chr4:114693882	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.948	rs34110012	MIMAT0003242	hsa-miR-577	31.12	1.01e-116	0.87	0.82	Hemoglobin concentration;	chr4:114710498	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs13133286	MIMAT0003242	hsa-miR-577	30.66	1.11e-114	0.87	0.82	Hemoglobin concentration;	chr4:114701654	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs35217170	MIMAT0003242	hsa-miR-577	30.33	3.43e-113	0.84	0.81	Hemoglobin concentration;	chr4:114672701	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs7677294	MIMAT0003242	hsa-miR-577	30.01	9.79e-112	0.86	0.81	Hemoglobin concentration;	chr4:114633283	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs10011293	MIMAT0003242	hsa-miR-577	29.72	1.94e-110	0.83	0.81	Hemoglobin concentration;	chr4:114656225	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs55875005	MIMAT0003242	hsa-miR-577	29.7	2.3e-110	0.83	0.81	Hemoglobin concentration;	chr4:114691920	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs28390138	MIMAT0003242	hsa-miR-577	29.7	2.4e-110	0.83	0.81	Hemoglobin concentration;	chr4:114687320	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs10008981	MIMAT0003242	hsa-miR-577	29.69	2.71e-110	0.83	0.81	Hemoglobin concentration;	chr4:114650189	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.948	rs9884805	MIMAT0003242	hsa-miR-577	29.56	1.05e-109	0.83	0.8	Hemoglobin concentration;	chr4:114697040	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.948	rs13135834	MIMAT0003242	hsa-miR-577	29.54	1.21e-109	0.83	0.8	Hemoglobin concentration;	chr4:114678835	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.848	rs13328022	MIMAT0003242	hsa-miR-577	29.42	4.39e-109	0.83	0.8	Hemoglobin concentration;	chr4:114700701	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs34403669	MIMAT0003242	hsa-miR-577	29.42	4.39e-109	0.83	0.8	Hemoglobin concentration;	chr4:114703735	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs35271056	MIMAT0003242	hsa-miR-577	29.25	2.52e-108	0.83	0.8	Hemoglobin concentration;	chr4:114642195	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs6533803	MIMAT0003242	hsa-miR-577	28.87	1.33e-106	0.82	0.8	Hemoglobin concentration;	chr4:114637085	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs10049660	MIMAT0003242	hsa-miR-577	28.87	1.33e-106	0.82	0.8	Hemoglobin concentration;	chr4:114637758	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.948	rs7671477	MIMAT0003242	hsa-miR-577	28.76	4.48e-106	0.83	0.8	Hemoglobin concentration;	chr4:114632518	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs6828127	MIMAT0003242	hsa-miR-577	28.65	1.4e-105	0.81	0.8	Hemoglobin concentration;	chr4:114689927	chr4:114656774~114656794:+
LGG	cis	rs6841433	1	rs6841433	MIMAT0003242	hsa-miR-577	28.02	1.12e-102	0.81	0.79	Hemoglobin concentration;	chr4:114647874	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.904	rs4130705	MIMAT0003242	hsa-miR-577	25.53	3.99e-91	0.8	0.76	Hemoglobin concentration;	chr4:114609479	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.95	rs28696112	MIMAT0003242	hsa-miR-577	25.29	5.3e-90	0.8	0.76	Hemoglobin concentration;	chr4:114601833	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.904	rs11731984	MIMAT0003242	hsa-miR-577	-23.2	3.68e-80	-0.72	-0.73	Hemoglobin concentration;	chr4:114663873	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.718	rs7656139	MIMAT0003242	hsa-miR-577	-19.89	1.74e-64	-0.62	-0.67	Hemoglobin concentration;	chr4:114672622	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.687	rs12640227	MIMAT0003242	hsa-miR-577	-19.6	4.11e-63	-0.62	-0.67	Hemoglobin concentration;	chr4:114700788	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.75	rs6857337	MIMAT0003242	hsa-miR-577	19.38	4.32e-62	0.61	0.66	Hemoglobin concentration;	chr4:114667805	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.607	rs34695716	MIMAT0003242	hsa-miR-577	-19.28	1.33e-61	-0.62	-0.66	Hemoglobin concentration;	chr4:114658285	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.706	rs13147491	MIMAT0003242	hsa-miR-577	18.65	1.19e-58	0.82	0.65	Hemoglobin concentration;	chr4:114696462	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.688	rs2287629	MIMAT0014995	hsa-miR-3130-5p	18.27	7.1e-57	0.68	0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785690	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.688	rs2287629	MIMAT0014995_1	hsa-miR-3130-5p	18.27	7.1e-57	0.68	0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785690	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs13427002	MIMAT0014995	hsa-miR-3130-5p	-18.26	7.73e-57	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206778949	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs13427002	MIMAT0014995_1	hsa-miR-3130-5p	-18.26	7.73e-57	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206778949	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs12471008	MIMAT0014995	hsa-miR-3130-5p	-18.22	1.24e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206775059	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs12471008	MIMAT0014995_1	hsa-miR-3130-5p	-18.22	1.24e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206775059	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs768533	MIMAT0014995	hsa-miR-3130-5p	-18.22	1.24e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776113	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs768533	MIMAT0014995_1	hsa-miR-3130-5p	-18.22	1.24e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776113	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.688	rs28365797	MIMAT0014995	hsa-miR-3130-5p	-18.21	1.39e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765122	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.688	rs28365797	MIMAT0014995_1	hsa-miR-3130-5p	-18.21	1.39e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765122	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs725980	MIMAT0014995	hsa-miR-3130-5p	-18.16	2.3e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206773856	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs725980	MIMAT0014995_1	hsa-miR-3130-5p	-18.16	2.3e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206773856	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs2287628	MIMAT0014995	hsa-miR-3130-5p	-18.16	2.37e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785809	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs2287628	MIMAT0014995_1	hsa-miR-3130-5p	-18.16	2.37e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785809	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs2241347	MIMAT0014995	hsa-miR-3130-5p	-18.13	3.1e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206783257	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs2241347	MIMAT0014995_1	hsa-miR-3130-5p	-18.13	3.1e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206783257	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs7576591	MIMAT0014995	hsa-miR-3130-5p	-18.13	3.22e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784502	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs7576591	MIMAT0014995_1	hsa-miR-3130-5p	-18.13	3.22e-56	-0.68	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784502	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs10199766	MIMAT0014995	hsa-miR-3130-5p	-18.04	8.23e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206777144	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs10199766	MIMAT0014995_1	hsa-miR-3130-5p	-18.04	8.23e-56	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206777144	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs16838834	MIMAT0014995	hsa-miR-3130-5p	-17.97	1.88e-55	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765071	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs16838834	MIMAT0014995_1	hsa-miR-3130-5p	-17.97	1.88e-55	-0.69	-0.64	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765071	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.706	rs35571359	MIMAT0003242	hsa-miR-577	17.85	6.39e-55	0.82	0.63	Hemoglobin concentration;	chr4:114606130	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.706	rs13134858	MIMAT0003242	hsa-miR-577	17.81	1.02e-54	0.82	0.63	Hemoglobin concentration;	chr4:114601150	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.706	rs35759252	MIMAT0003242	hsa-miR-577	17.77	1.47e-54	0.82	0.63	Hemoglobin concentration;	chr4:114608520	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.636	rs11895370	MIMAT0014995	hsa-miR-3130-5p	-17.69	3.57e-54	-0.67	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206789990	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs11895370	MIMAT0014995_1	hsa-miR-3130-5p	-17.69	3.57e-54	-0.67	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206789990	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs957414	MIMAT0014995	hsa-miR-3130-5p	-17.63	6.74e-54	-0.68	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206800861	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs957414	MIMAT0014995_1	hsa-miR-3130-5p	-17.63	6.74e-54	-0.68	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206800861	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs888621	MIMAT0014995	hsa-miR-3130-5p	17.6	9.53e-54	0.66	0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784626	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs888621	MIMAT0014995_1	hsa-miR-3130-5p	17.6	9.53e-54	0.66	0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784626	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.699	rs12643031	MIMAT0003242	hsa-miR-577	17.5	2.76e-53	0.68	0.63	Hemoglobin concentration;	chr4:114541449	chr4:114656774~114656794:+
LGG	cis	rs7182946	1	rs3809579	MIMAT0000268	hsa-miR-211-5p	-16.98	6.96e-51	-0.6	-0.61	Advanced age-related macular degeneration;	chr15:31102119	chr15:31065095~31065116:-
LGG	cis	rs75358501	0.636	rs3815686	MIMAT0014995	hsa-miR-3130-5p	-16.74	8.58e-50	-0.66	-0.61	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206768278	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs3815686	MIMAT0014995_1	hsa-miR-3130-5p	-16.74	8.58e-50	-0.66	-0.61	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206768278	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.636	rs4673363	MIMAT0014995	hsa-miR-3130-5p	-16.64	2.66e-49	-0.67	-0.61	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206804687	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs4673363	MIMAT0014995_1	hsa-miR-3130-5p	-16.64	2.66e-49	-0.67	-0.61	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206804687	chr2:206783246~206783266:+
LGG	cis	rs7182946	1	rs7182946	MIMAT0000268	hsa-miR-211-5p	-16.59	4.41e-49	-0.59	-0.61	Advanced age-related macular degeneration;	chr15:31102665	chr15:31065095~31065116:-
LGG	cis	rs75358501	0.636	rs57600974	MIMAT0014995	hsa-miR-3130-5p	-16.56	6.07e-49	-0.67	-0.6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206805471	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs57600974	MIMAT0014995_1	hsa-miR-3130-5p	-16.56	6.07e-49	-0.67	-0.6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206805471	chr2:206783246~206783266:+
LGG	cis	rs7182946	1	rs4779820	MIMAT0000268	hsa-miR-211-5p	-16.52	9.15e-49	-0.61	-0.6	Advanced age-related macular degeneration;	chr15:31102607	chr15:31065095~31065116:-
LGG	cis	rs75358501	0.636	rs12478466	MIMAT0014995	hsa-miR-3130-5p	-16.5	1.15e-48	-0.67	-0.6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206806288	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs12478466	MIMAT0014995_1	hsa-miR-3130-5p	-16.5	1.15e-48	-0.67	-0.6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206806288	chr2:206783246~206783266:+
LGG	cis	rs7182946	1	rs6493454	MIMAT0000268	hsa-miR-211-5p	-16.47	1.49e-48	-0.58	-0.6	Advanced age-related macular degeneration;	chr15:31101742	chr15:31065095~31065116:-
LGG	cis	rs6841433	0.561	rs13148598	MIMAT0003242	hsa-miR-577	-16.29	9.67e-48	-0.53	-0.6	Hemoglobin concentration;	chr4:114676939	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs56149980	MIMAT0003242	hsa-miR-577	16.25	1.58e-47	0.72	0.6	Hemoglobin concentration;	chr4:114576580	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs1380932	MIMAT0003242	hsa-miR-577	16.24	1.79e-47	0.73	0.6	Hemoglobin concentration;	chr4:114565923	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs17047239	MIMAT0003242	hsa-miR-577	16.23	1.95e-47	0.73	0.6	Hemoglobin concentration;	chr4:114570559	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs17047244	MIMAT0003242	hsa-miR-577	16.23	1.95e-47	0.73	0.6	Hemoglobin concentration;	chr4:114571532	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs17047246	MIMAT0003242	hsa-miR-577	16.23	1.95e-47	0.73	0.6	Hemoglobin concentration;	chr4:114571876	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs34948407	MIMAT0003242	hsa-miR-577	16.2	2.51e-47	0.74	0.6	Hemoglobin concentration;	chr4:114575280	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs57930571	MIMAT0003242	hsa-miR-577	16.15	4.26e-47	0.72	0.6	Hemoglobin concentration;	chr4:114580433	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12642541	MIMAT0003242	hsa-miR-577	16.13	5.18e-47	0.72	0.59	Hemoglobin concentration;	chr4:114579576	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs17047238	MIMAT0003242	hsa-miR-577	16.11	6.44e-47	0.73	0.59	Hemoglobin concentration;	chr4:114568870	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13144260	MIMAT0003242	hsa-miR-577	16.1	7.55e-47	0.73	0.59	Hemoglobin concentration;	chr4:114573271	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs33914856	MIMAT0003242	hsa-miR-577	16.09	7.96e-47	0.73	0.59	Hemoglobin concentration;	chr4:114564668	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35789595	MIMAT0003242	hsa-miR-577	16.09	8.06e-47	0.72	0.59	Hemoglobin concentration;	chr4:114594055	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35732213	MIMAT0003242	hsa-miR-577	16.09	8.34e-47	0.72	0.59	Hemoglobin concentration;	chr4:114581427	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35936834	MIMAT0003242	hsa-miR-577	16.09	8.34e-47	0.72	0.59	Hemoglobin concentration;	chr4:114581520	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs6813229	MIMAT0003242	hsa-miR-577	16.09	8.34e-47	0.72	0.59	Hemoglobin concentration;	chr4:114582721	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs6839189	MIMAT0003242	hsa-miR-577	16.09	8.34e-47	0.72	0.59	Hemoglobin concentration;	chr4:114582848	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs4834428	MIMAT0003242	hsa-miR-577	-16.09	8.45e-47	-0.53	-0.59	Hemoglobin concentration;	chr4:114683908	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13110751	MIMAT0003242	hsa-miR-577	16.08	8.8e-47	0.72	0.59	Hemoglobin concentration;	chr4:114563572	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13105144	MIMAT0003242	hsa-miR-577	16.08	8.8e-47	0.72	0.59	Hemoglobin concentration;	chr4:114563873	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs13129837	MIMAT0003242	hsa-miR-577	16.08	8.8e-47	0.72	0.59	Hemoglobin concentration;	chr4:114563925	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13101831	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114552771	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.66	rs13127941	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114553520	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13147198	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114553935	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs34403145	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114554629	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12643074	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114555226	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs2100783	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114555821	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35252674	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114556583	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs71606719	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114557814	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.511	rs13125495	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114558326	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12650115	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114560232	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12644238	MIMAT0003242	hsa-miR-577	16.07	1.01e-46	0.72	0.59	Hemoglobin concentration;	chr4:114560598	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs77422558	MIMAT0003242	hsa-miR-577	16.05	1.19e-46	0.73	0.59	Hemoglobin concentration;	chr4:114540944	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs7437576	MIMAT0003242	hsa-miR-577	16.04	1.37e-46	0.72	0.59	Hemoglobin concentration;	chr4:114595467	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13135560	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114547331	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35777558	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114548111	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs34685786	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114549280	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs79776742	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114550195	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs57059575	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114551237	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13147106	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114552206	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13147485	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114552321	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13120552	MIMAT0003242	hsa-miR-577	16.04	1.39e-46	0.71	0.59	Hemoglobin concentration;	chr4:114552518	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs1903365	MIMAT0003242	hsa-miR-577	16.03	1.62e-46	0.71	0.59	Hemoglobin concentration;	chr4:114561897	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12641516	MIMAT0003242	hsa-miR-577	16	2.03e-46	0.71	0.59	Hemoglobin concentration;	chr4:114556972	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35594431	MIMAT0003242	hsa-miR-577	16	2.04e-46	0.71	0.59	Hemoglobin concentration;	chr4:114554497	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs35578985	MIMAT0003242	hsa-miR-577	16	2.12e-46	0.72	0.59	Hemoglobin concentration;	chr4:114594500	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs34001486	MIMAT0003242	hsa-miR-577	16	2.12e-46	0.72	0.59	Hemoglobin concentration;	chr4:114594792	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs6533807	MIMAT0003242	hsa-miR-577	-15.99	2.27e-46	-0.53	-0.59	Hemoglobin concentration;	chr4:114699454	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs35082726	MIMAT0003242	hsa-miR-577	15.97	3.01e-46	0.73	0.59	Hemoglobin concentration;	chr4:114566777	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13127912	MIMAT0003242	hsa-miR-577	15.93	4.54e-46	0.71	0.59	Hemoglobin concentration;	chr4:114546019	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs10516604	MIMAT0003242	hsa-miR-577	15.93	4.54e-46	0.71	0.59	Hemoglobin concentration;	chr4:114546112	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs10516603	MIMAT0003242	hsa-miR-577	15.93	4.54e-46	0.71	0.59	Hemoglobin concentration;	chr4:114546303	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12648803	MIMAT0003242	hsa-miR-577	-15.93	4.54e-46	-0.71	-0.59	Hemoglobin concentration;	chr4:114546228	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs6813283	MIMAT0003242	hsa-miR-577	15.92	4.98e-46	0.71	0.59	Hemoglobin concentration;	chr4:114582806	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.584	rs11894165	MIMAT0014995	hsa-miR-3130-5p	-15.9	6.21e-46	-0.66	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206759688	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.584	rs11894165	MIMAT0014995_1	hsa-miR-3130-5p	-15.9	6.21e-46	-0.66	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206759688	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.688	rs1862087	MIMAT0014995	hsa-miR-3130-5p	-15.9	6.21e-46	-0.66	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206760843	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.688	rs1862087	MIMAT0014995_1	hsa-miR-3130-5p	-15.9	6.21e-46	-0.66	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206760843	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.615	rs17047198	MIMAT0003242	hsa-miR-577	15.86	9.51e-46	0.71	0.59	Hemoglobin concentration;	chr4:114544338	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs7434753	MIMAT0003242	hsa-miR-577	15.84	1.07e-45	0.73	0.59	Hemoglobin concentration;	chr4:114596387	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs79261962	MIMAT0003242	hsa-miR-577	15.83	1.23e-45	0.72	0.59	Hemoglobin concentration;	chr4:114539953	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.571	rs12649041	MIMAT0003242	hsa-miR-577	15.83	1.23e-45	0.72	0.59	Hemoglobin concentration;	chr4:114541220	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs7679995	MIMAT0003242	hsa-miR-577	-15.79	1.79e-45	-0.52	-0.59	Hemoglobin concentration;	chr4:114665137	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.636	rs7580138	MIMAT0014995	hsa-miR-3130-5p	-15.75	2.87e-45	-0.65	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206750560	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs7580138	MIMAT0014995_1	hsa-miR-3130-5p	-15.75	2.87e-45	-0.65	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206750560	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.615	rs17047201	MIMAT0003242	hsa-miR-577	15.7	4.78e-45	0.7	0.58	Hemoglobin concentration;	chr4:114544945	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13136602	MIMAT0003242	hsa-miR-577	15.69	5.17e-45	0.71	0.58	Hemoglobin concentration;	chr4:114541864	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12649943	MIMAT0003242	hsa-miR-577	15.69	5.17e-45	0.71	0.58	Hemoglobin concentration;	chr4:114542460	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12649963	MIMAT0003242	hsa-miR-577	15.69	5.17e-45	0.71	0.58	Hemoglobin concentration;	chr4:114542537	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13114989	MIMAT0003242	hsa-miR-577	15.56	2.11e-44	0.7	0.58	Hemoglobin concentration;	chr4:114538869	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs7699896	MIMAT0003242	hsa-miR-577	15.43	7.59e-44	0.52	0.58	Hemoglobin concentration;	chr4:114617357	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs13106767	MIMAT0003242	hsa-miR-577	-15.42	8.54e-44	-0.51	-0.58	Hemoglobin concentration;	chr4:114635719	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs35717197	MIMAT0003242	hsa-miR-577	-15.42	8.54e-44	-0.51	-0.58	Hemoglobin concentration;	chr4:114639584	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs12511581	MIMAT0003242	hsa-miR-577	-15.27	3.93e-43	-0.7	-0.57	Hemoglobin concentration;	chr4:114598400	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs4585328	MIMAT0003242	hsa-miR-577	-15.15	1.35e-42	-0.52	-0.57	Hemoglobin concentration;	chr4:114613660	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs13152031	MIMAT0003242	hsa-miR-577	-15.13	1.65e-42	-0.51	-0.57	Hemoglobin concentration;	chr4:114644503	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs7685523	MIMAT0003242	hsa-miR-577	-15.01	5.67e-42	-0.51	-0.57	Hemoglobin concentration;	chr4:114621913	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs6849357	MIMAT0003242	hsa-miR-577	-14.95	1.07e-41	-0.69	-0.57	Hemoglobin concentration;	chr4:114598115	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs13112553	MIMAT0003242	hsa-miR-577	-14.95	1.07e-41	-0.69	-0.57	Hemoglobin concentration;	chr4:114598194	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.632	rs10034697	MIMAT0003242	hsa-miR-577	-14.86	2.72e-41	-0.51	-0.56	Hemoglobin concentration;	chr4:114614102	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.636	rs1862089	MIMAT0014995	hsa-miR-3130-5p	-14.8	5.05e-41	-0.62	-0.56	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206755794	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs1862089	MIMAT0014995_1	hsa-miR-3130-5p	-14.8	5.05e-41	-0.62	-0.56	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206755794	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.56	rs11098260	MIMAT0003242	hsa-miR-577	-14.7	1.42e-40	-0.7	-0.56	Hemoglobin concentration;	chr4:114598670	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.516	rs11098259	MIMAT0003242	hsa-miR-577	-14.66	2.14e-40	-0.69	-0.56	Hemoglobin concentration;	chr4:114598669	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.615	rs17047236	MIMAT0003242	hsa-miR-577	14.63	2.81e-40	0.67	0.56	Hemoglobin concentration;	chr4:114564575	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.636	rs10932164	MIMAT0014995	hsa-miR-3130-5p	-14.58	4.61e-40	-0.64	-0.56	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206751601	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs10932164	MIMAT0014995_1	hsa-miR-3130-5p	-14.58	4.61e-40	-0.64	-0.56	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206751601	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.748	rs12470963	MIMAT0014995	hsa-miR-3130-5p	-14.15	3.67e-38	-0.64	-0.54	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206774869	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.748	rs12470963	MIMAT0014995_1	hsa-miR-3130-5p	-14.15	3.67e-38	-0.64	-0.54	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206774869	chr2:206783246~206783266:+
LGG	cis	rs6841433	0.511	rs34534063	MIMAT0003242	hsa-miR-577	13.19	4.35e-34	0.56	0.52	Hemoglobin concentration;	chr4:114538077	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.511	rs36078253	MIMAT0003242	hsa-miR-577	13.19	4.35e-34	0.56	0.52	Hemoglobin concentration;	chr4:114538112	chr4:114656774~114656794:+
LGG	cis	rs6841433	0.503	rs4425400	MIMAT0003242	hsa-miR-577	-13.1	1.06e-33	-0.48	-0.52	Hemoglobin concentration;	chr4:114613788	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.967	rs880827	MIMAT0017994	hsa-miR-3615	11.97	4.88e-29	0.49	0.48	Monocyte count;	chr17:74771296	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.934	rs895692	MIMAT0017994	hsa-miR-3615	-11.92	7.63e-29	-0.49	-0.48	Monocyte count;	chr17:74770113	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.967	rs3744208	MIMAT0017994	hsa-miR-3615	-11.91	8.81e-29	-0.49	-0.48	Monocyte count;	chr17:74771426	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.967	rs7420	MIMAT0017994	hsa-miR-3615	11.7	5.83e-28	0.49	0.47	Monocyte count;	chr17:74769076	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.967	rs878906	MIMAT0017994	hsa-miR-3615	-11.56	2.03e-27	-0.49	-0.47	Monocyte count;	chr17:74773195	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.967	rs878907	MIMAT0017994	hsa-miR-3615	-11.48	4.33e-27	-0.49	-0.47	Monocyte count;	chr17:74773555	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.967	rs878905	MIMAT0017994	hsa-miR-3615	-11.47	4.74e-27	-0.49	-0.47	Monocyte count;	chr17:74773272	chr17:74748663~74748683:+
LGG	cis	rs8064299	1	rs8064299	MIMAT0017994	hsa-miR-3615	-11.09	1.47e-25	-0.46	-0.45	Monocyte count;	chr17:74766507	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.577	rs34941812	MIMAT0003242	hsa-miR-577	-10.93	5.89e-25	-0.38	-0.45	Optic disc area;	chr4:114673260	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.597	rs12508215	MIMAT0003242	hsa-miR-577	-10.87	9.91e-25	-0.37	-0.45	Optic disc area;	chr4:114699103	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.597	rs11098263	MIMAT0003242	hsa-miR-577	-10.78	2.2e-24	-0.37	-0.44	Optic disc area;	chr4:114686481	chr4:114656774~114656794:+
LGG	cis	rs1867631	1	rs11208927	MIMAT0014979	hsa-miR-3117-3p	-10.59	1.12e-23	-0.47	-0.44	Menopause (age at onset);	chr1:66623878	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs11208928	MIMAT0014979	hsa-miR-3117-3p	-10.4	5.65e-23	-0.47	-0.43	Menopause (age at onset);	chr1:66623879	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.958	rs7536188	MIMAT0014979	hsa-miR-3117-3p	10.15	4.84e-22	0.45	0.42	Menopause (age at onset);	chr1:66622243	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs10889640	MIMAT0014979	hsa-miR-3117-3p	-10.13	5.89e-22	-0.45	-0.42	Menopause (age at onset);	chr1:66662168	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.625	rs12138066	MIMAT0014979	hsa-miR-3117-3p	-10.1	7.37e-22	-0.43	-0.42	Presence of antiphospholipid antibodies;	chr1:66638133	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.625	rs6696812	MIMAT0014979	hsa-miR-3117-3p	-10.09	7.96e-22	-0.43	-0.42	Presence of antiphospholipid antibodies;	chr1:66634626	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.876	rs10889637	MIMAT0014979	hsa-miR-3117-3p	-10.07	9.85e-22	-0.45	-0.42	Menopause (age at onset);	chr1:66631782	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs10789212	MIMAT0014979	hsa-miR-3117-3p	-10.06	1.05e-21	-0.45	-0.42	Menopause (age at onset);	chr1:66662472	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs10789213	MIMAT0014979	hsa-miR-3117-3p	-10.06	1.05e-21	-0.45	-0.42	Menopause (age at onset);	chr1:66662518	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.565	rs1536112	MIMAT0014979	hsa-miR-3117-3p	10.04	1.26e-21	0.42	0.42	Presence of antiphospholipid antibodies;	chr1:66641542	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs10889636	MIMAT0014979	hsa-miR-3117-3p	9.98	2.06e-21	0.44	0.42	Menopause (age at onset);	chr1:66624241	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.625	rs6680364	MIMAT0014979	hsa-miR-3117-3p	-9.9	3.94e-21	-0.43	-0.41	Presence of antiphospholipid antibodies;	chr1:66639151	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.625	rs12127199	MIMAT0014979	hsa-miR-3117-3p	-9.9	4.05e-21	-0.43	-0.41	Presence of antiphospholipid antibodies;	chr1:66638059	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.604	rs7546825	MIMAT0014979	hsa-miR-3117-3p	-9.89	4.21e-21	-0.43	-0.41	Presence of antiphospholipid antibodies;	chr1:66636119	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.782	rs2388975	MIMAT0003242	hsa-miR-577	9.86	5.5e-21	0.34	0.41	Optic disc area;	chr4:114592899	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.809	rs12650546	MIMAT0003242	hsa-miR-577	9.8	8.73e-21	0.34	0.41	Optic disc area;	chr4:114578518	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.782	rs12650319	MIMAT0003242	hsa-miR-577	9.78	1.05e-20	0.34	0.41	Optic disc area;	chr4:114594734	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.809	rs12647519	MIMAT0003242	hsa-miR-577	9.78	1.05e-20	0.34	0.41	Optic disc area;	chr4:114594742	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.809	rs9884212	MIMAT0003242	hsa-miR-577	9.72	1.67e-20	0.34	0.41	Optic disc area;	chr4:114580888	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.744	rs2388976	MIMAT0003242	hsa-miR-577	9.72	1.67e-20	0.34	0.41	Optic disc area;	chr4:114581250	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.809	rs7655987	MIMAT0003242	hsa-miR-577	9.71	1.9e-20	0.34	0.41	Optic disc area;	chr4:114596146	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.867	rs12507591	MIMAT0003242	hsa-miR-577	9.67	2.57e-20	0.34	0.41	Optic disc area;	chr4:114574339	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.782	rs7437569	MIMAT0003242	hsa-miR-577	-9.62	3.8e-20	-0.33	-0.4	Optic disc area;	chr4:114595431	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.809	rs35733223	MIMAT0003242	hsa-miR-577	9.57	5.75e-20	0.33	0.4	Optic disc area;	chr4:114566454	chr4:114656774~114656794:+
LGG	cis	rs1867631	1	rs7546090	MIMAT0014979	hsa-miR-3117-3p	-9.5	1.02e-19	-0.44	-0.4	Menopause (age at onset);	chr1:66618298	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs6665859	MIMAT0014979	hsa-miR-3117-3p	-9.45	1.54e-19	-0.44	-0.4	Menopause (age at onset);	chr1:66611872	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.958	rs7520226	MIMAT0014979	hsa-miR-3117-3p	-9.43	1.85e-19	-0.44	-0.4	Menopause (age at onset);	chr1:66615312	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.735	rs9995962	MIMAT0003242	hsa-miR-577	9.37	2.97e-19	0.32	0.39	Optic disc area;	chr4:114551671	chr4:114656774~114656794:+
LGG	cis	rs75358501	0.901	rs79499040	MIMAT0014995	hsa-miR-3130-5p	-9.29	5.78e-19	-0.59	-0.39	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776206	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.901	rs79499040	MIMAT0014995_1	hsa-miR-3130-5p	-9.29	5.78e-19	-0.59	-0.39	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776206	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.901	rs76270461	MIMAT0014995	hsa-miR-3130-5p	-9.06	3.35e-18	-0.58	-0.38	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206788929	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.901	rs76270461	MIMAT0014995_1	hsa-miR-3130-5p	-9.06	3.35e-18	-0.58	-0.38	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206788929	chr2:206783246~206783266:+
LGG	cis	rs6681460	0.584	rs7528182	MIMAT0014979	hsa-miR-3117-3p	-8.86	1.63e-17	-0.38	-0.38	Presence of antiphospholipid antibodies;	chr1:66601686	chr1:66628485~66628505:+
LGG	cis	rs1867631	1	rs1867631	MIMAT0014979	hsa-miR-3117-3p	-8.84	1.87e-17	-0.4	-0.38	Menopause (age at onset);	chr1:66580443	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.718	rs7655989	MIMAT0003242	hsa-miR-577	-8.83	2.04e-17	-0.3	-0.38	Optic disc area;	chr4:114528134	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.931	rs7249520	MIMAT0021017	hsa-miR-4999-5p	8.83	2.06e-17	0.42	0.38	HDL cholesterol;	chr19:8381172	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs7249624	MIMAT0021017	hsa-miR-4999-5p	8.83	2.06e-17	0.42	0.38	HDL cholesterol;	chr19:8381251	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.83	rs4350678	MIMAT0021017	hsa-miR-4999-5p	8.83	2.06e-17	0.42	0.38	HDL cholesterol;	chr19:8382482	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.718	rs10857031	MIMAT0003242	hsa-miR-577	-8.82	2.18e-17	-0.3	-0.38	Optic disc area;	chr4:114527690	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.631	rs11098253	MIMAT0003242	hsa-miR-577	-8.81	2.44e-17	-0.3	-0.37	Optic disc area;	chr4:114527990	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.756	rs28787070	MIMAT0003242	hsa-miR-577	-8.79	2.86e-17	-0.31	-0.37	Optic disc area;	chr4:114556918	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.756	rs1460783	MIMAT0003242	hsa-miR-577	-8.78	2.9e-17	-0.31	-0.37	Optic disc area;	chr4:114540109	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.744	rs6814022	MIMAT0003242	hsa-miR-577	-8.77	3.27e-17	-0.3	-0.37	Optic disc area;	chr4:114528667	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.693	rs114243292	MIMAT0003242	hsa-miR-577	-8.76	3.59e-17	-0.3	-0.37	Optic disc area;	chr4:114516751	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.965	rs11666233	MIMAT0021017	hsa-miR-4999-5p	8.75	3.67e-17	0.42	0.37	HDL cholesterol;	chr19:8387161	chr19:8389340~8389360:-
LGG	cis	rs7255436	1	rs7255436	MIMAT0021017	hsa-miR-4999-5p	8.74	3.99e-17	0.42	0.37	HDL cholesterol;	chr19:8368312	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.718	rs10857032	MIMAT0003242	hsa-miR-577	-8.74	4.18e-17	-0.3	-0.37	Optic disc area;	chr4:114527831	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.681	rs11098254	MIMAT0003242	hsa-miR-577	8.73	4.2e-17	0.3	0.37	Optic disc area;	chr4:114531300	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs11098255	MIMAT0003242	hsa-miR-577	8.73	4.2e-17	0.3	0.37	Optic disc area;	chr4:114531393	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.756	rs35235288	MIMAT0003242	hsa-miR-577	-8.73	4.27e-17	-0.3	-0.37	Optic disc area;	chr4:114547620	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1460779	MIMAT0003242	hsa-miR-577	8.72	4.55e-17	0.3	0.37	Optic disc area;	chr4:114528894	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs12108520	MIMAT0003242	hsa-miR-577	-8.71	5.12e-17	-0.3	-0.37	Optic disc area;	chr4:114522087	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13117126	MIMAT0003242	hsa-miR-577	-8.71	5.12e-17	-0.3	-0.37	Optic disc area;	chr4:114526758	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs12505597	MIMAT0003242	hsa-miR-577	-8.7	5.34e-17	-0.3	-0.37	Optic disc area;	chr4:114527954	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7683270	MIMAT0003242	hsa-miR-577	8.69	5.69e-17	0.3	0.37	Optic disc area;	chr4:114532438	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13103719	MIMAT0003242	hsa-miR-577	8.69	5.69e-17	0.3	0.37	Optic disc area;	chr4:114532620	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.681	rs13109008	MIMAT0003242	hsa-miR-577	8.69	5.69e-17	0.3	0.37	Optic disc area;	chr4:114532769	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13109803	MIMAT0003242	hsa-miR-577	8.69	5.69e-17	0.3	0.37	Optic disc area;	chr4:114532837	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7440658	MIMAT0003242	hsa-miR-577	8.69	5.69e-17	0.3	0.37	Optic disc area;	chr4:114533303	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.965	rs4044435	MIMAT0021017	hsa-miR-4999-5p	8.68	6.46e-17	0.42	0.37	HDL cholesterol;	chr19:8383293	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.718	rs2100782	MIMAT0003242	hsa-miR-577	8.68	6.6e-17	0.3	0.37	Optic disc area;	chr4:114530452	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.756	rs1460782	MIMAT0003242	hsa-miR-577	-8.67	6.62e-17	-0.31	-0.37	Optic disc area;	chr4:114540002	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7669767	MIMAT0003242	hsa-miR-577	8.67	6.77e-17	0.3	0.37	Optic disc area;	chr4:114530264	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs12508960	MIMAT0003242	hsa-miR-577	8.67	6.77e-17	0.3	0.37	Optic disc area;	chr4:114531061	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1824490	MIMAT0003242	hsa-miR-577	8.67	6.79e-17	0.3	0.37	Optic disc area;	chr4:114529766	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1824489	MIMAT0003242	hsa-miR-577	8.67	6.79e-17	0.3	0.37	Optic disc area;	chr4:114529776	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.655	rs12797	MIMAT0017994	hsa-miR-3615	-8.66	7.47e-17	-0.39	-0.37	Monocyte count;	chr17:74770854	chr17:74748663~74748683:+
LGG	cis	rs7255436	0.965	rs11668346	MIMAT0021017	hsa-miR-4999-5p	8.66	7.6e-17	0.41	0.37	HDL cholesterol;	chr19:8385970	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs12981318	MIMAT0021017	hsa-miR-4999-5p	8.65	7.81e-17	0.41	0.37	HDL cholesterol;	chr19:8386546	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs7351098	MIMAT0021017	hsa-miR-4999-5p	8.65	7.81e-17	0.41	0.37	HDL cholesterol;	chr19:8386787	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs11666003	MIMAT0021017	hsa-miR-4999-5p	8.65	7.81e-17	0.41	0.37	HDL cholesterol;	chr19:8387218	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.692	rs13105714	MIMAT0003242	hsa-miR-577	-8.65	8.26e-17	-0.3	-0.37	Optic disc area;	chr4:114511171	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.965	rs62117510	MIMAT0021017	hsa-miR-4999-5p	8.64	8.61e-17	0.42	0.37	HDL cholesterol;	chr19:8387729	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs28729307	MIMAT0021017	hsa-miR-4999-5p	8.64	8.61e-17	0.42	0.37	HDL cholesterol;	chr19:8387858	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.894	rs10413136	MIMAT0021017	hsa-miR-4999-5p	8.64	8.61e-17	0.42	0.37	HDL cholesterol;	chr19:8387995	chr19:8389340~8389360:-
LGG	cis	rs75358501	0.901	rs16838691	MIMAT0014995	hsa-miR-3130-5p	-8.64	8.7e-17	-0.54	-0.37	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206718128	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.901	rs16838691	MIMAT0014995_1	hsa-miR-3130-5p	-8.64	8.7e-17	-0.54	-0.37	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206718128	chr2:206783246~206783266:+
LGG	cis	rs10021731	0.692	rs12108281	MIMAT0003242	hsa-miR-577	-8.64	8.82e-17	-0.3	-0.37	Optic disc area;	chr4:114522147	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs6834235	MIMAT0003242	hsa-miR-577	-8.64	8.89e-17	-0.3	-0.37	Optic disc area;	chr4:114531582	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1599320	MIMAT0003242	hsa-miR-577	-8.64	8.89e-17	-0.3	-0.37	Optic disc area;	chr4:114532227	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs993460	MIMAT0003242	hsa-miR-577	-8.64	8.95e-17	-0.3	-0.37	Optic disc area;	chr4:114510521	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs66482879	MIMAT0003242	hsa-miR-577	-8.63	9.09e-17	-0.3	-0.37	Optic disc area;	chr4:114517522	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs28657376	MIMAT0003242	hsa-miR-577	-8.63	9.09e-17	-0.3	-0.37	Optic disc area;	chr4:114517650	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs7684322	MIMAT0003242	hsa-miR-577	-8.63	9.09e-17	-0.3	-0.37	Optic disc area;	chr4:114519788	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs28361366	MIMAT0003242	hsa-miR-577	-8.63	9.32e-17	-0.3	-0.37	Optic disc area;	chr4:114512809	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs28656197	MIMAT0003242	hsa-miR-577	-8.63	9.32e-17	-0.3	-0.37	Optic disc area;	chr4:114512821	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.693	rs7686100	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114511670	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4295329	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114511945	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs4409027	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114511985	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4413472	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114512090	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs11936113	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114512224	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs2199314	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114513555	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs28736894	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114514184	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs17622270	MIMAT0003242	hsa-miR-577	-8.63	9.39e-17	-0.3	-0.37	Optic disc area;	chr4:114514205	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs1599317	MIMAT0003242	hsa-miR-577	-8.62	1.03e-16	-0.3	-0.37	Optic disc area;	chr4:114503010	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.655	rs734232	MIMAT0017994	hsa-miR-3615	-8.6	1.14e-16	-0.39	-0.37	Monocyte count;	chr17:74769592	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.718	rs7698790	MIMAT0003242	hsa-miR-577	8.6	1.2e-16	0.3	0.37	Optic disc area;	chr4:114492647	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2126028	MIMAT0003242	hsa-miR-577	-8.59	1.25e-16	-0.29	-0.37	Optic disc area;	chr4:114533453	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.655	rs895691	MIMAT0017994	hsa-miR-3615	-8.59	1.28e-16	-0.38	-0.37	Monocyte count;	chr17:74770161	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.718	rs11936150	MIMAT0003242	hsa-miR-577	-8.57	1.42e-16	-0.29	-0.37	Optic disc area;	chr4:114512391	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2054306	MIMAT0003242	hsa-miR-577	-8.54	1.83e-16	-0.29	-0.36	Optic disc area;	chr4:114496204	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2035059	MIMAT0003242	hsa-miR-577	-8.54	1.83e-16	-0.29	-0.36	Optic disc area;	chr4:114496530	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.625	rs4488004	MIMAT0014979	hsa-miR-3117-3p	-8.54	1.86e-16	-0.37	-0.36	Presence of antiphospholipid antibodies;	chr1:66607631	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.718	rs958771	MIMAT0003242	hsa-miR-577	-8.53	1.94e-16	-0.29	-0.36	Optic disc area;	chr4:114514506	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.625	rs2312154	MIMAT0014979	hsa-miR-3117-3p	8.51	2.24e-16	0.37	0.36	Presence of antiphospholipid antibodies;	chr1:66607293	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.692	rs13103833	MIMAT0003242	hsa-miR-577	-8.49	2.71e-16	-0.29	-0.36	Optic disc area;	chr4:114495414	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs62309866	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114479583	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7685549	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114479772	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7686774	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114480357	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7687413	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114480417	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.644	rs7665675	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114480704	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7692571	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114480792	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs11724670	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114482122	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs11724674	MIMAT0003242	hsa-miR-577	-8.48	2.84e-16	-0.29	-0.36	Optic disc area;	chr4:114482175	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs13104693	MIMAT0003242	hsa-miR-577	-8.48	2.87e-16	-0.29	-0.36	Optic disc area;	chr4:114495600	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.645	rs7698524	MIMAT0003242	hsa-miR-577	-8.47	3.08e-16	-0.3	-0.36	Optic disc area;	chr4:114492417	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs12512563	MIMAT0003242	hsa-miR-577	-8.44	3.96e-16	-0.29	-0.36	Optic disc area;	chr4:114493973	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.6	rs12504927	MIMAT0003242	hsa-miR-577	-8.44	3.96e-16	-0.29	-0.36	Optic disc area;	chr4:114493975	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.645	rs13147121	MIMAT0003242	hsa-miR-577	-8.44	3.96e-16	-0.29	-0.36	Optic disc area;	chr4:114493994	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs13147488	MIMAT0003242	hsa-miR-577	-8.44	4e-16	-0.29	-0.36	Optic disc area;	chr4:114494051	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs7690858	MIMAT0003242	hsa-miR-577	-8.43	4.16e-16	-0.29	-0.36	Optic disc area;	chr4:114511804	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13104656	MIMAT0003242	hsa-miR-577	-8.43	4.21e-16	-0.29	-0.36	Optic disc area;	chr4:114495547	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs13104685	MIMAT0003242	hsa-miR-577	-8.43	4.21e-16	-0.29	-0.36	Optic disc area;	chr4:114495590	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1460771	MIMAT0003242	hsa-miR-577	8.43	4.25e-16	0.29	0.36	Optic disc area;	chr4:114486755	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2054304	MIMAT0003242	hsa-miR-577	-8.42	4.5e-16	-0.29	-0.36	Optic disc area;	chr4:114495902	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4833458	MIMAT0003242	hsa-miR-577	-8.42	4.51e-16	-0.29	-0.36	Optic disc area;	chr4:114493571	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4833459	MIMAT0003242	hsa-miR-577	-8.42	4.51e-16	-0.29	-0.36	Optic disc area;	chr4:114493734	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs12501292	MIMAT0003242	hsa-miR-577	-8.42	4.51e-16	-0.29	-0.36	Optic disc area;	chr4:114493876	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.622	rs12711027	MIMAT0003242	hsa-miR-577	-8.42	4.51e-16	-0.29	-0.36	Optic disc area;	chr4:114494204	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13148430	MIMAT0003242	hsa-miR-577	-8.42	4.51e-16	-0.29	-0.36	Optic disc area;	chr4:114494469	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13103158	MIMAT0003242	hsa-miR-577	-8.41	4.72e-16	-0.29	-0.36	Optic disc area;	chr4:114493188	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs13127680	MIMAT0003242	hsa-miR-577	-8.41	4.72e-16	-0.29	-0.36	Optic disc area;	chr4:114493217	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.693	rs4834415	MIMAT0003242	hsa-miR-577	-8.41	4.72e-16	-0.29	-0.36	Optic disc area;	chr4:114493245	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs10002657	MIMAT0003242	hsa-miR-577	-8.4	5.34e-16	-0.29	-0.36	Optic disc area;	chr4:114483120	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2199312	MIMAT0003242	hsa-miR-577	-8.38	5.84e-16	-0.29	-0.36	Optic disc area;	chr4:114513322	chr4:114656774~114656794:+
LGG	cis	rs1867631	0.959	rs11208914	MIMAT0014979	hsa-miR-3117-3p	-8.38	5.97e-16	-0.39	-0.36	Menopause (age at onset);	chr1:66584045	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.668	rs7698363	MIMAT0003242	hsa-miR-577	-8.38	6.2e-16	-0.29	-0.36	Optic disc area;	chr4:114492418	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.928	rs7250870	MIMAT0021017	hsa-miR-4999-5p	8.37	6.51e-16	0.4	0.36	HDL cholesterol;	chr19:8388798	chr19:8389340~8389360:-
LGG	cis	rs7255436	0.965	rs2042900	MIMAT0021017	hsa-miR-4999-5p	8.37	6.62e-16	0.41	0.36	HDL cholesterol;	chr19:8374818	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.692	rs7662125	MIMAT0003242	hsa-miR-577	-8.37	6.72e-16	-0.29	-0.36	Optic disc area;	chr4:114495706	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs2054303	MIMAT0003242	hsa-miR-577	-8.37	6.72e-16	-0.29	-0.36	Optic disc area;	chr4:114495803	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs6839599	MIMAT0003242	hsa-miR-577	-8.35	7.31e-16	-0.29	-0.36	Optic disc area;	chr4:114494754	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1460772	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114487028	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs10028232	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114487644	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7671026	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114487736	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs10031142	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114488433	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs17678686	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114489100	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs28766989	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114489752	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs11722125	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114490374	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs11722162	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114490460	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs11722201	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114490577	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1585447	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114490912	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs1585448	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114491050	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1870655	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114491625	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2219591	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114491902	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs2199310	MIMAT0003242	hsa-miR-577	-8.34	8.07e-16	-0.29	-0.36	Optic disc area;	chr4:114492246	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.521	rs116635794	MIMAT0003242	hsa-miR-577	-8.33	8.62e-16	-0.29	-0.36	Optic disc area;	chr4:114520865	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.655	rs2305214	MIMAT0017994	hsa-miR-3615	-8.32	9.64e-16	-0.38	-0.36	Monocyte count;	chr17:74772831	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.718	rs2054305	MIMAT0003242	hsa-miR-577	-8.31	1.03e-15	-0.29	-0.36	Optic disc area;	chr4:114496175	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs10516602	MIMAT0003242	hsa-miR-577	-8.3	1.06e-15	-0.29	-0.36	Optic disc area;	chr4:114486174	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4409025	MIMAT0003242	hsa-miR-577	-8.3	1.06e-15	-0.29	-0.36	Optic disc area;	chr4:114511785	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs4409026	MIMAT0003242	hsa-miR-577	-8.3	1.06e-15	-0.29	-0.36	Optic disc area;	chr4:114511787	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13102706	MIMAT0003242	hsa-miR-577	-8.3	1.07e-15	-0.29	-0.36	Optic disc area;	chr4:114492998	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13102910	MIMAT0003242	hsa-miR-577	-8.3	1.07e-15	-0.29	-0.36	Optic disc area;	chr4:114493049	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13127839	MIMAT0003242	hsa-miR-577	-8.3	1.07e-15	-0.29	-0.36	Optic disc area;	chr4:114493059	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.965	rs7254882	MIMAT0021017	hsa-miR-4999-5p	8.3	1.09e-15	0.4	0.36	HDL cholesterol;	chr19:8388938	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.692	rs6840798	MIMAT0003242	hsa-miR-577	-8.3	1.09e-15	-0.29	-0.36	Optic disc area;	chr4:114495078	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs6817762	MIMAT0003242	hsa-miR-577	-8.3	1.09e-15	-0.29	-0.36	Optic disc area;	chr4:114495098	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs7689158	MIMAT0003242	hsa-miR-577	-8.3	1.11e-15	-0.29	-0.36	Optic disc area;	chr4:114495770	chr4:114656774~114656794:+
LGG	cis	rs75358501	1	rs75358501	MIMAT0014995	hsa-miR-3130-5p	-8.29	1.16e-15	-0.54	-0.36	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206713131	chr2:206783276~206783296:-
LGG	cis	rs75358501	1	rs75358501	MIMAT0014995_1	hsa-miR-3130-5p	-8.29	1.16e-15	-0.54	-0.36	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206713131	chr2:206783246~206783266:+
LGG	cis	rs8064299	0.655	rs16978176	MIMAT0017994	hsa-miR-3615	-8.28	1.26e-15	-0.37	-0.36	Monocyte count;	chr17:74765103	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.546	rs12503437	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114534955	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.546	rs12503481	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114535080	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.546	rs7668023	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114535366	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs1599316	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114490702	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs1585446	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114490871	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs2199311	MIMAT0003242	hsa-miR-577	-8.27	1.32e-15	-0.29	-0.35	Optic disc area;	chr4:114492288	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.692	rs10021252	MIMAT0003242	hsa-miR-577	-8.23	1.76e-15	-0.29	-0.35	Optic disc area;	chr4:114515190	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13127822	MIMAT0003242	hsa-miR-577	-8.23	1.8e-15	-0.28	-0.35	Optic disc area;	chr4:114493024	chr4:114656774~114656794:+
LGG	cis	rs7255436	0.898	rs7252574	MIMAT0021017	hsa-miR-4999-5p	8.2	2.28e-15	0.4	0.35	HDL cholesterol;	chr19:8376895	chr19:8389340~8389360:-
LGG	cis	rs10021731	0.668	rs62309894	MIMAT0003242	hsa-miR-577	-8.17	2.74e-15	-0.29	-0.35	Optic disc area;	chr4:114504575	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.706	rs1380931	MIMAT0003242	hsa-miR-577	-8.17	2.74e-15	-0.29	-0.35	Optic disc area;	chr4:114506853	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs2199313	MIMAT0003242	hsa-miR-577	-8.15	3.31e-15	-0.29	-0.35	Optic disc area;	chr4:114513488	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.718	rs13104081	MIMAT0003242	hsa-miR-577	-8.13	3.74e-15	-0.28	-0.35	Optic disc area;	chr4:114532641	chr4:114656774~114656794:+
LGG	cis	rs6681460	1	rs2031478	MIMAT0014979	hsa-miR-3117-3p	-8.1	4.75e-15	-0.35	-0.35	Presence of antiphospholipid antibodies;	chr1:66658059	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.604	rs11208920	MIMAT0014979	hsa-miR-3117-3p	-8.09	4.88e-15	-0.36	-0.35	Presence of antiphospholipid antibodies;	chr1:66609629	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6659968	MIMAT0014979	hsa-miR-3117-3p	-8.07	5.85e-15	-0.34	-0.35	Presence of antiphospholipid antibodies;	chr1:66657776	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.668	rs28651771	MIMAT0003242	hsa-miR-577	-8.07	6.01e-15	-0.28	-0.35	Optic disc area;	chr4:114501291	chr4:114656774~114656794:+
LGG	cis	rs6120849	0.754	rs3746436	MIMAT0004772	hsa-miR-499a-3p	-8.03	7.49e-15	-0.49	-0.35	Protein C levels;	chr20:34998390	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs3746446	MIMAT0004772	hsa-miR-499a-3p	-8.03	7.85e-15	-0.5	-0.35	Protein C levels;	chr20:34986962	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6088682	MIMAT0004772	hsa-miR-499a-3p	-8.03	7.88e-15	-0.49	-0.35	Protein C levels;	chr20:35027899	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120793	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35016604	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120797	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35018199	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6119560	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35019174	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs6120798	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35023019	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs11167253	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35026646	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs6120799	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35027152	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs13433216	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35028498	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6088686	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35035634	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120804	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35035898	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6087666	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35052439	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120813	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35054309	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs17319032	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35055493	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.617	rs12480442	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35060585	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6087667	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35064084	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs6088694	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35064568	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs6120826	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.13e-15	-0.49	-0.35	Protein C levels;	chr20:35084028	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120788	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.26e-15	-0.49	-0.35	Protein C levels;	chr20:34995913	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs3746435	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.45e-15	-0.49	-0.35	Protein C levels;	chr20:34999395	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs36003887	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.45e-15	-0.49	-0.35	Protein C levels;	chr20:35001304	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs8501	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.45e-15	-0.49	-0.35	Protein C levels;	chr20:35002781	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs752075	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.45e-15	-0.49	-0.35	Protein C levels;	chr20:35003788	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs752448	MIMAT0004772	hsa-miR-499a-3p	-8.02	8.45e-15	-0.49	-0.35	Protein C levels;	chr20:35004445	chr20:34990445~34990466:+
LGG	cis	rs10021731	0.692	rs62309904	MIMAT0003242	hsa-miR-577	-8.02	8.57e-15	-0.28	-0.35	Optic disc area;	chr4:114514011	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs1599322	MIMAT0003242	hsa-miR-577	-8.01	9.24e-15	-0.28	-0.34	Optic disc area;	chr4:114531895	chr4:114656774~114656794:+
LGG	cis	rs6120849	0.754	rs1885116	MIMAT0004772	hsa-miR-499a-3p	-8	9.36e-15	-0.49	-0.34	Protein C levels;	chr20:35012757	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs1885117	MIMAT0004772	hsa-miR-499a-3p	-8	9.36e-15	-0.49	-0.34	Protein C levels;	chr20:35012937	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120812	MIMAT0004772	hsa-miR-499a-3p	-7.99	1.05e-14	-0.49	-0.34	Protein C levels;	chr20:35041624	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs6088690	MIMAT0004772	hsa-miR-499a-3p	-7.99	1.05e-14	-0.49	-0.34	Protein C levels;	chr20:35045523	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6088691	MIMAT0004772	hsa-miR-499a-3p	-7.99	1.05e-14	-0.49	-0.34	Protein C levels;	chr20:35045955	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.518	rs11696652	MIMAT0004772	hsa-miR-499a-3p	-7.99	1.05e-14	-0.49	-0.34	Protein C levels;	chr20:35049257	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.525	rs2271751	MIMAT0005951	hsa-miR-1307-3p	-7.99	1.05e-14	-0.22	-0.34	Migraine;	chr10:103415374	chr10:103394301~103394322:-
LGG	cis	rs6120849	0.754	rs7268266	MIMAT0004772	hsa-miR-499a-3p	-7.98	1.12e-14	-0.49	-0.34	Protein C levels;	chr20:34994086	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6088678	MIMAT0004772	hsa-miR-499a-3p	7.97	1.16e-14	0.49	0.34	Protein C levels;	chr20:35019748	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.966	rs10889644	MIMAT0014979	hsa-miR-3117-3p	-7.97	1.18e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66679639	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.754	rs6120819	MIMAT0004772	hsa-miR-499a-3p	-7.97	1.21e-14	-0.49	-0.34	Protein C levels;	chr20:35065235	chr20:34990445~34990466:+
LGG	cis	rs10021731	0.668	rs55968476	MIMAT0003242	hsa-miR-577	-7.96	1.31e-14	-0.28	-0.34	Optic disc area;	chr4:114532478	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs13103537	MIMAT0003242	hsa-miR-577	-7.94	1.43e-14	-0.28	-0.34	Optic disc area;	chr4:114495092	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.966	rs10789214	MIMAT0014979	hsa-miR-3117-3p	-7.94	1.45e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66681134	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.707	rs6088703	MIMAT0004772	hsa-miR-499a-3p	-7.9	1.91e-14	-0.49	-0.34	Protein C levels;	chr20:35088246	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.707	rs3746444	MIMAT0004772	hsa-miR-499a-3p	-7.88	2.31e-14	-0.48	-0.34	Protein C levels;	chr20:34990448	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.966	rs4655650	MIMAT0014979	hsa-miR-3117-3p	-7.85	2.78e-14	-0.35	-0.34	Presence of antiphospholipid antibodies;	chr1:66676603	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.754	rs3818253	MIMAT0004772	hsa-miR-499a-3p	-7.84	3.04e-14	-0.48	-0.34	Protein C levels;	chr20:35009073	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs6681460	MIMAT0014979	hsa-miR-3117-3p	7.83	3.16e-14	0.33	0.34	Presence of antiphospholipid antibodies;	chr1:66657374	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.668	rs13112732	MIMAT0003242	hsa-miR-577	-7.83	3.31e-14	-0.28	-0.34	Optic disc area;	chr4:114483845	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.625	rs6679568	MIMAT0014979	hsa-miR-3117-3p	-7.82	3.43e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66608494	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6680944	MIMAT0014979	hsa-miR-3117-3p	-7.81	3.6e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66656882	chr1:66628485~66628505:+
LGG	cis	rs3746446	0.678	rs6120777	MIMAT0004772	hsa-miR-499a-3p	-7.81	3.82e-14	-0.52	-0.34	Congenital left-sided heart lesions;	chr20:34972369	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.754	rs6120828	MIMAT0004772	hsa-miR-499a-3p	-7.78	4.55e-14	-0.46	-0.34	Protein C levels;	chr20:35086657	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs9662962	MIMAT0014979	hsa-miR-3117-3p	-7.77	4.88e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66655681	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs9659879	MIMAT0014979	hsa-miR-3117-3p	-7.77	4.88e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66655751	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs11208932	MIMAT0014979	hsa-miR-3117-3p	-7.76	5.14e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66632170	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs7521111	MIMAT0014979	hsa-miR-3117-3p	-7.76	5.25e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66655951	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs7521123	MIMAT0014979	hsa-miR-3117-3p	-7.76	5.25e-14	-0.34	-0.34	Presence of antiphospholipid antibodies;	chr1:66655980	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.754	rs6120790	MIMAT0004772	hsa-miR-499a-3p	-7.74	6.11e-14	-0.47	-0.33	Protein C levels;	chr20:35011287	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs6670378	MIMAT0014979	hsa-miR-3117-3p	-7.72	6.77e-14	-0.34	-0.33	Presence of antiphospholipid antibodies;	chr1:66660902	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.615	rs11167248	MIMAT0004772	hsa-miR-499a-3p	-7.72	7.16e-14	-0.47	-0.33	Protein C levels;	chr20:34950918	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.586	rs2025096	MIMAT0004772	hsa-miR-499a-3p	-7.72	7.16e-14	-0.47	-0.33	Protein C levels;	chr20:34952197	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs2147777	MIMAT0014979	hsa-miR-3117-3p	-7.7	7.78e-14	-0.34	-0.33	Presence of antiphospholipid antibodies;	chr1:66663571	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6680876	MIMAT0014979	hsa-miR-3117-3p	-7.7	7.78e-14	-0.34	-0.33	Presence of antiphospholipid antibodies;	chr1:66663799	chr1:66628485~66628505:+
LGG	cis	rs62084913	0.511	rs895690	MIMAT0017994	hsa-miR-3615	-7.69	8.32e-14	-0.35	-0.33	Breast cancer;	chr17:74788510	chr17:74748663~74748683:+
LGG	cis	rs10021731	1	rs11098258	MIMAT0003242	hsa-miR-577	7.68	8.98e-14	0.27	0.33	Optic disc area;	chr4:114564528	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.668	rs7676684	MIMAT0003242	hsa-miR-577	7.68	9.15e-14	0.27	0.33	Optic disc area;	chr4:114492371	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.966	rs7524851	MIMAT0014979	hsa-miR-3117-3p	-7.67	9.52e-14	-0.34	-0.33	Presence of antiphospholipid antibodies;	chr1:66627335	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs4655646	MIMAT0014979	hsa-miR-3117-3p	-7.67	9.52e-14	-0.34	-0.33	Presence of antiphospholipid antibodies;	chr1:66628653	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.708	rs6087659	MIMAT0004772	hsa-miR-499a-3p	-7.66	1.05e-13	-0.48	-0.33	Protein C levels;	chr20:35018580	chr20:34990445~34990466:+
LGG	cis	rs1867631	0.585	rs11208940	MIMAT0014979	hsa-miR-3117-3p	7.65	1.1e-13	0.33	0.33	Menopause (age at onset);	chr1:66661559	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.585	rs12094526	MIMAT0014979	hsa-miR-3117-3p	-7.64	1.23e-13	-0.32	-0.33	Menopause (age at onset);	chr1:66660431	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.56	rs11077763	MIMAT0017994	hsa-miR-3615	-7.61	1.46e-13	-0.35	-0.33	Monocyte count;	chr17:74789890	chr17:74748663~74748683:+
LGG	cis	rs1867631	0.585	rs6694782	MIMAT0014979	hsa-miR-3117-3p	7.6	1.55e-13	0.32	0.33	Menopause (age at onset);	chr1:66661079	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs4655647	MIMAT0014979	hsa-miR-3117-3p	-7.6	1.56e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66640394	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs4655640	MIMAT0014979	hsa-miR-3117-3p	-7.6	1.58e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66623537	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6656550	MIMAT0014979	hsa-miR-3117-3p	-7.6	1.58e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66656869	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.565	rs12453550	MIMAT0017994	hsa-miR-3615	-7.59	1.67e-13	-0.35	-0.33	Monocyte count;	chr17:74789947	chr17:74748663~74748683:+
LGG	cis	rs6120849	0.663	rs6119548	MIMAT0004772	hsa-miR-499a-3p	-7.59	1.73e-13	-0.46	-0.33	Protein C levels;	chr20:34964809	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.663	rs13041792	MIMAT0004772	hsa-miR-499a-3p	-7.59	1.73e-13	-0.46	-0.33	Protein C levels;	chr20:34957252	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs2872078	MIMAT0014979	hsa-miR-3117-3p	-7.58	1.84e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66661684	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.585	rs6670827	MIMAT0014979	hsa-miR-3117-3p	-7.58	1.85e-13	-0.32	-0.33	Menopause (age at onset);	chr1:66661323	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.663	rs11698868	MIMAT0004772	hsa-miR-499a-3p	-7.57	1.99e-13	-0.46	-0.33	Protein C levels;	chr20:34962143	chr20:34990445~34990466:+
LGG	cis	rs6681460	1	rs1325263	MIMAT0014979	hsa-miR-3117-3p	-7.55	2.3e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66664108	chr1:66628485~66628505:+
LGG	cis	rs10021731	1	rs13104222	MIMAT0003242	hsa-miR-577	7.55	2.31e-13	0.27	0.33	Optic disc area;	chr4:114549757	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.966	rs2025595	MIMAT0014979	hsa-miR-3117-3p	-7.54	2.39e-13	-0.32	-0.33	Presence of antiphospholipid antibodies;	chr1:66686816	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs1536115	MIMAT0014979	hsa-miR-3117-3p	-7.54	2.46e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66655318	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs7519747	MIMAT0014979	hsa-miR-3117-3p	-7.53	2.55e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66675040	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs10749765	MIMAT0014979	hsa-miR-3117-3p	-7.52	2.68e-13	-0.32	-0.33	Presence of antiphospholipid antibodies;	chr1:66684597	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.901	rs1570815	MIMAT0014979	hsa-miR-3117-3p	-7.52	2.69e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66673984	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.636	rs9915279	MIMAT0017994	hsa-miR-3615	-7.51	2.94e-13	-0.35	-0.33	Monocyte count;	chr17:74776709	chr17:74748663~74748683:+
LGG	cis	rs6681460	0.966	rs1325261	MIMAT0014979	hsa-miR-3117-3p	-7.5	3.06e-13	-0.33	-0.33	Presence of antiphospholipid antibodies;	chr1:66644833	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.754	rs6088667	MIMAT0004772	hsa-miR-499a-3p	-7.49	3.28e-13	-0.46	-0.33	Protein C levels;	chr20:34978919	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.932	rs2146904	MIMAT0014979	hsa-miR-3117-3p	7.49	3.33e-13	0.34	0.33	Presence of antiphospholipid antibodies;	chr1:66694653	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.933	rs7554101	MIMAT0014979	hsa-miR-3117-3p	7.49	3.34e-13	0.32	0.33	Presence of antiphospholipid antibodies;	chr1:66690789	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.663	rs6088662	MIMAT0004772	hsa-miR-499a-3p	-7.49	3.46e-13	-0.45	-0.32	Protein C levels;	chr20:34959830	chr20:34990445~34990466:+
LGG	cis	rs8064299	0.597	rs6501736	MIMAT0017994	hsa-miR-3615	-7.48	3.7e-13	-0.34	-0.32	Monocyte count;	chr17:74779219	chr17:74748663~74748683:+
LGG	cis	rs10021731	1	rs6533801	MIMAT0003242	hsa-miR-577	7.48	3.72e-13	0.27	0.32	Optic disc area;	chr4:114553199	chr4:114656774~114656794:+
LGG	cis	rs10021731	1	rs4834419	MIMAT0003242	hsa-miR-577	7.45	4.4e-13	0.26	0.32	Optic disc area;	chr4:114548870	chr4:114656774~114656794:+
LGG	cis	rs10021731	1	rs10021731	MIMAT0003242	hsa-miR-577	7.45	4.54e-13	0.27	0.32	Optic disc area;	chr4:114560759	chr4:114656774~114656794:+
LGG	cis	rs10021731	1	rs1599323	MIMAT0003242	hsa-miR-577	7.44	4.72e-13	0.26	0.32	Optic disc area;	chr4:114549176	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.584	rs2384957	MIMAT0017994	hsa-miR-3615	-7.43	4.96e-13	-0.34	-0.32	Monocyte count;	chr17:74788491	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.597	rs9944506	MIMAT0017994	hsa-miR-3615	-7.43	5.12e-13	-0.34	-0.32	Monocyte count;	chr17:74786587	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.597	rs2016126	MIMAT0017994	hsa-miR-3615	-7.42	5.29e-13	-0.34	-0.32	Monocyte count;	chr17:74788793	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.597	rs7210318	MIMAT0017994	hsa-miR-3615	-7.41	5.73e-13	-0.34	-0.32	Monocyte count;	chr17:74787246	chr17:74748663~74748683:+
LGG	cis	rs6681460	0.866	rs996123	MIMAT0014979	hsa-miR-3117-3p	-7.4	6.27e-13	-0.33	-0.32	Presence of antiphospholipid antibodies;	chr1:66559660	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.597	rs2166703	MIMAT0017994	hsa-miR-3615	-7.4	6.32e-13	-0.34	-0.32	Monocyte count;	chr17:74785673	chr17:74748663~74748683:+
LGG	cis	rs6681460	0.932	rs492109	MIMAT0014979	hsa-miR-3117-3p	7.4	6.33e-13	0.31	0.32	Presence of antiphospholipid antibodies;	chr1:66721450	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs10889641	MIMAT0014979	hsa-miR-3117-3p	-7.39	6.85e-13	-0.33	-0.32	Presence of antiphospholipid antibodies;	chr1:66672684	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs10889643	MIMAT0014979	hsa-miR-3117-3p	-7.38	7e-13	-0.32	-0.32	Presence of antiphospholipid antibodies;	chr1:66677685	chr1:66628485~66628505:+
LGG	cis	rs1163656	0.502	rs10862209	MIMAT0003287	hsa-miR-618	-7.38	7.22e-13	-0.51	-0.32	Dental caries;	chr12:80933176	chr12:80935796~80935818:-
LGG	cis	rs1163656	0.502	rs11114658	MIMAT0003287	hsa-miR-618	-7.38	7.22e-13	-0.51	-0.32	Dental caries;	chr12:80933378	chr12:80935796~80935818:-
LGG	cis	rs1163656	0.502	rs7310000	MIMAT0003287	hsa-miR-618	-7.38	7.22e-13	-0.51	-0.32	Dental caries;	chr12:80933498	chr12:80935796~80935818:-
LGG	cis	rs8064299	0.574	rs1879455	MIMAT0017994	hsa-miR-3615	-7.38	7.27e-13	-0.34	-0.32	Monocyte count;	chr17:74778599	chr17:74748663~74748683:+
LGG	cis	rs4808779	0.924	rs4531856	MIMAT0015070	hsa-miR-3188	7.36	8.06e-13	0.39	0.32	Granulocyte percentage of myeloid white cells;	chr19:18277573	chr19:18282129~18282151:+
LGG	cis	rs4808779	0.924	rs12608504	MIMAT0015070	hsa-miR-3188	7.36	8.32e-13	0.38	0.32	Granulocyte percentage of myeloid white cells;	chr19:18278325	chr19:18282129~18282151:+
LGG	cis	rs1163656	0.534	rs11114656	MIMAT0003287	hsa-miR-618	-7.35	8.45e-13	-0.44	-0.32	Dental caries;	chr12:80925906	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.966	rs6588215	MIMAT0014979	hsa-miR-3117-3p	-7.35	8.74e-13	-0.32	-0.32	Presence of antiphospholipid antibodies;	chr1:66676266	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.847	rs8113367	MIMAT0015070	hsa-miR-3188	7.35	8.74e-13	0.38	0.32	Granulocyte percentage of myeloid white cells;	chr19:18277440	chr19:18282129~18282151:+
LGG	cis	rs6681460	0.866	rs1856318	MIMAT0014979	hsa-miR-3117-3p	-7.35	8.83e-13	-0.33	-0.32	Presence of antiphospholipid antibodies;	chr1:66558532	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.951	rs55670307	MIMAT0004772	hsa-miR-499a-3p	-7.35	8.95e-13	-0.41	-0.32	Protein C levels;	chr20:35132691	chr20:34990445~34990466:+
LGG	cis	rs1163656	0.819	rs1716537	MIMAT0003287	hsa-miR-618	7.33	1.01e-12	0.4	0.32	Dental caries;	chr12:80940959	chr12:80935796~80935818:-
LGG	cis	rs10021731	0.83	rs12648883	MIMAT0003242	hsa-miR-577	-7.33	1.01e-12	-0.27	-0.32	Optic disc area;	chr4:114576504	chr4:114656774~114656794:+
LGG	cis	rs1163656	0.502	rs17007704	MIMAT0003287	hsa-miR-618	-7.33	1.03e-12	-0.5	-0.32	Dental caries;	chr12:80932218	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.932	rs536410	MIMAT0014979	hsa-miR-3117-3p	-7.32	1.07e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66725401	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.83	rs17622401	MIMAT0003242	hsa-miR-577	7.31	1.14e-12	0.27	0.32	Optic disc area;	chr4:114571551	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.932	rs2483705	MIMAT0014979	hsa-miR-3117-3p	7.31	1.15e-12	0.31	0.32	Presence of antiphospholipid antibodies;	chr1:66725497	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.966	rs10889642	MIMAT0014979	hsa-miR-3117-3p	-7.31	1.17e-12	-0.32	-0.32	Presence of antiphospholipid antibodies;	chr1:66677651	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.924	rs10416600	MIMAT0015070	hsa-miR-3188	7.3	1.22e-12	0.39	0.32	Granulocyte percentage of myeloid white cells;	chr19:18275253	chr19:18282129~18282151:+
LGG	cis	rs6681460	0.899	rs502690	MIMAT0014979	hsa-miR-3117-3p	-7.29	1.27e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66716720	chr1:66628485~66628505:+
LGG	cis	rs1163656	0.502	rs17007711	MIMAT0003287	hsa-miR-618	7.29	1.34e-12	0.48	0.32	Dental caries;	chr12:80934305	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.966	rs10789215	MIMAT0014979	hsa-miR-3117-3p	7.29	1.34e-12	0.32	0.32	Presence of antiphospholipid antibodies;	chr1:66685502	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6689864	MIMAT0014979	hsa-miR-3117-3p	-7.28	1.38e-12	-0.32	-0.32	Presence of antiphospholipid antibodies;	chr1:66602429	chr1:66628485~66628505:+
LGG	cis	rs4808779	1	rs4808779	MIMAT0015070	hsa-miR-3188	7.27	1.52e-12	0.38	0.32	Granulocyte percentage of myeloid white cells;	chr19:18294126	chr19:18282129~18282151:+
LGG	cis	rs1163656	0.819	rs1795515	MIMAT0003287	hsa-miR-618	7.27	1.53e-12	0.39	0.32	Dental caries;	chr12:80941888	chr12:80935796~80935818:-
LGG	cis	rs8064299	0.597	rs9893035	MIMAT0017994	hsa-miR-3615	-7.26	1.54e-12	-0.34	-0.32	Monocyte count;	chr17:74787659	chr17:74748663~74748683:+
LGG	cis	rs6681460	0.932	rs523956	MIMAT0014979	hsa-miR-3117-3p	7.26	1.6e-12	0.31	0.32	Presence of antiphospholipid antibodies;	chr1:66722593	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs618093	MIMAT0014979	hsa-miR-3117-3p	-7.26	1.6e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66712745	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs665319	MIMAT0014979	hsa-miR-3117-3p	-7.26	1.62e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66709805	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.884	rs7247222	MIMAT0015070	hsa-miR-3188	7.26	1.63e-12	0.38	0.32	Granulocyte percentage of myeloid white cells;	chr19:18282063	chr19:18282129~18282151:+
LGG	cis	rs6681460	0.899	rs499263	MIMAT0014979	hsa-miR-3117-3p	-7.26	1.64e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66714254	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.924	rs11086102	MIMAT0015070	hsa-miR-3188	7.25	1.67e-12	0.38	0.32	Granulocyte percentage of myeloid white cells;	chr19:18287818	chr19:18282129~18282151:+
LGG	cis	rs8064299	0.574	rs12452204	MIMAT0017994	hsa-miR-3615	-7.25	1.68e-12	-0.33	-0.32	Monocyte count;	chr17:74777989	chr17:74748663~74748683:+
LGG	cis	rs1867631	0.585	rs12062570	MIMAT0014979	hsa-miR-3117-3p	-7.25	1.72e-12	-0.31	-0.32	Menopause (age at onset);	chr1:66620602	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs659291	MIMAT0014979	hsa-miR-3117-3p	-7.23	1.9e-12	-0.31	-0.32	Presence of antiphospholipid antibodies;	chr1:66715063	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.597	rs4789098	MIMAT0017994	hsa-miR-3615	-7.23	1.91e-12	-0.33	-0.31	Monocyte count;	chr17:74785153	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.597	rs4789097	MIMAT0017994	hsa-miR-3615	7.23	1.93e-12	0.33	0.31	Monocyte count;	chr17:74785069	chr17:74748663~74748683:+
LGG	cis	rs8064299	0.597	rs3785539	MIMAT0017994	hsa-miR-3615	-7.23	1.96e-12	-0.33	-0.31	Monocyte count;	chr17:74778960	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.729	rs17047190	MIMAT0003242	hsa-miR-577	7.22	2.08e-12	0.26	0.31	Optic disc area;	chr4:114536699	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.966	rs7542924	MIMAT0014979	hsa-miR-3117-3p	-7.21	2.23e-12	-0.34	-0.31	Presence of antiphospholipid antibodies;	chr1:66677372	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.83	rs28734840	MIMAT0003242	hsa-miR-577	7.19	2.49e-12	0.27	0.31	Optic disc area;	chr4:114575934	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.798	rs34581144	MIMAT0003242	hsa-miR-577	7.19	2.53e-12	0.27	0.31	Optic disc area;	chr4:114583571	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.8	rs539014	MIMAT0014979	hsa-miR-3117-3p	7.18	2.66e-12	0.33	0.31	Presence of antiphospholipid antibodies;	chr1:66746204	chr1:66628485~66628505:+
LGG	cis	rs8064299	0.597	rs2053748	MIMAT0017994	hsa-miR-3615	7.18	2.77e-12	0.33	0.31	Monocyte count;	chr17:74779772	chr17:74748663~74748683:+
LGG	cis	rs6681460	1	rs1329978	MIMAT0014979	hsa-miR-3117-3p	-7.17	2.85e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66650548	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs1445575	MIMAT0014979	hsa-miR-3117-3p	-7.17	2.9e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66586481	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.934	rs4655628	MIMAT0014979	hsa-miR-3117-3p	-7.17	2.9e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66586926	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs603750	MIMAT0014979	hsa-miR-3117-3p	-7.16	2.99e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66711805	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.83	rs4834421	MIMAT0003242	hsa-miR-577	7.15	3.39e-12	0.27	0.31	Optic disc area;	chr4:114572686	chr4:114656774~114656794:+
LGG	cis	rs8064299	0.597	rs6501737	MIMAT0017994	hsa-miR-3615	7.14	3.54e-12	0.32	0.31	Monocyte count;	chr17:74784691	chr17:74748663~74748683:+
LGG	cis	rs10021731	0.793	rs12650568	MIMAT0003242	hsa-miR-577	7.14	3.61e-12	0.27	0.31	Optic disc area;	chr4:114578461	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.932	rs2044399	MIMAT0014979	hsa-miR-3117-3p	-7.13	3.68e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66588397	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs2044400	MIMAT0014979	hsa-miR-3117-3p	-7.13	3.68e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66588398	chr1:66628485~66628505:+
LGG	cis	rs1163656	0.534	rs17007709	MIMAT0003287	hsa-miR-618	-7.11	4.24e-12	-0.43	-0.31	Dental caries;	chr12:80934267	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.899	rs1280280	MIMAT0014979	hsa-miR-3117-3p	-7.1	4.52e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66708220	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.884	rs12973608	MIMAT0015070	hsa-miR-3188	7.09	4.73e-12	0.37	0.31	Granulocyte percentage of myeloid white cells;	chr19:18287220	chr19:18282129~18282151:+
LGG	cis	rs4808779	0.924	rs12980403	MIMAT0015070	hsa-miR-3188	7.09	4.73e-12	0.37	0.31	Granulocyte percentage of myeloid white cells;	chr19:18287329	chr19:18282129~18282151:+
LGG	cis	rs4808779	0.924	rs12610373	MIMAT0015070	hsa-miR-3188	7.09	4.73e-12	0.37	0.31	Granulocyte percentage of myeloid white cells;	chr19:18287474	chr19:18282129~18282151:+
LGG	cis	rs6681460	1	rs10889634	MIMAT0014979	hsa-miR-3117-3p	7.07	5.39e-12	0.3	0.31	Presence of antiphospholipid antibodies;	chr1:66600228	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs523188	MIMAT0014979	hsa-miR-3117-3p	-7.07	5.73e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66708739	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.837	rs6669023	MIMAT0014979	hsa-miR-3117-3p	-7.05	6.34e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66706185	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.951	rs6120848	MIMAT0004772	hsa-miR-499a-3p	-7.04	6.77e-12	-0.41	-0.31	Protein C levels;	chr20:35140875	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.566	rs7076274	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.19e-12	-0.2	-0.31	Migraine;	chr10:103286250	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.545	rs3740381	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.19e-12	-0.2	-0.31	Migraine;	chr10:103286932	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.566	rs7917388	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.19e-12	-0.2	-0.31	Migraine;	chr10:103295206	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.525	rs11191642	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.19e-12	-0.2	-0.31	Migraine;	chr10:103296155	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.588	rs12220267	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.19e-12	-0.2	-0.31	Migraine;	chr10:103315955	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.503	rs72846198	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.26e-12	-0.2	-0.31	Migraine;	chr10:103338267	chr10:103394301~103394322:-
LGG	cis	rs6681460	1	rs964574	MIMAT0014979	hsa-miR-3117-3p	-7.01	8.28e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66597202	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.526	rs113528138	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.31e-12	-0.2	-0.31	Migraine;	chr10:103365694	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.525	rs11191667	MIMAT0005951	hsa-miR-1307-3p	-7.01	8.31e-12	-0.2	-0.31	Migraine;	chr10:103369141	chr10:103394301~103394322:-
LGG	cis	rs6681460	1	rs4655648	MIMAT0014979	hsa-miR-3117-3p	-7	8.67e-12	-0.31	-0.31	Presence of antiphospholipid antibodies;	chr1:66648626	chr1:66628485~66628505:+
LGG	cis	rs6120849	1	rs6120849	MIMAT0004772	hsa-miR-499a-3p	-7	9.05e-12	-0.4	-0.31	Protein C levels;	chr20:35142584	chr20:34990445~34990466:+
LGG	cis	rs10021731	0.83	rs1460785	MIMAT0003242	hsa-miR-577	6.99	9.32e-12	0.26	0.31	Optic disc area;	chr4:114545757	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.671	rs628655	MIMAT0014979	hsa-miR-3117-3p	6.98	1.01e-11	0.32	0.3	Presence of antiphospholipid antibodies;	chr1:66747890	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.83	rs28870381	MIMAT0003242	hsa-miR-577	6.97	1.05e-11	0.26	0.3	Optic disc area;	chr4:114557343	chr4:114656774~114656794:+
LGG	cis	rs6681460	1	rs1562217	MIMAT0014979	hsa-miR-3117-3p	6.95	1.17e-11	0.3	0.3	Presence of antiphospholipid antibodies;	chr1:66607883	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.649	rs967325	MIMAT0014979	hsa-miR-3117-3p	-6.94	1.25e-11	-0.32	-0.3	Presence of antiphospholipid antibodies;	chr1:66538039	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs9662943	MIMAT0014979	hsa-miR-3117-3p	6.94	1.26e-11	0.33	0.3	Presence of antiphospholipid antibodies;	chr1:66655449	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.566	rs1163073	MIMAT0005951	hsa-miR-1307-3p	6.93	1.34e-11	0.19	0.3	Migraine;	chr10:103263177	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.525	rs2271751	MIMAT0022727	hsa-miR-1307-5p	-6.93	1.35e-11	-0.21	-0.3	Migraine;	chr10:103415374	chr10:103394341~103394361:-
LGG	cis	rs6681460	1	rs7532173	MIMAT0014979	hsa-miR-3117-3p	-6.92	1.49e-11	-0.3	-0.3	Presence of antiphospholipid antibodies;	chr1:66620428	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.898	rs536527	MIMAT0014979	hsa-miR-3117-3p	-6.91	1.59e-11	-0.3	-0.3	Presence of antiphospholipid antibodies;	chr1:66728110	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.525	rs7911488	MIMAT0005951	hsa-miR-1307-3p	-6.91	1.6e-11	-0.2	-0.3	Migraine;	chr10:103394332	chr10:103394301~103394322:-
LGG	cis	rs6681460	0.8	rs485543	MIMAT0014979	hsa-miR-3117-3p	6.89	1.74e-11	0.31	0.3	Presence of antiphospholipid antibodies;	chr1:66728689	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.898	rs1032635	MIMAT0014979	hsa-miR-3117-3p	6.88	1.93e-11	0.3	0.3	Presence of antiphospholipid antibodies;	chr1:66729501	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.524	rs1712509	MIMAT0005951	hsa-miR-1307-3p	-6.86	2.13e-11	-0.2	-0.3	Migraine;	chr10:103254113	chr10:103394301~103394322:-
LGG	cis	rs10021731	0.718	rs7698391	MIMAT0003242	hsa-miR-577	-6.85	2.26e-11	-0.25	-0.3	Optic disc area;	chr4:114492457	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.932	rs602513	MIMAT0014979	hsa-miR-3117-3p	-6.85	2.28e-11	-0.3	-0.3	Presence of antiphospholipid antibodies;	chr1:66711587	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs4655636	MIMAT0014979	hsa-miR-3117-3p	-6.84	2.43e-11	-0.29	-0.3	Presence of antiphospholipid antibodies;	chr1:66602854	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs523132	MIMAT0014979	hsa-miR-3117-3p	6.83	2.57e-11	0.3	0.3	Presence of antiphospholipid antibodies;	chr1:66708757	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs7524818	MIMAT0014979	hsa-miR-3117-3p	-6.82	2.81e-11	-0.29	-0.3	Presence of antiphospholipid antibodies;	chr1:66606348	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.524	rs4917384	MIMAT0022727	hsa-miR-1307-5p	6.8	3.19e-11	0.21	0.3	Migraine;	chr10:103236031	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.934	rs10889635	MIMAT0014979	hsa-miR-3117-3p	-6.79	3.3e-11	-0.3	-0.3	Presence of antiphospholipid antibodies;	chr1:66609892	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs10789210	MIMAT0014979	hsa-miR-3117-3p	-6.78	3.48e-11	-0.29	-0.3	Presence of antiphospholipid antibodies;	chr1:66600347	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6588207	MIMAT0014979	hsa-miR-3117-3p	-6.78	3.6e-11	-0.29	-0.3	Presence of antiphospholipid antibodies;	chr1:66600872	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs6060266	MIMAT0004772	hsa-miR-499a-3p	-6.77	3.72e-11	-0.38	-0.3	Protein C levels;	chr20:35145275	chr20:34990445~34990466:+
LGG	cis	rs4917385	1	rs4917385	MIMAT0022727	hsa-miR-1307-5p	6.77	3.83e-11	0.21	0.3	Systemic lupus erythematosus;	chr10:103243964	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.524	rs4917384	MIMAT0005951	hsa-miR-1307-3p	6.76	4.08e-11	0.2	0.3	Migraine;	chr10:103236031	chr10:103394301~103394322:-
LGG	cis	rs6120849	0.901	rs6058194	MIMAT0004772	hsa-miR-499a-3p	-6.75	4.37e-11	-0.38	-0.3	Protein C levels;	chr20:35152028	chr20:34990445~34990466:+
LGG	cis	rs1867631	0.585	rs9787219	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.51e-11	-0.29	-0.3	Menopause (age at onset);	chr1:66614476	chr1:66628485~66628505:+
LGG	cis	rs1867631	0.585	rs11208922	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.51e-11	-0.29	-0.3	Menopause (age at onset);	chr1:66614543	chr1:66628485~66628505:+
LGG	cis	rs4808779	0.787	rs10406080	MIMAT0015070	hsa-miR-3188	6.74	4.51e-11	0.35	0.3	Granulocyte percentage of myeloid white cells;	chr19:18291332	chr19:18282129~18282151:+
LGG	cis	rs6681460	0.898	rs1032634	MIMAT0014979	hsa-miR-3117-3p	6.74	4.52e-11	0.3	0.3	Presence of antiphospholipid antibodies;	chr1:66729509	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6697088	MIMAT0014979	hsa-miR-3117-3p	6.74	4.55e-11	0.3	0.3	Presence of antiphospholipid antibodies;	chr1:66579041	chr1:66628485~66628505:+
LGG	cis	rs6681460	1	rs6696927	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.63e-11	-0.3	-0.3	Presence of antiphospholipid antibodies;	chr1:66604698	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs6058193	MIMAT0004772	hsa-miR-499a-3p	-6.74	4.65e-11	-0.38	-0.3	Protein C levels;	chr20:35146661	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.634	rs4142763	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.69e-11	-0.32	-0.3	Presence of antiphospholipid antibodies;	chr1:66532353	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs6060270	MIMAT0004772	hsa-miR-499a-3p	-6.73	4.78e-11	-0.38	-0.3	Protein C levels;	chr20:35149011	chr20:34990445~34990466:+
LGG	cis	rs4917385	1	rs4917385	MIMAT0005951	hsa-miR-1307-3p	6.73	4.89e-11	0.19	0.3	Systemic lupus erythematosus;	chr10:103243964	chr10:103394301~103394322:-
LGG	cis	rs6120849	0.901	rs6060278	MIMAT0004772	hsa-miR-499a-3p	-6.73	5.02e-11	-0.37	-0.29	Protein C levels;	chr20:35165459	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.802	rs6087681	MIMAT0004772	hsa-miR-499a-3p	-6.72	5.2e-11	-0.37	-0.29	Protein C levels;	chr20:35165093	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.802	rs6087682	MIMAT0004772	hsa-miR-499a-3p	-6.72	5.2e-11	-0.37	-0.29	Protein C levels;	chr20:35165094	chr20:34990445~34990466:+
LGG	cis	rs10021731	0.83	rs1460784	MIMAT0003242	hsa-miR-577	6.7	5.73e-11	0.25	0.29	Optic disc area;	chr4:114541947	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.966	rs4655506	MIMAT0014979	hsa-miR-3117-3p	-6.68	6.61e-11	-0.3	-0.29	Presence of antiphospholipid antibodies;	chr1:66685128	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.934	rs4655635	MIMAT0014979	hsa-miR-3117-3p	-6.68	6.7e-11	-0.29	-0.29	Presence of antiphospholipid antibodies;	chr1:66602557	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs11696967	MIMAT0004772	hsa-miR-499a-3p	-6.67	7e-11	-0.37	-0.29	Protein C levels;	chr20:35155806	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.8	rs481681	MIMAT0014979	hsa-miR-3117-3p	6.67	7.01e-11	0.29	0.29	Presence of antiphospholipid antibodies;	chr1:66728695	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs6060273	MIMAT0004772	hsa-miR-499a-3p	-6.67	7.35e-11	-0.36	-0.29	Protein C levels;	chr20:35156520	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.524	rs1712509	MIMAT0022727	hsa-miR-1307-5p	-6.65	8.19e-11	-0.21	-0.29	Migraine;	chr10:103254113	chr10:103394341~103394361:-
LGG	cis	rs6120849	0.901	rs6088733	MIMAT0004772	hsa-miR-499a-3p	-6.65	8.2e-11	-0.37	-0.29	Protein C levels;	chr20:35157101	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.901	rs1373911	MIMAT0014979	hsa-miR-3117-3p	-6.62	9.78e-11	-0.3	-0.29	Presence of antiphospholipid antibodies;	chr1:66575382	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs13037296	MIMAT0004772	hsa-miR-499a-3p	-6.61	1.03e-10	-0.36	-0.29	Protein C levels;	chr20:35161425	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.634	rs12143964	MIMAT0014979	hsa-miR-3117-3p	-6.6	1.08e-10	-0.29	-0.29	Presence of antiphospholipid antibodies;	chr1:66544583	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.851	rs13040631	MIMAT0004772	hsa-miR-499a-3p	-6.56	1.37e-10	-0.36	-0.29	Protein C levels;	chr20:35159911	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.901	rs6088735	MIMAT0004772	hsa-miR-499a-3p	-6.56	1.38e-10	-0.36	-0.29	Protein C levels;	chr20:35157873	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.901	rs6088737	MIMAT0004772	hsa-miR-499a-3p	-6.56	1.38e-10	-0.36	-0.29	Protein C levels;	chr20:35158135	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.525	rs7911488	MIMAT0022727	hsa-miR-1307-5p	-6.56	1.39e-10	-0.2	-0.29	Migraine;	chr10:103394332	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.526	rs113528138	MIMAT0022727	hsa-miR-1307-5p	-6.56	1.39e-10	-0.2	-0.29	Migraine;	chr10:103365694	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.525	rs11191667	MIMAT0022727	hsa-miR-1307-5p	-6.56	1.39e-10	-0.2	-0.29	Migraine;	chr10:103369141	chr10:103394341~103394361:-
LGG	cis	rs6120849	0.901	rs6088739	MIMAT0004772	hsa-miR-499a-3p	-6.55	1.49e-10	-0.36	-0.29	Protein C levels;	chr20:35160921	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.566	rs7076274	MIMAT0022727	hsa-miR-1307-5p	-6.53	1.72e-10	-0.2	-0.29	Migraine;	chr10:103286250	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.545	rs3740381	MIMAT0022727	hsa-miR-1307-5p	-6.53	1.72e-10	-0.2	-0.29	Migraine;	chr10:103286932	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.566	rs7917388	MIMAT0022727	hsa-miR-1307-5p	-6.53	1.72e-10	-0.2	-0.29	Migraine;	chr10:103295206	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.525	rs11191642	MIMAT0022727	hsa-miR-1307-5p	-6.53	1.72e-10	-0.2	-0.29	Migraine;	chr10:103296155	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.588	rs12220267	MIMAT0022727	hsa-miR-1307-5p	-6.53	1.72e-10	-0.2	-0.29	Migraine;	chr10:103315955	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.649	rs7540195	MIMAT0014979	hsa-miR-3117-3p	6.48	2.36e-10	0.32	0.28	Presence of antiphospholipid antibodies;	chr1:66536723	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.932	rs524114	MIMAT0014979	hsa-miR-3117-3p	6.47	2.41e-10	0.3	0.28	Presence of antiphospholipid antibodies;	chr1:66722652	chr1:66628485~66628505:+
LGG	cis	rs1163656	0.534	rs12311427	MIMAT0003287	hsa-miR-618	-6.44	2.96e-10	-0.36	-0.28	Dental caries;	chr12:80934053	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.576	rs7354930	MIMAT0014979	hsa-miR-3117-3p	-6.44	2.99e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66520694	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.576	rs1338194	MIMAT0014979	hsa-miR-3117-3p	-6.44	2.99e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66520793	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.503	rs72846198	MIMAT0022727	hsa-miR-1307-5p	-6.44	2.99e-10	-0.2	-0.28	Migraine;	chr10:103338267	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.566	rs1163073	MIMAT0022727	hsa-miR-1307-5p	6.43	3.16e-10	0.2	0.28	Migraine;	chr10:103263177	chr10:103394341~103394361:-
LGG	cis	rs1163656	0.572	rs1402349	MIMAT0003287	hsa-miR-618	-6.42	3.26e-10	-0.36	-0.28	Dental caries;	chr12:80919985	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.649	rs4655494	MIMAT0014979	hsa-miR-3117-3p	-6.42	3.39e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66537193	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.725	rs1460770	MIMAT0003242	hsa-miR-577	-6.4	3.66e-10	-0.23	-0.28	Optic disc area;	chr4:114484189	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.649	rs967322	MIMAT0014979	hsa-miR-3117-3p	-6.4	3.77e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66537763	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.725	rs72676244	MIMAT0003242	hsa-miR-577	6.38	4.11e-10	0.23	0.28	Optic disc area;	chr4:114479168	chr4:114656774~114656794:+
LGG	cis	rs1163656	0.572	rs7303026	MIMAT0003287	hsa-miR-618	-6.38	4.17e-10	-0.35	-0.28	Dental caries;	chr12:80921967	chr12:80935796~80935818:-
LGG	cis	rs1163656	0.572	rs7134652	MIMAT0003287	hsa-miR-618	-6.38	4.17e-10	-0.35	-0.28	Dental caries;	chr12:80922054	chr12:80935796~80935818:-
LGG	cis	rs1163656	0.572	rs7134827	MIMAT0003287	hsa-miR-618	-6.38	4.17e-10	-0.35	-0.28	Dental caries;	chr12:80922229	chr12:80935796~80935818:-
LGG	cis	rs6681460	0.576	rs7355221	MIMAT0014979	hsa-miR-3117-3p	-6.38	4.23e-10	-0.29	-0.28	Presence of antiphospholipid antibodies;	chr1:66520618	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.934	rs4655631	MIMAT0014979	hsa-miR-3117-3p	-6.37	4.36e-10	-0.28	-0.28	Presence of antiphospholipid antibodies;	chr1:66589224	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.901	rs6088738	MIMAT0004772	hsa-miR-499a-3p	6.37	4.58e-10	0.36	0.28	Protein C levels;	chr20:35159528	chr20:34990445~34990466:+
LGG	cis	rs6120849	0.662	rs6060300	MIMAT0004772	hsa-miR-499a-3p	-6.35	4.96e-10	-0.38	-0.28	Protein C levels;	chr20:35193167	chr20:34990445~34990466:+
LGG	cis	rs1163656	0.572	rs1402348	MIMAT0003287	hsa-miR-618	-6.35	5.09e-10	-0.35	-0.28	Dental caries;	chr12:80919695	chr12:80935796~80935818:-
LGG	cis	rs10021731	0.725	rs7674990	MIMAT0003242	hsa-miR-577	6.34	5.38e-10	0.23	0.28	Optic disc area;	chr4:114506467	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs11931563	MIMAT0003242	hsa-miR-577	6.32	6.17e-10	0.23	0.28	Optic disc area;	chr4:114496527	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.576	rs7354983	MIMAT0014979	hsa-miR-3117-3p	-6.31	6.23e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66522466	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.898	rs2483704	MIMAT0014979	hsa-miR-3117-3p	6.29	7.39e-10	0.29	0.28	Presence of antiphospholipid antibodies;	chr1:66729670	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.95	rs6088732	MIMAT0004772	hsa-miR-499a-3p	6.26	8.63e-10	0.35	0.28	Protein C levels;	chr20:35156331	chr20:34990445~34990466:+
LGG	cis	rs10021731	0.725	rs12502750	MIMAT0003242	hsa-miR-577	6.24	9.46e-10	0.22	0.28	Optic disc area;	chr4:114499194	chr4:114656774~114656794:+
LGG	cis	rs6681460	1	rs6656912	MIMAT0014979	hsa-miR-3117-3p	-6.24	9.86e-10	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66617988	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.725	rs922199	MIMAT0003242	hsa-miR-577	-6.24	9.94e-10	-0.23	-0.28	Optic disc area;	chr4:114485362	chr4:114656774~114656794:+
LGG	cis	rs10454142	0.664	rs72820499	MIMAT0031175	hsa-miR-548ba	-6.23	1.05e-09	-0.34	-0.27	Sex hormone-binding globulin levels;	chr2:48435941	chr2:49059603~49059624:+
LGG	cis	rs6681460	0.576	rs1338200	MIMAT0014979	hsa-miR-3117-3p	-6.21	1.13e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66526514	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.691	rs6849064	MIMAT0003242	hsa-miR-577	-6.21	1.16e-09	-0.22	-0.27	Optic disc area;	chr4:114483807	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs36096691	MIMAT0003242	hsa-miR-577	6.2	1.2e-09	0.22	0.27	Optic disc area;	chr4:114509770	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.649	rs10889625	MIMAT0014979	hsa-miR-3117-3p	-6.2	1.21e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66541552	chr1:66628485~66628505:+
LGG	cis	rs7072216	0.655	rs3830025	MIMAT0005878	hsa-miR-1287-5p	6.2	1.26e-09	0.18	0.27	Metabolite levels;	chr10:98416347	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.655	rs3830024	MIMAT0005878	hsa-miR-1287-5p	6.2	1.26e-09	0.18	0.27	Metabolite levels;	chr10:98416349	chr10:98395271~98395292:-
LGG	cis	rs10021731	0.725	rs66806558	MIMAT0003242	hsa-miR-577	6.18	1.4e-09	0.22	0.27	Optic disc area;	chr4:114515499	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs62309917	MIMAT0003242	hsa-miR-577	6.18	1.4e-09	0.22	0.27	Optic disc area;	chr4:114522432	chr4:114656774~114656794:+
LGG	cis	rs1163656	0.605	rs7487519	MIMAT0003287	hsa-miR-618	-6.17	1.45e-09	-0.34	-0.27	Dental caries;	chr12:80921469	chr12:80935796~80935818:-
LGG	cis	rs10021731	0.725	rs12641633	MIMAT0003242	hsa-miR-577	6.16	1.52e-09	0.22	0.27	Optic disc area;	chr4:114488186	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs4833457	MIMAT0003242	hsa-miR-577	6.16	1.52e-09	0.22	0.27	Optic disc area;	chr4:114490891	chr4:114656774~114656794:+
LGG	cis	rs7072216	0.763	rs7914401	MIMAT0005878	hsa-miR-1287-5p	6.16	1.55e-09	0.17	0.27	Metabolite levels;	chr10:98404171	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.844	rs1163087	MIMAT0005951	hsa-miR-1307-3p	-6.16	1.56e-09	-0.16	-0.27	Migraine;	chr10:103283532	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.787	rs1163089	MIMAT0005951	hsa-miR-1307-3p	-6.16	1.56e-09	-0.16	-0.27	Migraine;	chr10:103284207	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.844	rs4918003	MIMAT0022727	hsa-miR-1307-5p	-6.16	1.59e-09	-0.17	-0.27	Migraine;	chr10:103284400	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.838	rs6584543	MIMAT0022727	hsa-miR-1307-5p	6.15	1.66e-09	0.17	0.27	Migraine;	chr10:103237257	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.649	rs1415974	MIMAT0014979	hsa-miR-3117-3p	6.14	1.7e-09	0.27	0.27	Presence of antiphospholipid antibodies;	chr1:66539820	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.691	rs7654273	MIMAT0003242	hsa-miR-577	-6.13	1.81e-09	-0.22	-0.27	Optic disc area;	chr4:114501231	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs6839138	MIMAT0003242	hsa-miR-577	-6.13	1.81e-09	-0.22	-0.27	Optic disc area;	chr4:114501793	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs13103303	MIMAT0003242	hsa-miR-577	6.13	1.85e-09	0.22	0.27	Optic disc area;	chr4:114532477	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs13103327	MIMAT0003242	hsa-miR-577	6.13	1.85e-09	0.22	0.27	Optic disc area;	chr4:114532551	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs12503513	MIMAT0003242	hsa-miR-577	6.13	1.85e-09	0.22	0.27	Optic disc area;	chr4:114534996	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs7667556	MIMAT0003242	hsa-miR-577	6.13	1.85e-09	0.22	0.27	Optic disc area;	chr4:114535359	chr4:114656774~114656794:+
LGG	cis	rs1712517	1	rs3123794	MIMAT0022727	hsa-miR-1307-5p	-6.13	1.89e-09	-0.17	-0.27	Migraine;	chr10:103273985	chr10:103394341~103394361:-
LGG	cis	rs10021731	0.725	rs6850121	MIMAT0003242	hsa-miR-577	-6.12	2e-09	-0.22	-0.27	Optic disc area;	chr4:114484294	chr4:114656774~114656794:+
LGG	cis	rs1163656	0.592	rs1795514	MIMAT0003287	hsa-miR-618	6.11	2.02e-09	0.48	0.27	Dental caries;	chr12:80939088	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.726	rs4474372	MIMAT0005878	hsa-miR-1287-5p	6.11	2.08e-09	0.17	0.27	Metabolite levels;	chr10:98404814	chr10:98395271~98395292:-
LGG	cis	rs10021731	0.659	rs28564476	MIMAT0003242	hsa-miR-577	-6.1	2.15e-09	-0.22	-0.27	Optic disc area;	chr4:114484592	chr4:114656774~114656794:+
LGG	cis	rs1712517	1	rs1163084	MIMAT0022727	hsa-miR-1307-5p	-6.1	2.16e-09	-0.17	-0.27	Migraine;	chr10:103279291	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.576	rs2859914	MIMAT0014979	hsa-miR-3117-3p	-6.1	2.18e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66524157	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.576	rs6588203	MIMAT0014979	hsa-miR-3117-3p	-6.09	2.29e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66525168	chr1:66628485~66628505:+
LGG	cis	rs7072216	0.763	rs733345	MIMAT0005878	hsa-miR-1287-5p	6.08	2.54e-09	0.17	0.27	Metabolite levels;	chr10:98404458	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs733346	MIMAT0005878	hsa-miR-1287-5p	6.08	2.54e-09	0.17	0.27	Metabolite levels;	chr10:98404568	chr10:98395271~98395292:-
LGG	cis	rs1712517	1	rs1712517	MIMAT0022727	hsa-miR-1307-5p	-6.08	2.54e-09	-0.17	-0.27	Migraine;	chr10:103273258	chr10:103394341~103394361:-
LGG	cis	rs10021731	0.725	rs6839694	MIMAT0003242	hsa-miR-577	-6.07	2.65e-09	-0.22	-0.27	Optic disc area;	chr4:114502041	chr4:114656774~114656794:+
LGG	cis	rs1712517	0.873	rs7913461	MIMAT0022727	hsa-miR-1307-5p	-6.06	2.71e-09	-0.17	-0.27	Migraine;	chr10:103241568	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.535	rs6588204	MIMAT0014979	hsa-miR-3117-3p	-6.06	2.72e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66525325	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.691	rs10015704	MIMAT0003242	hsa-miR-577	-6.06	2.73e-09	-0.22	-0.27	Optic disc area;	chr4:114507972	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs7665770	MIMAT0003242	hsa-miR-577	-6.06	2.73e-09	-0.22	-0.27	Optic disc area;	chr4:114508383	chr4:114656774~114656794:+
LGG	cis	rs6681460	0.649	rs1856315	MIMAT0014979	hsa-miR-3117-3p	-6.04	3.18e-09	-0.27	-0.27	Presence of antiphospholipid antibodies;	chr1:66539546	chr1:66628485~66628505:+
LGG	cis	rs6681460	0.649	rs1947083	MIMAT0014979	hsa-miR-3117-3p	-6.03	3.28e-09	-0.27	-0.27	Presence of antiphospholipid antibodies;	chr1:66539118	chr1:66628485~66628505:+
LGG	cis	rs6120849	0.707	rs3746448	MIMAT0004772	hsa-miR-499a-3p	-6.02	3.42e-09	-0.41	-0.27	Protein C levels;	chr20:34985176	chr20:34990445~34990466:+
LGG	cis	rs6681460	0.608	rs10889624	MIMAT0014979	hsa-miR-3117-3p	-6.02	3.44e-09	-0.27	-0.27	Presence of antiphospholipid antibodies;	chr1:66540124	chr1:66628485~66628505:+
LGG	cis	rs1163656	0.536	rs7306751	MIMAT0003287	hsa-miR-618	-6.02	3.47e-09	-0.37	-0.27	Dental caries;	chr12:80922459	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.763	rs4475861	MIMAT0005878	hsa-miR-1287-5p	6.02	3.53e-09	0.16	0.27	Metabolite levels;	chr10:98405232	chr10:98395271~98395292:-
LGG	cis	rs6681460	0.649	rs1415984	MIMAT0014979	hsa-miR-3117-3p	-6.02	3.55e-09	-0.31	-0.27	Presence of antiphospholipid antibodies;	chr1:66536434	chr1:66628485~66628505:+
LGG	cis	rs10021731	0.628	rs6533791	MIMAT0003242	hsa-miR-577	-6.02	3.56e-09	-0.22	-0.27	Optic disc area;	chr4:114491869	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.691	rs2126027	MIMAT0003242	hsa-miR-577	-6.02	3.59e-09	-0.22	-0.27	Optic disc area;	chr4:114533510	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.725	rs2126026	MIMAT0003242	hsa-miR-577	-6.02	3.59e-09	-0.22	-0.27	Optic disc area;	chr4:114533531	chr4:114656774~114656794:+
LGG	cis	rs6120849	0.573	rs3746429	MIMAT0004772	hsa-miR-499a-3p	6.01	3.63e-09	0.41	0.27	Protein C levels;	chr20:35115804	chr20:34990445~34990466:+
LGG	cis	rs1712517	0.835	rs2506961	MIMAT0022727	hsa-miR-1307-5p	6.01	3.73e-09	0.17	0.27	Migraine;	chr10:103248169	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs1712510	MIMAT0022727	hsa-miR-1307-5p	6.01	3.73e-09	0.17	0.27	Migraine;	chr10:103249329	chr10:103394341~103394361:-
LGG	cis	rs10021731	0.725	rs1551742	MIMAT0003242	hsa-miR-577	5.99	4.14e-09	0.22	0.27	Optic disc area;	chr4:114485894	chr4:114656774~114656794:+
LGG	cis	rs10021731	0.659	rs13105730	MIMAT0003242	hsa-miR-577	-5.98	4.36e-09	-0.21	-0.26	Optic disc area;	chr4:114490021	chr4:114656774~114656794:+
LGG	cis	rs7072216	0.763	rs12259939	MIMAT0005878	hsa-miR-1287-5p	5.98	4.37e-09	0.16	0.26	Metabolite levels;	chr10:98409264	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs9787550	MIMAT0005878	hsa-miR-1287-5p	5.98	4.37e-09	0.16	0.26	Metabolite levels;	chr10:98409294	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.873	rs1712516	MIMAT0005951	hsa-miR-1307-3p	-5.97	4.57e-09	-0.16	-0.26	Migraine;	chr10:103273871	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.873	rs7916056	MIMAT0022727	hsa-miR-1307-5p	5.97	4.59e-09	0.17	0.26	Migraine;	chr10:103238157	chr10:103394341~103394361:-
LGG	cis	rs6681460	0.649	rs1338184	MIMAT0014979	hsa-miR-3117-3p	5.97	4.71e-09	0.26	0.26	Presence of antiphospholipid antibodies;	chr1:66539389	chr1:66628485~66628505:+
LGG	cis	rs1712517	0.904	rs10883863	MIMAT0022727	hsa-miR-1307-5p	5.96	4.97e-09	0.17	0.26	Migraine;	chr10:103402122	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs1163083	MIMAT0022727	hsa-miR-1307-5p	-5.95	5.16e-09	-0.17	-0.26	Migraine;	chr10:103278698	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs1163086	MIMAT0005951	hsa-miR-1307-3p	-5.94	5.55e-09	-0.16	-0.26	Migraine;	chr10:103279822	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.844	rs1163081	MIMAT0005951	hsa-miR-1307-3p	-5.93	5.71e-09	-0.16	-0.26	Migraine;	chr10:103270083	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs1061437	MIMAT0005878	hsa-miR-1287-5p	5.92	6.21e-09	0.16	0.26	Metabolite levels;	chr10:98416397	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs942804	MIMAT0005878	hsa-miR-1287-5p	5.91	6.59e-09	0.16	0.26	Metabolite levels;	chr10:98408742	chr10:98395271~98395292:-
LGG	cis	rs1163656	0.527	rs1402347	MIMAT0003287	hsa-miR-618	5.9	6.76e-09	0.48	0.26	Dental caries;	chr12:80913217	chr12:80935796~80935818:-
LGG	cis	rs1712517	0.873	rs7894240	MIMAT0022727	hsa-miR-1307-5p	5.9	6.94e-09	0.17	0.26	Migraine;	chr10:103240612	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.691	rs7910973	MIMAT0005878	hsa-miR-1287-5p	5.89	7.19e-09	0.16	0.26	Metabolite levels;	chr10:98406975	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.844	rs1163074	MIMAT0022727	hsa-miR-1307-5p	-5.89	7.44e-09	-0.17	-0.26	Migraine;	chr10:103262005	chr10:103394341~103394361:-
LGG	cis	rs1163656	0.559	rs17007699	MIMAT0003287	hsa-miR-618	-5.88	7.69e-09	-0.52	-0.26	Dental caries;	chr12:80930007	chr12:80935796~80935818:-
LGG	cis	rs1712517	0.844	rs1163075	MIMAT0022727	hsa-miR-1307-5p	5.87	7.99e-09	0.17	0.26	Migraine;	chr10:103261506	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs10732782	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98406749	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs7911036	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98407258	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs45523432	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98407679	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs12763044	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98407694	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs942808	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98408345	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs942807	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98408462	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs942803	MIMAT0005878	hsa-miR-1287-5p	5.87	8.06e-09	0.16	0.26	Metabolite levels;	chr10:98408874	chr10:98395271~98395292:-
LGG	cis	rs1163656	0.559	rs17007693	MIMAT0003287	hsa-miR-618	-5.86	8.7e-09	-0.51	-0.26	Dental caries;	chr12:80925305	chr12:80935796~80935818:-
LGG	cis	rs1712517	0.904	rs4918007	MIMAT0022727	hsa-miR-1307-5p	5.86	8.74e-09	0.16	0.26	Migraine;	chr10:103347713	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs10883090	MIMAT0005878	hsa-miR-1287-5p	5.85	9.14e-09	0.16	0.26	Metabolite levels;	chr10:98407479	chr10:98395271~98395292:-
LGG	cis	rs736408	0.812	rs2071508	MIMAT0000414	hsa-let-7g-5p	-5.85	9.28e-09	-0.18	-0.26	Bipolar disorder;	chr3:52792830	chr3:52268336~52268357:-
LGG	cis	rs9982086	0.557	rs9978876	MIMAT0000646	hsa-miR-155-5p	5.84	9.46e-09	0.39	0.26	Carboplatin disposition in epthelial ovarian cancer;	chr21:25454393	chr21:25573983~25574006:+
LGG	cis	rs1163656	0.559	rs7136415	MIMAT0003287	hsa-miR-618	-5.84	9.64e-09	-0.5	-0.26	Dental caries;	chr12:80915511	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.763	rs942805	MIMAT0005878	hsa-miR-1287-5p	5.84	9.83e-09	0.16	0.26	Metabolite levels;	chr10:98408615	chr10:98395271~98395292:-
LGG	cis	rs1163656	0.559	rs1163657	MIMAT0003287	hsa-miR-618	5.83	1.05e-08	0.49	0.26	Dental caries;	chr12:80943890	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.763	rs10748729	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411614	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs10748730	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411683	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs3814140	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411005	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs3814142	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411347	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.691	rs3829853	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411417	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs10748728	MIMAT0005878	hsa-miR-1287-5p	5.81	1.14e-08	0.16	0.26	Metabolite levels;	chr10:98411441	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.844	rs1163087	MIMAT0022727	hsa-miR-1307-5p	-5.8	1.2e-08	-0.17	-0.26	Migraine;	chr10:103283532	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.787	rs1163089	MIMAT0022727	hsa-miR-1307-5p	-5.8	1.2e-08	-0.17	-0.26	Migraine;	chr10:103284207	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs7910014	MIMAT0005878	hsa-miR-1287-5p	5.8	1.24e-08	0.16	0.26	Metabolite levels;	chr10:98412353	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs7910247	MIMAT0005878	hsa-miR-1287-5p	5.8	1.24e-08	0.16	0.26	Metabolite levels;	chr10:98412495	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs7913541	MIMAT0005878	hsa-miR-1287-5p	5.8	1.24e-08	0.16	0.26	Metabolite levels;	chr10:98412722	chr10:98395271~98395292:-
LGG	cis	rs9982086	0.557	rs9305252	MIMAT0000646	hsa-miR-155-5p	-5.78	1.34e-08	-0.39	-0.26	Carboplatin disposition in epthelial ovarian cancer;	chr21:25454038	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.557	rs7280875	MIMAT0000646	hsa-miR-155-5p	-5.78	1.34e-08	-0.39	-0.26	Carboplatin disposition in epthelial ovarian cancer;	chr21:25455292	chr21:25573983~25574006:+
LGG	cis	rs1712517	0.844	rs1163074	MIMAT0005951	hsa-miR-1307-3p	-5.78	1.39e-08	-0.15	-0.26	Migraine;	chr10:103262005	chr10:103394301~103394322:-
LGG	cis	rs1163656	0.536	rs4261347	MIMAT0003287	hsa-miR-618	-5.77	1.43e-08	-0.36	-0.26	Dental caries;	chr12:80921546	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.806	rs9804285	MIMAT0005878	hsa-miR-1287-5p	5.76	1.51e-08	0.16	0.26	Metabolite levels;	chr10:98409715	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.873	rs7903004	MIMAT0022727	hsa-miR-1307-5p	5.75	1.57e-08	0.16	0.26	Migraine;	chr10:103244344	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.838	rs1891293	MIMAT0022727	hsa-miR-1307-5p	5.75	1.6e-08	0.17	0.26	Migraine;	chr10:103242040	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs1891292	MIMAT0022727	hsa-miR-1307-5p	5.75	1.63e-08	0.16	0.25	Migraine;	chr10:103241753	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs7923729	MIMAT0005878	hsa-miR-1287-5p	5.74	1.66e-08	0.16	0.25	Metabolite levels;	chr10:98409708	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs6584198	MIMAT0005878	hsa-miR-1287-5p	5.74	1.66e-08	0.16	0.25	Metabolite levels;	chr10:98410149	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs6584199	MIMAT0005878	hsa-miR-1287-5p	5.74	1.66e-08	0.16	0.25	Metabolite levels;	chr10:98410226	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs6584201	MIMAT0005878	hsa-miR-1287-5p	5.74	1.66e-08	0.16	0.25	Metabolite levels;	chr10:98410452	chr10:98395271~98395292:-
LGG	cis	rs1163656	0.559	rs12228291	MIMAT0003287	hsa-miR-618	-5.74	1.68e-08	-0.5	-0.25	Dental caries;	chr12:80918034	chr12:80935796~80935818:-
LGG	cis	rs1712517	0.844	rs1163075	MIMAT0005951	hsa-miR-1307-3p	5.74	1.69e-08	0.15	0.25	Migraine;	chr10:103261506	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs6584200	MIMAT0005878	hsa-miR-1287-5p	5.74	1.73e-08	0.16	0.25	Metabolite levels;	chr10:98410280	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs12763326	MIMAT0005878	hsa-miR-1287-5p	-5.73	1.75e-08	-0.16	-0.25	Metabolite levels;	chr10:98407639	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs3750601	MIMAT0005878	hsa-miR-1287-5p	5.73	1.77e-08	0.16	0.25	Metabolite levels;	chr10:98414804	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs2147900	MIMAT0005878	hsa-miR-1287-5p	5.73	1.77e-08	0.16	0.25	Metabolite levels;	chr10:98414964	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs10736129	MIMAT0005878	hsa-miR-1287-5p	-5.73	1.78e-08	-0.16	-0.25	Metabolite levels;	chr10:98411814	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs6584205	MIMAT0005878	hsa-miR-1287-5p	5.72	1.9e-08	0.16	0.25	Metabolite levels;	chr10:98414049	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs2274246	MIMAT0005878	hsa-miR-1287-5p	5.72	1.9e-08	0.16	0.25	Metabolite levels;	chr10:98415303	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs2274245	MIMAT0005878	hsa-miR-1287-5p	5.72	1.9e-08	0.16	0.25	Metabolite levels;	chr10:98415325	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs2274244	MIMAT0005878	hsa-miR-1287-5p	5.72	1.9e-08	0.16	0.25	Metabolite levels;	chr10:98415461	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.763	rs6584204	MIMAT0005878	hsa-miR-1287-5p	5.69	2.25e-08	0.16	0.25	Metabolite levels;	chr10:98413823	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.844	rs4918003	MIMAT0005951	hsa-miR-1307-3p	-5.68	2.34e-08	-0.15	-0.25	Migraine;	chr10:103284400	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.844	rs1163081	MIMAT0022727	hsa-miR-1307-5p	-5.67	2.46e-08	-0.16	-0.25	Migraine;	chr10:103270083	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs2274243	MIMAT0005878	hsa-miR-1287-5p	5.64	2.85e-08	0.16	0.25	Metabolite levels;	chr10:98415510	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.873	rs1163083	MIMAT0005951	hsa-miR-1307-3p	-5.63	3.16e-08	-0.15	-0.25	Migraine;	chr10:103278698	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.74	rs4917387	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.19e-08	-0.15	-0.25	Migraine;	chr10:103348698	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs7921655	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.19e-08	-0.15	-0.25	Migraine;	chr10:103353944	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs7074749	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.19e-08	-0.15	-0.25	Migraine;	chr10:103356299	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.74	rs11191663	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.19e-08	-0.15	-0.25	Migraine;	chr10:103358705	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191664	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.19e-08	-0.15	-0.25	Migraine;	chr10:103358719	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191676	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.33e-08	-0.15	-0.25	Migraine;	chr10:103395309	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs2292807	MIMAT0005951	hsa-miR-1307-3p	-5.62	3.33e-08	-0.15	-0.25	Migraine;	chr10:103395888	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191672	MIMAT0005951	hsa-miR-1307-3p	-5.61	3.37e-08	-0.15	-0.25	Migraine;	chr10:103379204	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.69	rs113195335	MIMAT0005878	hsa-miR-1287-5p	5.61	3.47e-08	0.16	0.25	Metabolite levels;	chr10:98415775	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs3750603	MIMAT0005878	hsa-miR-1287-5p	5.61	3.47e-08	0.16	0.25	Metabolite levels;	chr10:98415779	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.771	rs2008530	MIMAT0005951	hsa-miR-1307-3p	-5.59	3.76e-08	-0.15	-0.25	Migraine;	chr10:103299082	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.873	rs1163086	MIMAT0022727	hsa-miR-1307-5p	-5.59	3.79e-08	-0.16	-0.25	Migraine;	chr10:103279822	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs1712516	MIMAT0022727	hsa-miR-1307-5p	-5.58	3.94e-08	-0.16	-0.25	Migraine;	chr10:103273871	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.773	rs1063461	MIMAT0005951	hsa-miR-1307-3p	-5.55	4.75e-08	-0.15	-0.25	Migraine;	chr10:103289348	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.74	rs4293062	MIMAT0005951	hsa-miR-1307-3p	-5.55	4.75e-08	-0.15	-0.25	Migraine;	chr10:103292867	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.744	rs11191641	MIMAT0005951	hsa-miR-1307-3p	-5.55	4.75e-08	-0.15	-0.25	Migraine;	chr10:103293183	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.744	rs4293063	MIMAT0005951	hsa-miR-1307-3p	-5.55	4.75e-08	-0.15	-0.25	Migraine;	chr10:103293219	chr10:103394301~103394322:-
LGG	cis	rs1163656	0.605	rs10778771	MIMAT0003287	hsa-miR-618	-5.52	5.65e-08	-0.37	-0.25	Dental caries;	chr12:80924235	chr12:80935796~80935818:-
LGG	cis	rs1712517	0.771	rs11191672	MIMAT0022727	hsa-miR-1307-5p	-5.52	5.68e-08	-0.16	-0.25	Migraine;	chr10:103379204	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs11191666	MIMAT0005951	hsa-miR-1307-3p	-5.51	5.8e-08	-0.15	-0.25	Migraine;	chr10:103367521	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs10883858	MIMAT0005951	hsa-miR-1307-3p	-5.51	5.8e-08	-0.15	-0.25	Migraine;	chr10:103367951	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.873	rs7916056	MIMAT0005951	hsa-miR-1307-3p	5.51	5.94e-08	0.15	0.25	Migraine;	chr10:103238157	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.904	rs10883863	MIMAT0005951	hsa-miR-1307-3p	5.5	6.16e-08	0.14	0.24	Migraine;	chr10:103402122	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs61871160	MIMAT0005951	hsa-miR-1307-3p	-5.5	6.27e-08	-0.15	-0.24	Migraine;	chr10:103384531	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs59744322	MIMAT0005951	hsa-miR-1307-3p	-5.5	6.27e-08	-0.15	-0.24	Migraine;	chr10:103386935	chr10:103394301~103394322:-
LGG	cis	rs9982086	0.557	rs9975439	MIMAT0000646	hsa-miR-155-5p	-5.5	6.32e-08	-0.37	-0.24	Carboplatin disposition in epthelial ovarian cancer;	chr21:25453762	chr21:25573983~25574006:+
LGG	cis	rs1712517	1	rs3123794	MIMAT0005951	hsa-miR-1307-3p	-5.49	6.66e-08	-0.14	-0.24	Migraine;	chr10:103273985	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191676	MIMAT0022727	hsa-miR-1307-5p	-5.48	7.1e-08	-0.16	-0.24	Migraine;	chr10:103395309	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs2292807	MIMAT0022727	hsa-miR-1307-5p	-5.48	7.1e-08	-0.16	-0.24	Migraine;	chr10:103395888	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs7903004	MIMAT0005951	hsa-miR-1307-3p	5.47	7.23e-08	0.15	0.24	Migraine;	chr10:103244344	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.904	rs6584547	MIMAT0022727	hsa-miR-1307-5p	-5.46	7.7e-08	-0.15	-0.24	Migraine;	chr10:103305652	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.836	rs11191649	MIMAT0022727	hsa-miR-1307-5p	-5.45	8.2e-08	-0.15	-0.24	Migraine;	chr10:103307280	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.904	rs7905968	MIMAT0022727	hsa-miR-1307-5p	-5.45	8.24e-08	-0.15	-0.24	Migraine;	chr10:103375562	chr10:103394341~103394361:-
LGG	cis	rs75358501	0.636	rs12473690	MIMAT0014995	hsa-miR-3130-5p	5.44	8.38e-08	0.27	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206734939	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.636	rs12473690	MIMAT0014995_1	hsa-miR-3130-5p	5.44	8.38e-08	0.27	0.24	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206734939	chr2:206783246~206783266:+
LGG	cis	rs7072216	0.763	rs2147901	MIMAT0005878	hsa-miR-1287-5p	-5.44	8.56e-08	-0.15	-0.24	Metabolite levels;	chr10:98405739	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.771	rs11191666	MIMAT0022727	hsa-miR-1307-5p	-5.44	8.67e-08	-0.16	-0.24	Migraine;	chr10:103367521	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs10883858	MIMAT0022727	hsa-miR-1307-5p	-5.44	8.67e-08	-0.16	-0.24	Migraine;	chr10:103367951	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.873	rs7894240	MIMAT0005951	hsa-miR-1307-3p	5.42	9.27e-08	0.14	0.24	Migraine;	chr10:103240612	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs10883092	MIMAT0005878	hsa-miR-1287-5p	5.42	9.29e-08	0.15	0.24	Metabolite levels;	chr10:98407519	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.873	rs1891292	MIMAT0005951	hsa-miR-1307-3p	5.42	9.37e-08	0.14	0.24	Migraine;	chr10:103241753	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs7909822	MIMAT0005878	hsa-miR-1287-5p	5.42	9.42e-08	0.15	0.24	Metabolite levels;	chr10:98412278	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.74	rs4917387	MIMAT0022727	hsa-miR-1307-5p	-5.42	9.61e-08	-0.16	-0.24	Migraine;	chr10:103348698	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs7921655	MIMAT0022727	hsa-miR-1307-5p	-5.42	9.61e-08	-0.16	-0.24	Migraine;	chr10:103353944	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs7074749	MIMAT0022727	hsa-miR-1307-5p	-5.42	9.61e-08	-0.16	-0.24	Migraine;	chr10:103356299	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.74	rs11191663	MIMAT0022727	hsa-miR-1307-5p	-5.42	9.61e-08	-0.16	-0.24	Migraine;	chr10:103358705	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs11191664	MIMAT0022727	hsa-miR-1307-5p	-5.42	9.61e-08	-0.16	-0.24	Migraine;	chr10:103358719	chr10:103394341~103394361:-
LGG	cis	rs7072216	0.763	rs7091709	MIMAT0005878	hsa-miR-1287-5p	5.41	1.02e-07	0.15	0.24	Metabolite levels;	chr10:98407848	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs942809	MIMAT0005878	hsa-miR-1287-5p	5.41	1.02e-07	0.15	0.24	Metabolite levels;	chr10:98408244	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.904	rs7905968	MIMAT0005951	hsa-miR-1307-3p	-5.41	1.02e-07	-0.14	-0.24	Migraine;	chr10:103375562	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs10883091	MIMAT0005878	hsa-miR-1287-5p	5.4	1.03e-07	0.15	0.24	Metabolite levels;	chr10:98407482	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs7915108	MIMAT0005878	hsa-miR-1287-5p	5.4	1.06e-07	0.15	0.24	Metabolite levels;	chr10:98404684	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.727	rs7901577	MIMAT0005878	hsa-miR-1287-5p	5.4	1.06e-07	0.15	0.24	Metabolite levels;	chr10:98404685	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.836	rs7093039	MIMAT0022727	hsa-miR-1307-5p	-5.4	1.07e-07	-0.15	-0.24	Migraine;	chr10:103389790	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.74	rs11191643	MIMAT0022727	hsa-miR-1307-5p	-5.38	1.16e-07	-0.15	-0.24	Migraine;	chr10:103297804	chr10:103394341~103394361:-
LGG	cis	rs10454142	1	rs10454142	MIMAT0031175	hsa-miR-548ba	-5.38	1.19e-07	-0.31	-0.24	Sex hormone-binding globulin levels;	chr2:48419260	chr2:49059603~49059624:+
LGG	cis	rs10454142	0.961	rs10454143	MIMAT0031175	hsa-miR-548ba	-5.38	1.19e-07	-0.31	-0.24	Sex hormone-binding globulin levels;	chr2:48419261	chr2:49059603~49059624:+
LGG	cis	rs7072216	0.763	rs6584202	MIMAT0005878	hsa-miR-1287-5p	5.37	1.22e-07	0.15	0.24	Metabolite levels;	chr10:98410626	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.836	rs7093039	MIMAT0005951	hsa-miR-1307-3p	-5.36	1.3e-07	-0.14	-0.24	Migraine;	chr10:103389790	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs10883857	MIMAT0005951	hsa-miR-1307-3p	5.35	1.4e-07	0.14	0.24	Migraine;	chr10:103367830	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191645	MIMAT0022727	hsa-miR-1307-5p	-5.34	1.44e-07	-0.15	-0.24	Migraine;	chr10:103299551	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs61350103	MIMAT0022727	hsa-miR-1307-5p	-5.34	1.44e-07	-0.15	-0.24	Migraine;	chr10:103309363	chr10:103394341~103394361:-
LGG	cis	rs7502590	1	rs72854146	MIMAT0015378	hsa-miR-3065-3p	-5.34	1.44e-07	-0.25	-0.24	Neuroticism;	chr17:81104810	chr17:81125926~81125948:+
LGG	cis	rs77637988	0.516	rs55744465	MIMAT0031175	hsa-miR-548ba	-5.33	1.54e-07	-0.3	-0.24	Joint mobility (Beighton score);	chr2:48405316	chr2:49059603~49059624:+
LGG	cis	rs1712517	0.771	rs11191654	MIMAT0022727	hsa-miR-1307-5p	-5.33	1.54e-07	-0.15	-0.24	Migraine;	chr10:103317367	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs61869827	MIMAT0022727	hsa-miR-1307-5p	-5.33	1.54e-07	-0.15	-0.24	Migraine;	chr10:103319682	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs61871160	MIMAT0022727	hsa-miR-1307-5p	-5.28	1.96e-07	-0.15	-0.24	Migraine;	chr10:103384531	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.771	rs59744322	MIMAT0022727	hsa-miR-1307-5p	-5.28	1.96e-07	-0.15	-0.24	Migraine;	chr10:103386935	chr10:103394341~103394361:-
LGG	cis	rs7502590	1	rs7502590	MIMAT0015378	hsa-miR-3065-3p	-5.28	1.97e-07	-0.25	-0.24	Neuroticism;	chr17:81108281	chr17:81125926~81125948:+
LGG	cis	rs1712517	1	rs1712517	MIMAT0005951	hsa-miR-1307-3p	-5.27	2.04e-07	-0.14	-0.24	Migraine;	chr10:103273258	chr10:103394301~103394322:-
LGG	cis	rs10454142	0.807	rs13399936	MIMAT0031175	hsa-miR-548ba	-5.27	2.1e-07	-0.31	-0.23	Sex hormone-binding globulin levels;	chr2:48426987	chr2:49059603~49059624:+
LGG	cis	rs1163656	1	rs1163656	MIMAT0003287	hsa-miR-618	-5.25	2.3e-07	-0.31	-0.23	Dental caries;	chr12:80943679	chr12:80935796~80935818:-
LGG	cis	rs7072216	0.587	rs3814141	MIMAT0005878	hsa-miR-1287-5p	5.23	2.48e-07	0.16	0.23	Metabolite levels;	chr10:98411271	chr10:98395271~98395292:-
LGG	cis	rs10454142	0.845	rs56391806	MIMAT0031175	hsa-miR-548ba	-5.23	2.52e-07	-0.3	-0.23	Sex hormone-binding globulin levels;	chr2:48404838	chr2:49059603~49059624:+
LGG	cis	rs1712517	1	rs1163084	MIMAT0005951	hsa-miR-1307-3p	-5.23	2.55e-07	-0.14	-0.23	Migraine;	chr10:103279291	chr10:103394301~103394322:-
LGG	cis	rs77637988	0.577	rs6705802	MIMAT0031175	hsa-miR-548ba	-5.23	2.57e-07	-0.28	-0.23	Joint mobility (Beighton score);	chr2:48376344	chr2:49059603~49059624:+
LGG	cis	rs1712517	0.771	rs11191645	MIMAT0005951	hsa-miR-1307-3p	-5.22	2.68e-07	-0.14	-0.23	Migraine;	chr10:103299551	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs61350103	MIMAT0005951	hsa-miR-1307-3p	-5.22	2.68e-07	-0.14	-0.23	Migraine;	chr10:103309363	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs11191654	MIMAT0005951	hsa-miR-1307-3p	-5.22	2.72e-07	-0.14	-0.23	Migraine;	chr10:103317367	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.771	rs61869827	MIMAT0005951	hsa-miR-1307-3p	-5.22	2.72e-07	-0.14	-0.23	Migraine;	chr10:103319682	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.763	rs8181292	MIMAT0005878	hsa-miR-1287-5p	5.22	2.73e-07	0.15	0.23	Metabolite levels;	chr10:98415720	chr10:98395271~98395292:-
LGG	cis	rs1712517	0.873	rs7913461	MIMAT0005951	hsa-miR-1307-3p	-5.21	2.81e-07	-0.14	-0.23	Migraine;	chr10:103241568	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.835	rs2506961	MIMAT0005951	hsa-miR-1307-3p	5.21	2.83e-07	0.14	0.23	Migraine;	chr10:103248169	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.873	rs1712510	MIMAT0005951	hsa-miR-1307-3p	5.21	2.83e-07	0.14	0.23	Migraine;	chr10:103249329	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.838	rs6584543	MIMAT0005951	hsa-miR-1307-3p	5.2	2.97e-07	0.14	0.23	Migraine;	chr10:103237257	chr10:103394301~103394322:-
LGG	cis	rs1712517	0.904	rs4918007	MIMAT0005951	hsa-miR-1307-3p	5.2	3.01e-07	0.13	0.23	Migraine;	chr10:103347713	chr10:103394301~103394322:-
LGG	cis	rs7502590	0.92	rs56084168	MIMAT0015378	hsa-miR-3065-3p	-5.18	3.23e-07	-0.25	-0.23	Neuroticism;	chr17:81110774	chr17:81125926~81125948:+
LGG	cis	rs1712517	0.74	rs11191643	MIMAT0005951	hsa-miR-1307-3p	-5.16	3.62e-07	-0.14	-0.23	Migraine;	chr10:103297804	chr10:103394301~103394322:-
LGG	cis	rs77637988	0.604	rs7566239	MIMAT0031175	hsa-miR-548ba	-5.16	3.63e-07	-0.28	-0.23	Joint mobility (Beighton score);	chr2:48371743	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.631	rs7587385	MIMAT0031175	hsa-miR-548ba	-5.16	3.63e-07	-0.28	-0.23	Joint mobility (Beighton score);	chr2:48373552	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.631	rs7573316	MIMAT0031175	hsa-miR-548ba	-5.16	3.63e-07	-0.28	-0.23	Joint mobility (Beighton score);	chr2:48373553	chr2:49059603~49059624:+
LGG	cis	rs1712517	0.771	rs10883857	MIMAT0022727	hsa-miR-1307-5p	5.15	3.75e-07	0.15	0.23	Migraine;	chr10:103367830	chr10:103394341~103394361:-
LGG	cis	rs77637988	0.578	rs7576964	MIMAT0031175	hsa-miR-548ba	-5.15	3.9e-07	-0.27	-0.23	Joint mobility (Beighton score);	chr2:48374309	chr2:49059603~49059624:+
LGG	cis	rs10454142	0.7	rs11690845	MIMAT0031175	hsa-miR-548ba	5.13	4.27e-07	0.31	0.23	Sex hormone-binding globulin levels;	chr2:48357687	chr2:49059603~49059624:+
LGG	cis	rs1712517	0.904	rs6584547	MIMAT0005951	hsa-miR-1307-3p	-5.12	4.46e-07	-0.13	-0.23	Migraine;	chr10:103305652	chr10:103394301~103394322:-
LGG	cis	rs77637988	0.723	rs7587917	MIMAT0031175	hsa-miR-548ba	-5.11	4.78e-07	-0.29	-0.23	Joint mobility (Beighton score);	chr2:48538939	chr2:49059603~49059624:+
LGG	cis	rs10454142	0.633	rs7559431	MIMAT0031175	hsa-miR-548ba	-5.1	5.02e-07	-0.31	-0.23	Sex hormone-binding globulin levels;	chr2:48364468	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.578	rs7577237	MIMAT0031175	hsa-miR-548ba	5.08	5.35e-07	0.27	0.23	Joint mobility (Beighton score);	chr2:48374677	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.603	rs72820445	MIMAT0031175	hsa-miR-548ba	-5.08	5.38e-07	-0.27	-0.23	Joint mobility (Beighton score);	chr2:48380717	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.578	rs11689645	MIMAT0031175	hsa-miR-548ba	-5.02	7.44e-07	-0.28	-0.22	Joint mobility (Beighton score);	chr2:48381420	chr2:49059603~49059624:+
LGG	cis	rs12712135	0.709	rs55664618	MIMAT0019927	hsa-miR-4772-3p	5	7.92e-07	0.23	0.22	Blood protein levels;	chr2:102399756	chr2:102432336~102432357:+
LGG	cis	rs1355223	0.583	rs2941044	MIMAT0019776	hsa-miR-1343-3p	5	8.18e-07	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34845897	chr11:34941888~34941909:+
LGG	cis	rs1712517	0.773	rs1063461	MIMAT0022727	hsa-miR-1307-5p	-4.97	9.35e-07	-0.15	-0.22	Migraine;	chr10:103289348	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.74	rs4293062	MIMAT0022727	hsa-miR-1307-5p	-4.97	9.35e-07	-0.15	-0.22	Migraine;	chr10:103292867	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.744	rs11191641	MIMAT0022727	hsa-miR-1307-5p	-4.97	9.35e-07	-0.15	-0.22	Migraine;	chr10:103293183	chr10:103394341~103394361:-
LGG	cis	rs1712517	0.744	rs4293063	MIMAT0022727	hsa-miR-1307-5p	-4.97	9.35e-07	-0.15	-0.22	Migraine;	chr10:103293219	chr10:103394341~103394361:-
LGG	cis	rs77637988	0.578	rs12328506	MIMAT0031175	hsa-miR-548ba	-4.97	9.45e-07	-0.27	-0.22	Joint mobility (Beighton score);	chr2:48396045	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.578	rs6718068	MIMAT0031175	hsa-miR-548ba	-4.96	9.66e-07	-0.27	-0.22	Joint mobility (Beighton score);	chr2:48377839	chr2:49059603~49059624:+
LGG	cis	rs1355223	0.583	rs2956074	MIMAT0019776	hsa-miR-1343-3p	4.95	1.01e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34843333	chr11:34941888~34941909:+
LGG	cis	rs1712517	0.771	rs2008530	MIMAT0022727	hsa-miR-1307-5p	-4.95	1.01e-06	-0.15	-0.22	Migraine;	chr10:103299082	chr10:103394341~103394361:-
LGG	cis	rs75358501	0.551	rs16838710	MIMAT0014995	hsa-miR-3130-5p	4.94	1.08e-06	0.24	0.22	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206724196	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs16838710	MIMAT0014995_1	hsa-miR-3130-5p	4.94	1.08e-06	0.24	0.22	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206724196	chr2:206783246~206783266:+
LGG	cis	rs10454142	0.7	rs72820427	MIMAT0031175	hsa-miR-548ba	-4.94	1.1e-06	-0.3	-0.22	Sex hormone-binding globulin levels;	chr2:48358367	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.604	rs78597273	MIMAT0031175	hsa-miR-548ba	-4.93	1.13e-06	-0.27	-0.22	Joint mobility (Beighton score);	chr2:48380665	chr2:49059603~49059624:+
LGG	cis	rs1355223	0.583	rs2116085	MIMAT0019776	hsa-miR-1343-3p	4.92	1.19e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34862454	chr11:34941888~34941909:+
LGG	cis	rs1355223	0.583	rs2915238	MIMAT0019776	hsa-miR-1343-3p	4.92	1.19e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34862858	chr11:34941888~34941909:+
LGG	cis	rs77637988	0.533	rs13398791	MIMAT0031175	hsa-miR-548ba	-4.92	1.21e-06	-0.27	-0.22	Joint mobility (Beighton score);	chr2:48395181	chr2:49059603~49059624:+
LGG	cis	rs1355223	0.583	rs2941041	MIMAT0019776	hsa-miR-1343-3p	4.92	1.22e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34853187	chr11:34941888~34941909:+
LGG	cis	rs1355223	0.583	rs2941057	MIMAT0019776	hsa-miR-1343-3p	4.91	1.27e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34860673	chr11:34941888~34941909:+
LGG	cis	rs1355223	0.552	rs2421743	MIMAT0019776	hsa-miR-1343-3p	4.91	1.27e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34861293	chr11:34941888~34941909:+
LGG	cis	rs1712517	0.836	rs11191649	MIMAT0005951	hsa-miR-1307-3p	-4.9	1.3e-06	-0.13	-0.22	Migraine;	chr10:103307280	chr10:103394301~103394322:-
LGG	cis	rs950880	0.71	rs11683700	MIMAT0019927	hsa-miR-4772-3p	4.88	1.46e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102380345	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs56258475	MIMAT0019927	hsa-miR-4772-3p	4.88	1.46e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102382852	chr2:102432336~102432357:+
LGG	cis	rs1355223	0.583	rs2915177	MIMAT0019776	hsa-miR-1343-3p	4.87	1.55e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34858719	chr11:34941888~34941909:+
LGG	cis	rs950880	0.71	rs2270298	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102375619	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs17027037	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102378424	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs2080289	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102378560	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3821203	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102380412	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3771162	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102380714	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11465633	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102381273	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs1035130	MIMAT0019927	hsa-miR-4772-3p	4.87	1.56e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102384942	chr2:102432336~102432357:+
LGG	cis	rs950880	0.668	rs3732126	MIMAT0019927	hsa-miR-4772-3p	4.86	1.59e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102397502	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3732125	MIMAT0019927	hsa-miR-4772-3p	4.86	1.59e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102397503	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs2287035	MIMAT0019927	hsa-miR-4772-3p	4.86	1.59e-06	0.26	0.22	Serum protein levels (sST2);	chr2:102394070	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.7	rs72820418	MIMAT0031175	hsa-miR-548ba	-4.86	1.63e-06	-0.3	-0.22	Sex hormone-binding globulin levels;	chr2:48349548	chr2:49059603~49059624:+
LGG	cis	rs874628	0.659	rs2384987	MIMAT0015070	hsa-miR-3188	-4.84	1.73e-06	-0.28	-0.22	Multiple sclerosis;	chr19:18246588	chr19:18282129~18282151:+
LGG	cis	rs1355223	0.583	rs2915178	MIMAT0019776	hsa-miR-1343-3p	4.84	1.76e-06	0.16	0.22	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34856504	chr11:34941888~34941909:+
LGG	cis	rs10454142	0.7	rs17037289	MIMAT0031175	hsa-miR-548ba	-4.84	1.79e-06	-0.29	-0.22	Sex hormone-binding globulin levels;	chr2:48360059	chr2:49059603~49059624:+
LGG	cis	rs7072216	0.621	rs3750605	MIMAT0005878	hsa-miR-1287-5p	4.83	1.8e-06	0.15	0.22	Metabolite levels;	chr10:98415897	chr10:98395271~98395292:-
LGG	cis	rs10454142	0.7	rs57537506	MIMAT0031175	hsa-miR-548ba	-4.83	1.88e-06	-0.3	-0.22	Sex hormone-binding globulin levels;	chr2:48349409	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs4851570	MIMAT0019927	hsa-miR-4772-3p	4.83	1.89e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102389927	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs17027060	MIMAT0019927	hsa-miR-4772-3p	4.83	1.89e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102391107	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs66919607	MIMAT0019927	hsa-miR-4772-3p	4.83	1.89e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102392509	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs1135354	MIMAT0019927	hsa-miR-4772-3p	4.83	1.89e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102397842	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs55742125	MIMAT0019927	hsa-miR-4772-3p	4.83	1.89e-06	0.25	0.22	Serum protein levels (sST2);	chr2:102403322	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.731	rs11680719	MIMAT0031175	hsa-miR-548ba	-4.81	2e-06	-0.27	-0.22	Sex hormone-binding globulin levels;	chr2:48430704	chr2:49059603~49059624:+
LGG	cis	rs77637988	0.604	rs17855177	MIMAT0031175	hsa-miR-548ba	-4.81	2.06e-06	-0.26	-0.22	Joint mobility (Beighton score);	chr2:48375113	chr2:49059603~49059624:+
LGG	cis	rs874628	0.659	rs4808120	MIMAT0015070	hsa-miR-3188	-4.8	2.1e-06	-0.28	-0.22	Multiple sclerosis;	chr19:18247019	chr19:18282129~18282151:+
LGG	cis	rs77637988	0.553	rs10169629	MIMAT0031175	hsa-miR-548ba	-4.8	2.17e-06	-0.26	-0.21	Joint mobility (Beighton score);	chr2:48397905	chr2:49059603~49059624:+
LGG	cis	rs874628	0.612	rs4808121	MIMAT0015070	hsa-miR-3188	-4.79	2.18e-06	-0.28	-0.21	Multiple sclerosis;	chr19:18247297	chr19:18282129~18282151:+
LGG	cis	rs950880	0.71	rs17027071	MIMAT0019927	hsa-miR-4772-3p	4.79	2.26e-06	0.25	0.21	Serum protein levels (sST2);	chr2:102396214	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.568	rs57131168	MIMAT0031175	hsa-miR-548ba	-4.77	2.48e-06	-0.29	-0.21	Sex hormone-binding globulin levels;	chr2:48317972	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs2287034	MIMAT0019927	hsa-miR-4772-3p	-4.76	2.6e-06	-0.25	-0.21	Serum protein levels (sST2);	chr2:102394128	chr2:102432336~102432357:+
LGG	cis	rs75358501	0.551	rs13394079	MIMAT0014995	hsa-miR-3130-5p	-4.74	2.81e-06	-0.23	-0.21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206729470	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs13394079	MIMAT0014995_1	hsa-miR-3130-5p	-4.74	2.81e-06	-0.23	-0.21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206729470	chr2:206783246~206783266:+
LGG	cis	rs874628	0.659	rs4808770	MIMAT0015070	hsa-miR-3188	-4.74	2.85e-06	-0.27	-0.21	Multiple sclerosis;	chr19:18247095	chr19:18282129~18282151:+
LGG	cis	rs9859260	0.744	rs539816	MIMAT0003235	hsa-miR-570-3p	-4.74	2.89e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196057205	chr3:195699460~195699481:+
LGG	cis	rs9859260	0.744	rs492349	MIMAT0003235	hsa-miR-570-3p	-4.74	2.89e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196057321	chr3:195699460~195699481:+
LGG	cis	rs9859260	0.744	rs492288	MIMAT0003235	hsa-miR-570-3p	-4.74	2.89e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196057339	chr3:195699460~195699481:+
LGG	cis	rs950880	0.71	rs3732123	MIMAT0019927	hsa-miR-4772-3p	4.73	2.9e-06	0.25	0.21	Serum protein levels (sST2);	chr2:102401617	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.666	rs55761545	MIMAT0031175	hsa-miR-548ba	-4.73	3.02e-06	-0.29	-0.21	Sex hormone-binding globulin levels;	chr2:48328482	chr2:49059603~49059624:+
LGG	cis	rs10454142	0.771	rs7569575	MIMAT0031175	hsa-miR-548ba	-4.72	3.12e-06	-0.27	-0.21	Sex hormone-binding globulin levels;	chr2:48490591	chr2:49059603~49059624:+
LGG	cis	rs1712517	0.838	rs1891293	MIMAT0005951	hsa-miR-1307-3p	4.71	3.19e-06	0.13	0.21	Migraine;	chr10:103242040	chr10:103394301~103394322:-
LGG	cis	rs9859260	0.744	rs3933	MIMAT0003235	hsa-miR-570-3p	-4.7	3.34e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196058126	chr3:195699460~195699481:+
LGG	cis	rs77637988	0.604	rs6722246	MIMAT0031175	hsa-miR-548ba	-4.68	3.72e-06	-0.26	-0.21	Joint mobility (Beighton score);	chr2:48369906	chr2:49059603~49059624:+
LGG	cis	rs9859260	0.71	rs41298097	MIMAT0003235	hsa-miR-570-3p	-4.68	3.8e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196052284	chr3:195699460~195699481:+
LGG	cis	rs8114671	0.545	rs2378335	MIMAT0004772	hsa-miR-499a-3p	-4.67	3.85e-06	-0.23	-0.21	Height;	chr20:35169027	chr20:34990445~34990466:+
LGG	cis	rs10454142	0.666	rs11678403	MIMAT0031175	hsa-miR-548ba	-4.66	4.06e-06	-0.29	-0.21	Sex hormone-binding globulin levels;	chr2:48323358	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs3771172	MIMAT0019927	hsa-miR-4772-3p	4.64	4.43e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102369352	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs2160202	MIMAT0019927	hsa-miR-4772-3p	4.64	4.43e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102369694	chr2:102432336~102432357:+
LGG	cis	rs77637988	0.578	rs4953572	MIMAT0031175	hsa-miR-548ba	4.64	4.45e-06	0.25	0.21	Joint mobility (Beighton score);	chr2:48396868	chr2:49059603~49059624:+
LGG	cis	rs950880	0.744	rs3771156	MIMAT0019927	hsa-miR-4772-3p	4.64	4.49e-06	0.25	0.21	Serum protein levels (sST2);	chr2:102420217	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.771	rs4296472	MIMAT0031175	hsa-miR-548ba	4.63	4.83e-06	0.27	0.21	Sex hormone-binding globulin levels;	chr2:48519940	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs3771171	MIMAT0019927	hsa-miR-4772-3p	4.62	4.86e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102369490	chr2:102432336~102432357:+
LGG	cis	rs12608504	0.503	rs11086103	MIMAT0015070	hsa-miR-3188	4.62	4.96e-06	0.24	0.21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;	chr19:18291307	chr19:18282129~18282151:+
LGG	cis	rs10454142	0.7	rs4293602	MIMAT0031175	hsa-miR-548ba	-4.62	5e-06	-0.27	-0.21	Sex hormone-binding globulin levels;	chr2:48505805	chr2:49059603~49059624:+
LGG	cis	rs34234989	1	rs34234989	MIMAT0004772	hsa-miR-499a-3p	-4.62	5.03e-06	-0.23	-0.21	Thrombosis;	chr20:35186731	chr20:34990445~34990466:+
LGG	cis	rs6087685	1	rs10747514	MIMAT0004772	hsa-miR-499a-3p	-4.62	5.03e-06	-0.23	-0.21	Venous thromboembolism;	chr20:35187566	chr20:34990445~34990466:+
LGG	cis	rs9982086	0.793	rs2829790	MIMAT0000646	hsa-miR-155-5p	-4.62	5.05e-06	-0.27	-0.21	Carboplatin disposition in epthelial ovarian cancer;	chr21:25539906	chr21:25573983~25574006:+
LGG	cis	rs77637988	0.578	rs11683099	MIMAT0031175	hsa-miR-548ba	-4.61	5.08e-06	-0.25	-0.21	Joint mobility (Beighton score);	chr2:48384380	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs55883125	MIMAT0019927	hsa-miR-4772-3p	4.61	5.17e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102407871	chr2:102432336~102432357:+
LGG	cis	rs950880	0.645	rs4851006	MIMAT0019927	hsa-miR-4772-3p	4.61	5.17e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102408278	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11693955	MIMAT0019927	hsa-miR-4772-3p	4.61	5.25e-06	0.24	0.21	Serum protein levels (sST2);	chr2:102412705	chr2:102432336~102432357:+
LGG	cis	rs9859260	0.71	rs34906439	MIMAT0003235	hsa-miR-570-3p	-4.6	5.41e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196052835	chr3:195699460~195699481:+
LGG	cis	rs9859260	0.744	rs557527	MIMAT0003235	hsa-miR-570-3p	-4.6	5.41e-06	-0.26	-0.21	Mean corpuscular volume;	chr3:196053838	chr3:195699460~195699481:+
LGG	cis	rs874628	0.659	rs62120396	MIMAT0015070	hsa-miR-3188	-4.56	6.54e-06	-0.26	-0.2	Multiple sclerosis;	chr19:18235193	chr19:18282129~18282151:+
LGG	cis	rs7894407	1	rs7894407	MIMAT0005951	hsa-miR-1307-3p	4.56	6.62e-06	0.13	0.2	White matter hyperintensity burden;	chr10:103416422	chr10:103394301~103394322:-
LGG	cis	rs7894407	0.76	rs4917386	MIMAT0022727	hsa-miR-1307-5p	4.56	6.67e-06	0.13	0.2	White matter hyperintensity burden;	chr10:103247771	chr10:103394341~103394361:-
LGG	cis	rs12608504	0.503	rs12610691	MIMAT0015070	hsa-miR-3188	4.55	6.87e-06	0.23	0.2	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;	chr19:18287525	chr19:18282129~18282151:+
LGG	cis	rs75358501	0.551	rs79761690	MIMAT0014995	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206717731	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs79761690	MIMAT0014995_1	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206717731	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.551	rs28619220	MIMAT0014995	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206720891	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs28619220	MIMAT0014995_1	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206720891	chr2:206783246~206783266:+
LGG	cis	rs75358501	0.551	rs12471939	MIMAT0014995	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206723545	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs12471939	MIMAT0014995_1	hsa-miR-3130-5p	-4.54	7e-06	-0.22	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206723545	chr2:206783246~206783266:+
LGG	cis	rs950880	0.677	rs17027087	MIMAT0019927	hsa-miR-4772-3p	4.54	7.23e-06	0.24	0.2	Serum protein levels (sST2);	chr2:102399458	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs67723747	MIMAT0019927	hsa-miR-4772-3p	4.54	7.27e-06	0.24	0.2	Serum protein levels (sST2);	chr2:102353347	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs56386507	MIMAT0019927	hsa-miR-4772-3p	4.54	7.27e-06	0.24	0.2	Serum protein levels (sST2);	chr2:102354705	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs4817026	MIMAT0000646	hsa-miR-155-5p	-4.53	7.31e-06	-0.27	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25545043	chr21:25573983~25574006:+
LGG	cis	rs7894407	1	rs7894407	MIMAT0022727	hsa-miR-1307-5p	4.53	7.47e-06	0.14	0.2	White matter hyperintensity burden;	chr10:103416422	chr10:103394341~103394361:-
LGG	cis	rs6087685	1	rs6087685	MIMAT0004772	hsa-miR-499a-3p	-4.52	7.98e-06	-0.23	-0.2	Venous thromboembolism;	chr20:35189809	chr20:34990445~34990466:+
LGG	cis	rs1912702	0.592	rs17138382	MIMAT0022270	hsa-miR-5579-3p	4.5	8.47e-06	0.25	0.2	Hair greying;	chr11:79463336	chr11:79422169~79422190:-
LGG	cis	rs950880	0.553	rs2241116	MIMAT0019927	hsa-miR-4772-3p	4.5	8.65e-06	0.25	0.2	Serum protein levels (sST2);	chr2:102386805	chr2:102432336~102432357:+
LGG	cis	rs9859260	0.614	rs493661	MIMAT0003235	hsa-miR-570-3p	-4.5	8.7e-06	-0.25	-0.2	Mean corpuscular volume;	chr3:196059618	chr3:195699460~195699481:+
LGG	cis	rs7619708	1	rs7619708	MIMAT0003235	hsa-miR-570-3p	-4.49	9.02e-06	-0.27	-0.2	Red cell distribution width;	chr3:196083316	chr3:195699460~195699481:+
LGG	cis	rs7072216	0.621	rs11189595	MIMAT0005878	hsa-miR-1287-5p	4.48	9.27e-06	0.14	0.2	Metabolite levels;	chr10:98407565	chr10:98395271~98395292:-
LGG	cis	rs9859260	0.71	rs419068	MIMAT0003235	hsa-miR-570-3p	-4.47	9.66e-06	-0.25	-0.2	Mean corpuscular volume;	chr3:196055305	chr3:195699460~195699481:+
LGG	cis	rs9859260	0.71	rs366268	MIMAT0003235	hsa-miR-570-3p	-4.47	9.66e-06	-0.25	-0.2	Mean corpuscular volume;	chr3:196055306	chr3:195699460~195699481:+
LGG	cis	rs9859260	0.744	rs419059	MIMAT0003235	hsa-miR-570-3p	-4.47	9.66e-06	-0.25	-0.2	Mean corpuscular volume;	chr3:196055313	chr3:195699460~195699481:+
LGG	cis	rs7072216	0.621	rs3750604	MIMAT0005878	hsa-miR-1287-5p	4.46	1.01e-05	0.14	0.2	Metabolite levels;	chr10:98415824	chr10:98395271~98395292:-
LGG	cis	rs9859260	0.744	rs406271	MIMAT0003235	hsa-miR-570-3p	-4.44	1.1e-05	-0.25	-0.2	Mean corpuscular volume;	chr3:196050105	chr3:195699460~195699481:+
LGG	cis	rs10454142	0.7	rs6545046	MIMAT0031175	hsa-miR-548ba	4.44	1.11e-05	0.26	0.2	Sex hormone-binding globulin levels;	chr2:48523271	chr2:49059603~49059624:+
LGG	cis	rs7894407	0.76	rs1163085	MIMAT0022727	hsa-miR-1307-5p	-4.44	1.14e-05	-0.13	-0.2	White matter hyperintensity burden;	chr10:103279484	chr10:103394341~103394361:-
LGG	cis	rs7894407	0.76	rs1163072	MIMAT0022727	hsa-miR-1307-5p	4.43	1.15e-05	0.13	0.2	White matter hyperintensity burden;	chr10:103264621	chr10:103394341~103394361:-
LGG	cis	rs950880	0.593	rs887971	MIMAT0019927	hsa-miR-4772-3p	4.43	1.16e-05	0.23	0.2	Serum protein levels (sST2);	chr2:102424707	chr2:102432336~102432357:+
LGG	cis	rs453301	0.598	rs2921383	MIMAT0019728	hsa-miR-4660	4.43	1.17e-05	0.23	0.2	Joint mobility (Beighton score);	chr8:9034711	chr8:9048453~9048475:+
LGG	cis	rs950880	0.593	rs887972	MIMAT0019927	hsa-miR-4772-3p	4.43	1.19e-05	0.23	0.2	Serum protein levels (sST2);	chr2:102424485	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs10201184	MIMAT0019927	hsa-miR-4772-3p	-4.42	1.25e-05	-0.21	-0.2	Blood protein levels;	chr2:102472618	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs12469506	MIMAT0019927	hsa-miR-4772-3p	4.41	1.29e-05	0.23	0.2	Serum protein levels (sST2);	chr2:102349411	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs915860	MIMAT0000646	hsa-miR-155-5p	4.41	1.29e-05	0.29	0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25566173	chr21:25573983~25574006:+
LGG	cis	rs12712135	0.677	rs6705385	MIMAT0019927	hsa-miR-4772-3p	4.4	1.34e-05	0.21	0.2	Blood protein levels;	chr2:102460109	chr2:102432336~102432357:+
LGG	cis	rs7894407	0.892	rs10883859	MIMAT0022727	hsa-miR-1307-5p	4.4	1.35e-05	0.13	0.2	White matter hyperintensity burden;	chr10:103368377	chr10:103394341~103394361:-
LGG	cis	rs874628	0.707	rs11670370	MIMAT0015070	hsa-miR-3188	-4.39	1.4e-05	-0.25	-0.2	Multiple sclerosis;	chr19:18230946	chr19:18282129~18282151:+
LGG	cis	rs11678825	0.683	rs74684569	MIMAT0031175	hsa-miR-548ba	-4.39	1.4e-05	-0.31	-0.2	Reticulocyte fraction of red cells;	chr2:48435911	chr2:49059603~49059624:+
LGG	cis	rs9982086	0.793	rs73336148	MIMAT0000646	hsa-miR-155-5p	-4.39	1.42e-05	-0.26	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25544544	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs73336150	MIMAT0000646	hsa-miR-155-5p	-4.39	1.42e-05	-0.26	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25544650	chr21:25573983~25574006:+
LGG	cis	rs12712135	0.651	rs12712150	MIMAT0019927	hsa-miR-4772-3p	4.38	1.47e-05	0.21	0.2	Blood protein levels;	chr2:102458353	chr2:102432336~102432357:+
LGG	cis	rs7477	0.557	rs3785626	MIMAT0005942	hsa-miR-1288-3p	-4.37	1.56e-05	-0.19	-0.2	Amyotrophic lateral sclerosis;	chr17:16281934	chr17:16282058~16282078:+
LGG	cis	rs9982086	0.793	rs972389	MIMAT0000646	hsa-miR-155-5p	4.36	1.63e-05	0.29	0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25567997	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.655	rs2211763	MIMAT0000646	hsa-miR-155-5p	4.36	1.63e-05	0.29	0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25571293	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs1547355	MIMAT0000646	hsa-miR-155-5p	4.36	1.63e-05	0.29	0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25575427	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.655	rs915861	MIMAT0000646	hsa-miR-155-5p	4.36	1.63e-05	0.29	0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25582820	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs11701533	MIMAT0000646	hsa-miR-155-5p	-4.36	1.63e-05	-0.29	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25551562	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs11087965	MIMAT0000646	hsa-miR-155-5p	-4.36	1.63e-05	-0.29	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25557717	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs36059302	MIMAT0000646	hsa-miR-155-5p	-4.36	1.63e-05	-0.29	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25563201	chr21:25573983~25574006:+
LGG	cis	rs546131	0.6	rs502857	MIMAT0019776	hsa-miR-1343-3p	4.34	1.75e-05	0.15	0.2	Lung disease severity in cystic fibrosis;	chr11:34833115	chr11:34941888~34941909:+
LGG	cis	rs950880	0.71	rs55927292	MIMAT0019927	hsa-miR-4772-3p	4.34	1.76e-05	0.23	0.2	Serum protein levels (sST2);	chr2:102348401	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs74335692	MIMAT0000646	hsa-miR-155-5p	-4.34	1.77e-05	-0.31	-0.2	Carboplatin disposition in epthelial ovarian cancer;	chr21:25619097	chr21:25573983~25574006:+
LGG	cis	rs12712135	0.677	rs11678721	MIMAT0019927	hsa-miR-4772-3p	4.33	1.79e-05	0.2	0.2	Blood protein levels;	chr2:102456778	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs11677555	MIMAT0019927	hsa-miR-4772-3p	4.33	1.79e-05	0.2	0.2	Blood protein levels;	chr2:102456833	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs6705498	MIMAT0019927	hsa-miR-4772-3p	4.33	1.79e-05	0.2	0.2	Blood protein levels;	chr2:102460210	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs6719196	MIMAT0019927	hsa-miR-4772-3p	4.33	1.79e-05	0.2	0.2	Blood protein levels;	chr2:102460428	chr2:102432336~102432357:+
LGG	cis	rs7502590	1	rs4969386	MIMAT0015378	hsa-miR-3065-3p	-4.33	1.81e-05	-0.22	-0.19	Neuroticism;	chr17:81102976	chr17:81125926~81125948:+
LGG	cis	rs12712135	0.709	rs4140786	MIMAT0019927	hsa-miR-4772-3p	4.33	1.85e-05	0.2	0.19	Blood protein levels;	chr2:102471716	chr2:102432336~102432357:+
LGG	cis	rs10454142	0.633	rs72818477	MIMAT0031175	hsa-miR-548ba	-4.31	1.94e-05	-0.27	-0.19	Sex hormone-binding globulin levels;	chr2:48268641	chr2:49059603~49059624:+
LGG	cis	rs12712135	0.709	rs11465728	MIMAT0019927	hsa-miR-4772-3p	4.31	1.98e-05	0.2	0.19	Blood protein levels;	chr2:102448051	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs79282113	MIMAT0000646	hsa-miR-155-5p	-4.31	2e-05	-0.29	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25544362	chr21:25573983~25574006:+
LGG	cis	rs11678825	0.683	rs56226059	MIMAT0031175	hsa-miR-548ba	-4.3	2.07e-05	-0.31	-0.19	Reticulocyte fraction of red cells;	chr2:48452796	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs17027006	MIMAT0019927	hsa-miR-4772-3p	-4.3	2.08e-05	-0.23	-0.19	Serum protein levels (sST2);	chr2:102348872	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs4851011	MIMAT0019927	hsa-miR-4772-3p	-4.3	2.11e-05	-0.23	-0.19	Serum protein levels (sST2);	chr2:102473219	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs12483717	MIMAT0000646	hsa-miR-155-5p	-4.29	2.16e-05	-0.25	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25537199	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs9941908	MIMAT0000646	hsa-miR-155-5p	-4.29	2.16e-05	-0.25	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25537583	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs2829791	MIMAT0000646	hsa-miR-155-5p	-4.29	2.16e-05	-0.25	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25541255	chr21:25573983~25574006:+
LGG	cis	rs11678825	0.683	rs74483911	MIMAT0031175	hsa-miR-548ba	-4.29	2.19e-05	-0.31	-0.19	Reticulocyte fraction of red cells;	chr2:48436480	chr2:49059603~49059624:+
LGG	cis	rs12712135	0.652	rs11465727	MIMAT0019927	hsa-miR-4772-3p	4.28	2.24e-05	0.2	0.19	Blood protein levels;	chr2:102448043	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs11465729	MIMAT0019927	hsa-miR-4772-3p	4.28	2.24e-05	0.2	0.19	Blood protein levels;	chr2:102448052	chr2:102432336~102432357:+
LGG	cis	rs1461503	0.966	rs10892936	MIMAT0000062	hsa-let-7a-5p	-4.28	2.25e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971012	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10892936	MIMAT0000062_1	hsa-let-7a-5p	-4.28	2.25e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971012	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10892936	MIMAT0000062_2	hsa-let-7a-5p	-4.28	2.25e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971012	chr9:94175962~94175983:+
LGG	cis	rs1355223	0.583	rs1396880	MIMAT0019776	hsa-miR-1343-3p	-4.27	2.34e-05	-0.14	-0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34849005	chr11:34941888~34941909:+
LGG	cis	rs453301	0.653	rs7853	MIMAT0019728	hsa-miR-4660	4.27	2.34e-05	0.22	0.19	Joint mobility (Beighton score);	chr8:9033304	chr8:9048453~9048475:+
LGG	cis	rs11678825	0.789	rs112492778	MIMAT0031175	hsa-miR-548ba	-4.27	2.38e-05	-0.31	-0.19	Reticulocyte fraction of red cells;	chr2:48440788	chr2:49059603~49059624:+
LGG	cis	rs950880	0.71	rs4140785	MIMAT0019927	hsa-miR-4772-3p	4.26	2.42e-05	0.23	0.19	Serum protein levels (sST2);	chr2:102472057	chr2:102432336~102432357:+
LGG	cis	rs9982086	0.793	rs3989369	MIMAT0000646	hsa-miR-155-5p	4.26	2.45e-05	0.28	0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25606638	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.793	rs7278974	MIMAT0000646	hsa-miR-155-5p	4.26	2.45e-05	0.28	0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25609669	chr21:25573983~25574006:+
LGG	cis	rs9982086	0.557	rs13046103	MIMAT0000646	hsa-miR-155-5p	4.26	2.45e-05	0.28	0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25611163	chr21:25573983~25574006:+
LGG	cis	rs12712135	0.709	rs10195075	MIMAT0019927	hsa-miR-4772-3p	4.26	2.48e-05	0.2	0.19	Blood protein levels;	chr2:102471192	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs1403553	MIMAT0019927	hsa-miR-4772-3p	4.26	2.48e-05	0.2	0.19	Blood protein levels;	chr2:102471202	chr2:102432336~102432357:+
LGG	cis	rs9398586	0.803	rs17058157	MIMAT0009206	hsa-miR-2113	4.25	2.53e-05	0.28	0.19	Neuroticism;	chr6:98042139	chr6:98024586~98024606:+
LGG	cis	rs12712135	0.709	rs12463588	MIMAT0019927	hsa-miR-4772-3p	4.25	2.55e-05	0.2	0.19	Blood protein levels;	chr2:102468797	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs2310302	MIMAT0019927	hsa-miR-4772-3p	4.25	2.55e-05	0.2	0.19	Blood protein levels;	chr2:102469589	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.709	rs12469887	MIMAT0019927	hsa-miR-4772-3p	4.25	2.55e-05	0.2	0.19	Blood protein levels;	chr2:102470298	chr2:102432336~102432357:+
LGG	cis	rs1355223	0.583	rs2941058	MIMAT0019776	hsa-miR-1343-3p	4.25	2.57e-05	0.14	0.19	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34858698	chr11:34941888~34941909:+
LGG	cis	rs2284932	0.556	rs2014766	MIMAT0016895	hsa-miR-2355-5p	4.25	2.62e-05	0.15	0.19	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207126660	chr2:207110043~207110063:-
LGG	cis	rs12712135	0.709	rs11676236	MIMAT0019927	hsa-miR-4772-3p	4.24	2.71e-05	0.2	0.19	Blood protein levels;	chr2:102465235	chr2:102432336~102432357:+
LGG	cis	rs12712135	0.677	rs11687013	MIMAT0019927	hsa-miR-4772-3p	4.24	2.71e-05	0.2	0.19	Blood protein levels;	chr2:102465261	chr2:102432336~102432357:+
LGG	cis	rs6087685	1	rs6088764	MIMAT0004772	hsa-miR-499a-3p	4.24	2.74e-05	0.21	0.19	Venous thromboembolism;	chr20:35205356	chr20:34990445~34990466:+
LGG	cis	rs9982086	0.793	rs7278807	MIMAT0000646	hsa-miR-155-5p	4.23	2.76e-05	0.26	0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25553754	chr21:25573983~25574006:+
LGG	cis	rs950880	0.553	rs3755272	MIMAT0019927	hsa-miR-4772-3p	4.23	2.81e-05	0.24	0.19	Serum protein levels (sST2);	chr2:102417365	chr2:102432336~102432357:+
LGG	cis	rs950880	0.553	rs2293225	MIMAT0019927	hsa-miR-4772-3p	4.23	2.81e-05	0.24	0.19	Serum protein levels (sST2);	chr2:102419429	chr2:102432336~102432357:+
LGG	cis	rs9303542	0.694	rs4793854	MIMAT0000253	hsa-miR-10a-5p	4.23	2.84e-05	0.26	0.19	Epithelial ovarian cancer;Ovarian cancer;	chr17:48494771	chr17:48579904~48579926:-
LGG	cis	rs11678825	0.683	rs80016200	MIMAT0031175	hsa-miR-548ba	-4.23	2.86e-05	-0.3	-0.19	Reticulocyte fraction of red cells;	chr2:48462338	chr2:49059603~49059624:+
LGG	cis	rs11678825	0.789	rs56088423	MIMAT0031175	hsa-miR-548ba	-4.23	2.87e-05	-0.3	-0.19	Reticulocyte fraction of red cells;	chr2:48452359	chr2:49059603~49059624:+
LGG	cis	rs1461503	0.868	rs10790543	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967603	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.868	rs10790543	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967603	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.868	rs10790543	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967603	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10790545	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967642	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10790545	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967642	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10790545	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967642	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10790546	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967718	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10790546	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967718	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10790546	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967718	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.9	rs10892935	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967882	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs10892935	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967882	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs10892935	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122967882	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs7944630	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968136	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs7944630	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968136	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs7944630	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968136	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.868	rs7126785	MIMAT0000062	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968856	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.868	rs7126785	MIMAT0000062_1	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968856	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.868	rs7126785	MIMAT0000062_2	hsa-let-7a-5p	-4.22	2.92e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122968856	chr9:94175962~94175983:+
LGG	cis	rs9982086	0.546	rs13049829	MIMAT0000646	hsa-miR-155-5p	4.21	3.04e-05	0.27	0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25626335	chr21:25573983~25574006:+
LGG	cis	rs1461503	0.932	rs56778812	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122969783	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs56778812	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122969783	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs56778812	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122969783	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs11218907	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970854	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs11218907	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970854	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs11218907	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970854	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs11218908	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970979	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs11218908	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970979	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs11218908	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122970979	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10892939	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971251	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10892939	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971251	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10892939	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971251	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10790547	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971402	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10790547	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971402	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10790547	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971402	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.932	rs11218909	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971905	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs11218909	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971905	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs11218909	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971905	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs11218910	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972153	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs11218910	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972153	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs11218910	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972153	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs7110154	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972592	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs7110154	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972592	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs7110154	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972592	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs7113725	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972803	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs7113725	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972803	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs7113725	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972803	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.932	rs6589962	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972827	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs6589962	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972827	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs6589962	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122972827	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs1461501	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973708	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs1461501	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973708	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs1461501	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973708	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs4936764	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973784	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs4936764	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973784	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs4936764	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122973784	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs1461502	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974219	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs1461502	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974219	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs1461502	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974219	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs1461504	MIMAT0000062	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974421	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs1461504	MIMAT0000062_1	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974421	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs1461504	MIMAT0000062_2	hsa-let-7a-5p	-4.21	3.05e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122974421	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs11218905	MIMAT0000062	hsa-let-7a-5p	4.21	3.12e-05	0.15	0.19	Menarche (age at onset);	chr11:122969595	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs11218905	MIMAT0000062_1	hsa-let-7a-5p	4.21	3.12e-05	0.15	0.19	Menarche (age at onset);	chr11:122969595	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs11218905	MIMAT0000062_2	hsa-let-7a-5p	4.21	3.12e-05	0.15	0.19	Menarche (age at onset);	chr11:122969595	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10892937	MIMAT0000062	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971196	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10892937	MIMAT0000062_1	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971196	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10892937	MIMAT0000062_2	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971196	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.966	rs10892938	MIMAT0000062	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971213	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.966	rs10892938	MIMAT0000062_1	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971213	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.966	rs10892938	MIMAT0000062_2	hsa-let-7a-5p	-4.2	3.13e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971213	chr9:94175962~94175983:+
LGG	cis	rs874628	0.659	rs11667487	MIMAT0015070	hsa-miR-3188	4.2	3.14e-05	0.23	0.19	Multiple sclerosis;	chr19:18240397	chr19:18282129~18282151:+
LGG	cis	rs7829975	0.633	rs2979181	MIMAT0019728	hsa-miR-4660	4.2	3.14e-05	0.21	0.19	Mood instability;	chr8:8465578	chr8:9048453~9048475:+
LGG	cis	rs6088590	1	rs11698977	MIMAT0004772	hsa-miR-499a-3p	-4.2	3.18e-05	-0.21	-0.19	Coronary artery disease;	chr20:34861888	chr20:34990445~34990466:+
LGG	cis	rs453301	0.624	rs2288673	MIMAT0019728	hsa-miR-4660	4.2	3.18e-05	0.22	0.19	Joint mobility (Beighton score);	chr8:9002766	chr8:9048453~9048475:+
LGG	cis	rs950880	0.71	rs1474309	MIMAT0019927	hsa-miR-4772-3p	4.2	3.2e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102474542	chr2:102432336~102432357:+
LGG	cis	rs453301	0.624	rs2288671	MIMAT0019728	hsa-miR-4660	4.2	3.21e-05	0.21	0.19	Joint mobility (Beighton score);	chr8:9003384	chr8:9048453~9048475:+
LGG	cis	rs1461503	0.868	rs11602682	MIMAT0000062	hsa-let-7a-5p	-4.2	3.23e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971607	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.868	rs11602682	MIMAT0000062_1	hsa-let-7a-5p	-4.2	3.23e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971607	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.868	rs11602682	MIMAT0000062_2	hsa-let-7a-5p	-4.2	3.23e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971607	chr9:94175962~94175983:+
LGG	cis	rs11678825	0.639	rs77468632	MIMAT0031175	hsa-miR-548ba	-4.2	3.23e-05	-0.31	-0.19	Reticulocyte fraction of red cells;	chr2:48444051	chr2:49059603~49059624:+
LGG	cis	rs453301	0.653	rs7016139	MIMAT0019728	hsa-miR-4660	-4.19	3.32e-05	-0.22	-0.19	Joint mobility (Beighton score);	chr8:9037960	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.694	rs9906950	MIMAT0000253	hsa-miR-10a-5p	4.19	3.37e-05	0.25	0.19	Epithelial ovarian cancer;Ovarian cancer;	chr17:48499805	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.694	rs8071207	MIMAT0000253	hsa-miR-10a-5p	4.19	3.37e-05	0.25	0.19	Epithelial ovarian cancer;Ovarian cancer;	chr17:48506654	chr17:48579904~48579926:-
LGG	cis	rs6504340	0.6	rs2325946	MIMAT0000253	hsa-miR-10a-5p	4.19	3.37e-05	0.25	0.19	Primary tooth development (number of teeth);	chr17:48507269	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.571	rs2202895	MIMAT0000253	hsa-miR-10a-5p	4.19	3.37e-05	0.25	0.19	Epithelial ovarian cancer;Ovarian cancer;	chr17:48507295	chr17:48579904~48579926:-
LGG	cis	rs11678825	0.789	rs78051501	MIMAT0031175	hsa-miR-548ba	-4.19	3.38e-05	-0.3	-0.19	Reticulocyte fraction of red cells;	chr2:48449807	chr2:49059603~49059624:+
LGG	cis	rs11678825	0.538	rs76875602	MIMAT0031175	hsa-miR-548ba	-4.18	3.42e-05	-0.3	-0.19	Reticulocyte fraction of red cells;	chr2:48449683	chr2:49059603~49059624:+
LGG	cis	rs7072216	0.587	rs2296435	MIMAT0005878	hsa-miR-1287-5p	-4.18	3.43e-05	-0.13	-0.19	Metabolite levels;	chr10:98422528	chr10:98395271~98395292:-
LGG	cis	rs453301	0.653	rs1045529	MIMAT0019728	hsa-miR-4660	-4.18	3.49e-05	-0.21	-0.19	Joint mobility (Beighton score);	chr8:9032588	chr8:9048453~9048475:+
LGG	cis	rs9982086	1	rs9977558	MIMAT0000646	hsa-miR-155-5p	-4.18	3.51e-05	-0.25	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25626753	chr21:25573983~25574006:+
LGG	cis	rs1461503	0.78	rs75981430	MIMAT0000062	hsa-let-7a-5p	-4.18	3.53e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971761	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.78	rs75981430	MIMAT0000062_1	hsa-let-7a-5p	-4.18	3.53e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971761	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.78	rs75981430	MIMAT0000062_2	hsa-let-7a-5p	-4.18	3.53e-05	-0.15	-0.19	Menarche (age at onset);	chr11:122971761	chr9:94175962~94175983:+
LGG	cis	rs453301	0.624	rs6987558	MIMAT0019728	hsa-miR-4660	4.17	3.58e-05	0.21	0.19	Joint mobility (Beighton score);	chr8:9005011	chr8:9048453~9048475:+
LGG	cis	rs9859260	0.701	rs9872347	MIMAT0003235	hsa-miR-570-3p	4.17	3.7e-05	0.23	0.19	Mean corpuscular volume;	chr3:196104366	chr3:195699460~195699481:+
LGG	cis	rs453301	0.592	rs4841084	MIMAT0019728	hsa-miR-4660	4.16	3.7e-05	0.22	0.19	Joint mobility (Beighton score);	chr8:9026395	chr8:9048453~9048475:+
LGG	cis	rs453301	0.653	rs2956244	MIMAT0019728	hsa-miR-4660	4.16	3.7e-05	0.22	0.19	Joint mobility (Beighton score);	chr8:9027656	chr8:9048453~9048475:+
LGG	cis	rs2284932	0.556	rs6727168	MIMAT0016895	hsa-miR-2355-5p	-4.16	3.73e-05	-0.14	-0.19	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207124746	chr2:207110043~207110063:-
LGG	cis	rs12712135	0.709	rs11465730	MIMAT0019927	hsa-miR-4772-3p	4.16	3.78e-05	0.19	0.19	Blood protein levels;	chr2:102450398	chr2:102432336~102432357:+
LGG	cis	rs453301	0.624	rs2979265	MIMAT0019728	hsa-miR-4660	4.16	3.81e-05	0.21	0.19	Joint mobility (Beighton score);	chr8:9001207	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.625	rs9905940	MIMAT0000253	hsa-miR-10a-5p	4.16	3.85e-05	0.26	0.19	Epithelial ovarian cancer;Ovarian cancer;	chr17:48536740	chr17:48579904~48579926:-
LGG	cis	rs9982086	0.793	rs73336046	MIMAT0000646	hsa-miR-155-5p	-4.15	3.88e-05	-0.25	-0.19	Carboplatin disposition in epthelial ovarian cancer;	chr21:25554713	chr21:25573983~25574006:+
LGG	cis	rs950880	0.71	rs17027255	MIMAT0019927	hsa-miR-4772-3p	4.15	3.93e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102473668	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs17027258	MIMAT0019927	hsa-miR-4772-3p	4.15	3.93e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102475081	chr2:102432336~102432357:+
LGG	cis	rs4927850	1	rs10881563	MIMAT0003235	hsa-miR-570-3p	4.15	4.01e-05	0.23	0.19	Pancreatic cancer;	chr3:196023354	chr3:195699460~195699481:+
LGG	cis	rs7072216	0.555	rs2296433	MIMAT0005878	hsa-miR-1287-5p	4.14	4.1e-05	0.13	0.19	Metabolite levels;	chr10:98424305	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.555	rs2296432	MIMAT0005878	hsa-miR-1287-5p	4.14	4.1e-05	0.13	0.19	Metabolite levels;	chr10:98424306	chr10:98395271~98395292:-
LGG	cis	rs2284932	0.533	rs918282	MIMAT0016895	hsa-miR-2355-5p	4.14	4.15e-05	0.14	0.19	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207127274	chr2:207110043~207110063:-
LGG	cis	rs950880	0.71	rs873022	MIMAT0019927	hsa-miR-4772-3p	4.13	4.26e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102339223	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3771177	MIMAT0019927	hsa-miR-4772-3p	4.13	4.26e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102339400	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3732129	MIMAT0019927	hsa-miR-4772-3p	4.13	4.26e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102341072	chr2:102432336~102432357:+
LGG	cis	rs1461503	0.932	rs10892944	MIMAT0000062	hsa-let-7a-5p	-4.13	4.3e-05	-0.14	-0.19	Menarche (age at onset);	chr11:122973187	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs10892944	MIMAT0000062_1	hsa-let-7a-5p	-4.13	4.3e-05	-0.14	-0.19	Menarche (age at onset);	chr11:122973187	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs10892944	MIMAT0000062_2	hsa-let-7a-5p	-4.13	4.3e-05	-0.14	-0.19	Menarche (age at onset);	chr11:122973187	chr9:94175962~94175983:+
LGG	cis	rs2284932	0.533	rs16839275	MIMAT0016895	hsa-miR-2355-5p	4.12	4.38e-05	0.14	0.19	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207127431	chr2:207110043~207110063:-
LGG	cis	rs950880	0.71	rs56117144	MIMAT0019927	hsa-miR-4772-3p	4.12	4.44e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102458191	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs57081652	MIMAT0019927	hsa-miR-4772-3p	4.12	4.44e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102458921	chr2:102432336~102432357:+
LGG	cis	rs2494663	0.61	rs6670019	MIMAT0022491	hsa-miR-5698	4.12	4.52e-05	0.24	0.19	Mean platelet volume;	chr1:154045516	chr1:154104562~154104583:-
LGG	cis	rs6088590	1	rs6120747	MIMAT0004772	hsa-miR-499a-3p	-4.12	4.53e-05	-0.21	-0.19	Coronary artery disease;	chr20:34861966	chr20:34990445~34990466:+
LGG	cis	rs950880	0.71	rs3821204	MIMAT0019927	hsa-miR-4772-3p	4.12	4.56e-05	0.22	0.19	Serum protein levels (sST2);	chr2:102343821	chr2:102432336~102432357:+
LGG	cis	rs453301	0.653	rs7005133	MIMAT0019728	hsa-miR-4660	4.11	4.61e-05	0.21	0.19	Joint mobility (Beighton score);	chr8:9043712	chr8:9048453~9048475:+
LGG	cis	rs453301	0.653	rs11784393	MIMAT0019728	hsa-miR-4660	4.11	4.72e-05	0.21	0.19	Joint mobility (Beighton score);	chr8:9045624	chr8:9048453~9048475:+
LGG	cis	rs6993244	1	rs6993244	MIMAT0019728	hsa-miR-4660	4.11	4.74e-05	0.21	0.19	Mean corpuscular hemoglobin;	chr8:9005549	chr8:9048453~9048475:+
LGG	cis	rs111803315	1	rs112952088	MIMAT0022287	hsa-miR-5586-5p	4.1	4.83e-05	0.34	0.18	Schizophrenia;	chr14:59561189	chr14:59646999~59647020:-
LGG	cis	rs950880	0.71	rs12905	MIMAT0019927	hsa-miR-4772-3p	4.1	4.91e-05	0.22	0.18	Serum protein levels (sST2);	chr2:102343547	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs10490204	MIMAT0019927	hsa-miR-4772-3p	4.09	5e-05	0.22	0.18	Serum protein levels (sST2);	chr2:102440074	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs3771150	MIMAT0019927	hsa-miR-4772-3p	4.09	5e-05	0.22	0.18	Serum protein levels (sST2);	chr2:102444391	chr2:102432336~102432357:+
LGG	cis	rs2980436	1	rs2980436	MIMAT0019728	hsa-miR-4660	-4.09	5.04e-05	-0.21	-0.18	Schizophrenia;	chr8:8234503	chr8:9048453~9048475:+
LGG	cis	rs950880	0.614	rs60038017	MIMAT0019927	hsa-miR-4772-3p	4.09	5.11e-05	0.22	0.18	Serum protein levels (sST2);	chr2:102459541	chr2:102432336~102432357:+
LGG	cis	rs7162943	0.887	rs293366	MIMAT0004554	hsa-miR-7-2-3p	4.08	5.2e-05	0.17	0.18	Mean platelet volume;	chr15:89072556	chr15:88611896~88611917:+
LGG	cis	rs453301	0.653	rs1562211	MIMAT0019728	hsa-miR-4660	-4.08	5.32e-05	-0.21	-0.18	Joint mobility (Beighton score);	chr8:9044914	chr8:9048453~9048475:+
LGG	cis	rs111803315	0.661	rs112337414	MIMAT0022287	hsa-miR-5586-5p	4.07	5.41e-05	0.35	0.18	Schizophrenia;	chr14:59490767	chr14:59646999~59647020:-
LGG	cis	rs10216189	0.785	rs4352753	MIMAT0004799	hsa-miR-589-5p	-4.06	5.75e-05	-0.16	-0.18	Relative hand skill in reading disability;	chr7:5487592	chr7:5495873~5495894:-
LGG	cis	rs1912702	0.592	rs4447199	MIMAT0022270	hsa-miR-5579-3p	4.06	5.76e-05	0.22	0.18	Hair greying;	chr11:79462973	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs11237845	MIMAT0022270	hsa-miR-5579-3p	4.06	5.76e-05	0.22	0.18	Hair greying;	chr11:79463095	chr11:79422169~79422190:-
LGG	cis	rs111803315	1	rs78177356	MIMAT0022287	hsa-miR-5586-5p	4.05	5.89e-05	0.33	0.18	Schizophrenia;	chr14:59542249	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs111745772	MIMAT0022287	hsa-miR-5586-5p	4.05	5.89e-05	0.33	0.18	Schizophrenia;	chr14:59544542	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.744	rs113568656	MIMAT0022287	hsa-miR-5586-5p	4.05	5.89e-05	0.33	0.18	Schizophrenia;	chr14:59545204	chr14:59646999~59647020:-
LGG	cis	rs1461503	0.932	rs10892934	MIMAT0000062	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967242	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs10892934	MIMAT0000062_1	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967242	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs10892934	MIMAT0000062_2	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967242	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.932	rs10790542	MIMAT0000062	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967535	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs10790542	MIMAT0000062_1	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967535	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs10790542	MIMAT0000062_2	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967535	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.932	rs10790544	MIMAT0000062	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967622	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs10790544	MIMAT0000062_1	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967622	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs10790544	MIMAT0000062_2	hsa-let-7a-5p	-4.05	5.95e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122967622	chr9:94175962~94175983:+
LGG	cis	rs1912702	0.592	rs4644671	MIMAT0022270	hsa-miR-5579-3p	4.04	6.15e-05	0.22	0.18	Hair greying;	chr11:79462986	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs17138383	MIMAT0022270	hsa-miR-5579-3p	4.04	6.29e-05	0.22	0.18	Hair greying;	chr11:79463378	chr11:79422169~79422190:-
LGG	cis	rs111803315	1	rs112819780	MIMAT0022287	hsa-miR-5586-5p	4.04	6.34e-05	0.34	0.18	Schizophrenia;	chr14:59534846	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs112879614	MIMAT0022287	hsa-miR-5586-5p	4.04	6.34e-05	0.34	0.18	Schizophrenia;	chr14:59534963	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.661	rs113008598	MIMAT0022287	hsa-miR-5586-5p	4.04	6.34e-05	0.34	0.18	Schizophrenia;	chr14:59535594	chr14:59646999~59647020:-
LGG	cis	rs1018697	0.966	rs6584526	MIMAT0022727	hsa-miR-1307-5p	4.03	6.37e-05	0.12	0.18	Colorectal adenoma (advanced);	chr10:102806484	chr10:103394341~103394361:-
LGG	cis	rs1461503	0.934	rs7121840	MIMAT0000062	hsa-let-7a-5p	-4.03	6.43e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974652	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs7121840	MIMAT0000062_1	hsa-let-7a-5p	-4.03	6.43e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974652	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs7121840	MIMAT0000062_2	hsa-let-7a-5p	-4.03	6.43e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974652	chr9:94175962~94175983:+
LGG	cis	rs10216189	0.785	rs4623325	MIMAT0004799	hsa-miR-589-5p	4.03	6.43e-05	0.16	0.18	Relative hand skill in reading disability;	chr7:5487176	chr7:5495873~5495894:-
LGG	cis	rs1912702	0.592	rs7129961	MIMAT0022270	hsa-miR-5579-3p	-4.03	6.48e-05	-0.22	-0.18	Hair greying;	chr11:79464128	chr11:79422169~79422190:-
LGG	cis	rs950880	0.71	rs56331791	MIMAT0019927	hsa-miR-4772-3p	4.02	6.67e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102431697	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11681718	MIMAT0019927	hsa-miR-4772-3p	4.02	6.67e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102434684	chr2:102432336~102432357:+
LGG	cis	rs2980439	0.807	rs2980438	MIMAT0019728	hsa-miR-4660	4.02	6.67e-05	0.2	0.18	Neuroticism;	chr8:8237303	chr8:9048453~9048475:+
LGG	cis	rs2284932	0.533	rs2241263	MIMAT0016895	hsa-miR-2355-5p	4.02	6.7e-05	0.14	0.18	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207131139	chr2:207110043~207110063:-
LGG	cis	rs9859260	0.555	rs9877493	MIMAT0003235	hsa-miR-570-3p	4.02	6.77e-05	0.22	0.18	Mean corpuscular volume;	chr3:196105276	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.529	rs6800500	MIMAT0003235	hsa-miR-570-3p	4.02	6.87e-05	0.23	0.18	Pancreatic cancer;	chr3:196106636	chr3:195699460~195699481:+
LGG	cis	rs2980439	0.818	rs2945249	MIMAT0019728	hsa-miR-4660	4.02	6.9e-05	0.2	0.18	Neuroticism;	chr8:8237204	chr8:9048453~9048475:+
LGG	cis	rs11678825	0.85	rs115289925	MIMAT0031175	hsa-miR-548ba	-4.01	6.99e-05	-0.29	-0.18	Reticulocyte fraction of red cells;	chr2:48440744	chr2:49059603~49059624:+
LGG	cis	rs9398586	0.908	rs2503775	MIMAT0009206	hsa-miR-2113	4.01	7e-05	0.27	0.18	Neuroticism;	chr6:98073724	chr6:98024586~98024606:+
LGG	cis	rs6504340	0.739	rs66459980	MIMAT0000253	hsa-miR-10a-5p	-4.01	7.06e-05	-0.29	-0.18	Primary tooth development (number of teeth);	chr17:48595354	chr17:48579904~48579926:-
LGG	cis	rs4927850	1	rs6799572	MIMAT0003235	hsa-miR-570-3p	4.01	7.1e-05	0.23	0.18	Pancreatic cancer;	chr3:196013537	chr3:195699460~195699481:+
LGG	cis	rs17109512	1	rs942812	MIMAT0005878	hsa-miR-1287-5p	4.01	7.15e-05	0.22	0.18	Aspartate aminotransferase levels;	chr10:98393907	chr10:98395271~98395292:-
LGG	cis	rs17109512	1	rs7073497	MIMAT0005878	hsa-miR-1287-5p	4.01	7.15e-05	0.22	0.18	Aspartate aminotransferase levels;	chr10:98393931	chr10:98395271~98395292:-
LGG	cis	rs1912702	0.592	rs5015504	MIMAT0022270	hsa-miR-5579-3p	4	7.34e-05	0.22	0.18	Hair greying;	chr11:79463452	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs4582999	MIMAT0022270	hsa-miR-5579-3p	4	7.34e-05	0.22	0.18	Hair greying;	chr11:79463472	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs4604915	MIMAT0022270	hsa-miR-5579-3p	4	7.34e-05	0.22	0.18	Hair greying;	chr11:79463487	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs4604916	MIMAT0022270	hsa-miR-5579-3p	4	7.34e-05	0.22	0.18	Hair greying;	chr11:79463503	chr11:79422169~79422190:-
LGG	cis	rs1870653	0.516	rs80050223	MIMAT0003242	hsa-miR-577	4	7.5e-05	0.24	0.18	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114503554	chr4:114656774~114656794:+
LGG	cis	rs1870653	0.516	rs73848142	MIMAT0003242	hsa-miR-577	4	7.5e-05	0.24	0.18	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114506178	chr4:114656774~114656794:+
LGG	cis	rs6088590	0.965	rs6087639	MIMAT0004772	hsa-miR-499a-3p	-3.99	7.52e-05	-0.2	-0.18	Coronary artery disease;	chr20:34856063	chr20:34990445~34990466:+
LGG	cis	rs950880	0.71	rs66566526	MIMAT0019927	hsa-miR-4772-3p	3.99	7.54e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102431342	chr2:102432336~102432357:+
LGG	cis	rs950880	0.645	rs56044378	MIMAT0019927	hsa-miR-4772-3p	3.99	7.56e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102448907	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11123928	MIMAT0019927	hsa-miR-4772-3p	3.99	7.58e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102444826	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11123929	MIMAT0019927	hsa-miR-4772-3p	3.99	7.58e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102450683	chr2:102432336~102432357:+
LGG	cis	rs1461503	0.934	rs7113330	MIMAT0000062	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122972650	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs7113330	MIMAT0000062_1	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122972650	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs7113330	MIMAT0000062_2	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122972650	chr9:94175962~94175983:+
LGG	cis	rs1461503	1	rs1461499	MIMAT0000062	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122973279	chr11:122146568~122146589:-
LGG	cis	rs1461503	1	rs1461499	MIMAT0000062_1	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122973279	chr22:46112752~46112773:+
LGG	cis	rs1461503	1	rs1461499	MIMAT0000062_2	hsa-let-7a-5p	-3.99	7.61e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122973279	chr9:94175962~94175983:+
LGG	cis	rs453301	0.624	rs2979256	MIMAT0019728	hsa-miR-4660	3.99	7.62e-05	0.21	0.18	Joint mobility (Beighton score);	chr8:9014200	chr8:9048453~9048475:+
LGG	cis	rs6088590	0.931	rs6088624	MIMAT0004772	hsa-miR-499a-3p	-3.99	7.68e-05	-0.2	-0.18	Coronary artery disease;	chr20:34849049	chr20:34990445~34990466:+
LGG	cis	rs7120482	0.853	rs17547839	MIMAT0005892	hsa-miR-1304-5p	-3.99	7.72e-05	-0.22	-0.18	Adverse response to radiation therapy;	chr11:93042714	chr11:93733724~93733745:-
LGG	cis	rs111803315	0.661	rs111547327	MIMAT0022287	hsa-miR-5586-5p	3.99	7.72e-05	0.35	0.18	Schizophrenia;	chr14:59567174	chr14:59646999~59647020:-
LGG	cis	rs1355223	0.583	rs1553757	MIMAT0019776	hsa-miR-1343-3p	3.99	7.73e-05	0.13	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34845542	chr11:34941888~34941909:+
LGG	cis	rs1355223	0.583	rs1549789	MIMAT0019776	hsa-miR-1343-3p	3.98	7.9e-05	0.13	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34846400	chr11:34941888~34941909:+
LGG	cis	rs950880	0.71	rs11678975	MIMAT0019927	hsa-miR-4772-3p	3.98	7.99e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102427279	chr2:102432336~102432357:+
LGG	cis	rs453301	0.624	rs4841083	MIMAT0019728	hsa-miR-4660	3.98	8.05e-05	0.21	0.18	Joint mobility (Beighton score);	chr8:9012918	chr8:9048453~9048475:+
LGG	cis	rs2980439	0.783	rs2955587	MIMAT0019728	hsa-miR-4660	3.97	8.28e-05	0.2	0.18	Neuroticism;	chr8:8240557	chr8:9048453~9048475:+
LGG	cis	rs1912702	0.592	rs4644672	MIMAT0022270	hsa-miR-5579-3p	-3.97	8.39e-05	-0.22	-0.18	Hair greying;	chr11:79463733	chr11:79422169~79422190:-
LGG	cis	rs6088590	1	rs2076668	MIMAT0004772	hsa-miR-499a-3p	-3.97	8.39e-05	-0.2	-0.18	Coronary artery disease;	chr20:34849818	chr20:34990445~34990466:+
LGG	cis	rs950880	0.71	rs55645612	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102439201	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs56166614	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102439636	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs17027179	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102440699	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11123927	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102442343	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs10490203	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102442777	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs4851583	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102443840	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs11694360	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102444687	chr2:102432336~102432357:+
LGG	cis	rs950880	0.71	rs7597017	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102445656	chr2:102432336~102432357:+
LGG	cis	rs950880	0.677	rs4851585	MIMAT0019927	hsa-miR-4772-3p	3.97	8.44e-05	0.21	0.18	Serum protein levels (sST2);	chr2:102446294	chr2:102432336~102432357:+
LGG	cis	rs1461503	0.934	rs7107560	MIMAT0000062	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974672	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs7107560	MIMAT0000062_1	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974672	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs7107560	MIMAT0000062_2	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974672	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.809	rs7121955	MIMAT0000062	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974770	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.809	rs7121955	MIMAT0000062_1	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974770	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.809	rs7121955	MIMAT0000062_2	hsa-let-7a-5p	-3.97	8.47e-05	-0.14	-0.18	Menarche (age at onset);	chr11:122974770	chr9:94175962~94175983:+
LGG	cis	rs1355223	0.583	rs2941060	MIMAT0019776	hsa-miR-1343-3p	3.96	8.65e-05	0.13	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34857607	chr11:34941888~34941909:+
LGG	cis	rs7502590	1	rs72854146	MIMAT0015066	hsa-miR-3065-5p	-3.96	8.7e-05	-0.2	-0.18	Neuroticism;	chr17:81104810	chr17:81125886~81125908:+
LGG	cis	rs4927850	1	rs7627706	MIMAT0003235	hsa-miR-570-3p	3.96	8.73e-05	0.22	0.18	Pancreatic cancer;	chr3:196026482	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.881	rs7630489	MIMAT0003235	hsa-miR-570-3p	3.96	8.73e-05	0.22	0.18	Pancreatic cancer;	chr3:196026530	chr3:195699460~195699481:+
LGG	cis	rs4927850	1	rs7627868	MIMAT0003235	hsa-miR-570-3p	3.96	8.73e-05	0.22	0.18	Pancreatic cancer;	chr3:196026602	chr3:195699460~195699481:+
LGG	cis	rs546131	0.515	rs731727	MIMAT0019776	hsa-miR-1343-3p	-3.96	8.82e-05	-0.15	-0.18	Lung disease severity in cystic fibrosis;	chr11:34836287	chr11:34941888~34941909:+
LGG	cis	rs9303542	0.625	rs8073963	MIMAT0000253	hsa-miR-10a-5p	3.95	8.85e-05	0.25	0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48532556	chr17:48579904~48579926:-
LGG	cis	rs10928112	0.804	rs12621499	MIMAT0028224	hsa-miR-7157-5p	-3.95	8.92e-05	-0.21	-0.18	Schizophrenia;	chr2:141566967	chr2:140586663~140586685:-
LGG	cis	rs10928112	0.804	rs2200192	MIMAT0028224	hsa-miR-7157-5p	-3.95	8.92e-05	-0.21	-0.18	Schizophrenia;	chr2:141572996	chr2:140586663~140586685:-
LGG	cis	rs7477	0.557	rs11654658	MIMAT0005942	hsa-miR-1288-3p	-3.95	8.94e-05	-0.17	-0.18	Amyotrophic lateral sclerosis;	chr17:16304141	chr17:16282058~16282078:+
LGG	cis	rs1912702	0.592	rs4517555	MIMAT0022270	hsa-miR-5579-3p	3.95	9.08e-05	0.22	0.18	Hair greying;	chr11:79463840	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.592	rs4554918	MIMAT0022270	hsa-miR-5579-3p	3.95	9.08e-05	0.22	0.18	Hair greying;	chr11:79463847	chr11:79422169~79422190:-
LGG	cis	rs1355223	0.583	rs2956076	MIMAT0019776	hsa-miR-1343-3p	3.95	9.16e-05	0.13	0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34852577	chr11:34941888~34941909:+
LGG	cis	rs4927850	1	rs7630875	MIMAT0003235	hsa-miR-570-3p	3.94	9.28e-05	0.22	0.18	Pancreatic cancer;	chr3:196026895	chr3:195699460~195699481:+
LGG	cis	rs4927850	1	rs10881564	MIMAT0003235	hsa-miR-570-3p	3.94	9.29e-05	0.22	0.18	Pancreatic cancer;	chr3:196023455	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.958	rs1975582	MIMAT0003235	hsa-miR-570-3p	3.94	9.38e-05	0.22	0.18	Pancreatic cancer;	chr3:196024568	chr3:195699460~195699481:+
LGG	cis	rs546131	0.642	rs566798	MIMAT0019776	hsa-miR-1343-3p	-3.93	9.62e-05	-0.14	-0.18	Lung disease severity in cystic fibrosis;	chr11:34830730	chr11:34941888~34941909:+
LGG	cis	rs4927850	0.881	rs7624638	MIMAT0003235	hsa-miR-570-3p	3.93	9.67e-05	0.22	0.18	Pancreatic cancer;	chr3:196021858	chr3:195699460~195699481:+
LGG	cis	rs9303542	0.625	rs11868098	MIMAT0000253	hsa-miR-10a-5p	3.93	9.74e-05	0.25	0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48493507	chr17:48579904~48579926:-
LGG	cis	rs2284932	0.591	rs2269078	MIMAT0016895	hsa-miR-2355-5p	3.93	9.75e-05	0.13	0.18	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207121339	chr2:207110043~207110063:-
LGG	cis	rs7894407	0.76	rs1163085	MIMAT0005951	hsa-miR-1307-3p	-3.93	9.82e-05	-0.11	-0.18	White matter hyperintensity burden;	chr10:103279484	chr10:103394301~103394322:-
LGG	cis	rs9303542	0.625	rs7222242	MIMAT0000253	hsa-miR-10a-5p	-3.93	9.89e-05	-0.26	-0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48488124	chr17:48579904~48579926:-
LGG	cis	rs2494663	0.585	rs7531051	MIMAT0022491	hsa-miR-5698	3.92	1e-04	0.23	0.18	Mean platelet volume;	chr1:154047541	chr1:154104562~154104583:-
LGG	cis	rs950880	0.71	rs4851582	MIMAT0019927	hsa-miR-4772-3p	3.92	0.000101	0.21	0.18	Serum protein levels (sST2);	chr2:102435098	chr2:102432336~102432357:+
LGG	cis	rs7502590	1	rs7502590	MIMAT0015066	hsa-miR-3065-5p	-3.92	0.000101	-0.19	-0.18	Neuroticism;	chr17:81108281	chr17:81125886~81125908:+
LGG	cis	rs9303542	0.625	rs17703660	MIMAT0000253	hsa-miR-10a-5p	-3.92	0.000103	-0.26	-0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48489772	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.625	rs8064626	MIMAT0000253	hsa-miR-10a-5p	-3.92	0.000103	-0.26	-0.18	Epithelial ovarian cancer;Ovarian cancer;	chr17:48490489	chr17:48579904~48579926:-
LGG	cis	rs6504340	0.739	rs1123630	MIMAT0000253	hsa-miR-10a-5p	-3.91	0.000104	-0.28	-0.18	Primary tooth development (number of teeth);	chr17:48594454	chr17:48579904~48579926:-
LGG	cis	rs950880	0.71	rs17027230	MIMAT0019927	hsa-miR-4772-3p	3.91	0.000106	0.21	0.18	Serum protein levels (sST2);	chr2:102462870	chr2:102432336~102432357:+
LGG	cis	rs10993397	0.528	rs356665	MIMAT0019208	hsa-miR-3074-5p	-3.91	0.000106	-0.15	-0.18	Polycystic ovary syndrome;	chr9:95298349	chr9:95086063~95086083:-
LGG	cis	rs1912702	0.861	rs7952683	MIMAT0022270	hsa-miR-5579-3p	3.9	0.000108	0.19	0.18	Hair greying;	chr11:79459472	chr11:79422169~79422190:-
LGG	cis	rs7931462	0.655	rs6483208	MIMAT0005892	hsa-miR-1304-5p	-3.9	0.000108	-0.37	-0.18	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93733724~93733745:-
LGG	cis	rs10928112	0.804	rs7578643	MIMAT0028224	hsa-miR-7157-5p	-3.9	0.000109	-0.21	-0.18	Schizophrenia;	chr2:141577130	chr2:140586663~140586685:-
LGG	cis	rs950880	0.71	rs56043441	MIMAT0019927	hsa-miR-4772-3p	3.9	0.000109	0.21	0.18	Serum protein levels (sST2);	chr2:102470923	chr2:102432336~102432357:+
LGG	cis	rs2494663	0.61	rs11265082	MIMAT0022491	hsa-miR-5698	3.9	0.000109	0.23	0.18	Mean platelet volume;	chr1:154102600	chr1:154104562~154104583:-
LGG	cis	rs7172677	0.737	rs4886669	MIMAT0027665	hsa-miR-6882-3p	-3.9	0.000112	-0.21	-0.18	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155840	chr15:74840642~74840665:-
LGG	cis	rs7829975	0.502	rs7820738	MIMAT0019728	hsa-miR-4660	-3.9	0.000112	-0.2	-0.18	Mood instability;	chr8:8845097	chr8:9048453~9048475:+
LGG	cis	rs11992186	0.505	rs7845203	MIMAT0019728	hsa-miR-4660	3.89	0.000113	0.2	0.18	Neuroticism;	chr8:8287918	chr8:9048453~9048475:+
LGG	cis	rs2494663	0.61	rs7526558	MIMAT0022491	hsa-miR-5698	3.89	0.000113	0.22	0.18	Mean platelet volume;	chr1:154042952	chr1:154104562~154104583:-
LGG	cis	rs10928112	0.73	rs7589997	MIMAT0028224	hsa-miR-7157-5p	-3.89	0.000114	-0.2	-0.18	Schizophrenia;	chr2:141541231	chr2:140586663~140586685:-
LGG	cis	rs860295	0.871	rs12724079	MIMAT0000442	hsa-miR-9-3p	-3.89	0.000115	-0.12	-0.18	Body mass index;	chr1:155464151	chr1:156420354~156420375:-
LGG	cis	rs860295	0.871	rs12724079	MIMAT0000442_1	hsa-miR-9-3p	-3.89	0.000115	-0.12	-0.18	Body mass index;	chr1:155464151	chr15:89368071~89368092:+
LGG	cis	rs860295	0.871	rs12724079	MIMAT0000442_2	hsa-miR-9-3p	-3.89	0.000115	-0.12	-0.18	Body mass index;	chr1:155464151	chr5:88666866~88666887:-
LGG	cis	rs7829975	0.572	rs7005000	MIMAT0019728	hsa-miR-4660	-3.89	0.000115	-0.2	-0.18	Mood instability;	chr8:8939092	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.509	rs7838674	MIMAT0019728	hsa-miR-4660	-3.89	0.000115	-0.2	-0.18	Mood instability;	chr8:8939563	chr8:9048453~9048475:+
LGG	cis	rs4927850	1	rs7625570	MIMAT0003235	hsa-miR-570-3p	3.89	0.000116	0.22	0.18	Pancreatic cancer;	chr3:196020527	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.957	rs4927851	MIMAT0003235	hsa-miR-570-3p	3.89	0.000116	0.22	0.18	Pancreatic cancer;	chr3:196024982	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.918	rs4361313	MIMAT0003235	hsa-miR-570-3p	3.89	0.000116	0.22	0.18	Pancreatic cancer;	chr3:196025389	chr3:195699460~195699481:+
LGG	cis	rs1452787	1	rs1452787	MIMAT0019068	hsa-miR-4529-3p	-3.88	0.000118	-0.22	-0.18	Sclerosing cholangitis and ulcerative colitis (combined);	chr18:55539976	chr18:55479270~55479290:+
LGG	cis	rs7829975	0.536	rs2980439	MIMAT0019728	hsa-miR-4660	3.88	0.000118	0.19	0.18	Mood instability;	chr8:8237348	chr8:9048453~9048475:+
LGG	cis	rs6504340	0.739	rs4793939	MIMAT0000253	hsa-miR-10a-5p	-3.88	0.000119	-0.29	-0.18	Primary tooth development (number of teeth);	chr17:48587873	chr17:48579904~48579926:-
LGG	cis	rs7829975	0.564	rs2976855	MIMAT0019728	hsa-miR-4660	3.88	0.000119	0.2	0.18	Mood instability;	chr8:8444284	chr8:9048453~9048475:+
LGG	cis	rs950880	0.56	rs59247511	MIMAT0019927	hsa-miR-4772-3p	3.88	0.000119	0.18	0.18	Serum protein levels (sST2);	chr2:102337730	chr2:102432336~102432357:+
LGG	cis	rs7894407	0.76	rs4917386	MIMAT0005951	hsa-miR-1307-3p	3.88	0.000121	0.1	0.18	White matter hyperintensity burden;	chr10:103247771	chr10:103394301~103394322:-
LGG	cis	rs9982086	0.557	rs1015045	MIMAT0000646	hsa-miR-155-5p	-3.88	0.000121	-0.21	-0.18	Carboplatin disposition in epthelial ovarian cancer;	chr21:25485824	chr21:25573983~25574006:+
LGG	cis	rs546131	0.515	rs6484737	MIMAT0019776	hsa-miR-1343-3p	-3.87	0.000122	-0.14	-0.18	Lung disease severity in cystic fibrosis;	chr11:34836032	chr11:34941888~34941909:+
LGG	cis	rs1964356	0.967	rs2953802	MIMAT0019728	hsa-miR-4660	3.87	0.000123	0.2	0.17	Mean corpuscular volume;	chr8:8994371	chr8:9048453~9048475:+
LGG	cis	rs453301	0.522	rs1964356	MIMAT0019728	hsa-miR-4660	3.87	0.000123	0.2	0.17	Joint mobility (Beighton score);	chr8:8995760	chr8:9048453~9048475:+
LGG	cis	rs9982086	0.655	rs7277134	MIMAT0000646	hsa-miR-155-5p	3.87	0.000124	0.25	0.17	Carboplatin disposition in epthelial ovarian cancer;	chr21:25609190	chr21:25573983~25574006:+
LGG	cis	rs1950626	0.743	rs1956734	MIMAT0000736	hsa-miR-381-3p	3.87	0.000124	0.06	0.17	Pelvic organ prolapse (moderate/severe);	chr14:100933493	chr14:101045968~101045989:+
LGG	cis	rs7502590	0.92	rs56084168	MIMAT0015066	hsa-miR-3065-5p	-3.87	0.000125	-0.19	-0.17	Neuroticism;	chr17:81110774	chr17:81125886~81125908:+
LGG	cis	rs7829975	0.606	rs10112585	MIMAT0019728	hsa-miR-4660	-3.87	0.000125	-0.2	-0.17	Mood instability;	chr8:8937520	chr8:9048453~9048475:+
LGG	cis	rs9398586	1	rs4476839	MIMAT0009206	hsa-miR-2113	-3.87	0.000125	-0.26	-0.17	Neuroticism;	chr6:97894316	chr6:98024586~98024606:+
LGG	cis	rs111803315	1	rs113284747	MIMAT0022287	hsa-miR-5586-5p	3.86	0.000127	0.33	0.17	Schizophrenia;	chr14:59489219	chr14:59646999~59647020:-
LGG	cis	rs2494663	0.585	rs7547663	MIMAT0022491	hsa-miR-5698	3.86	0.000128	0.22	0.17	Mean platelet volume;	chr1:154057763	chr1:154104562~154104583:-
LGG	cis	rs9982086	0.793	rs2226328	MIMAT0000646	hsa-miR-155-5p	3.86	0.000128	0.25	0.17	Carboplatin disposition in epthelial ovarian cancer;	chr21:25614096	chr21:25573983~25574006:+
LGG	cis	rs1355223	0.583	rs2915179	MIMAT0019776	hsa-miR-1343-3p	3.86	0.000129	0.12	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34850396	chr11:34941888~34941909:+
LGG	cis	rs75358501	0.551	rs10171736	MIMAT0014995	hsa-miR-3130-5p	-3.86	0.00013	-0.18	-0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206728167	chr2:206783276~206783296:-
LGG	cis	rs75358501	0.551	rs10171736	MIMAT0014995_1	hsa-miR-3130-5p	-3.86	0.00013	-0.18	-0.17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206728167	chr2:206783246~206783266:+
LGG	cis	rs1355223	0.583	rs1828298	MIMAT0019776	hsa-miR-1343-3p	3.86	0.00013	0.12	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848892	chr11:34941888~34941909:+
LGG	cis	rs1355223	0.583	rs1396881	MIMAT0019776	hsa-miR-1343-3p	3.86	0.00013	0.12	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34848959	chr11:34941888~34941909:+
LGG	cis	rs9303542	0.625	rs4793889	MIMAT0000253	hsa-miR-10a-5p	3.86	0.00013	0.24	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48514990	chr17:48579904~48579926:-
LGG	cis	rs453301	0.624	rs2915251	MIMAT0019728	hsa-miR-4660	3.86	0.000132	0.2	0.17	Joint mobility (Beighton score);	chr8:9009901	chr8:9048453~9048475:+
LGG	cis	rs6088590	1	rs11696546	MIMAT0004772	hsa-miR-499a-3p	-3.85	0.000132	-0.2	-0.17	Coronary artery disease;	chr20:34865196	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs6120748	MIMAT0004772	hsa-miR-499a-3p	-3.85	0.000132	-0.2	-0.17	Coronary artery disease;	chr20:34870481	chr20:34990445~34990466:+
LGG	cis	rs6504340	0.739	rs4793938	MIMAT0000253	hsa-miR-10a-5p	-3.85	0.000134	-0.29	-0.17	Primary tooth development (number of teeth);	chr17:48587867	chr17:48579904~48579926:-
LGG	cis	rs6088590	0.965	rs6120730	MIMAT0004772	hsa-miR-499a-3p	-3.85	0.000136	-0.19	-0.17	Coronary artery disease;	chr20:34797299	chr20:34990445~34990466:+
LGG	cis	rs9303542	0.729	rs56385452	MIMAT0000253	hsa-miR-10a-5p	-3.85	0.000136	-0.23	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48462049	chr17:48579904~48579926:-
LGG	cis	rs2980439	0.783	rs2948305	MIMAT0019728	hsa-miR-4660	3.85	0.000137	0.2	0.17	Neuroticism;	chr8:8241055	chr8:9048453~9048475:+
LGG	cis	rs1870653	0.516	rs7671567	MIMAT0003242	hsa-miR-577	3.85	0.000137	0.23	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114517952	chr4:114656774~114656794:+
LGG	cis	rs1870653	0.516	rs115941533	MIMAT0003242	hsa-miR-577	3.85	0.000137	0.23	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114521099	chr4:114656774~114656794:+
LGG	cis	rs1870653	0.516	rs7682565	MIMAT0003242	hsa-miR-577	3.85	0.000137	0.23	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114532315	chr4:114656774~114656794:+
LGG	cis	rs1870653	0.516	rs56228000	MIMAT0003242	hsa-miR-577	3.85	0.000137	0.23	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114533268	chr4:114656774~114656794:+
LGG	cis	rs7172677	0.737	rs11072528	MIMAT0027665	hsa-miR-6882-3p	-3.84	0.000138	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144114	chr15:74840642~74840665:-
LGG	cis	rs546131	0.571	rs4351790	MIMAT0019776	hsa-miR-1343-3p	-3.84	0.000139	-0.14	-0.17	Lung disease severity in cystic fibrosis;	chr11:34835344	chr11:34941888~34941909:+
LGG	cis	rs546131	0.571	rs4593984	MIMAT0019776	hsa-miR-1343-3p	-3.84	0.000139	-0.14	-0.17	Lung disease severity in cystic fibrosis;	chr11:34835387	chr11:34941888~34941909:+
LGG	cis	rs546131	0.571	rs2421741	MIMAT0019776	hsa-miR-1343-3p	-3.84	0.000139	-0.14	-0.17	Lung disease severity in cystic fibrosis;	chr11:34835429	chr11:34941888~34941909:+
LGG	cis	rs9398586	1	rs9398586	MIMAT0009206	hsa-miR-2113	3.84	0.00014	0.28	0.17	Neuroticism;	chr6:97884983	chr6:98024586~98024606:+
LGG	cis	rs9303542	0.625	rs4239209	MIMAT0000253	hsa-miR-10a-5p	3.84	0.00014	0.24	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48496955	chr17:48579904~48579926:-
LGG	cis	rs6088590	1	rs6120750	MIMAT0004772	hsa-miR-499a-3p	-3.84	0.00014	-0.19	-0.17	Coronary artery disease;	chr20:34877486	chr20:34990445~34990466:+
LGG	cis	rs1461503	0.9	rs7102462	MIMAT0000062	hsa-let-7a-5p	-3.84	0.000141	-0.13	-0.17	Menarche (age at onset);	chr11:122958059	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs7102462	MIMAT0000062_1	hsa-let-7a-5p	-3.84	0.000141	-0.13	-0.17	Menarche (age at onset);	chr11:122958059	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs7102462	MIMAT0000062_2	hsa-let-7a-5p	-3.84	0.000141	-0.13	-0.17	Menarche (age at onset);	chr11:122958059	chr9:94175962~94175983:+
LGG	cis	rs10928112	0.804	rs12477753	MIMAT0028224	hsa-miR-7157-5p	-3.84	0.000141	-0.21	-0.17	Schizophrenia;	chr2:141573433	chr2:140586663~140586685:-
LGG	cis	rs6088590	1	rs6088590	MIMAT0004772	hsa-miR-499a-3p	-3.84	0.000142	-0.19	-0.17	Coronary artery disease;	chr20:34725762	chr20:34990445~34990466:+
LGG	cis	rs6088590	0.965	rs6087619	MIMAT0004772	hsa-miR-499a-3p	-3.84	0.000142	-0.19	-0.17	Coronary artery disease;	chr20:34700707	chr20:34990445~34990466:+
LGG	cis	rs1870653	0.85	rs7687339	MIMAT0003242	hsa-miR-577	3.84	0.000142	0.22	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114450571	chr4:114656774~114656794:+
LGG	cis	rs1912702	0.565	rs7952698	MIMAT0022270	hsa-miR-5579-3p	3.83	0.000144	0.21	0.17	Hair greying;	chr11:79459511	chr11:79422169~79422190:-
LGG	cis	rs2613964	0.626	rs3732812	MIMAT0018965	hsa-miR-4446-3p	3.83	0.000146	0.21	0.17	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);	chr3:113144180	chr3:113594918~113594939:+
LGG	cis	rs7172677	0.737	rs6495154	MIMAT0027665	hsa-miR-6882-3p	-3.83	0.000146	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144921	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs12442410	MIMAT0027665	hsa-miR-6882-3p	-3.83	0.000146	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145169	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs12910348	MIMAT0027665	hsa-miR-6882-3p	-3.83	0.000146	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145301	chr15:74840642~74840665:-
LGG	cis	rs1950626	0.699	rs12880424	MIMAT0000736	hsa-miR-381-3p	-3.83	0.000147	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100993323	chr14:101045968~101045989:+
LGG	cis	rs1912702	0.861	rs869317	MIMAT0022270	hsa-miR-5579-3p	3.82	0.000149	0.18	0.17	Hair greying;	chr11:79457187	chr11:79422169~79422190:-
LGG	cis	rs6088590	1	rs6119524	MIMAT0004772	hsa-miR-499a-3p	-3.82	0.000149	-0.19	-0.17	Coronary artery disease;	chr20:34786010	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs6088607	MIMAT0004772	hsa-miR-499a-3p	-3.82	0.000149	-0.19	-0.17	Coronary artery disease;	chr20:34790930	chr20:34990445~34990466:+
LGG	cis	rs7172677	0.737	rs7169545	MIMAT0027665	hsa-miR-6882-3p	-3.82	0.00015	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143782	chr15:74840642~74840665:-
LGG	cis	rs1950626	0.699	rs12896504	MIMAT0000736	hsa-miR-381-3p	3.82	0.00015	0.06	0.17	Pelvic organ prolapse (moderate/severe);	chr14:101001611	chr14:101045968~101045989:+
LGG	cis	rs2494663	0.61	rs7521303	MIMAT0022491	hsa-miR-5698	3.82	0.00015	0.22	0.17	Mean platelet volume;	chr1:154039129	chr1:154104562~154104583:-
LGG	cis	rs17730929	0.722	rs13101728	MIMAT0005923	hsa-miR-1269a	-3.82	0.000151	-0.43	-0.17	Colorectal cancer (SNP x SNP interaction);	chr4:66289547	chr4:66276890~66276911:+
LGG	cis	rs17730929	0.656	rs61224431	MIMAT0005923	hsa-miR-1269a	-3.82	0.000151	-0.43	-0.17	Colorectal cancer (SNP x SNP interaction);	chr4:66290047	chr4:66276890~66276911:+
LGG	cis	rs17730929	0.722	rs67668930	MIMAT0005923	hsa-miR-1269a	-3.82	0.000151	-0.43	-0.17	Colorectal cancer (SNP x SNP interaction);	chr4:66290585	chr4:66276890~66276911:+
LGG	cis	rs1461503	0.9	rs3751047	MIMAT0000062	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122957731	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs3751047	MIMAT0000062_1	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122957731	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs3751047	MIMAT0000062_2	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122957731	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.838	rs7107012	MIMAT0000062	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959105	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.838	rs7107012	MIMAT0000062_1	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959105	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.838	rs7107012	MIMAT0000062_2	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959105	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.9	rs7107502	MIMAT0000062	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959506	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs7107502	MIMAT0000062_1	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959506	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs7107502	MIMAT0000062_2	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959506	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.838	rs7126962	MIMAT0000062	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959843	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.838	rs7126962	MIMAT0000062_1	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959843	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.838	rs7126962	MIMAT0000062_2	hsa-let-7a-5p	-3.82	0.000152	-0.13	-0.17	Menarche (age at onset);	chr11:122959843	chr9:94175962~94175983:+
LGG	cis	rs9303542	0.625	rs17703636	MIMAT0000253	hsa-miR-10a-5p	3.82	0.000153	0.26	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48489528	chr17:48579904~48579926:-
LGG	cis	rs1018697	0.966	rs10748832	MIMAT0022727	hsa-miR-1307-5p	3.81	0.000154	0.11	0.17	Colorectal adenoma (advanced);	chr10:102808723	chr10:103394341~103394361:-
LGG	cis	rs9303542	0.625	rs9904760	MIMAT0000253	hsa-miR-10a-5p	-3.81	0.000156	-0.24	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48497669	chr17:48579904~48579926:-
LGG	cis	rs7829975	0.606	rs7819827	MIMAT0019728	hsa-miR-4660	-3.81	0.000156	-0.2	-0.17	Mood instability;	chr8:8939545	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.573	rs7842359	MIMAT0019728	hsa-miR-4660	-3.81	0.000156	-0.2	-0.17	Mood instability;	chr8:8939568	chr8:9048453~9048475:+
LGG	cis	rs7172677	0.737	rs6495158	MIMAT0027665	hsa-miR-6882-3p	-3.81	0.000156	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75156472	chr15:74840642~74840665:-
LGG	cis	rs7894407	0.856	rs7093667	MIMAT0022727	hsa-miR-1307-5p	-3.81	0.000156	-0.11	-0.17	White matter hyperintensity burden;	chr10:103320818	chr10:103394341~103394361:-
LGG	cis	rs950880	0.71	rs17027166	MIMAT0019927	hsa-miR-4772-3p	3.81	0.000156	0.21	0.17	Serum protein levels (sST2);	chr2:102438960	chr2:102432336~102432357:+
LGG	cis	rs1950626	0.75	rs34228453	MIMAT0000736	hsa-miR-381-3p	-3.81	0.000158	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100973984	chr14:101045968~101045989:+
LGG	cis	rs1950626	0.662	rs72700538	MIMAT0000736	hsa-miR-381-3p	-3.81	0.000158	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100975574	chr14:101045968~101045989:+
LGG	cis	rs1950626	0.75	rs12895798	MIMAT0000736	hsa-miR-381-3p	-3.81	0.000158	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100976456	chr14:101045968~101045989:+
LGG	cis	rs6504340	0.739	rs3087996	MIMAT0000253	hsa-miR-10a-5p	3.81	0.000158	0.25	0.17	Primary tooth development (number of teeth);	chr17:48592001	chr17:48579904~48579926:-
LGG	cis	rs2980439	0.517	rs17594093	MIMAT0019728	hsa-miR-4660	-3.81	0.00016	-0.21	-0.17	Neuroticism;	chr8:8248884	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.625	rs8072250	MIMAT0000253	hsa-miR-10a-5p	-3.81	0.00016	-0.24	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48491854	chr17:48579904~48579926:-
LGG	cis	rs1964356	0.967	rs17701675	MIMAT0019728	hsa-miR-4660	-3.8	0.000161	-0.2	-0.17	Mean corpuscular volume;	chr8:8993123	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.593	rs2921061	MIMAT0019728	hsa-miR-4660	3.8	0.000163	0.19	0.17	Mood instability;	chr8:8460105	chr8:9048453~9048475:+
LGG	cis	rs10928112	0.689	rs6429908	MIMAT0028224	hsa-miR-7157-5p	-3.8	0.000163	-0.21	-0.17	Schizophrenia;	chr2:141577292	chr2:140586663~140586685:-
LGG	cis	rs7826238	0.564	rs2921053	MIMAT0019728	hsa-miR-4660	3.8	0.000164	0.19	0.17	Systolic blood pressure;	chr8:8462453	chr8:9048453~9048475:+
LGG	cis	rs2980439	0.818	rs2948294	MIMAT0019728	hsa-miR-4660	3.8	0.000164	0.19	0.17	Neuroticism;	chr8:8237439	chr8:9048453~9048475:+
LGG	cis	rs1355223	0.583	rs2941043	MIMAT0019776	hsa-miR-1343-3p	-3.8	0.000164	-0.12	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr11:34849447	chr11:34941888~34941909:+
LGG	cis	rs7162943	0.734	rs513903	MIMAT0004554	hsa-miR-7-2-3p	3.8	0.000165	0.16	0.17	Mean platelet volume;	chr15:89063264	chr15:88611896~88611917:+
LGG	cis	rs7172677	0.737	rs7181933	MIMAT0027665	hsa-miR-6882-3p	-3.79	0.000167	-0.21	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145574	chr15:74840642~74840665:-
LGG	cis	rs10908557	0.79	rs1547766	MIMAT0022491	hsa-miR-5698	3.79	0.000168	0.22	0.17	Age at first birth;	chr1:153979729	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.75	rs1547767	MIMAT0022491	hsa-miR-5698	3.79	0.000168	0.22	0.17	Age at first birth;	chr1:153979744	chr1:154104562~154104583:-
LGG	cis	rs7162943	0.708	rs293365	MIMAT0004554	hsa-miR-7-2-3p	-3.79	0.000168	-0.16	-0.17	Mean platelet volume;	chr15:89070777	chr15:88611896~88611917:+
LGG	cis	rs7894407	0.856	rs10883855	MIMAT0022727	hsa-miR-1307-5p	-3.79	0.000168	-0.11	-0.17	White matter hyperintensity burden;	chr10:103332690	chr10:103394341~103394361:-
LGG	cis	rs9982086	0.557	rs2829771	MIMAT0000646	hsa-miR-155-5p	-3.79	0.000173	-0.21	-0.17	Carboplatin disposition in epthelial ovarian cancer;	chr21:25468785	chr21:25573983~25574006:+
LGG	cis	rs9303542	0.625	rs7207109	MIMAT0000253	hsa-miR-10a-5p	-3.78	0.000174	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48530455	chr17:48579904~48579926:-
LGG	cis	rs6504340	0.793	rs12946855	MIMAT0000253	hsa-miR-10a-5p	-3.78	0.000174	-0.25	-0.17	Primary tooth development (number of teeth);	chr17:48530668	chr17:48579904~48579926:-
LGG	cis	rs2494663	0.61	rs58300038	MIMAT0022491	hsa-miR-5698	3.78	0.000175	0.22	0.17	Mean platelet volume;	chr1:154098231	chr1:154104562~154104583:-
LGG	cis	rs6088590	1	rs6087623	MIMAT0004772	hsa-miR-499a-3p	-3.78	0.000178	-0.19	-0.17	Coronary artery disease;	chr20:34729858	chr20:34990445~34990466:+
LGG	cis	rs6504340	0.739	rs4793943	MIMAT0000253	hsa-miR-10a-5p	-3.78	0.00018	-0.28	-0.17	Primary tooth development (number of teeth);	chr17:48589575	chr17:48579904~48579926:-
LGG	cis	rs6504340	0.739	rs4793589	MIMAT0000253	hsa-miR-10a-5p	-3.78	0.00018	-0.28	-0.17	Primary tooth development (number of teeth);	chr17:48590501	chr17:48579904~48579926:-
LGG	cis	rs6504340	0.739	rs872760	MIMAT0000253	hsa-miR-10a-5p	-3.78	0.00018	-0.28	-0.17	Primary tooth development (number of teeth);	chr17:48591589	chr17:48579904~48579926:-
LGG	cis	rs7894407	0.76	rs1163072	MIMAT0005951	hsa-miR-1307-3p	3.77	0.00018	0.1	0.17	White matter hyperintensity burden;	chr10:103264621	chr10:103394301~103394322:-
LGG	cis	rs6088590	1	rs6120708	MIMAT0004772	hsa-miR-499a-3p	-3.77	0.000183	-0.19	-0.17	Coronary artery disease;	chr20:34747722	chr20:34990445~34990466:+
LGG	cis	rs7477	0.684	rs12948680	MIMAT0005942	hsa-miR-1288-3p	-3.77	0.000183	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr17:16337031	chr17:16282058~16282078:+
LGG	cis	rs1912702	0.592	rs12279260	MIMAT0022270	hsa-miR-5579-3p	3.77	0.000183	0.21	0.17	Hair greying;	chr11:79460974	chr11:79422169~79422190:-
LGG	cis	rs6088590	0.901	rs6087631	MIMAT0004772	hsa-miR-499a-3p	-3.77	0.000185	-0.19	-0.17	Coronary artery disease;	chr20:34815706	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs6119512	MIMAT0004772	hsa-miR-499a-3p	-3.77	0.000187	-0.19	-0.17	Coronary artery disease;	chr20:34719100	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs6120705	MIMAT0004772	hsa-miR-499a-3p	-3.77	0.000187	-0.19	-0.17	Coronary artery disease;	chr20:34725936	chr20:34990445~34990466:+
LGG	cis	rs7829975	0.606	rs11776838	MIMAT0019728	hsa-miR-4660	-3.76	0.000188	-0.19	-0.17	Mood instability;	chr8:8937291	chr8:9048453~9048475:+
LGG	cis	rs9636107	0.623	rs2123393	MIMAT0019068	hsa-miR-4529-3p	-3.76	0.000189	-0.2	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr18:55547692	chr18:55479270~55479290:+
LGG	cis	rs7829975	0.572	rs28730413	MIMAT0019728	hsa-miR-4660	-3.76	0.000191	-0.19	-0.17	Mood instability;	chr8:8937937	chr8:9048453~9048475:+
LGG	cis	rs9982086	0.557	rs73336106	MIMAT0000646	hsa-miR-155-5p	-3.76	0.000191	-0.2	-0.17	Carboplatin disposition in epthelial ovarian cancer;	chr21:25488159	chr21:25573983~25574006:+
LGG	cis	rs111803315	1	rs76472382	MIMAT0022287	hsa-miR-5586-5p	3.76	0.000192	0.31	0.17	Schizophrenia;	chr14:59487667	chr14:59646999~59647020:-
LGG	cis	rs9299	0.691	rs10853101	MIMAT0000253	hsa-miR-10a-5p	3.76	0.000192	0.21	0.17	Obesity;	chr17:48599098	chr17:48579904~48579926:-
LGG	cis	rs6088590	0.965	rs6120727	MIMAT0004772	hsa-miR-499a-3p	-3.76	0.000193	-0.19	-0.17	Coronary artery disease;	chr20:34786299	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs28542147	MIMAT0004772	hsa-miR-499a-3p	-3.76	0.000193	-0.19	-0.17	Coronary artery disease;	chr20:34788520	chr20:34990445~34990466:+
LGG	cis	rs1461503	0.9	rs1057704	MIMAT0000062	hsa-let-7a-5p	-3.76	0.000194	-0.13	-0.17	Menarche (age at onset);	chr11:122959566	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs1057704	MIMAT0000062_1	hsa-let-7a-5p	-3.76	0.000194	-0.13	-0.17	Menarche (age at onset);	chr11:122959566	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs1057704	MIMAT0000062_2	hsa-let-7a-5p	-3.76	0.000194	-0.13	-0.17	Menarche (age at onset);	chr11:122959566	chr9:94175962~94175983:+
LGG	cis	rs7172677	1	rs11638746	MIMAT0027665	hsa-miR-6882-3p	3.75	0.000196	0.21	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75110767	chr15:74840642~74840665:-
LGG	cis	rs2289583	0.642	rs7162941	MIMAT0027665	hsa-miR-6882-3p	3.75	0.000196	0.19	0.17	Systemic lupus erythematosus;	chr15:75093281	chr15:74840642~74840665:-
LGG	cis	rs2494663	0.61	rs11265040	MIMAT0022491	hsa-miR-5698	3.75	0.000197	0.22	0.17	Mean platelet volume;	chr1:154083103	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.61	rs11586701	MIMAT0022491	hsa-miR-5698	3.75	0.000197	0.22	0.17	Mean platelet volume;	chr1:154083116	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.61	rs11588942	MIMAT0022491	hsa-miR-5698	3.75	0.000197	0.22	0.17	Mean platelet volume;	chr1:154072067	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.61	rs7514662	MIMAT0022491	hsa-miR-5698	3.75	0.000197	0.22	0.17	Mean platelet volume;	chr1:154072239	chr1:154104562~154104583:-
LGG	cis	rs6088590	1	rs2236270	MIMAT0004772	hsa-miR-499a-3p	-3.75	0.000198	-0.19	-0.17	Coronary artery disease;	chr20:34935352	chr20:34990445~34990466:+
LGG	cis	rs1018697	1	rs7080587	MIMAT0022727	hsa-miR-1307-5p	3.75	0.000198	0.11	0.17	Colorectal adenoma (advanced);	chr10:102785517	chr10:103394341~103394361:-
LGG	cis	rs7172677	0.737	rs7178625	MIMAT0027665	hsa-miR-6882-3p	-3.75	2e-04	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75148676	chr15:74840642~74840665:-
LGG	cis	rs1018697	1	rs7896903	MIMAT0022727	hsa-miR-1307-5p	3.75	0.000201	0.11	0.17	Colorectal adenoma (advanced);	chr10:102806660	chr10:103394341~103394361:-
LGG	cis	rs1912702	0.861	rs7941024	MIMAT0022270	hsa-miR-5579-3p	3.75	0.000201	0.18	0.17	Hair greying;	chr11:79456063	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.894	rs12275540	MIMAT0022270	hsa-miR-5579-3p	-3.74	0.000203	-0.18	-0.17	Hair greying;	chr11:79458419	chr11:79422169~79422190:-
LGG	cis	rs1950626	0.743	rs12887333	MIMAT0000736	hsa-miR-381-3p	-3.74	0.000204	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100996275	chr14:101045968~101045989:+
LGG	cis	rs11678825	0.733	rs55707610	MIMAT0031175	hsa-miR-548ba	-3.74	0.000204	-0.27	-0.17	Reticulocyte fraction of red cells;	chr2:48452676	chr2:49059603~49059624:+
LGG	cis	rs6088590	1	rs2295353	MIMAT0004772	hsa-miR-499a-3p	-3.74	0.000204	-0.19	-0.17	Coronary artery disease;	chr20:34768708	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs2295354	MIMAT0004772	hsa-miR-499a-3p	-3.74	0.000204	-0.19	-0.17	Coronary artery disease;	chr20:34768738	chr20:34990445~34990466:+
LGG	cis	rs6088590	0.93	rs6120723	MIMAT0004772	hsa-miR-499a-3p	-3.74	0.000204	-0.19	-0.17	Coronary artery disease;	chr20:34776852	chr20:34990445~34990466:+
LGG	cis	rs111803315	1	rs113482756	MIMAT0022287	hsa-miR-5586-5p	3.74	0.000204	0.31	0.17	Schizophrenia;	chr14:59481904	chr14:59646999~59647020:-
LGG	cis	rs6087685	1	rs6060308	MIMAT0004772	hsa-miR-499a-3p	-3.74	0.000204	-0.19	-0.17	Venous thromboembolism;	chr20:35206575	chr20:34990445~34990466:+
LGG	cis	rs2494663	0.61	rs11264886	MIMAT0022491	hsa-miR-5698	-3.74	0.000204	-0.21	-0.17	Mean platelet volume;	chr1:154024870	chr1:154104562~154104583:-
LGG	cis	rs7172677	0.737	rs7163083	MIMAT0027665	hsa-miR-6882-3p	-3.74	0.000204	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149996	chr15:74840642~74840665:-
LGG	cis	rs2289583	0.597	rs12148708	MIMAT0027665	hsa-miR-6882-3p	3.74	0.000205	0.19	0.17	Systemic lupus erythematosus;	chr15:75092056	chr15:74840642~74840665:-
LGG	cis	rs2289583	0.642	rs8034281	MIMAT0027665	hsa-miR-6882-3p	-3.74	0.000205	-0.19	-0.17	Systemic lupus erythematosus;	chr15:75091886	chr15:74840642~74840665:-
LGG	cis	rs6088590	0.93	rs6087618	MIMAT0004772	hsa-miR-499a-3p	-3.74	0.000205	-0.18	-0.17	Coronary artery disease;	chr20:34700603	chr20:34990445~34990466:+
LGG	cis	rs2921073	0.51	rs2976945	MIMAT0019728	hsa-miR-4660	3.74	0.000206	0.19	0.17	Parkinson's disease;	chr8:8413361	chr8:9048453~9048475:+
LGG	cis	rs10908557	0.957	rs11264743	MIMAT0022491	hsa-miR-5698	3.74	0.000206	0.22	0.17	Age at first birth;	chr1:153969038	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.957	rs12023699	MIMAT0022491	hsa-miR-5698	3.74	0.000206	0.22	0.17	Age at first birth;	chr1:153969680	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.586	rs4845600	MIMAT0022491	hsa-miR-5698	-3.74	0.000207	-0.2	-0.17	Platelet distribution width;	chr1:154133218	chr1:154104562~154104583:-
LGG	cis	rs1018697	1	rs7909612	MIMAT0022727	hsa-miR-1307-5p	3.74	0.000208	0.11	0.17	Colorectal adenoma (advanced);	chr10:102801699	chr10:103394341~103394361:-
LGG	cis	rs7829975	0.542	rs7844374	MIMAT0019728	hsa-miR-4660	-3.74	0.000209	-0.2	-0.17	Mood instability;	chr8:8941174	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.606	rs6601274	MIMAT0019728	hsa-miR-4660	-3.74	0.000209	-0.2	-0.17	Mood instability;	chr8:8941549	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.625	rs7225995	MIMAT0000253	hsa-miR-10a-5p	-3.74	0.000209	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48518906	chr17:48579904~48579926:-
LGG	cis	rs2494663	0.61	rs72694297	MIMAT0022491	hsa-miR-5698	3.74	0.00021	0.22	0.17	Mean platelet volume;	chr1:154078284	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.56	rs11265036	MIMAT0022491	hsa-miR-5698	3.74	0.00021	0.22	0.17	Mean platelet volume;	chr1:154081950	chr1:154104562~154104583:-
LGG	cis	rs9636107	0.623	rs2123392	MIMAT0019068	hsa-miR-4529-3p	-3.73	0.000211	-0.2	-0.17	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr18:55547634	chr18:55479270~55479290:+
LGG	cis	rs10908557	0.758	rs11264865	MIMAT0022491	hsa-miR-5698	3.73	0.000213	0.21	0.17	Age at first birth;	chr1:154014161	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.758	rs12408260	MIMAT0022491	hsa-miR-5698	3.73	0.000214	0.21	0.17	Age at first birth;	chr1:154010449	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.758	rs6672856	MIMAT0022491	hsa-miR-5698	3.73	0.000214	0.21	0.17	Age at first birth;	chr1:154013643	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.758	rs11264866	MIMAT0022491	hsa-miR-5698	3.73	0.000214	0.21	0.17	Age at first birth;	chr1:154014574	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.716	rs6679907	MIMAT0022491	hsa-miR-5698	3.73	0.000214	0.21	0.17	Age at first birth;	chr1:154015676	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.758	rs113165037	MIMAT0022491	hsa-miR-5698	3.73	0.000214	0.21	0.17	Age at first birth;	chr1:154017260	chr1:154104562~154104583:-
LGG	cis	rs7172677	0.695	rs8029756	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143449	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs8029760	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75143499	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs6495153	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144669	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs6495155	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144970	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs7178005	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145079	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs12442392	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145137	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs12914536	MIMAT0027665	hsa-miR-6882-3p	-3.73	0.000216	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75145374	chr15:74840642~74840665:-
LGG	cis	rs2494663	0.61	rs11265049	MIMAT0022491	hsa-miR-5698	3.73	0.000217	0.22	0.17	Mean platelet volume;	chr1:154087468	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.61	rs10908691	MIMAT0022491	hsa-miR-5698	3.73	0.000217	0.22	0.17	Mean platelet volume;	chr1:154089866	chr1:154104562~154104583:-
LGG	cis	rs4927850	1	rs7614767	MIMAT0003235	hsa-miR-570-3p	3.73	0.000218	0.21	0.17	Pancreatic cancer;	chr3:196026580	chr3:195699460~195699481:+
LGG	cis	rs1870653	0.516	rs28555162	MIMAT0003242	hsa-miR-577	3.73	0.000218	0.22	0.17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114517408	chr4:114656774~114656794:+
LGG	cis	rs950880	0.71	rs17026974	MIMAT0019927	hsa-miR-4772-3p	-3.73	0.000218	-0.2	-0.17	Serum protein levels (sST2);	chr2:102335900	chr2:102432336~102432357:+
LGG	cis	rs60311166	1	rs934839	MIMAT0004595	hsa-miR-135a-3p	-3.72	0.000219	-0.35	-0.17	CTACK levels;	chr3:52649882	chr3:52294232~52294253:-
LGG	cis	rs4927850	0.709	rs6783079	MIMAT0003235	hsa-miR-570-3p	3.72	0.000221	0.22	0.17	Pancreatic cancer;	chr3:195925837	chr3:195699460~195699481:+
LGG	cis	rs4927850	0.709	rs6765762	MIMAT0003235	hsa-miR-570-3p	3.72	0.000221	0.22	0.17	Pancreatic cancer;	chr3:195925980	chr3:195699460~195699481:+
LGG	cis	rs10908557	0.635	rs12564669	MIMAT0022491	hsa-miR-5698	3.72	0.000221	0.21	0.17	Age at first birth;	chr1:153993605	chr1:154104562~154104583:-
LGG	cis	rs453301	0.574	rs10081437	MIMAT0019728	hsa-miR-4660	-3.72	0.000221	-0.2	-0.17	Joint mobility (Beighton score);	chr8:9091469	chr8:9048453~9048475:+
LGG	cis	rs7477	0.647	rs7219687	MIMAT0005942	hsa-miR-1288-3p	-3.72	0.000222	-0.17	-0.17	Amyotrophic lateral sclerosis;	chr17:16274073	chr17:16282058~16282078:+
LGG	cis	rs1950626	0.75	rs35820579	MIMAT0000736	hsa-miR-381-3p	-3.72	0.000222	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:100969178	chr14:101045968~101045989:+
LGG	cis	rs6088590	0.965	rs6088620	MIMAT0004772	hsa-miR-499a-3p	-3.72	0.000222	-0.18	-0.17	Coronary artery disease;	chr20:34824219	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs6119535	MIMAT0004772	hsa-miR-499a-3p	-3.72	0.000223	-0.19	-0.17	Coronary artery disease;	chr20:34854335	chr20:34990445~34990466:+
LGG	cis	rs10908557	0.957	rs12403956	MIMAT0022491	hsa-miR-5698	3.72	0.000223	0.22	0.17	Age at first birth;	chr1:153970603	chr1:154104562~154104583:-
LGG	cis	rs10928112	1	rs4363973	MIMAT0028224	hsa-miR-7157-5p	-3.72	0.000224	-0.19	-0.17	Schizophrenia;	chr2:141578535	chr2:140586663~140586685:-
LGG	cis	rs453301	0.598	rs10104303	MIMAT0019728	hsa-miR-4660	3.72	0.000224	0.19	0.17	Joint mobility (Beighton score);	chr8:8977018	chr8:9048453~9048475:+
LGG	cis	rs6495122	0.651	rs11636952	MIMAT0027665	hsa-miR-6882-3p	-3.72	0.000226	-0.19	-0.17	Coffee consumption;Caffeine consumption;Diastolic blood pressure;	chr15:74821981	chr15:74840642~74840665:-
LGG	cis	rs1018697	0.966	rs1475643	MIMAT0022727	hsa-miR-1307-5p	3.72	0.000227	0.11	0.17	Colorectal adenoma (advanced);	chr10:102786710	chr10:103394341~103394361:-
LGG	cis	rs2289583	0.642	rs11635266	MIMAT0027665	hsa-miR-6882-3p	3.72	0.000227	0.19	0.17	Systemic lupus erythematosus;	chr15:75094308	chr15:74840642~74840665:-
LGG	cis	rs7829975	0.567	rs6601273	MIMAT0019728	hsa-miR-4660	-3.72	0.000227	-0.19	-0.17	Mood instability;	chr8:8939009	chr8:9048453~9048475:+
LGG	cis	rs7172677	0.711	rs8035588	MIMAT0027665	hsa-miR-6882-3p	-3.71	0.000232	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75144502	chr15:74840642~74840665:-
LGG	cis	rs7829975	0.509	rs2945269	MIMAT0019728	hsa-miR-4660	3.71	0.000233	0.19	0.17	Mood instability;	chr8:8258056	chr8:9048453~9048475:+
LGG	cis	rs7826238	0.509	rs2948288	MIMAT0019728	hsa-miR-4660	3.71	0.000234	0.19	0.17	Systolic blood pressure;	chr8:8257782	chr8:9048453~9048475:+
LGG	cis	rs2494663	0.585	rs11264996	MIMAT0022491	hsa-miR-5698	3.71	0.000235	0.22	0.17	Mean platelet volume;	chr1:154071080	chr1:154104562~154104583:-
LGG	cis	rs7829975	0.564	rs2921057	MIMAT0019728	hsa-miR-4660	3.71	0.000236	0.19	0.17	Mood instability;	chr8:8461157	chr8:9048453~9048475:+
LGG	cis	rs7172677	0.961	rs4421941	MIMAT0027665	hsa-miR-6882-3p	3.7	0.000237	0.21	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75108399	chr15:74840642~74840665:-
LGG	cis	rs6088590	1	rs6119530	MIMAT0004772	hsa-miR-499a-3p	-3.7	0.000238	-0.18	-0.17	Coronary artery disease;	chr20:34816127	chr20:34990445~34990466:+
LGG	cis	rs2494663	0.585	rs11265076	MIMAT0022491	hsa-miR-5698	3.7	0.00024	0.22	0.17	Mean platelet volume;	chr1:154101823	chr1:154104562~154104583:-
LGG	cis	rs2494663	0.61	rs11264974	MIMAT0022491	hsa-miR-5698	3.7	0.000242	0.21	0.17	Mean platelet volume;	chr1:154063657	chr1:154104562~154104583:-
LGG	cis	rs9398586	1	rs1933718	MIMAT0009206	hsa-miR-2113	-3.7	0.000242	-0.25	-0.17	Neuroticism;	chr6:97893581	chr6:98024586~98024606:+
LGG	cis	rs1018697	1	rs7092346	MIMAT0022727	hsa-miR-1307-5p	3.7	0.000245	0.11	0.17	Colorectal adenoma (advanced);	chr10:102800007	chr10:103394341~103394361:-
LGG	cis	rs1018697	1	rs7086400	MIMAT0022727	hsa-miR-1307-5p	3.7	0.000245	0.11	0.17	Colorectal adenoma (advanced);	chr10:102802340	chr10:103394341~103394361:-
LGG	cis	rs7829975	0.606	rs891570	MIMAT0019728	hsa-miR-4660	-3.7	0.000245	-0.19	-0.17	Mood instability;	chr8:8936944	chr8:9048453~9048475:+
LGG	cis	rs2494663	0.585	rs12049128	MIMAT0022491	hsa-miR-5698	3.69	0.000246	0.21	0.17	Mean platelet volume;	chr1:154021734	chr1:154104562~154104583:-
LGG	cis	rs1018697	0.966	rs1953930	MIMAT0022727	hsa-miR-1307-5p	3.69	0.000247	0.11	0.17	Colorectal adenoma (advanced);	chr10:102789704	chr10:103394341~103394361:-
LGG	cis	rs7172677	1	rs7166695	MIMAT0027665	hsa-miR-6882-3p	3.69	0.000248	0.21	0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75112061	chr15:74840642~74840665:-
LGG	cis	rs7120482	1	rs7120482	MIMAT0005892	hsa-miR-1304-5p	-3.69	0.000248	-0.21	-0.17	Adverse response to radiation therapy;	chr11:93058934	chr11:93733724~93733745:-
LGG	cis	rs11621121	0.547	rs2127869	MIMAT0004808	hsa-miR-625-3p	3.69	0.00025	0.11	0.17	N-glycan levels;	chr14:65327634	chr14:65471153~65471174:+
LGG	cis	rs6088590	1	rs6058111	MIMAT0004772	hsa-miR-499a-3p	-3.69	0.000251	-0.18	-0.17	Coronary artery disease;	chr20:34723195	chr20:34990445~34990466:+
LGG	cis	rs11678825	0.561	rs11674683	MIMAT0031175	hsa-miR-548ba	-3.69	0.000252	-0.31	-0.17	Reticulocyte fraction of red cells;	chr2:48546595	chr2:49059603~49059624:+
LGG	cis	rs2494663	0.61	rs7552737	MIMAT0022491	hsa-miR-5698	3.69	0.000252	0.21	0.17	Mean platelet volume;	chr1:154025328	chr1:154104562~154104583:-
LGG	cis	rs6543140	0.964	rs10200081	MIMAT0019927	hsa-miR-4772-3p	-3.69	0.000252	-0.19	-0.17	Blood protein levels;	chr2:102475097	chr2:102432336~102432357:+
LGG	cis	rs9303542	0.625	rs62065846	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000253	-0.24	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48515496	chr17:48579904~48579926:-
LGG	cis	rs10928112	0.575	rs72853570	MIMAT0028224	hsa-miR-7157-5p	-3.69	0.000253	-0.2	-0.17	Schizophrenia;	chr2:141548968	chr2:140586663~140586685:-
LGG	cis	rs7829975	0.572	rs28446104	MIMAT0019728	hsa-miR-4660	-3.69	0.000254	-0.19	-0.17	Mood instability;	chr8:8938391	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.559	rs56038617	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000255	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48535216	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs55859232	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000255	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48535283	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs12946931	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000255	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48536718	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs12938390	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000255	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48537360	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs12947405	MIMAT0000253	hsa-miR-10a-5p	-3.69	0.000255	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48537393	chr17:48579904~48579926:-
LGG	cis	rs6088590	1	rs2378256	MIMAT0004772	hsa-miR-499a-3p	-3.68	0.000256	-0.18	-0.17	Coronary artery disease;	chr20:34704323	chr20:34990445~34990466:+
LGG	cis	rs6088590	0.965	rs910869	MIMAT0004772	hsa-miR-499a-3p	-3.68	0.000256	-0.18	-0.17	Coronary artery disease;	chr20:34704973	chr20:34990445~34990466:+
LGG	cis	rs1950626	0.699	rs12880855	MIMAT0000736	hsa-miR-381-3p	-3.68	0.000256	-0.06	-0.17	Pelvic organ prolapse (moderate/severe);	chr14:101002045	chr14:101045968~101045989:+
LGG	cis	rs9663711	1	rs9663711	MIMAT0022727	hsa-miR-1307-5p	3.68	0.000257	0.11	0.17	Carotid plaque burden;	chr10:102787871	chr10:103394341~103394361:-
LGG	cis	rs111803315	1	rs77789667	MIMAT0022287	hsa-miR-5586-5p	3.68	0.000263	0.3	0.17	Schizophrenia;	chr14:59473700	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs79021324	MIMAT0022287	hsa-miR-5586-5p	3.68	0.000263	0.3	0.17	Schizophrenia;	chr14:59474706	chr14:59646999~59647020:-
LGG	cis	rs10928112	0.583	rs2890615	MIMAT0028224	hsa-miR-7157-5p	-3.68	0.000265	-0.2	-0.17	Schizophrenia;	chr2:141545351	chr2:140586663~140586685:-
LGG	cis	rs2494663	0.61	rs12048137	MIMAT0022491	hsa-miR-5698	3.67	0.000265	0.21	0.17	Mean platelet volume;	chr1:154020258	chr1:154104562~154104583:-
LGG	cis	rs2289583	0.642	rs12148697	MIMAT0027665	hsa-miR-6882-3p	-3.67	0.000267	-0.19	-0.17	Systemic lupus erythematosus;	chr15:75092034	chr15:74840642~74840665:-
LGG	cis	rs2494663	0.56	rs55696120	MIMAT0022491	hsa-miR-5698	3.67	0.000269	0.21	0.17	Mean platelet volume;	chr1:154077123	chr1:154104562~154104583:-
LGG	cis	rs6088590	1	rs6119516	MIMAT0004772	hsa-miR-499a-3p	-3.67	0.00027	-0.18	-0.17	Coronary artery disease;	chr20:34740220	chr20:34990445~34990466:+
LGG	cis	rs7829975	0.628	rs1109618	MIMAT0019728	hsa-miR-4660	-3.67	0.00027	-0.19	-0.17	Mood instability;	chr8:8713854	chr8:9048453~9048475:+
LGG	cis	rs56184018	0.709	rs10868843	MIMAT0000265	hsa-miR-204-5p	-3.67	0.000271	-0.15	-0.17	Mean platelet volume;	chr9:70504799	chr9:70810031~70810052:-
LGG	cis	rs6695223	1	rs7527292	MIMAT0019232	hsa-miR-4423-5p	3.67	0.000272	0.23	0.17	Venous thromboembolism (SNP x SNP interaction);	chr1:85072207	chr1:85133806~85133827:+
LGG	cis	rs9398586	0.803	rs62420424	MIMAT0009206	hsa-miR-2113	-3.67	0.000272	-0.25	-0.17	Neuroticism;	chr6:98049112	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs12529845	MIMAT0009206	hsa-miR-2113	-3.67	0.000272	-0.25	-0.17	Neuroticism;	chr6:98051074	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs62420439	MIMAT0009206	hsa-miR-2113	-3.67	0.000272	-0.25	-0.17	Neuroticism;	chr6:98057348	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.708	rs9375113	MIMAT0009206	hsa-miR-2113	-3.67	0.000272	-0.25	-0.17	Neuroticism;	chr6:98058249	chr6:98024586~98024606:+
LGG	cis	rs6695223	1	rs6576747	MIMAT0019232	hsa-miR-4423-5p	3.67	0.000273	0.26	0.17	Venous thromboembolism (SNP x SNP interaction);	chr1:85064531	chr1:85133806~85133827:+
LGG	cis	rs111803315	1	rs113172694	MIMAT0022287	hsa-miR-5586-5p	3.67	0.000273	0.31	0.17	Schizophrenia;	chr14:59531501	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs113558975	MIMAT0022287	hsa-miR-5586-5p	3.67	0.000273	0.31	0.17	Schizophrenia;	chr14:59531667	chr14:59646999~59647020:-
LGG	cis	rs6088590	1	rs3787222	MIMAT0004772	hsa-miR-499a-3p	-3.67	0.000274	-0.18	-0.17	Coronary artery disease;	chr20:34745236	chr20:34990445~34990466:+
LGG	cis	rs7829975	0.564	rs2921060	MIMAT0019728	hsa-miR-4660	-3.67	0.000274	-0.18	-0.17	Mood instability;	chr8:8460307	chr8:9048453~9048475:+
LGG	cis	rs2494663	0.61	rs11264875	MIMAT0022491	hsa-miR-5698	3.66	0.000275	0.21	0.17	Mean platelet volume;	chr1:154022171	chr1:154104562~154104583:-
LGG	cis	rs1018697	0.966	rs1953930	MIMAT0005951	hsa-miR-1307-3p	3.66	0.000276	0.1	0.17	Colorectal adenoma (advanced);	chr10:102789704	chr10:103394301~103394322:-
LGG	cis	rs2494663	0.585	rs12021641	MIMAT0022491	hsa-miR-5698	3.66	0.000276	0.21	0.17	Mean platelet volume;	chr1:154091967	chr1:154104562~154104583:-
LGG	cis	rs111803315	0.661	rs111908790	MIMAT0022287	hsa-miR-5586-5p	3.66	0.000277	0.31	0.17	Schizophrenia;	chr14:59532419	chr14:59646999~59647020:-
LGG	cis	rs10928112	0.662	rs16846484	MIMAT0028224	hsa-miR-7157-5p	-3.66	0.000281	-0.21	-0.17	Schizophrenia;	chr2:141562108	chr2:140586663~140586685:-
LGG	cis	rs4400599	0.586	rs4845597	MIMAT0022491	hsa-miR-5698	3.66	0.000282	0.2	0.17	Platelet distribution width;	chr1:154116962	chr1:154104562~154104583:-
LGG	cis	rs6088590	1	rs6087626	MIMAT0004772	hsa-miR-499a-3p	-3.66	0.000283	-0.18	-0.17	Coronary artery disease;	chr20:34759525	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs2180276	MIMAT0004772	hsa-miR-499a-3p	-3.66	0.000283	-0.18	-0.17	Coronary artery disease;	chr20:34772982	chr20:34990445~34990466:+
LGG	cis	rs6088590	1	rs10048849	MIMAT0004772	hsa-miR-499a-3p	-3.66	0.000284	-0.18	-0.17	Coronary artery disease;	chr20:34831877	chr20:34990445~34990466:+
LGG	cis	rs7172677	0.737	rs8025412	MIMAT0027665	hsa-miR-6882-3p	-3.66	0.000284	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75151692	chr15:74840642~74840665:-
LGG	cis	rs56184018	0.709	rs10780937	MIMAT0000265	hsa-miR-204-5p	-3.65	0.000287	-0.15	-0.17	Mean platelet volume;	chr9:70507149	chr9:70810031~70810052:-
LGG	cis	rs7172677	0.711	rs8027552	MIMAT0027665	hsa-miR-6882-3p	-3.65	0.000287	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147052	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs7179426	MIMAT0027665	hsa-miR-6882-3p	-3.65	0.000287	-0.2	-0.17	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75149147	chr15:74840642~74840665:-
LGG	cis	rs6088590	1	rs6087632	MIMAT0004772	hsa-miR-499a-3p	-3.65	0.000287	-0.18	-0.17	Coronary artery disease;	chr20:34819901	chr20:34990445~34990466:+
LGG	cis	rs6088590	0.931	rs6088617	MIMAT0004772	hsa-miR-499a-3p	-3.65	0.000287	-0.18	-0.17	Coronary artery disease;	chr20:34820233	chr20:34990445~34990466:+
LGG	cis	rs9502893	0.513	rs7763984	MIMAT0025851	hsa-miR-6720-3p	3.65	0.000288	0.21	0.17	Pancreatic cancer;	chr6:1323214	chr6:1390324~1390345:-
LGG	cis	rs6088590	1	rs6087625	MIMAT0004772	hsa-miR-499a-3p	3.65	0.000288	0.18	0.17	Coronary artery disease;	chr20:34754674	chr20:34990445~34990466:+
LGG	cis	rs546131	0.515	rs7128804	MIMAT0019776	hsa-miR-1343-3p	-3.65	0.000288	-0.14	-0.17	Lung disease severity in cystic fibrosis;	chr11:34836401	chr11:34941888~34941909:+
LGG	cis	rs950880	0.56	rs66780767	MIMAT0019927	hsa-miR-4772-3p	3.65	0.00029	0.17	0.17	Serum protein levels (sST2);	chr2:102323249	chr2:102432336~102432357:+
LGG	cis	rs6011674	1	rs45469101	MIMAT0016888	hsa-miR-4326	-3.65	0.000291	-0.33	-0.17	Response to cytadine analogues (cytosine arabinoside);	chr20:63243655	chr20:63286818~63286837:+
LGG	cis	rs9303542	0.625	rs6504340	MIMAT0000253	hsa-miR-10a-5p	3.65	0.000292	0.22	0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48539657	chr17:48579904~48579926:-
LGG	cis	rs6088590	1	rs1998028	MIMAT0004772	hsa-miR-499a-3p	-3.65	0.000292	-0.18	-0.17	Coronary artery disease;	chr20:34756792	chr20:34990445~34990466:+
LGG	cis	rs9303542	0.559	rs35621842	MIMAT0000253	hsa-miR-10a-5p	-3.65	0.000293	-0.25	-0.17	Epithelial ovarian cancer;Ovarian cancer;	chr17:48528860	chr17:48579904~48579926:-
LGG	cis	rs7829975	0.711	rs4481596	MIMAT0019728	hsa-miR-4660	3.65	0.000295	0.18	0.17	Mood instability;	chr8:8846820	chr8:9048453~9048475:+
LGG	cis	rs1461503	0.932	rs7107575	MIMAT0000062	hsa-let-7a-5p	3.65	0.000295	0.13	0.17	Menarche (age at onset);	chr11:122974698	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.932	rs7107575	MIMAT0000062_1	hsa-let-7a-5p	3.65	0.000295	0.13	0.17	Menarche (age at onset);	chr11:122974698	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.932	rs7107575	MIMAT0000062_2	hsa-let-7a-5p	3.65	0.000295	0.13	0.17	Menarche (age at onset);	chr11:122974698	chr9:94175962~94175983:+
LGG	cis	rs4919669	0.719	rs12573474	MIMAT0005951	hsa-miR-1307-3p	-3.64	0.000298	-0.17	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102633749	chr10:103394301~103394322:-
LGG	cis	rs2980439	0.846	rs2980437	MIMAT0019728	hsa-miR-4660	-3.64	0.000299	-0.18	-0.16	Neuroticism;	chr8:8237241	chr8:9048453~9048475:+
LGG	cis	rs1950626	0.743	rs12884454	MIMAT0000736	hsa-miR-381-3p	-3.64	0.000299	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100999290	chr14:101045968~101045989:+
LGG	cis	rs1018697	1	rs7088711	MIMAT0022727	hsa-miR-1307-5p	-3.64	0.000299	-0.11	-0.16	Colorectal adenoma (advanced);	chr10:102799509	chr10:103394341~103394361:-
LGG	cis	rs7894407	0.892	rs10883859	MIMAT0005951	hsa-miR-1307-3p	3.64	3e-04	0.1	0.16	White matter hyperintensity burden;	chr10:103368377	chr10:103394301~103394322:-
LGG	cis	rs1950626	0.75	rs34144313	MIMAT0000736	hsa-miR-381-3p	-3.64	0.000303	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100964879	chr14:101045968~101045989:+
LGG	cis	rs1018697	1	rs7073114	MIMAT0022727	hsa-miR-1307-5p	3.64	0.000303	0.11	0.16	Colorectal adenoma (advanced);	chr10:102795894	chr10:103394341~103394361:-
LGG	cis	rs10928112	0.689	rs12615716	MIMAT0028224	hsa-miR-7157-5p	-3.64	0.000304	-0.2	-0.16	Schizophrenia;	chr2:141563739	chr2:140586663~140586685:-
LGG	cis	rs10928112	0.689	rs1842934	MIMAT0028224	hsa-miR-7157-5p	-3.64	0.000304	-0.2	-0.16	Schizophrenia;	chr2:141576564	chr2:140586663~140586685:-
LGG	cis	rs1018697	1	rs1018696	MIMAT0005951	hsa-miR-1307-3p	3.64	0.000304	0.1	0.16	Colorectal adenoma (advanced);	chr10:102789309	chr10:103394301~103394322:-
LGG	cis	rs1018697	0.897	rs2150929	MIMAT0005951	hsa-miR-1307-3p	3.64	0.000304	0.1	0.16	Colorectal adenoma (advanced);	chr10:102791180	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs2150928	MIMAT0005951	hsa-miR-1307-3p	3.64	0.000304	0.1	0.16	Colorectal adenoma (advanced);	chr10:102791228	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs7911528	MIMAT0005951	hsa-miR-1307-3p	3.64	0.000304	0.1	0.16	Colorectal adenoma (advanced);	chr10:102791810	chr10:103394301~103394322:-
LGG	cis	rs10908557	0.758	rs6701341	MIMAT0022491	hsa-miR-5698	3.64	0.000305	0.21	0.16	Age at first birth;	chr1:154002145	chr1:154104562~154104583:-
LGG	cis	rs1018697	1	rs4919678	MIMAT0022727	hsa-miR-1307-5p	3.64	0.000305	0.11	0.16	Colorectal adenoma (advanced);	chr10:102794606	chr10:103394341~103394361:-
LGG	cis	rs7829975	0.593	rs2921077	MIMAT0019728	hsa-miR-4660	3.64	0.000306	0.18	0.16	Mood instability;	chr8:8446992	chr8:9048453~9048475:+
LGG	cis	rs4919669	0.668	rs17114641	MIMAT0005951	hsa-miR-1307-3p	-3.64	0.000308	-0.17	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102527602	chr10:103394301~103394322:-
LGG	cis	rs1452787	0.515	rs72627232	MIMAT0019068	hsa-miR-4529-3p	-3.64	0.000308	-0.26	-0.16	Sclerosing cholangitis and ulcerative colitis (combined);	chr18:55572685	chr18:55479270~55479290:+
LGG	cis	rs9858542	0.953	rs9814873	MIMAT0003393	hsa-miR-425-5p	3.63	0.000309	0.12	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chr3:49020199~49020221:-
LGG	cis	rs7172677	0.737	rs11855234	MIMAT0027665	hsa-miR-6882-3p	-3.63	0.000309	-0.19	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75154493	chr15:74840642~74840665:-
LGG	cis	rs1018697	1	rs1018696	MIMAT0022727	hsa-miR-1307-5p	3.63	0.000309	0.11	0.16	Colorectal adenoma (advanced);	chr10:102789309	chr10:103394341~103394361:-
LGG	cis	rs1018697	0.897	rs2150929	MIMAT0022727	hsa-miR-1307-5p	3.63	0.000309	0.11	0.16	Colorectal adenoma (advanced);	chr10:102791180	chr10:103394341~103394361:-
LGG	cis	rs1018697	1	rs2150928	MIMAT0022727	hsa-miR-1307-5p	3.63	0.000309	0.11	0.16	Colorectal adenoma (advanced);	chr10:102791228	chr10:103394341~103394361:-
LGG	cis	rs1018697	1	rs7911528	MIMAT0022727	hsa-miR-1307-5p	3.63	0.000309	0.11	0.16	Colorectal adenoma (advanced);	chr10:102791810	chr10:103394341~103394361:-
LGG	cis	rs7477	0.616	rs35762856	MIMAT0005942	hsa-miR-1288-3p	3.63	0.00031	0.17	0.16	Amyotrophic lateral sclerosis;	chr17:16334921	chr17:16282058~16282078:+
LGG	cis	rs17604090	0.55	rs111649163	MIMAT0004800	hsa-miR-550a-5p	3.63	0.000312	0.2	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649560	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.55	rs111649163	MIMAT0004800_1	hsa-miR-550a-5p	3.63	0.000312	0.2	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649560	chr7:32733002~32733024:+
LGG	cis	rs7829975	0.54	rs2976909	MIMAT0019728	hsa-miR-4660	-3.63	0.000312	-0.18	-0.16	Mood instability;	chr8:8489180	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.592	rs34378400	MIMAT0000253	hsa-miR-10a-5p	-3.63	0.000313	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48511903	chr17:48579904~48579926:-
LGG	cis	rs1018697	1	rs6584525	MIMAT0022727	hsa-miR-1307-5p	3.63	0.000314	0.11	0.16	Colorectal adenoma (advanced);	chr10:102792224	chr10:103394341~103394361:-
LGG	cis	rs111803315	1	rs111882043	MIMAT0022287	hsa-miR-5586-5p	3.63	0.000315	0.29	0.16	Schizophrenia;	chr14:59432638	chr14:59646999~59647020:-
LGG	cis	rs9982086	1	rs1537088	MIMAT0000646	hsa-miR-155-5p	-3.63	0.000315	-0.24	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr21:25592548	chr21:25573983~25574006:+
LGG	cis	rs2945232	1	rs2945232	MIMAT0019728	hsa-miR-4660	3.63	0.000318	0.18	0.16	Schizophrenia;	chr8:8240516	chr8:9048453~9048475:+
LGG	cis	rs4927850	1	rs4927850	MIMAT0003235	hsa-miR-570-3p	-3.63	0.000319	-0.2	-0.16	Pancreatic cancer;	chr3:196024759	chr3:195699460~195699481:+
LGG	cis	rs1018697	1	rs10786710	MIMAT0022727	hsa-miR-1307-5p	3.63	0.00032	0.11	0.16	Colorectal adenoma (advanced);	chr10:102788982	chr10:103394341~103394361:-
LGG	cis	rs6088590	1	rs55753039	MIMAT0004772	hsa-miR-499a-3p	-3.62	0.000321	-0.18	-0.16	Coronary artery disease;	chr20:34807137	chr20:34990445~34990466:+
LGG	cis	rs950880	0.56	rs1362349	MIMAT0019927	hsa-miR-4772-3p	3.62	0.000321	0.17	0.16	Serum protein levels (sST2);	chr2:102335512	chr2:102432336~102432357:+
LGG	cis	rs9858542	0.953	rs11715915	MIMAT0003393	hsa-miR-425-5p	-3.62	0.000321	-0.12	-0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chr3:49020199~49020221:-
LGG	cis	rs10928112	0.804	rs12620304	MIMAT0028224	hsa-miR-7157-5p	-3.62	0.000322	-0.2	-0.16	Schizophrenia;	chr2:141578122	chr2:140586663~140586685:-
LGG	cis	rs6543140	0.964	rs10193485	MIMAT0019927	hsa-miR-4772-3p	-3.62	0.000323	-0.18	-0.16	Blood protein levels;	chr2:102473114	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs10196334	MIMAT0019927	hsa-miR-4772-3p	-3.62	0.000323	-0.18	-0.16	Blood protein levels;	chr2:102473582	chr2:102432336~102432357:+
LGG	cis	rs4400599	0.586	rs11265122	MIMAT0022491	hsa-miR-5698	3.62	0.000324	0.2	0.16	Platelet distribution width;	chr1:154114557	chr1:154104562~154104583:-
LGG	cis	rs7829975	0.511	rs2921028	MIMAT0019728	hsa-miR-4660	3.62	0.000324	0.18	0.16	Mood instability;	chr8:8482967	chr8:9048453~9048475:+
LGG	cis	rs7072216	1	rs7072216	MIMAT0005878	hsa-miR-1287-5p	3.62	0.000324	0.09	0.16	Metabolite levels;	chr10:98397096	chr10:98395271~98395292:-
LGG	cis	rs1461503	1	rs1461503	MIMAT0000062	hsa-let-7a-5p	-3.62	0.000325	-0.12	-0.16	Menarche (age at onset);	chr11:122974367	chr11:122146568~122146589:-
LGG	cis	rs1461503	1	rs1461503	MIMAT0000062_1	hsa-let-7a-5p	-3.62	0.000325	-0.12	-0.16	Menarche (age at onset);	chr11:122974367	chr22:46112752~46112773:+
LGG	cis	rs1461503	1	rs1461503	MIMAT0000062_2	hsa-let-7a-5p	-3.62	0.000325	-0.12	-0.16	Menarche (age at onset);	chr11:122974367	chr9:94175962~94175983:+
LGG	cis	rs7172677	0.501	rs8040061	MIMAT0027665	hsa-miR-6882-3p	3.62	0.000326	0.18	0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75101379	chr15:74840642~74840665:-
LGG	cis	rs546131	0.642	rs561477	MIMAT0019776	hsa-miR-1343-3p	3.62	0.000326	0.13	0.16	Lung disease severity in cystic fibrosis;	chr11:34830605	chr11:34941888~34941909:+
LGG	cis	rs9398586	0.803	rs9388076	MIMAT0009206	hsa-miR-2113	-3.62	0.000327	-0.25	-0.16	Neuroticism;	chr6:98072693	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs9490465	MIMAT0009206	hsa-miR-2113	-3.62	0.000327	-0.25	-0.16	Neuroticism;	chr6:98076403	chr6:98024586~98024606:+
LGG	cis	rs111803315	1	rs112661971	MIMAT0022287	hsa-miR-5586-5p	3.62	0.000331	0.29	0.16	Schizophrenia;	chr14:59434336	chr14:59646999~59647020:-
LGG	cis	rs7172677	0.737	rs8033754	MIMAT0027665	hsa-miR-6882-3p	3.62	0.000332	0.19	0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75147439	chr15:74840642~74840665:-
LGG	cis	rs10908557	0.915	rs11583896	MIMAT0022491	hsa-miR-5698	3.61	0.000333	0.21	0.16	Age at first birth;	chr1:153796506	chr1:154104562~154104583:-
LGG	cis	rs11743006	0.626	rs78078532	MIMAT0004911	hsa-miR-874-3p	-3.61	0.000335	-0.13	-0.16	Mathematical ability;	chr5:137127456	chr5:137647582~137647603:-
LGG	cis	rs11743006	0.626	rs76667027	MIMAT0004911	hsa-miR-874-3p	-3.61	0.000335	-0.13	-0.16	Mathematical ability;	chr5:137134672	chr5:137647582~137647603:-
LGG	cis	rs9303542	0.625	rs8066613	MIMAT0000253	hsa-miR-10a-5p	-3.61	0.000336	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48506158	chr17:48579904~48579926:-
LGG	cis	rs2494663	0.585	rs7520349	MIMAT0022491	hsa-miR-5698	3.61	0.000336	0.21	0.16	Mean platelet volume;	chr1:154109173	chr1:154104562~154104583:-
LGG	cis	rs309064	1	rs309064	MIMAT0000429	hsa-miR-137-3p	3.61	0.00034	0.1	0.16	Blood pressure;Blood pressure (anthropometric measures interaction);	chr1:98954812	chr1:98046091~98046113:-
LGG	cis	rs10908557	0.957	rs6724	MIMAT0022491	hsa-miR-5698	3.61	0.000341	0.21	0.16	Age at first birth;	chr1:153959736	chr1:154104562~154104583:-
LGG	cis	rs1950626	0.75	rs72700530	MIMAT0000736	hsa-miR-381-3p	-3.61	0.000342	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100963122	chr14:101045968~101045989:+
LGG	cis	rs1018697	0.966	rs11191396	MIMAT0022727	hsa-miR-1307-5p	3.61	0.000342	0.11	0.16	Colorectal adenoma (advanced);	chr10:102793108	chr10:103394341~103394361:-
LGG	cis	rs1018697	1	rs4919677	MIMAT0022727	hsa-miR-1307-5p	3.61	0.000342	0.11	0.16	Colorectal adenoma (advanced);	chr10:102794547	chr10:103394341~103394361:-
LGG	cis	rs1018697	1	rs7092051	MIMAT0022727	hsa-miR-1307-5p	3.61	0.000342	0.11	0.16	Colorectal adenoma (advanced);	chr10:102799720	chr10:103394341~103394361:-
LGG	cis	rs7829975	0.582	rs11783950	MIMAT0019728	hsa-miR-4660	-3.61	0.000343	-0.18	-0.16	Mood instability;	chr8:8740321	chr8:9048453~9048475:+
LGG	cis	rs7172677	0.737	rs8027604	MIMAT0027665	hsa-miR-6882-3p	-3.61	0.000343	-0.19	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155432	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.737	rs4886668	MIMAT0027665	hsa-miR-6882-3p	-3.61	0.000343	-0.19	-0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75155693	chr15:74840642~74840665:-
LGG	cis	rs7894407	0.634	rs56060736	MIMAT0022727	hsa-miR-1307-5p	3.61	0.000344	0.12	0.16	White matter hyperintensity burden;	chr10:103310496	chr10:103394341~103394361:-
LGG	cis	rs7894407	0.675	rs72846190	MIMAT0022727	hsa-miR-1307-5p	3.61	0.000344	0.12	0.16	White matter hyperintensity burden;	chr10:103319660	chr10:103394341~103394361:-
LGG	cis	rs10928112	0.73	rs12467062	MIMAT0028224	hsa-miR-7157-5p	-3.6	0.000347	-0.19	-0.16	Schizophrenia;	chr2:141551545	chr2:140586663~140586685:-
LGG	cis	rs1018697	1	rs6584525	MIMAT0005951	hsa-miR-1307-3p	3.6	0.000347	0.1	0.16	Colorectal adenoma (advanced);	chr10:102792224	chr10:103394301~103394322:-
LGG	cis	rs10928112	0.73	rs12478973	MIMAT0028224	hsa-miR-7157-5p	-3.6	0.000348	-0.19	-0.16	Schizophrenia;	chr2:141551761	chr2:140586663~140586685:-
LGG	cis	rs111803315	1	rs76579763	MIMAT0022287	hsa-miR-5586-5p	3.6	0.000352	0.3	0.16	Schizophrenia;	chr14:59469253	chr14:59646999~59647020:-
LGG	cis	rs1682825	0.615	rs350661	MIMAT0004947	hsa-miR-885-5p	3.6	0.000353	0.16	0.16	Economic and political preferences (feminism/equality);	chr3:10738018	chr3:10394531~10394552:-
LGG	cis	rs111803315	1	rs111237243	MIMAT0022287	hsa-miR-5586-5p	3.6	0.000353	0.29	0.16	Schizophrenia;	chr14:59524312	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs112476368	MIMAT0022287	hsa-miR-5586-5p	3.6	0.000353	0.29	0.16	Schizophrenia;	chr14:59524734	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs111489600	MIMAT0022287	hsa-miR-5586-5p	3.6	0.000353	0.29	0.16	Schizophrenia;	chr14:59526303	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.661	rs111876050	MIMAT0022287	hsa-miR-5586-5p	3.6	0.000353	0.29	0.16	Schizophrenia;	chr14:59527949	chr14:59646999~59647020:-
LGG	cis	rs9398586	0.803	rs9401542	MIMAT0009206	hsa-miR-2113	-3.6	0.000356	-0.25	-0.16	Neuroticism;	chr6:98070322	chr6:98024586~98024606:+
LGG	cis	rs9663711	1	rs9663711	MIMAT0005951	hsa-miR-1307-3p	3.6	0.000358	0.1	0.16	Carotid plaque burden;	chr10:102787871	chr10:103394301~103394322:-
LGG	cis	rs6543140	0.964	rs4851593	MIMAT0019927	hsa-miR-4772-3p	3.59	0.000359	0.18	0.16	Blood protein levels;	chr2:102472767	chr2:102432336~102432357:+
LGG	cis	rs56184018	0.686	rs3923699	MIMAT0000265	hsa-miR-204-5p	3.59	0.000359	0.15	0.16	Mean platelet volume;	chr9:70487908	chr9:70810031~70810052:-
LGG	cis	rs111803315	1	rs111355947	MIMAT0022287	hsa-miR-5586-5p	3.59	0.00036	0.29	0.16	Schizophrenia;	chr14:59445267	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs113878281	MIMAT0022287	hsa-miR-5586-5p	3.59	0.00036	0.29	0.16	Schizophrenia;	chr14:59450776	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs112261101	MIMAT0022287	hsa-miR-5586-5p	3.59	0.00036	0.29	0.16	Schizophrenia;	chr14:59450826	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs111476301	MIMAT0022287	hsa-miR-5586-5p	3.59	0.00036	0.29	0.16	Schizophrenia;	chr14:59453473	chr14:59646999~59647020:-
LGG	cis	rs1018697	1	rs10748830	MIMAT0022727	hsa-miR-1307-5p	3.59	0.00036	0.11	0.16	Colorectal adenoma (advanced);	chr10:102788625	chr10:103394341~103394361:-
LGG	cis	rs9858542	0.953	rs9859556	MIMAT0003393	hsa-miR-425-5p	3.59	0.000362	0.12	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chr3:49020199~49020221:-
LGG	cis	rs546131	0.642	rs568529	MIMAT0019776	hsa-miR-1343-3p	3.59	0.000362	0.13	0.16	Lung disease severity in cystic fibrosis;	chr11:34820959	chr11:34941888~34941909:+
LGG	cis	rs1950626	0.743	rs12889283	MIMAT0000736	hsa-miR-381-3p	-3.59	0.000364	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100999664	chr14:101045968~101045989:+
LGG	cis	rs10928112	0.73	rs7597633	MIMAT0028224	hsa-miR-7157-5p	-3.59	0.000364	-0.19	-0.16	Schizophrenia;	chr2:141552528	chr2:140586663~140586685:-
LGG	cis	rs1018697	0.966	rs10748831	MIMAT0022727	hsa-miR-1307-5p	3.59	0.000365	0.11	0.16	Colorectal adenoma (advanced);	chr10:102798986	chr10:103394341~103394361:-
LGG	cis	rs1870653	0.516	rs76290069	MIMAT0003242	hsa-miR-577	3.59	0.000367	0.21	0.16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114582168	chr4:114656774~114656794:+
LGG	cis	rs9303542	0.729	rs8074054	MIMAT0000253	hsa-miR-10a-5p	-3.59	0.000369	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48465225	chr17:48579904~48579926:-
LGG	cis	rs10908557	0.709	rs72694300	MIMAT0022491	hsa-miR-5698	3.59	0.000369	0.21	0.16	Age at first birth;	chr1:154084358	chr1:154104562~154104583:-
LGG	cis	rs7829975	0.606	rs6422352	MIMAT0019728	hsa-miR-4660	-3.59	0.00037	-0.19	-0.16	Mood instability;	chr8:8936683	chr8:9048453~9048475:+
LGG	cis	rs9303542	0.643	rs34791545	MIMAT0000253	hsa-miR-10a-5p	-3.59	0.00037	-0.21	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48411085	chr17:48579904~48579926:-
LGG	cis	rs4243849	0.736	rs10105839	MIMAT0000245	hsa-miR-30d-5p	3.58	0.000376	0.13	0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135734738	chr8:134804919~134804940:-
LGG	cis	rs6011674	1	rs11908424	MIMAT0016888	hsa-miR-4326	-3.58	0.000376	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63232603	chr20:63286818~63286837:+
LGG	cis	rs10928112	1	rs10928112	MIMAT0028224	hsa-miR-7157-5p	-3.58	0.000376	-0.19	-0.16	Schizophrenia;	chr2:141573400	chr2:140586663~140586685:-
LGG	cis	rs7829975	0.517	rs12542733	MIMAT0019728	hsa-miR-4660	-3.58	0.000378	-0.18	-0.16	Mood instability;	chr8:8967348	chr8:9048453~9048475:+
LGG	cis	rs1018697	1	rs7080587	MIMAT0005951	hsa-miR-1307-3p	3.58	0.000379	0.1	0.16	Colorectal adenoma (advanced);	chr10:102785517	chr10:103394301~103394322:-
LGG	cis	rs7829975	0.511	rs2976906	MIMAT0019728	hsa-miR-4660	3.58	0.000379	0.18	0.16	Mood instability;	chr8:8484905	chr8:9048453~9048475:+
LGG	cis	rs6088590	0.965	rs13040449	MIMAT0004772	hsa-miR-499a-3p	-3.58	0.000382	-0.18	-0.16	Coronary artery disease;	chr20:34771098	chr20:34990445~34990466:+
LGG	cis	rs56184018	0.709	rs7357742	MIMAT0000265	hsa-miR-204-5p	3.58	0.000384	0.15	0.16	Mean platelet volume;	chr9:70490810	chr9:70810031~70810052:-
LGG	cis	rs6543140	0.964	rs13393175	MIMAT0019927	hsa-miR-4772-3p	-3.57	0.000388	-0.18	-0.16	Blood protein levels;	chr2:102462389	chr2:102432336~102432357:+
LGG	cis	rs702485	0.903	rs836526	MIMAT0027648	hsa-miR-6874-5p	-3.57	0.000388	-0.2	-0.16	HDL cholesterol levels;HDL cholesterol;	chr7:6426458	chr7:5711883~5711905:-
LGG	cis	rs1018697	0.966	rs1475643	MIMAT0005951	hsa-miR-1307-3p	3.57	0.000388	0.1	0.16	Colorectal adenoma (advanced);	chr10:102786710	chr10:103394301~103394322:-
LGG	cis	rs9398586	0.803	rs62420423	MIMAT0009206	hsa-miR-2113	-3.57	0.000388	-0.24	-0.16	Neuroticism;	chr6:98042908	chr6:98024586~98024606:+
LGG	cis	rs4243849	0.769	rs9644461	MIMAT0000245	hsa-miR-30d-5p	3.57	0.000389	0.13	0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135735683	chr8:134804919~134804940:-
LGG	cis	rs1461503	0.512	rs4259833	MIMAT0000062	hsa-let-7a-5p	-3.57	0.000389	-0.12	-0.16	Menarche (age at onset);	chr11:122938497	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.512	rs4259833	MIMAT0000062_1	hsa-let-7a-5p	-3.57	0.000389	-0.12	-0.16	Menarche (age at onset);	chr11:122938497	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.512	rs4259833	MIMAT0000062_2	hsa-let-7a-5p	-3.57	0.000389	-0.12	-0.16	Menarche (age at onset);	chr11:122938497	chr9:94175962~94175983:+
LGG	cis	rs546131	0.642	rs512013	MIMAT0019776	hsa-miR-1343-3p	3.57	0.000389	0.13	0.16	Lung disease severity in cystic fibrosis;	chr11:34820678	chr11:34941888~34941909:+
LGG	cis	rs546131	0.642	rs2956073	MIMAT0019776	hsa-miR-1343-3p	3.57	0.000389	0.13	0.16	Lung disease severity in cystic fibrosis;	chr11:34821336	chr11:34941888~34941909:+
LGG	cis	rs7829975	0.617	rs4841071	MIMAT0019728	hsa-miR-4660	3.57	0.00039	0.18	0.16	Mood instability;	chr8:8933634	chr8:9048453~9048475:+
LGG	cis	rs9665626	1	rs9665626	MIMAT0005951	hsa-miR-1307-3p	3.57	0.00039	0.16	0.16	Schizophrenia;	chr10:102540881	chr10:103394301~103394322:-
LGG	cis	rs1950626	0.705	rs34991312	MIMAT0000736	hsa-miR-381-3p	-3.57	0.00039	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100968830	chr14:101045968~101045989:+
LGG	cis	rs1950626	0.75	rs34061904	MIMAT0000736	hsa-miR-381-3p	-3.57	0.00039	-0.06	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100969637	chr14:101045968~101045989:+
LGG	cis	rs56184018	0.709	rs4472581	MIMAT0000265	hsa-miR-204-5p	3.57	0.000391	0.15	0.16	Mean platelet volume;	chr9:70489967	chr9:70810031~70810052:-
LGG	cis	rs9398586	0.803	rs4499937	MIMAT0009206	hsa-miR-2113	-3.57	0.000396	-0.24	-0.16	Neuroticism;	chr6:98045133	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs62420425	MIMAT0009206	hsa-miR-2113	-3.57	0.000396	-0.24	-0.16	Neuroticism;	chr6:98049219	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs9375110	MIMAT0009206	hsa-miR-2113	-3.57	0.000396	-0.24	-0.16	Neuroticism;	chr6:98054918	chr6:98024586~98024606:+
LGG	cis	rs9303542	0.729	rs8067857	MIMAT0000253	hsa-miR-10a-5p	-3.57	0.000396	-0.22	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48464878	chr17:48579904~48579926:-
LGG	cis	rs1018697	1	rs11191397	MIMAT0022727	hsa-miR-1307-5p	3.57	0.000397	0.11	0.16	Colorectal adenoma (advanced);	chr10:102798517	chr10:103394341~103394361:-
LGG	cis	rs9398586	0.803	rs4466255	MIMAT0009206	hsa-miR-2113	-3.57	0.000398	-0.25	-0.16	Neuroticism;	chr6:98069219	chr6:98024586~98024606:+
LGG	cis	rs9398586	0.803	rs9372699	MIMAT0009206	hsa-miR-2113	-3.57	0.000398	-0.25	-0.16	Neuroticism;	chr6:98070407	chr6:98024586~98024606:+
LGG	cis	rs1912702	0.599	rs80234131	MIMAT0022270	hsa-miR-5579-3p	3.57	0.000399	0.2	0.16	Hair greying;	chr11:79477515	chr11:79422169~79422190:-
LGG	cis	rs1912702	0.514	rs17138398	MIMAT0022270	hsa-miR-5579-3p	-3.57	4e-04	-0.2	-0.16	Hair greying;	chr11:79470010	chr11:79422169~79422190:-
LGG	cis	rs9858542	0.953	rs10640	MIMAT0003393	hsa-miR-425-5p	3.56	0.000401	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chr3:49020199~49020221:-
LGG	cis	rs1018697	1	rs7073114	MIMAT0005951	hsa-miR-1307-3p	3.56	0.000401	0.1	0.16	Colorectal adenoma (advanced);	chr10:102795894	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs7088711	MIMAT0005951	hsa-miR-1307-3p	-3.56	0.000404	-0.1	-0.16	Colorectal adenoma (advanced);	chr10:102799509	chr10:103394301~103394322:-
LGG	cis	rs6543140	0.865	rs6760275	MIMAT0019927	hsa-miR-4772-3p	-3.56	0.000408	-0.18	-0.16	Blood protein levels;	chr2:102463147	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs6734203	MIMAT0019927	hsa-miR-4772-3p	-3.56	0.000408	-0.18	-0.16	Blood protein levels;	chr2:102463606	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs6543142	MIMAT0019927	hsa-miR-4772-3p	-3.56	0.000408	-0.18	-0.16	Blood protein levels;	chr2:102465546	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.929	rs6742530	MIMAT0019927	hsa-miR-4772-3p	-3.56	0.000408	-0.18	-0.16	Blood protein levels;	chr2:102465820	chr2:102432336~102432357:+
LGG	cis	rs56184018	0.686	rs7875663	MIMAT0000265	hsa-miR-204-5p	-3.56	0.000408	-0.15	-0.16	Mean platelet volume;	chr9:70484287	chr9:70810031~70810052:-
LGG	cis	rs6011674	1	rs6011691	MIMAT0016888	hsa-miR-4326	-3.56	0.00041	-0.3	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63236102	chr20:63286818~63286837:+
LGG	cis	rs2289583	0.642	rs67624860	MIMAT0027665	hsa-miR-6882-3p	3.56	0.000411	0.18	0.16	Systemic lupus erythematosus;	chr15:75099216	chr15:74840642~74840665:-
LGG	cis	rs7172677	0.501	rs56266638	MIMAT0027665	hsa-miR-6882-3p	3.56	0.000411	0.18	0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75100864	chr15:74840642~74840665:-
LGG	cis	rs1018697	1	rs4919678	MIMAT0005951	hsa-miR-1307-3p	3.56	0.000412	0.1	0.16	Colorectal adenoma (advanced);	chr10:102794606	chr10:103394301~103394322:-
LGG	cis	rs4725617	0.822	rs7792901	MIMAT0027684	hsa-miR-6892-5p	3.56	0.000416	0.24	0.16	Blood protein levels;	chr7:143410226	chr7:143382686~143382706:+
LGG	cis	rs111803315	0.59	rs111376178	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000417	0.28	0.16	Schizophrenia;	chr14:59418084	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.59	rs79180690	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000417	0.28	0.16	Schizophrenia;	chr14:59424675	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.59	rs76724542	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000417	0.28	0.16	Schizophrenia;	chr14:59424889	chr14:59646999~59647020:-
LGG	cis	rs35489971	0.512	rs5018106	MIMAT0017994	hsa-miR-3615	3.55	0.000417	0.26	0.16	Fibrinogen levels;Coronary artery disease;	chr17:74716250	chr17:74748663~74748683:+
LGG	cis	rs7829975	0.582	rs6982832	MIMAT0019728	hsa-miR-4660	-3.55	0.000418	-0.19	-0.16	Mood instability;	chr8:8934707	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.582	rs6983150	MIMAT0019728	hsa-miR-4660	-3.55	0.000418	-0.19	-0.16	Mood instability;	chr8:8934916	chr8:9048453~9048475:+
LGG	cis	rs2289583	0.573	rs12148555	MIMAT0027665	hsa-miR-6882-3p	3.55	0.00042	0.18	0.16	Systemic lupus erythematosus;	chr15:75103134	chr15:74840642~74840665:-
LGG	cis	rs4927850	0.752	rs7618864	MIMAT0003235	hsa-miR-570-3p	3.55	0.000422	0.19	0.16	Pancreatic cancer;	chr3:196022690	chr3:195699460~195699481:+
LGG	cis	rs1018697	1	rs7909612	MIMAT0005951	hsa-miR-1307-3p	3.55	0.000424	0.1	0.16	Colorectal adenoma (advanced);	chr10:102801699	chr10:103394301~103394322:-
LGG	cis	rs111803315	0.59	rs112236139	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000425	0.28	0.16	Schizophrenia;	chr14:59422166	chr14:59646999~59647020:-
LGG	cis	rs7477	0.712	rs4792735	MIMAT0005942	hsa-miR-1288-3p	3.55	0.000425	0.16	0.16	Amyotrophic lateral sclerosis;	chr17:16333074	chr17:16282058~16282078:+
LGG	cis	rs4919669	0.623	rs2031604	MIMAT0005951	hsa-miR-1307-3p	3.55	0.000426	0.16	0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102538034	chr10:103394301~103394322:-
LGG	cis	rs1018697	0.966	rs11191396	MIMAT0005951	hsa-miR-1307-3p	3.55	0.000427	0.1	0.16	Colorectal adenoma (advanced);	chr10:102793108	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs4919677	MIMAT0005951	hsa-miR-1307-3p	3.55	0.000427	0.1	0.16	Colorectal adenoma (advanced);	chr10:102794547	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs7092051	MIMAT0005951	hsa-miR-1307-3p	3.55	0.000427	0.1	0.16	Colorectal adenoma (advanced);	chr10:102799720	chr10:103394301~103394322:-
LGG	cis	rs7829975	0.5	rs7841082	MIMAT0019728	hsa-miR-4660	-3.55	0.000428	-0.19	-0.16	Mood instability;	chr8:8311465	chr8:9048453~9048475:+
LGG	cis	rs11743006	0.626	rs75472741	MIMAT0004911	hsa-miR-874-3p	-3.55	0.000429	-0.13	-0.16	Mathematical ability;	chr5:137124385	chr5:137647582~137647603:-
LGG	cis	rs111803315	0.59	rs113562114	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000431	0.28	0.16	Schizophrenia;	chr14:59408334	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.744	rs112971523	MIMAT0022287	hsa-miR-5586-5p	3.55	0.000431	0.28	0.16	Schizophrenia;	chr14:59408444	chr14:59646999~59647020:-
LGG	cis	rs2205299	0.77	rs9978234	MIMAT0000064	hsa-let-7c-5p	3.55	0.000431	0.1	0.16	Schizophrenia;	chr21:16835949	chr21:16539838~16539859:+
LGG	cis	rs1461503	0.834	rs6589961	MIMAT0000062	hsa-let-7a-5p	-3.54	0.000432	-0.12	-0.16	Menarche (age at onset);	chr11:122949573	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.834	rs6589961	MIMAT0000062_1	hsa-let-7a-5p	-3.54	0.000432	-0.12	-0.16	Menarche (age at onset);	chr11:122949573	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.834	rs6589961	MIMAT0000062_2	hsa-let-7a-5p	-3.54	0.000432	-0.12	-0.16	Menarche (age at onset);	chr11:122949573	chr9:94175962~94175983:+
LGG	cis	rs56184018	0.709	rs7871523	MIMAT0000265	hsa-miR-204-5p	3.54	0.000432	0.14	0.16	Mean platelet volume;	chr9:70499363	chr9:70810031~70810052:-
LGG	cis	rs7829975	0.626	rs907183	MIMAT0019728	hsa-miR-4660	-3.54	0.000432	-0.18	-0.16	Mood instability;	chr8:8872251	chr8:9048453~9048475:+
LGG	cis	rs11678825	0.639	rs77134676	MIMAT0031175	hsa-miR-548ba	-3.54	0.000435	-0.23	-0.16	Reticulocyte fraction of red cells;	chr2:48440510	chr2:49059603~49059624:+
LGG	cis	rs7072216	0.853	rs6584194	MIMAT0005878	hsa-miR-1287-5p	3.54	0.000436	0.09	0.16	Metabolite levels;	chr10:98400642	chr10:98395271~98395292:-
LGG	cis	rs7829975	0.593	rs2979241	MIMAT0019728	hsa-miR-4660	3.54	0.000436	0.18	0.16	Mood instability;	chr8:8445843	chr8:9048453~9048475:+
LGG	cis	rs950880	0.71	rs11693204	MIMAT0019927	hsa-miR-4772-3p	3.54	0.000436	0.19	0.16	Serum protein levels (sST2);	chr2:102319514	chr2:102432336~102432357:+
LGG	cis	rs1018697	1	rs10786710	MIMAT0005951	hsa-miR-1307-3p	3.54	0.000438	0.1	0.16	Colorectal adenoma (advanced);	chr10:102788982	chr10:103394301~103394322:-
LGG	cis	rs7894407	0.856	rs7093667	MIMAT0005951	hsa-miR-1307-3p	-3.54	0.000438	-0.1	-0.16	White matter hyperintensity burden;	chr10:103320818	chr10:103394301~103394322:-
LGG	cis	rs2289583	0.642	rs55798479	MIMAT0027665	hsa-miR-6882-3p	3.54	0.00044	0.18	0.16	Systemic lupus erythematosus;	chr15:75099869	chr15:74840642~74840665:-
LGG	cis	rs56184018	0.709	rs7037072	MIMAT0000265	hsa-miR-204-5p	-3.54	0.000441	-0.15	-0.16	Mean platelet volume;	chr9:70506382	chr9:70810031~70810052:-
LGG	cis	rs59191668	0.675	rs7171486	MIMAT0000458	hsa-miR-190a-5p	3.54	0.000441	0.12	0.16	Immature fraction of reticulocytes;	chr15:62524847	chr15:62823971~62823992:+
LGG	cis	rs111803315	1	rs1752435	MIMAT0022287	hsa-miR-5586-5p	3.54	0.000441	0.28	0.16	Schizophrenia;	chr14:59479376	chr14:59646999~59647020:-
LGG	cis	rs4400599	0.586	rs6661101	MIMAT0022491	hsa-miR-5698	3.54	0.000441	0.19	0.16	Platelet distribution width;	chr1:154118541	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.586	rs6664278	MIMAT0022491	hsa-miR-5698	3.54	0.000441	0.19	0.16	Platelet distribution width;	chr1:154119254	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.586	rs6678826	MIMAT0022491	hsa-miR-5698	3.54	0.000441	0.19	0.16	Platelet distribution width;	chr1:154119300	chr1:154104562~154104583:-
LGG	cis	rs2921073	0.51	rs2976944	MIMAT0019728	hsa-miR-4660	3.54	0.000446	0.18	0.16	Parkinson's disease;	chr8:8413404	chr8:9048453~9048475:+
LGG	cis	rs4073416	0.691	rs10483785	MIMAT0004808	hsa-miR-625-3p	3.54	0.000446	0.09	0.16	N-glycan levels;	chr14:65752799	chr14:65471153~65471174:+
LGG	cis	rs1018697	1	rs11191397	MIMAT0005951	hsa-miR-1307-3p	3.54	0.000446	0.1	0.16	Colorectal adenoma (advanced);	chr10:102798517	chr10:103394301~103394322:-
LGG	cis	rs9303542	0.559	rs8079617	MIMAT0000253	hsa-miR-10a-5p	-3.54	0.000447	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48532666	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.527	rs8074125	MIMAT0000253	hsa-miR-10a-5p	-3.54	0.000447	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48532698	chr17:48579904~48579926:-
LGG	cis	rs4919669	0.546	rs4919652	MIMAT0005951	hsa-miR-1307-3p	3.53	0.000448	0.16	0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102514400	chr10:103394301~103394322:-
LGG	cis	rs56184018	0.709	rs3901151	MIMAT0000265	hsa-miR-204-5p	3.53	0.000448	0.14	0.16	Mean platelet volume;	chr9:70488225	chr9:70810031~70810052:-
LGG	cis	rs4927850	0.752	rs7624460	MIMAT0003235	hsa-miR-570-3p	3.53	0.000448	0.19	0.16	Pancreatic cancer;	chr3:196021659	chr3:195699460~195699481:+
LGG	cis	rs7829975	0.626	rs332040	MIMAT0019728	hsa-miR-4660	3.53	0.000448	0.18	0.16	Mood instability;	chr8:8872978	chr8:9048453~9048475:+
LGG	cis	rs10908557	0.957	rs10796956	MIMAT0022491	hsa-miR-5698	3.53	0.000451	0.2	0.16	Age at first birth;	chr1:153823093	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs4612664	MIMAT0022491	hsa-miR-5698	3.53	0.000451	0.2	0.16	Lentiform nucleus volume;	chr1:153850197	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs72694234	MIMAT0022491	hsa-miR-5698	3.53	0.000451	0.2	0.16	Lentiform nucleus volume;	chr1:153851442	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs12038577	MIMAT0022491	hsa-miR-5698	3.53	0.000451	0.2	0.16	Lentiform nucleus volume;	chr1:153853693	chr1:154104562~154104583:-
LGG	cis	rs7172677	0.501	rs8041446	MIMAT0027665	hsa-miR-6882-3p	3.53	0.000451	0.18	0.16	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75102176	chr15:74840642~74840665:-
LGG	cis	rs2289583	0.573	rs8025880	MIMAT0027665	hsa-miR-6882-3p	3.53	0.000451	0.18	0.16	Systemic lupus erythematosus;	chr15:75102540	chr15:74840642~74840665:-
LGG	cis	rs9426935	0.505	rs4077168	MIMAT0022491	hsa-miR-5698	3.53	0.000452	0.2	0.16	Lentiform nucleus volume;	chr1:153802541	chr1:154104562~154104583:-
LGG	cis	rs9858542	0.953	rs6997	MIMAT0003393	hsa-miR-425-5p	3.53	0.000455	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chr3:49020199~49020221:-
LGG	cis	rs7120482	1	rs17630638	MIMAT0005892	hsa-miR-1304-5p	3.53	0.000457	0.2	0.16	Adverse response to radiation therapy;	chr11:93062046	chr11:93733724~93733745:-
LGG	cis	rs6011674	1	rs59784306	MIMAT0016888	hsa-miR-4326	-3.53	0.000458	-0.3	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63228244	chr20:63286818~63286837:+
LGG	cis	rs7851726	0.834	rs10993418	MIMAT0019208	hsa-miR-3074-5p	3.53	0.000458	0.14	0.16	Urinary albumin-to-creatinine ratio;	chr9:94969974	chr9:95086063~95086083:-
LGG	cis	rs9303542	0.527	rs62066689	MIMAT0000253	hsa-miR-10a-5p	-3.53	0.000462	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48531730	chr17:48579904~48579926:-
LGG	cis	rs950880	0.71	rs12470867	MIMAT0019927	hsa-miR-4772-3p	3.52	0.000465	0.19	0.16	Serum protein levels (sST2);	chr2:102309906	chr2:102432336~102432357:+
LGG	cis	rs10928112	0.866	rs10928111	MIMAT0028224	hsa-miR-7157-5p	-3.52	0.000466	-0.19	-0.16	Schizophrenia;	chr2:141567595	chr2:140586663~140586685:-
LGG	cis	rs4927850	0.723	rs7630825	MIMAT0003235	hsa-miR-570-3p	3.52	0.000471	0.19	0.16	Pancreatic cancer;	chr3:196026869	chr3:195699460~195699481:+
LGG	cis	rs7826238	0.535	rs2979179	MIMAT0019728	hsa-miR-4660	3.52	0.000476	0.18	0.16	Systolic blood pressure;	chr8:8462519	chr8:9048453~9048475:+
LGG	cis	rs6543140	0.964	rs2141781	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000478	-0.18	-0.16	Blood protein levels;	chr2:102466446	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs11903551	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000478	-0.18	-0.16	Blood protein levels;	chr2:102467721	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs6543143	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000478	-0.18	-0.16	Blood protein levels;	chr2:102468960	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs13383602	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000478	-0.18	-0.16	Blood protein levels;	chr2:102469502	chr2:102432336~102432357:+
LGG	cis	rs6011674	0.901	rs56783811	MIMAT0016888	hsa-miR-4326	-3.52	0.000478	-0.3	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63229153	chr20:63286818~63286837:+
LGG	cis	rs1018697	1	rs10748830	MIMAT0005951	hsa-miR-1307-3p	3.52	0.000478	0.1	0.16	Colorectal adenoma (advanced);	chr10:102788625	chr10:103394301~103394322:-
LGG	cis	rs7829975	0.686	rs907180	MIMAT0019728	hsa-miR-4660	3.52	0.000479	0.18	0.16	Mood instability;	chr8:8845317	chr8:9048453~9048475:+
LGG	cis	rs1870653	0.516	rs73848130	MIMAT0003242	hsa-miR-577	3.52	0.00048	0.21	0.16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114489234	chr4:114656774~114656794:+
LGG	cis	rs6480314	0.615	rs61857179	MIMAT0028212	hsa-miR-7151-5p	3.52	0.000481	0.25	0.16	Optic nerve measurement (disc area);	chr10:68188243	chr10:67403388~67403410:-
LGG	cis	rs7826238	0.524	rs2921055	MIMAT0019728	hsa-miR-4660	3.51	0.000484	0.18	0.16	Systolic blood pressure;	chr8:8461832	chr8:9048453~9048475:+
LGG	cis	rs10908557	0.915	rs113422987	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Age at first birth;	chr1:153814803	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.527	rs72694220	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Lentiform nucleus volume;	chr1:153815735	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs4363451	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Lentiform nucleus volume;	chr1:153818025	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs7512766	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Lentiform nucleus volume;	chr1:153838088	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.957	rs72694231	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Age at first birth;	chr1:153844276	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs59308681	MIMAT0022491	hsa-miR-5698	3.51	0.000484	0.2	0.16	Lentiform nucleus volume;	chr1:153863687	chr1:154104562~154104583:-
LGG	cis	rs2205299	0.77	rs9977075	MIMAT0000064	hsa-let-7c-5p	-3.51	0.000484	-0.1	-0.16	Schizophrenia;	chr21:16838228	chr21:16539838~16539859:+
LGG	cis	rs7829975	0.755	rs3789849	MIMAT0019728	hsa-miR-4660	3.51	0.000484	0.18	0.16	Mood instability;	chr8:8829544	chr8:9048453~9048475:+
LGG	cis	rs309064	0.964	rs177916	MIMAT0000429	hsa-miR-137-3p	3.51	0.000487	0.1	0.16	Blood pressure;Blood pressure (anthropometric measures interaction);	chr1:98949668	chr1:98046091~98046113:-
LGG	cis	rs1461503	1	rs1461503	MIMAT0000423	hsa-miR-125b-5p	3.51	0.00049	0.12	0.16	Menarche (age at onset);	chr11:122974367	chr11:122099809~122099830:-
LGG	cis	rs1461503	1	rs1461503	MIMAT0000423_1	hsa-miR-125b-5p	3.51	0.00049	0.12	0.16	Menarche (age at onset);	chr11:122974367	chr21:16590253~16590274:+
LGG	cis	rs7162943	1	rs7162943	MIMAT0004554	hsa-miR-7-2-3p	3.51	0.000492	0.16	0.16	Mean platelet volume;	chr15:89072044	chr15:88611896~88611917:+
LGG	cis	rs1018697	0.966	rs10748831	MIMAT0005951	hsa-miR-1307-3p	3.51	0.000493	0.1	0.16	Colorectal adenoma (advanced);	chr10:102798986	chr10:103394301~103394322:-
LGG	cis	rs7072216	0.922	rs4488133	MIMAT0005878	hsa-miR-1287-5p	-3.51	0.000494	-0.09	-0.16	Metabolite levels;	chr10:98399379	chr10:98395271~98395292:-
LGG	cis	rs950880	0.56	rs1997466	MIMAT0019927	hsa-miR-4772-3p	3.51	0.000495	0.17	0.16	Serum protein levels (sST2);	chr2:102335007	chr2:102432336~102432357:+
LGG	cis	rs10928112	0.662	rs16846467	MIMAT0028224	hsa-miR-7157-5p	-3.51	0.000497	-0.2	-0.16	Schizophrenia;	chr2:141559308	chr2:140586663~140586685:-
LGG	cis	rs2980439	0.557	rs2921056	MIMAT0019728	hsa-miR-4660	3.51	0.000497	0.18	0.16	Neuroticism;	chr8:8461672	chr8:9048453~9048475:+
LGG	cis	rs9426935	0.505	rs4845576	MIMAT0022491	hsa-miR-5698	3.51	0.000499	0.2	0.16	Lentiform nucleus volume;	chr1:153852928	chr1:154104562~154104583:-
LGG	cis	rs7342953	0.85	rs8081457	MIMAT0019865	hsa-miR-3064-3p	3.5	0.000501	0.33	0.16	Large artery stroke;	chr17:65230740	chr17:64500775~64500797:-
LGG	cis	rs7342953	0.51	rs1554050	MIMAT0019865	hsa-miR-3064-3p	3.5	0.000501	0.33	0.16	Large artery stroke;	chr17:65231172	chr17:64500775~64500797:-
LGG	cis	rs12145833	1	rs76473275	MIMAT0019761	hsa-miR-4677-3p	3.5	0.000501	0.21	0.16	Obesity (early onset extreme);	chr1:243297253	chr1:243346225~243346246:+
LGG	cis	rs9426935	0.505	rs4520447	MIMAT0022491	hsa-miR-5698	3.5	0.000501	0.2	0.16	Lentiform nucleus volume;	chr1:153856913	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs4845578	MIMAT0022491	hsa-miR-5698	3.5	0.000501	0.2	0.16	Lentiform nucleus volume;	chr1:153857517	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs34805562	MIMAT0022491	hsa-miR-5698	3.5	0.000501	0.2	0.16	Lentiform nucleus volume;	chr1:153866569	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs12041920	MIMAT0022491	hsa-miR-5698	3.5	0.000501	0.2	0.16	Lentiform nucleus volume;	chr1:153878630	chr1:154104562~154104583:-
LGG	cis	rs28512361	0.557	rs136030	MIMAT0004481	hsa-let-7a-3p	-3.5	0.000501	-0.24	-0.16	Breast cancer;	chr22:45846268	chr22:46112800~46112820:+
LGG	cis	rs28512361	0.557	rs136030	MIMAT0004481_1	hsa-let-7a-3p	-3.5	0.000501	-0.24	-0.16	Breast cancer;	chr22:45846268	chr9:94176013~94176033:+
LGG	cis	rs6543140	0.964	rs1523206	MIMAT0019927	hsa-miR-4772-3p	-3.5	0.000505	-0.18	-0.16	Blood protein levels;	chr2:102453715	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs1523205	MIMAT0019927	hsa-miR-4772-3p	-3.5	0.000505	-0.18	-0.16	Blood protein levels;	chr2:102453716	chr2:102432336~102432357:+
LGG	cis	rs874628	0.754	rs8112975	MIMAT0015070	hsa-miR-3188	-3.5	0.000511	-0.2	-0.16	Multiple sclerosis;	chr19:18230100	chr19:18282129~18282151:+
LGG	cis	rs7826238	0.543	rs2976908	MIMAT0019728	hsa-miR-4660	3.5	0.000511	0.18	0.16	Systolic blood pressure;	chr8:8488264	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.593	rs2921051	MIMAT0019728	hsa-miR-4660	3.5	0.000512	0.17	0.16	Mood instability;	chr8:8462594	chr8:9048453~9048475:+
LGG	cis	rs111803315	1	rs1253099	MIMAT0022287	hsa-miR-5586-5p	3.5	0.000512	0.28	0.16	Schizophrenia;	chr14:59480112	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs1253102	MIMAT0022287	hsa-miR-5586-5p	3.5	0.000512	0.28	0.16	Schizophrenia;	chr14:59481143	chr14:59646999~59647020:-
LGG	cis	rs74233809	1	rs12413409	MIMAT0005951	hsa-miR-1307-3p	-3.5	0.000512	-0.18	-0.16	Birth weight;	chr10:102959339	chr10:103394301~103394322:-
LGG	cis	rs9398586	0.708	rs7765628	MIMAT0009206	hsa-miR-2113	-3.5	0.000512	-0.24	-0.16	Neuroticism;	chr6:98065336	chr6:98024586~98024606:+
LGG	cis	rs12712135	0.706	rs6543114	MIMAT0019927	hsa-miR-4772-3p	3.5	0.000512	0.18	0.16	Blood protein levels;	chr2:102309534	chr2:102432336~102432357:+
LGG	cis	rs7851726	0.585	rs7870160	MIMAT0019208	hsa-miR-3074-5p	-3.5	0.000513	-0.13	-0.16	Urinary albumin-to-creatinine ratio;	chr9:94950249	chr9:95086063~95086083:-
LGG	cis	rs546131	0.642	rs508062	MIMAT0019776	hsa-miR-1343-3p	3.5	0.000515	0.13	0.16	Lung disease severity in cystic fibrosis;	chr11:34822273	chr11:34941888~34941909:+
LGG	cis	rs9426935	0.505	rs12032914	MIMAT0022491	hsa-miR-5698	-3.5	0.000516	-0.2	-0.16	Lentiform nucleus volume;	chr1:153914286	chr1:154104562~154104583:-
LGG	cis	rs2205299	0.77	rs975183	MIMAT0000064	hsa-let-7c-5p	3.5	0.000518	0.1	0.16	Schizophrenia;	chr21:16836643	chr21:16539838~16539859:+
LGG	cis	rs9303542	0.559	rs12603976	MIMAT0000253	hsa-miR-10a-5p	-3.49	0.00052	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48539801	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs12602539	MIMAT0000253	hsa-miR-10a-5p	-3.49	0.00052	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48540097	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs62066693	MIMAT0000253	hsa-miR-10a-5p	-3.49	0.00052	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48540168	chr17:48579904~48579926:-
LGG	cis	rs950880	0.56	rs1558622	MIMAT0019927	hsa-miR-4772-3p	3.49	0.000521	0.16	0.16	Serum protein levels (sST2);	chr2:102313687	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs10189202	MIMAT0019927	hsa-miR-4772-3p	3.49	0.000521	0.16	0.16	Serum protein levels (sST2);	chr2:102313920	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs10191914	MIMAT0019927	hsa-miR-4772-3p	3.49	0.000521	0.16	0.16	Serum protein levels (sST2);	chr2:102314197	chr2:102432336~102432357:+
LGG	cis	rs73001065	0.504	rs80341032	MIMAT0015070	hsa-miR-3188	-3.49	0.000523	-0.39	-0.16	LDL cholesterol;	chr19:19096420	chr19:18282129~18282151:+
LGG	cis	rs546131	0.642	rs2915186	MIMAT0019776	hsa-miR-1343-3p	3.49	0.000523	0.12	0.16	Lung disease severity in cystic fibrosis;	chr11:34829636	chr11:34941888~34941909:+
LGG	cis	rs111803315	1	rs3850304	MIMAT0022287	hsa-miR-5586-5p	3.49	0.000525	0.28	0.16	Schizophrenia;	chr14:59428301	chr14:59646999~59647020:-
LGG	cis	rs7342953	0.85	rs8070837	MIMAT0019865	hsa-miR-3064-3p	3.49	0.000525	0.3	0.16	Large artery stroke;	chr17:65242581	chr17:64500775~64500797:-
LGG	cis	rs2205299	0.721	rs2824049	MIMAT0000064	hsa-let-7c-5p	3.49	0.000526	0.11	0.16	Schizophrenia;	chr21:16796595	chr21:16539838~16539859:+
LGG	cis	rs4400599	0.586	rs6671166	MIMAT0022491	hsa-miR-5698	3.49	0.000528	0.19	0.16	Platelet distribution width;	chr1:154121349	chr1:154104562~154104583:-
LGG	cis	rs950880	0.56	rs11685480	MIMAT0019927	hsa-miR-4772-3p	3.49	0.000529	0.16	0.16	Serum protein levels (sST2);	chr2:102310626	chr2:102432336~102432357:+
LGG	cis	rs7477	0.818	rs3112524	MIMAT0005942	hsa-miR-1288-3p	3.49	0.000529	0.16	0.16	Amyotrophic lateral sclerosis;	chr17:16342464	chr17:16282058~16282078:+
LGG	cis	rs4919669	0.668	rs10786701	MIMAT0005951	hsa-miR-1307-3p	-3.49	0.00053	-0.16	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102652551	chr10:103394301~103394322:-
LGG	cis	rs9858542	0.953	rs11706370	MIMAT0003393	hsa-miR-425-5p	3.49	0.00053	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chr3:49020199~49020221:-
LGG	cis	rs1461503	0.9	rs7110039	MIMAT0000062	hsa-let-7a-5p	3.49	0.000531	0.12	0.16	Menarche (age at onset);	chr11:122963293	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs7110039	MIMAT0000062_1	hsa-let-7a-5p	3.49	0.000531	0.12	0.16	Menarche (age at onset);	chr11:122963293	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs7110039	MIMAT0000062_2	hsa-let-7a-5p	3.49	0.000531	0.12	0.16	Menarche (age at onset);	chr11:122963293	chr9:94175962~94175983:+
LGG	cis	rs7072216	0.77	rs7896828	MIMAT0005878	hsa-miR-1287-5p	3.49	0.000533	0.09	0.16	Metabolite levels;	chr10:98410750	chr10:98395271~98395292:-
LGG	cis	rs546131	0.614	rs473885	MIMAT0019776	hsa-miR-1343-3p	3.49	0.000533	0.12	0.16	Lung disease severity in cystic fibrosis;	chr11:34830414	chr11:34941888~34941909:+
LGG	cis	rs546131	0.642	rs473848	MIMAT0019776	hsa-miR-1343-3p	3.49	0.000533	0.12	0.16	Lung disease severity in cystic fibrosis;	chr11:34830430	chr11:34941888~34941909:+
LGG	cis	rs9398586	0.803	rs9490443	MIMAT0009206	hsa-miR-2113	-3.49	0.000536	-0.24	-0.16	Neuroticism;	chr6:98064282	chr6:98024586~98024606:+
LGG	cis	rs9426935	0.505	rs4508047	MIMAT0022491	hsa-miR-5698	3.49	0.000538	0.2	0.16	Lentiform nucleus volume;	chr1:153858681	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs6700451	MIMAT0022491	hsa-miR-5698	3.49	0.000538	0.2	0.16	Lentiform nucleus volume;	chr1:153858770	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs11587151	MIMAT0022491	hsa-miR-5698	3.49	0.000538	0.2	0.16	Lentiform nucleus volume;	chr1:153864705	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs12567313	MIMAT0022491	hsa-miR-5698	3.49	0.000538	0.2	0.16	Lentiform nucleus volume;	chr1:153868029	chr1:154104562~154104583:-
LGG	cis	rs6543140	0.964	rs4851592	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000539	-0.18	-0.16	Blood protein levels;	chr2:102471181	chr2:102432336~102432357:+
LGG	cis	rs1018697	1	rs7092346	MIMAT0005951	hsa-miR-1307-3p	3.48	0.00054	0.1	0.16	Colorectal adenoma (advanced);	chr10:102800007	chr10:103394301~103394322:-
LGG	cis	rs1018697	1	rs7086400	MIMAT0005951	hsa-miR-1307-3p	3.48	0.00054	0.1	0.16	Colorectal adenoma (advanced);	chr10:102802340	chr10:103394301~103394322:-
LGG	cis	rs9398586	1	rs6922758	MIMAT0009206	hsa-miR-2113	-3.48	0.000541	-0.26	-0.16	Neuroticism;	chr6:97870350	chr6:98024586~98024606:+
LGG	cis	rs6681460	0.549	rs7537440	MIMAT0014979	hsa-miR-3117-3p	3.48	0.000541	0.15	0.16	Presence of antiphospholipid antibodies;	chr1:66566224	chr1:66628485~66628505:+
LGG	cis	rs7826238	0.653	rs2979202	MIMAT0019728	hsa-miR-4660	3.48	0.000543	0.18	0.16	Systolic blood pressure;	chr8:8486617	chr8:9048453~9048475:+
LGG	cis	rs4400599	0.564	rs72696208	MIMAT0022491	hsa-miR-5698	3.48	0.000543	0.19	0.16	Platelet distribution width;	chr1:154123621	chr1:154104562~154104583:-
LGG	cis	rs10928112	0.866	rs16846506	MIMAT0028224	hsa-miR-7157-5p	-3.48	0.000544	-0.19	-0.16	Schizophrenia;	chr2:141566194	chr2:140586663~140586685:-
LGG	cis	rs56184018	0.709	rs6560139	MIMAT0000265	hsa-miR-204-5p	3.48	0.000545	0.14	0.16	Mean platelet volume;	chr9:70490581	chr9:70810031~70810052:-
LGG	cis	rs4400599	0.586	rs6691825	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154122720	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.564	rs6691826	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154122731	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.564	rs6692026	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154122896	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.521	rs6692035	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154122904	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.542	rs12407062	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154124551	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.564	rs12405309	MIMAT0022491	hsa-miR-5698	3.48	0.000547	0.19	0.16	Platelet distribution width;	chr1:154124632	chr1:154104562~154104583:-
LGG	cis	rs74233809	0.901	rs17878846	MIMAT0005951	hsa-miR-1307-3p	-3.48	0.000547	-0.18	-0.16	Birth weight;	chr10:102870655	chr10:103394301~103394322:-
LGG	cis	rs56184018	0.709	rs7032346	MIMAT0000265	hsa-miR-204-5p	3.48	0.000549	0.14	0.16	Mean platelet volume;	chr9:70505116	chr9:70810031~70810052:-
LGG	cis	rs1461503	0.9	rs3751047	MIMAT0000423	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122957731	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.9	rs3751047	MIMAT0000423_1	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122957731	chr21:16590253~16590274:+
LGG	cis	rs1461503	0.838	rs7107012	MIMAT0000423	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959105	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.838	rs7107012	MIMAT0000423_1	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959105	chr21:16590253~16590274:+
LGG	cis	rs1461503	0.9	rs7107502	MIMAT0000423	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959506	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.9	rs7107502	MIMAT0000423_1	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959506	chr21:16590253~16590274:+
LGG	cis	rs1461503	0.838	rs7126962	MIMAT0000423	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959843	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.838	rs7126962	MIMAT0000423_1	hsa-miR-125b-5p	3.48	0.00055	0.12	0.16	Menarche (age at onset);	chr11:122959843	chr21:16590253~16590274:+
LGG	cis	rs6480314	0.711	rs61857175	MIMAT0028212	hsa-miR-7151-5p	3.48	0.00055	0.25	0.16	Optic nerve measurement (disc area);	chr10:68186026	chr10:67403388~67403410:-
LGG	cis	rs9303542	0.559	rs1042822	MIMAT0000253	hsa-miR-10a-5p	-3.48	0.000551	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48542733	chr17:48579904~48579926:-
LGG	cis	rs7243821	0.552	rs56396522	MIMAT0019068	hsa-miR-4529-3p	3.48	0.000552	0.19	0.16	Chin dimples;	chr18:54858544	chr18:55479270~55479290:+
LGG	cis	rs1461503	0.534	rs7944405	MIMAT0000062	hsa-let-7a-5p	-3.48	0.000552	-0.12	-0.16	Menarche (age at onset);	chr11:122945391	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.534	rs7944405	MIMAT0000062_1	hsa-let-7a-5p	-3.48	0.000552	-0.12	-0.16	Menarche (age at onset);	chr11:122945391	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.534	rs7944405	MIMAT0000062_2	hsa-let-7a-5p	-3.48	0.000552	-0.12	-0.16	Menarche (age at onset);	chr11:122945391	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.511	rs4129007	MIMAT0000062	hsa-let-7a-5p	-3.48	0.000553	-0.12	-0.16	Menarche (age at onset);	chr11:122941104	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.511	rs4129007	MIMAT0000062_1	hsa-let-7a-5p	-3.48	0.000553	-0.12	-0.16	Menarche (age at onset);	chr11:122941104	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.511	rs4129007	MIMAT0000062_2	hsa-let-7a-5p	-3.48	0.000553	-0.12	-0.16	Menarche (age at onset);	chr11:122941104	chr9:94175962~94175983:+
LGG	cis	rs4400599	0.586	rs4845363	MIMAT0022491	hsa-miR-5698	3.48	0.000553	0.19	0.16	Platelet distribution width;	chr1:154132540	chr1:154104562~154104583:-
LGG	cis	rs111803315	1	rs113869004	MIMAT0022287	hsa-miR-5586-5p	3.48	0.000553	0.29	0.16	Schizophrenia;	chr14:59452013	chr14:59646999~59647020:-
LGG	cis	rs7829975	0.511	rs2976902	MIMAT0019728	hsa-miR-4660	3.48	0.000555	0.18	0.16	Mood instability;	chr8:8483595	chr8:9048453~9048475:+
LGG	cis	rs7159888	0.577	rs1256540	MIMAT0004808	hsa-miR-625-3p	-3.48	0.000556	-0.1	-0.16	N-glycan levels;IgG glycosylation;	chr14:65297351	chr14:65471153~65471174:+
LGG	cis	rs950880	0.56	rs10189711	MIMAT0019927	hsa-miR-4772-3p	3.48	0.000556	0.16	0.16	Serum protein levels (sST2);	chr2:102314421	chr2:102432336~102432357:+
LGG	cis	rs10908557	0.957	rs11590099	MIMAT0022491	hsa-miR-5698	3.48	0.000556	0.2	0.16	Age at first birth;	chr1:153875732	chr1:154104562~154104583:-
LGG	cis	rs10011926	0.519	rs10452184	MIMAT0003241	hsa-miR-576-5p	-3.48	0.000557	-0.15	-0.16	Attention deficit hyperactivity disorder;	chr4:110067792	chr4:109488713~109488734:+
LGG	cis	rs453301	0.598	rs1025395	MIMAT0019728	hsa-miR-4660	3.47	0.00056	0.18	0.16	Joint mobility (Beighton score);	chr8:8979093	chr8:9048453~9048475:+
LGG	cis	rs950880	0.645	rs11679889	MIMAT0019927	hsa-miR-4772-3p	3.47	0.000562	0.18	0.16	Serum protein levels (sST2);	chr2:102324549	chr2:102432336~102432357:+
LGG	cis	rs4919669	0.591	rs10883731	MIMAT0005951	hsa-miR-1307-3p	-3.47	0.000564	-0.16	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102533370	chr10:103394301~103394322:-
LGG	cis	rs6480314	0.615	rs61857174	MIMAT0028212	hsa-miR-7151-5p	3.47	0.000565	0.25	0.16	Optic nerve measurement (disc area);	chr10:68184233	chr10:67403388~67403410:-
LGG	cis	rs2613964	0.626	rs6770160	MIMAT0018965	hsa-miR-4446-3p	-3.47	0.000568	-0.19	-0.16	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);	chr3:113144955	chr3:113594918~113594939:+
LGG	cis	rs6088765	0.606	rs2425024	MIMAT0004772	hsa-miR-499a-3p	3.47	0.000569	0.18	0.16	Ulcerative colitis;	chr20:35257135	chr20:34990445~34990466:+
LGG	cis	rs56184018	0.709	rs17054799	MIMAT0000265	hsa-miR-204-5p	3.47	0.000569	0.14	0.16	Mean platelet volume;	chr9:70490978	chr9:70810031~70810052:-
LGG	cis	rs4400599	0.586	rs72696220	MIMAT0022491	hsa-miR-5698	3.47	0.00057	0.19	0.16	Platelet distribution width;	chr1:154131849	chr1:154104562~154104583:-
LGG	cis	rs2277912	1	rs3762567	MIMAT0014995	hsa-miR-3130-5p	3.47	0.00057	0.18	0.16	Height;	chr2:206765614	chr2:206783276~206783296:-
LGG	cis	rs2277912	1	rs3762567	MIMAT0014995_1	hsa-miR-3130-5p	3.47	0.00057	0.18	0.16	Height;	chr2:206765614	chr2:206783246~206783266:+
LGG	cis	rs1912702	0.788	rs11603124	MIMAT0022270	hsa-miR-5579-3p	-3.47	0.000571	-0.17	-0.16	Hair greying;	chr11:79471001	chr11:79422169~79422190:-
LGG	cis	rs12145833	0.92	rs12354170	MIMAT0019761	hsa-miR-4677-3p	3.47	0.000571	0.2	0.16	Obesity (early onset extreme);	chr1:243294474	chr1:243346225~243346246:+
LGG	cis	rs7829975	0.501	rs2980769	MIMAT0019728	hsa-miR-4660	3.47	0.000572	0.17	0.16	Mood instability;	chr8:8462781	chr8:9048453~9048475:+
LGG	cis	rs2205299	0.721	rs2824050	MIMAT0000064	hsa-let-7c-5p	3.47	0.000574	0.1	0.16	Schizophrenia;	chr21:16797178	chr21:16539838~16539859:+
LGG	cis	rs17604090	0.775	rs76480599	MIMAT0004800	hsa-miR-550a-5p	3.47	0.000577	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649564	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.775	rs76480599	MIMAT0004800_1	hsa-miR-550a-5p	3.47	0.000577	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649564	chr7:32733002~32733024:+
LGG	cis	rs4926298	0.89	rs931067	MIMAT0004496	hsa-miR-23a-5p	3.47	0.000578	0.18	0.16	Bipolar disorder;	chr19:13047969	chr19:13836630~13836651:-
LGG	cis	rs1461503	0.9	rs7115852	MIMAT0000062	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961122	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs7115852	MIMAT0000062_1	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961122	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs7115852	MIMAT0000062_2	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961122	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.934	rs7115651	MIMAT0000062	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961174	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs7115651	MIMAT0000062_1	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961174	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs7115651	MIMAT0000062_2	hsa-let-7a-5p	-3.46	0.000581	-0.12	-0.16	Menarche (age at onset);	chr11:122961174	chr9:94175962~94175983:+
LGG	cis	rs9398586	0.803	rs9388073	MIMAT0009206	hsa-miR-2113	-3.46	0.000581	-0.24	-0.16	Neuroticism;	chr6:98068799	chr6:98024586~98024606:+
LGG	cis	rs4919669	0.668	rs11191365	MIMAT0005951	hsa-miR-1307-3p	-3.46	0.000583	-0.16	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102670494	chr10:103394301~103394322:-
LGG	cis	rs9303542	0.559	rs1042818	MIMAT0000253	hsa-miR-10a-5p	-3.46	0.000584	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48542749	chr17:48579904~48579926:-
LGG	cis	rs9303542	0.559	rs2229302	MIMAT0000253	hsa-miR-10a-5p	-3.46	0.000584	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48543040	chr17:48579904~48579926:-
LGG	cis	rs9858542	0.953	rs11711485	MIMAT0003393	hsa-miR-425-5p	3.46	0.000585	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chr3:49020199~49020221:-
LGG	cis	rs111803315	1	rs73301712	MIMAT0022287	hsa-miR-5586-5p	3.46	0.000588	0.27	0.16	Schizophrenia;	chr14:59431527	chr14:59646999~59647020:-
LGG	cis	rs6543140	0.855	rs4851591	MIMAT0019927	hsa-miR-4772-3p	-3.46	0.000588	-0.18	-0.16	Blood protein levels;	chr2:102460963	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs7561351	MIMAT0019927	hsa-miR-4772-3p	-3.46	0.000589	-0.18	-0.16	Blood protein levels;	chr2:102461320	chr2:102432336~102432357:+
LGG	cis	rs2494663	0.61	rs6427457	MIMAT0022491	hsa-miR-5698	3.46	0.00059	0.2	0.16	Mean platelet volume;	chr1:154106815	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.586	rs55677228	MIMAT0022491	hsa-miR-5698	3.46	0.000591	0.19	0.16	Platelet distribution width;	chr1:154128742	chr1:154104562~154104583:-
LGG	cis	rs2277912	1	rs2277912	MIMAT0014995	hsa-miR-3130-5p	3.46	0.000591	0.18	0.16	Height;	chr2:206769512	chr2:206783276~206783296:-
LGG	cis	rs2277912	1	rs2277912	MIMAT0014995_1	hsa-miR-3130-5p	3.46	0.000591	0.18	0.16	Height;	chr2:206769512	chr2:206783246~206783266:+
LGG	cis	rs2277912	1	rs12620432	MIMAT0014995	hsa-miR-3130-5p	3.46	0.000591	0.18	0.16	Height;	chr2:206771794	chr2:206783276~206783296:-
LGG	cis	rs2277912	1	rs12620432	MIMAT0014995_1	hsa-miR-3130-5p	3.46	0.000591	0.18	0.16	Height;	chr2:206771794	chr2:206783246~206783266:+
LGG	cis	rs691184	1	rs691184	MIMAT0000259	hsa-miR-182-5p	3.46	0.000592	0.34	0.16	Prudent dietary pattern;	chr7:129557567	chr7:129770447~129770470:-
LGG	cis	rs4281086	0.541	rs10094938	MIMAT0003266	hsa-miR-598-3p	3.46	0.000592	0.1	0.16	Obesity-related traits;	chr8:10537816	chr8:11035221~11035242:-
LGG	cis	rs56184018	0.709	rs7849735	MIMAT0000265	hsa-miR-204-5p	3.46	0.000594	0.14	0.16	Mean platelet volume;	chr9:70484538	chr9:70810031~70810052:-
LGG	cis	rs111803315	1	rs73301725	MIMAT0022287	hsa-miR-5586-5p	3.46	0.000595	0.27	0.16	Schizophrenia;	chr14:59435441	chr14:59646999~59647020:-
LGG	cis	rs246395	0.803	rs7736526	MIMAT0000731	hsa-miR-378a-5p	3.46	0.000596	0.11	0.16	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;	chr5:150109679	chr5:149732829~149732850:+
LGG	cis	rs950880	0.56	rs1558620	MIMAT0019927	hsa-miR-4772-3p	3.46	0.000596	0.16	0.16	Serum protein levels (sST2);	chr2:102314935	chr2:102432336~102432357:+
LGG	cis	rs9858542	0.953	rs6779524	MIMAT0003393	hsa-miR-425-5p	3.46	0.000598	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chr3:49020199~49020221:-
LGG	cis	rs7162943	0.887	rs11858077	MIMAT0004554	hsa-miR-7-2-3p	-3.46	0.000599	-0.15	-0.16	Mean platelet volume;	chr15:89068326	chr15:88611896~88611917:+
LGG	cis	rs7121616	0.733	rs10790554	MIMAT0000098	hsa-miR-100-5p	3.45	0.000603	0.12	0.16	Breast cancer;	chr11:123130376	chr11:122152275~122152296:-
LGG	cis	rs2289583	0.573	rs34582157	MIMAT0027665	hsa-miR-6882-3p	3.45	0.000605	0.18	0.16	Systemic lupus erythematosus;	chr15:75105474	chr15:74840642~74840665:-
LGG	cis	rs950880	0.56	rs10182639	MIMAT0019927	hsa-miR-4772-3p	3.45	0.000607	0.16	0.16	Serum protein levels (sST2);	chr2:102319345	chr2:102432336~102432357:+
LGG	cis	rs299175	0.565	rs299164	MIMAT0027505	hsa-miR-6802-3p	-3.45	0.000608	-0.15	-0.16	Multiple sclerosis (severity);	chr19:55808430	chr19:55239912~55239933:-
LGG	cis	rs11743006	0.626	rs6890599	MIMAT0004911	hsa-miR-874-3p	3.45	0.000608	0.13	0.16	Mathematical ability;	chr5:137122420	chr5:137647582~137647603:-
LGG	cis	rs9426935	0.505	rs6694061	MIMAT0022491	hsa-miR-5698	3.45	0.000608	0.2	0.16	Lentiform nucleus volume;	chr1:153862392	chr1:154104562~154104583:-
LGG	cis	rs4926298	0.89	rs745610	MIMAT0004496	hsa-miR-23a-5p	-3.45	0.00061	-0.18	-0.16	Bipolar disorder;	chr19:13046466	chr19:13836630~13836651:-
LGG	cis	rs4243849	0.832	rs4269576	MIMAT0000245	hsa-miR-30d-5p	-3.45	0.000612	-0.13	-0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135723508	chr8:134804919~134804940:-
LGG	cis	rs11603023	0.874	rs483598	MIMAT0025845	hsa-miR-6716-3p	-3.45	0.000613	-0.17	-0.16	Cholesterol, total;	chr11:118638950	chr11:118644048~118644069:+
LGG	cis	rs2205299	0.69	rs2824045	MIMAT0000064	hsa-let-7c-5p	3.45	0.000615	0.11	0.16	Schizophrenia;	chr21:16791678	chr21:16539838~16539859:+
LGG	cis	rs7072216	0.77	rs7897357	MIMAT0005878	hsa-miR-1287-5p	3.45	0.000615	0.09	0.16	Metabolite levels;	chr10:98403840	chr10:98395271~98395292:-
LGG	cis	rs2205299	0.69	rs11088595	MIMAT0000064	hsa-let-7c-5p	3.45	0.000616	0.11	0.16	Schizophrenia;	chr21:16791139	chr21:16539838~16539859:+
LGG	cis	rs56184018	0.686	rs7357739	MIMAT0000265	hsa-miR-204-5p	3.45	0.000616	0.14	0.16	Mean platelet volume;	chr9:70490744	chr9:70810031~70810052:-
LGG	cis	rs6543140	0.964	rs10169192	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000617	-0.17	-0.16	Blood protein levels;	chr2:102455751	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs11886793	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000617	-0.17	-0.16	Blood protein levels;	chr2:102455760	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs2310301	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000617	-0.17	-0.16	Blood protein levels;	chr2:102456475	chr2:102432336~102432357:+
LGG	cis	rs6543140	1	rs6543140	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000617	-0.17	-0.16	Blood protein levels;	chr2:102457814	chr2:102432336~102432357:+
LGG	cis	rs6543140	0.964	rs13390895	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000617	-0.17	-0.16	Blood protein levels;	chr2:102459039	chr2:102432336~102432357:+
LGG	cis	rs4243849	0.832	rs4074936	MIMAT0000245	hsa-miR-30d-5p	3.45	0.000618	0.13	0.16	Non-alcoholic fatty liver disease histology (other);	chr8:135725209	chr8:134804919~134804940:-
LGG	cis	rs7829975	0.658	rs907181	MIMAT0019728	hsa-miR-4660	3.45	0.000619	0.18	0.16	Mood instability;	chr8:8845365	chr8:9048453~9048475:+
LGG	cis	rs7827545	1	rs7846013	MIMAT0004589	hsa-miR-30b-3p	3.45	0.00062	0.2	0.16	Hypertension (SNP x SNP interaction);	chr8:134557724	chr8:134800532~134800553:-
LGG	cis	rs7929679	0.777	rs1396889	MIMAT0019776	hsa-miR-1343-3p	3.45	0.000621	0.12	0.16	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772751	chr11:34941888~34941909:+
LGG	cis	rs7929679	0.777	rs1396888	MIMAT0019776	hsa-miR-1343-3p	3.45	0.000621	0.12	0.16	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;	chr11:34772885	chr11:34941888~34941909:+
LGG	cis	rs11678825	0.562	rs77045342	MIMAT0031175	hsa-miR-548ba	-3.44	0.000623	-0.24	-0.16	Reticulocyte fraction of red cells;	chr2:48461427	chr2:49059603~49059624:+
LGG	cis	rs1461503	0.934	rs11605693	MIMAT0000423	hsa-miR-125b-5p	3.44	0.000624	0.12	0.16	Menarche (age at onset);	chr11:122966329	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.934	rs11605693	MIMAT0000423_1	hsa-miR-125b-5p	3.44	0.000624	0.12	0.16	Menarche (age at onset);	chr11:122966329	chr21:16590253~16590274:+
LGG	cis	rs9398586	0.803	rs6928075	MIMAT0009206	hsa-miR-2113	-3.44	0.000625	-0.24	-0.16	Neuroticism;	chr6:98067905	chr6:98024586~98024606:+
LGG	cis	rs111803315	1	rs73301741	MIMAT0022287	hsa-miR-5586-5p	3.44	0.000625	0.27	0.16	Schizophrenia;	chr14:59441726	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs73301746	MIMAT0022287	hsa-miR-5586-5p	3.44	0.000625	0.27	0.16	Schizophrenia;	chr14:59441767	chr14:59646999~59647020:-
LGG	cis	rs6681460	0.528	rs4655498	MIMAT0014979	hsa-miR-3117-3p	3.44	0.000627	0.15	0.16	Presence of antiphospholipid antibodies;	chr1:66573562	chr1:66628485~66628505:+
LGG	cis	rs7342953	0.85	rs4790953	MIMAT0019865	hsa-miR-3064-3p	3.44	0.000628	0.31	0.16	Large artery stroke;	chr17:65230912	chr17:64500775~64500797:-
LGG	cis	rs6088590	0.965	rs6058108	MIMAT0004772	hsa-miR-499a-3p	-3.44	0.00063	-0.17	-0.16	Coronary artery disease;	chr20:34700851	chr20:34990445~34990466:+
LGG	cis	rs950880	0.56	rs13020793	MIMAT0019927	hsa-miR-4772-3p	3.44	0.000631	0.16	0.16	Serum protein levels (sST2);	chr2:102315466	chr2:102432336~102432357:+
LGG	cis	rs950880	0.517	rs1968170	MIMAT0019927	hsa-miR-4772-3p	3.44	0.000631	0.16	0.16	Serum protein levels (sST2);	chr2:102317342	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs11123918	MIMAT0019927	hsa-miR-4772-3p	3.44	0.000631	0.16	0.16	Serum protein levels (sST2);	chr2:102318777	chr2:102432336~102432357:+
LGG	cis	rs2980439	0.557	rs2976876	MIMAT0019728	hsa-miR-4660	3.44	0.000632	0.17	0.16	Neuroticism;	chr8:8461340	chr8:9048453~9048475:+
LGG	cis	rs702485	0.967	rs836513	MIMAT0027648	hsa-miR-6874-5p	-3.44	0.000633	-0.19	-0.16	HDL cholesterol levels;HDL cholesterol;	chr7:6420638	chr7:5711883~5711905:-
LGG	cis	rs111803315	1	rs113097743	MIMAT0022287	hsa-miR-5586-5p	3.44	0.000633	0.29	0.16	Schizophrenia;	chr14:59551498	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.59	rs77119209	MIMAT0022287	hsa-miR-5586-5p	3.44	0.000635	0.28	0.16	Schizophrenia;	chr14:59421694	chr14:59646999~59647020:-
LGG	cis	rs7121616	0.733	rs10892967	MIMAT0000098	hsa-miR-100-5p	3.44	0.000636	0.12	0.16	Breast cancer;	chr11:123130350	chr11:122152275~122152296:-
LGG	cis	rs9899728	0.656	rs9904728	MIMAT0017994	hsa-miR-3615	3.44	0.000639	0.26	0.16	Alzheimer's disease or small vessel stroke;	chr17:75034540	chr17:74748663~74748683:+
LGG	cis	rs11678825	0.562	rs74654613	MIMAT0031175	hsa-miR-548ba	-3.44	0.00064	-0.24	-0.16	Reticulocyte fraction of red cells;	chr2:48456184	chr2:49059603~49059624:+
LGG	cis	rs9303542	0.559	rs12951076	MIMAT0000253	hsa-miR-10a-5p	-3.44	0.00064	-0.24	-0.16	Epithelial ovarian cancer;Ovarian cancer;	chr17:48547747	chr17:48579904~48579926:-
LGG	cis	rs4073416	0.712	rs8010876	MIMAT0004808	hsa-miR-625-3p	3.44	0.000643	0.09	0.16	N-glycan levels;	chr14:65740258	chr14:65471153~65471174:+
LGG	cis	rs1950626	0.833	rs2400963	MIMAT0000736	hsa-miR-381-3p	-3.44	0.000643	-0.05	-0.16	Pelvic organ prolapse (moderate/severe);	chr14:100929369	chr14:101045968~101045989:+
LGG	cis	rs9398586	0.803	rs9375098	MIMAT0009206	hsa-miR-2113	-3.44	0.000643	-0.24	-0.16	Neuroticism;	chr6:98033916	chr6:98024586~98024606:+
LGG	cis	rs950880	0.56	rs4142132	MIMAT0019927	hsa-miR-4772-3p	3.44	0.000644	0.16	0.16	Serum protein levels (sST2);	chr2:102321022	chr2:102432336~102432357:+
LGG	cis	rs9982086	1	rs9982086	MIMAT0000646	hsa-miR-155-5p	-3.43	0.000645	-0.24	-0.16	Carboplatin disposition in epthelial ovarian cancer;	chr21:25631797	chr21:25573983~25574006:+
LGG	cis	rs9426935	0.505	rs59678326	MIMAT0022491	hsa-miR-5698	3.43	0.000647	0.2	0.16	Lentiform nucleus volume;	chr1:153870767	chr1:154104562~154104583:-
LGG	cis	rs4919669	0.668	rs4244354	MIMAT0005951	hsa-miR-1307-3p	-3.43	0.000649	-0.16	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102666420	chr10:103394301~103394322:-
LGG	cis	rs1018697	0.966	rs6584526	MIMAT0005951	hsa-miR-1307-3p	3.43	0.00065	0.1	0.16	Colorectal adenoma (advanced);	chr10:102806484	chr10:103394301~103394322:-
LGG	cis	rs111803315	1	rs111803315	MIMAT0022287	hsa-miR-5586-5p	3.43	0.00065	0.28	0.16	Schizophrenia;	chr14:59498575	chr14:59646999~59647020:-
LGG	cis	rs1912702	0.788	rs11605311	MIMAT0022270	hsa-miR-5579-3p	3.43	0.00065	0.17	0.16	Hair greying;	chr11:79471142	chr11:79422169~79422190:-
LGG	cis	rs56184018	0.671	rs4548248	MIMAT0000265	hsa-miR-204-5p	3.43	0.00065	0.14	0.16	Mean platelet volume;	chr9:70492186	chr9:70810031~70810052:-
LGG	cis	rs950880	0.56	rs1362350	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000651	0.16	0.16	Serum protein levels (sST2);	chr2:102335338	chr2:102432336~102432357:+
LGG	cis	rs950880	0.517	rs1420088	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000651	0.16	0.16	Serum protein levels (sST2);	chr2:102322974	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs11123920	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000651	0.16	0.16	Serum protein levels (sST2);	chr2:102323373	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs11676075	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000651	0.16	0.16	Serum protein levels (sST2);	chr2:102324755	chr2:102432336~102432357:+
LGG	cis	rs950880	0.518	rs12996772	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000651	0.16	0.16	Serum protein levels (sST2);	chr2:102330741	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs12466380	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000652	0.16	0.16	Serum protein levels (sST2);	chr2:102332479	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs12712140	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000652	0.16	0.16	Serum protein levels (sST2);	chr2:102334602	chr2:102432336~102432357:+
LGG	cis	rs950880	0.58	rs1997467	MIMAT0019927	hsa-miR-4772-3p	3.43	0.000652	0.16	0.16	Serum protein levels (sST2);	chr2:102334613	chr2:102432336~102432357:+
LGG	cis	rs702485	0.811	rs2689420	MIMAT0027648	hsa-miR-6874-5p	-3.43	0.000653	-0.18	-0.16	HDL cholesterol levels;HDL cholesterol;	chr7:6370690	chr7:5711883~5711905:-
LGG	cis	rs7829975	0.682	rs7013471	MIMAT0019728	hsa-miR-4660	-3.43	0.000657	-0.18	-0.16	Mood instability;	chr8:8829815	chr8:9048453~9048475:+
LGG	cis	rs7829975	0.533	rs35900578	MIMAT0019728	hsa-miR-4660	3.43	0.000658	0.18	0.16	Mood instability;	chr8:8862003	chr8:9048453~9048475:+
LGG	cis	rs2277912	1	rs56243714	MIMAT0014995	hsa-miR-3130-5p	3.43	0.000658	0.18	0.16	Height;	chr2:206776345	chr2:206783276~206783296:-
LGG	cis	rs2277912	1	rs56243714	MIMAT0014995_1	hsa-miR-3130-5p	3.43	0.000658	0.18	0.16	Height;	chr2:206776345	chr2:206783246~206783266:+
LGG	cis	rs17604090	0.775	rs73090343	MIMAT0004800	hsa-miR-550a-5p	3.43	0.000659	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649152	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.775	rs73090343	MIMAT0004800_1	hsa-miR-550a-5p	3.43	0.000659	0.19	0.16	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29649152	chr7:32733002~32733024:+
LGG	cis	rs4400599	0.586	rs4845601	MIMAT0022491	hsa-miR-5698	3.43	0.00066	0.19	0.16	Platelet distribution width;	chr1:154137275	chr1:154104562~154104583:-
LGG	cis	rs4400599	0.586	rs6667928	MIMAT0022491	hsa-miR-5698	3.43	0.00066	0.19	0.16	Platelet distribution width;	chr1:154142229	chr1:154104562~154104583:-
LGG	cis	rs950880	0.56	rs4090473	MIMAT0019927	hsa-miR-4772-3p	3.43	0.00066	0.16	0.16	Serum protein levels (sST2);	chr2:102306527	chr2:102432336~102432357:+
LGG	cis	rs1884537	0.966	rs11160605	MIMAT0004690	hsa-miR-379-3p	3.43	0.000661	0.1	0.16	Optic nerve measurement (disc area);	chr14:100786079	chr14:101022109~101022130:+
LGG	cis	rs4919669	0.546	rs3740409	MIMAT0005951	hsa-miR-1307-3p	-3.43	0.000662	-0.15	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102476888	chr10:103394301~103394322:-
LGG	cis	rs17710780	0.803	rs11745024	MIMAT0000732	hsa-miR-378a-3p	-3.43	0.000662	-0.13	-0.16	Major depressive disorder;	chr5:149713345	chr5:149732867~149732888:+
LGG	cis	rs17710780	1	rs72828383	MIMAT0000732	hsa-miR-378a-3p	-3.43	0.000662	-0.13	-0.16	Major depressive disorder;	chr5:149713586	chr5:149732867~149732888:+
LGG	cis	rs17710780	0.803	rs11745748	MIMAT0000732	hsa-miR-378a-3p	-3.43	0.000662	-0.13	-0.16	Major depressive disorder;	chr5:149713609	chr5:149732867~149732888:+
LGG	cis	rs3096644	1	rs3096644	MIMAT0000253	hsa-miR-10a-5p	3.43	0.000664	0.18	0.16	Metabolite levels (Dihydroxy docosatrienoic acid);	chr17:48680213	chr17:48579904~48579926:-
LGG	cis	rs702485	0.836	rs836483	MIMAT0027648	hsa-miR-6874-5p	-3.43	0.000665	-0.19	-0.16	HDL cholesterol levels;HDL cholesterol;	chr7:6388110	chr7:5711883~5711905:-
LGG	cis	rs9858542	0.953	rs7646366	MIMAT0003393	hsa-miR-425-5p	3.42	0.000668	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chr3:49020199~49020221:-
LGG	cis	rs2980439	0.87	rs2945230	MIMAT0019728	hsa-miR-4660	3.42	0.000668	0.17	0.16	Neuroticism;	chr8:8252414	chr8:9048453~9048475:+
LGG	cis	rs950880	0.56	rs1420090	MIMAT0019927	hsa-miR-4772-3p	3.42	0.000668	0.16	0.16	Serum protein levels (sST2);	chr2:102302845	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs7565653	MIMAT0019927	hsa-miR-4772-3p	3.42	0.000668	0.16	0.16	Serum protein levels (sST2);	chr2:102302966	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs12712136	MIMAT0019927	hsa-miR-4772-3p	3.42	0.000669	0.16	0.16	Serum protein levels (sST2);	chr2:102319906	chr2:102432336~102432357:+
LGG	cis	rs4919669	0.668	rs12220810	MIMAT0005951	hsa-miR-1307-3p	-3.42	0.00067	-0.16	-0.16	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102545362	chr10:103394301~103394322:-
LGG	cis	rs7829975	0.514	rs2920983	MIMAT0019728	hsa-miR-4660	3.42	0.00067	0.17	0.16	Mood instability;	chr8:8410553	chr8:9048453~9048475:+
LGG	cis	rs9858542	0.953	rs67216675	MIMAT0003393	hsa-miR-425-5p	3.42	0.000671	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chr3:49020199~49020221:-
LGG	cis	rs9858542	0.953	rs9853683	MIMAT0003393	hsa-miR-425-5p	3.42	0.000671	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chr3:49020199~49020221:-
LGG	cis	rs9858542	0.953	rs12330269	MIMAT0003393	hsa-miR-425-5p	3.42	0.000671	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chr3:49020199~49020221:-
LGG	cis	rs9858542	0.953	rs34363169	MIMAT0003393	hsa-miR-425-5p	3.42	0.000671	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chr3:49020199~49020221:-
LGG	cis	rs9858542	0.953	rs6766581	MIMAT0003393	hsa-miR-425-5p	3.42	0.000671	0.11	0.16	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chr3:49020199~49020221:-
LGG	cis	rs7162943	0.887	rs11858280	MIMAT0004554	hsa-miR-7-2-3p	-3.42	0.000672	-0.15	-0.16	Mean platelet volume;	chr15:89069059	chr15:88611896~88611917:+
LGG	cis	rs6681460	0.549	rs7547794	MIMAT0014979	hsa-miR-3117-3p	3.42	0.000675	0.15	0.16	Presence of antiphospholipid antibodies;	chr1:66566195	chr1:66628485~66628505:+
LGG	cis	rs7829975	0.522	rs6601689	MIMAT0019728	hsa-miR-4660	3.42	0.000684	0.18	0.15	Mood instability;	chr8:8314761	chr8:9048453~9048475:+
LGG	cis	rs9426935	0.505	rs12042989	MIMAT0022491	hsa-miR-5698	3.42	0.000686	0.19	0.15	Lentiform nucleus volume;	chr1:153869812	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.957	rs9660089	MIMAT0022491	hsa-miR-5698	3.42	0.000686	0.19	0.15	Age at first birth;	chr1:153855143	chr1:154104562~154104583:-
LGG	cis	rs539096	0.749	rs12076635	MIMAT0027368	hsa-miR-6733-3p	-3.42	0.000687	-0.19	-0.15	Intelligence (multi-trait analysis);	chr1:43560985	chr1:43171652~43171671:-
LGG	cis	rs1158058	0.516	rs1014877	MIMAT0004550	hsa-miR-30c-2-3p	3.42	0.000687	0.11	0.15	Metabolite levels (MHPG);	chr6:71036475	chr6:71376964~71376985:-
LGG	cis	rs9990333	0.622	rs57783901	MIMAT0003235	hsa-miR-570-3p	3.42	0.000689	0.18	0.15	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195699460~195699481:+
LGG	cis	rs7477	0.679	rs11655906	MIMAT0005942	hsa-miR-1288-3p	3.41	0.000695	0.16	0.15	Amyotrophic lateral sclerosis;	chr17:16335183	chr17:16282058~16282078:+
LGG	cis	rs4919669	0.668	rs10883735	MIMAT0005951	hsa-miR-1307-3p	-3.41	0.000699	-0.16	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102548689	chr10:103394301~103394322:-
LGG	cis	rs950880	0.542	rs12996505	MIMAT0019927	hsa-miR-4772-3p	3.41	0.000702	0.16	0.15	Serum protein levels (sST2);	chr2:102315342	chr2:102432336~102432357:+
LGG	cis	rs6088813	0.677	rs6088832	MIMAT0004772	hsa-miR-499a-3p	-3.41	0.000702	-0.19	-0.15	Height;	chr20:35418373	chr20:34990445~34990466:+
LGG	cis	rs6088813	0.677	rs6088833	MIMAT0004772	hsa-miR-499a-3p	-3.41	0.000702	-0.19	-0.15	Height;	chr20:35419860	chr20:34990445~34990466:+
LGG	cis	rs9426935	0.505	rs11581644	MIMAT0022491	hsa-miR-5698	3.41	0.000702	0.19	0.15	Lentiform nucleus volume;	chr1:153918512	chr1:154104562~154104583:-
LGG	cis	rs9303542	0.512	rs67412921	MIMAT0000253	hsa-miR-10a-5p	-3.41	0.000703	-0.24	-0.15	Epithelial ovarian cancer;Ovarian cancer;	chr17:48559263	chr17:48579904~48579926:-
LGG	cis	rs4639966	0.589	rs480958	MIMAT0025845	hsa-miR-6716-3p	-3.41	0.000705	-0.17	-0.15	Systemic lupus erythematosus;	chr11:118707281	chr11:118644048~118644069:+
LGG	cis	rs10928112	0.689	rs79176502	MIMAT0028224	hsa-miR-7157-5p	-3.41	0.000706	-0.19	-0.15	Schizophrenia;	chr2:141572892	chr2:140586663~140586685:-
LGG	cis	rs1461503	0.9	rs1057704	MIMAT0000423	hsa-miR-125b-5p	3.41	0.000707	0.12	0.15	Menarche (age at onset);	chr11:122959566	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.9	rs1057704	MIMAT0000423_1	hsa-miR-125b-5p	3.41	0.000707	0.12	0.15	Menarche (age at onset);	chr11:122959566	chr21:16590253~16590274:+
LGG	cis	rs111803315	1	rs1253107	MIMAT0022287	hsa-miR-5586-5p	3.41	0.000709	0.26	0.15	Schizophrenia;	chr14:59486229	chr14:59646999~59647020:-
LGG	cis	rs2658782	0.789	rs56091149	MIMAT0005892	hsa-miR-1304-5p	3.41	0.000715	0.21	0.15	Pulmonary function decline;	chr11:93340474	chr11:93733724~93733745:-
LGG	cis	rs9858542	0.953	rs11719996	MIMAT0003393	hsa-miR-425-5p	3.41	0.000715	0.11	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chr3:49020199~49020221:-
LGG	cis	rs10928112	0.678	rs12476668	MIMAT0028224	hsa-miR-7157-5p	-3.4	0.000718	-0.19	-0.15	Schizophrenia;	chr2:141521965	chr2:140586663~140586685:-
LGG	cis	rs763318	0.841	rs7676856	MIMAT0021083	hsa-miR-5091	-3.4	0.000719	-0.16	-0.15	Height;	chr4:12963729	chr4:13627875~13627897:+
LGG	cis	rs702485	0.84	rs836480	MIMAT0027648	hsa-miR-6874-5p	-3.4	0.000719	-0.18	-0.15	HDL cholesterol levels;HDL cholesterol;	chr7:6391773	chr7:5711883~5711905:-
LGG	cis	rs7172677	0.96	rs11072526	MIMAT0027665	hsa-miR-6882-3p	-3.4	0.000723	-0.2	-0.15	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75140176	chr15:74840642~74840665:-
LGG	cis	rs4919669	0.546	rs45597333	MIMAT0005951	hsa-miR-1307-3p	-3.4	0.000725	-0.15	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102476215	chr10:103394301~103394322:-
LGG	cis	rs7618501	0.522	rs73077175	MIMAT0019957	hsa-miR-4787-3p	3.4	0.000726	0.14	0.15	Intelligence (multi-trait analysis);	chr3:49737225	chr3:50675130~50675153:+
LGG	cis	rs7162943	0.887	rs28556293	MIMAT0004554	hsa-miR-7-2-3p	-3.4	0.000726	-0.15	-0.15	Mean platelet volume;	chr15:89062078	chr15:88611896~88611917:+
LGG	cis	rs11603023	0.874	rs577396	MIMAT0025845	hsa-miR-6716-3p	-3.4	0.000727	-0.17	-0.15	Cholesterol, total;	chr11:118628753	chr11:118644048~118644069:+
LGG	cis	rs11603023	0.874	rs11216934	MIMAT0025845	hsa-miR-6716-3p	-3.4	0.000727	-0.17	-0.15	Cholesterol, total;	chr11:118630742	chr11:118644048~118644069:+
LGG	cis	rs111803315	1	rs113337957	MIMAT0022287	hsa-miR-5586-5p	3.4	0.00073	0.27	0.15	Schizophrenia;	chr14:59500611	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs113112586	MIMAT0022287	hsa-miR-5586-5p	3.4	0.00073	0.27	0.15	Schizophrenia;	chr14:59502424	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.661	rs113062316	MIMAT0022287	hsa-miR-5586-5p	3.4	0.00073	0.27	0.15	Schizophrenia;	chr14:59504616	chr14:59646999~59647020:-
LGG	cis	rs111803315	1	rs113613442	MIMAT0022287	hsa-miR-5586-5p	3.4	0.00073	0.27	0.15	Schizophrenia;	chr14:59505845	chr14:59646999~59647020:-
LGG	cis	rs4906172	1	rs2169926	MIMAT0026558	hsa-miR-410-5p	-3.4	0.00073	-0.15	-0.15	Menopause (age at onset);	chr14:101959535	chr14:101065925~101065945:+
LGG	cis	rs1870653	0.516	rs9995562	MIMAT0003242	hsa-miR-577	3.4	0.00073	0.2	0.15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);	chr4:114491077	chr4:114656774~114656794:+
LGG	cis	rs4919669	0.668	rs10883763	MIMAT0005951	hsa-miR-1307-3p	-3.4	0.000731	-0.16	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102668068	chr10:103394301~103394322:-
LGG	cis	rs7829975	0.514	rs2979139	MIMAT0019728	hsa-miR-4660	3.4	0.000732	0.17	0.15	Mood instability;	chr8:8410803	chr8:9048453~9048475:+
LGG	cis	rs9858542	0.953	rs7622302	MIMAT0003393	hsa-miR-425-5p	3.4	0.000733	0.11	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chr3:49020199~49020221:-
LGG	cis	rs12460587	0.587	rs10415150	MIMAT0000443	hsa-miR-125a-5p	-3.4	0.000733	-0.12	-0.15	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52101372	chr19:51693268~51693291:+
LGG	cis	rs6504340	0.641	rs12952262	MIMAT0000253	hsa-miR-10a-5p	-3.4	0.000736	-0.26	-0.15	Primary tooth development (number of teeth);	chr17:48606438	chr17:48579904~48579926:-
LGG	cis	rs10492002	0.636	rs11610708	MIMAT0003287	hsa-miR-618	3.4	0.000742	0.18	0.15	Response to antidepressant treatment (citalopram);	chr12:81138869	chr12:80935796~80935818:-
LGG	cis	rs4073416	0.684	rs12879805	MIMAT0004808	hsa-miR-625-3p	3.4	0.000742	0.09	0.15	N-glycan levels;	chr14:65581077	chr14:65471153~65471174:+
LGG	cis	rs12145833	1	rs10926984	MIMAT0019761	hsa-miR-4677-3p	3.4	0.000742	0.2	0.15	Obesity (early onset extreme);	chr1:243298851	chr1:243346225~243346246:+
LGG	cis	rs6088590	0.965	rs6119534	MIMAT0004772	hsa-miR-499a-3p	-3.4	0.000743	-0.18	-0.15	Coronary artery disease;	chr20:34853454	chr20:34990445~34990466:+
LGG	cis	rs950880	0.56	rs10183388	MIMAT0019927	hsa-miR-4772-3p	3.4	0.000743	0.16	0.15	Serum protein levels (sST2);	chr2:102315787	chr2:102432336~102432357:+
LGG	cis	rs8010715	0.816	rs6573565	MIMAT0004960	hsa-miR-208b-3p	3.4	0.000743	0.18	0.15	IgG glycosylation;	chr14:24125524	chr14:23417997~23418018:-
LGG	cis	rs9426935	0.505	rs11585416	MIMAT0022491	hsa-miR-5698	3.4	0.000744	0.19	0.15	Lentiform nucleus volume;	chr1:153860628	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs11583152	MIMAT0022491	hsa-miR-5698	3.4	0.000744	0.19	0.15	Lentiform nucleus volume;	chr1:153860677	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs7552274	MIMAT0022491	hsa-miR-5698	3.4	0.000744	0.19	0.15	Lentiform nucleus volume;	chr1:153861115	chr1:154104562~154104583:-
LGG	cis	rs1950626	0.671	rs34675695	MIMAT0000736	hsa-miR-381-3p	-3.39	0.000745	-0.06	-0.15	Pelvic organ prolapse (moderate/severe);	chr14:100981576	chr14:101045968~101045989:+
LGG	cis	rs17730929	0.79	rs11933206	MIMAT0005923	hsa-miR-1269a	-3.39	0.000746	-0.39	-0.15	Colorectal cancer (SNP x SNP interaction);	chr4:66415854	chr4:66276890~66276911:+
LGG	cis	rs4919669	0.668	rs10883740	MIMAT0005951	hsa-miR-1307-3p	-3.39	0.000747	-0.16	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102575065	chr10:103394301~103394322:-
LGG	cis	rs8036358	0.71	rs1948570	MIMAT0030021	hsa-miR-7706	-3.39	0.000747	-0.26	-0.15	Post bronchodilator FEV1/FVC ratio in COPD;	chr15:85964486	chr15:85380639~85380662:+
LGG	cis	rs9426935	0.505	rs4845358	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153923949	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs10796968	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153926854	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs12406003	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153928014	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs3748849	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153928673	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs3748848	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153928826	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs1572788	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153931407	chr1:154104562~154104583:-
LGG	cis	rs10908557	0.957	rs1043608	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Age at first birth;	chr1:153936593	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs6680140	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153944893	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs946682	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153947280	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs8450	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153947810	chr1:154104562~154104583:-
LGG	cis	rs9426935	0.505	rs10559	MIMAT0022491	hsa-miR-5698	3.39	0.000748	0.19	0.15	Lentiform nucleus volume;	chr1:153948088	chr1:154104562~154104583:-
LGG	cis	rs4073416	0.684	rs3783709	MIMAT0004808	hsa-miR-625-3p	3.39	0.00075	0.09	0.15	N-glycan levels;	chr14:65591946	chr14:65471153~65471174:+
LGG	cis	rs6504340	0.739	rs1062037	MIMAT0000253	hsa-miR-10a-5p	-3.39	0.000751	-0.24	-0.15	Primary tooth development (number of teeth);	chr17:48560792	chr17:48579904~48579926:-
LGG	cis	rs9426935	0.505	rs10127983	MIMAT0022491	hsa-miR-5698	3.39	0.000757	0.19	0.15	Lentiform nucleus volume;	chr1:153950800	chr1:154104562~154104583:-
LGG	cis	rs111803315	1	rs112555934	MIMAT0022287	hsa-miR-5586-5p	3.39	0.000757	0.27	0.15	Schizophrenia;	chr14:59510514	chr14:59646999~59647020:-
LGG	cis	rs111803315	0.661	rs112716995	MIMAT0022287	hsa-miR-5586-5p	3.39	0.000757	0.27	0.15	Schizophrenia;	chr14:59511286	chr14:59646999~59647020:-
LGG	cis	rs4073416	0.746	rs12887673	MIMAT0004808	hsa-miR-625-3p	3.39	0.00076	0.09	0.15	N-glycan levels;	chr14:65755053	chr14:65471153~65471174:+
LGG	cis	rs2980439	0.818	rs2948300	MIMAT0019728	hsa-miR-4660	3.39	0.000763	0.17	0.15	Neuroticism;	chr8:8248986	chr8:9048453~9048475:+
LGG	cis	rs728478	0.967	rs12452950	MIMAT0022696	hsa-miR-301a-5p	3.39	0.000765	0.09	0.15	QT interval;	chr17:59362992	chr17:59151187~59151208:-
LGG	cis	rs7072216	0.77	rs7909131	MIMAT0005878	hsa-miR-1287-5p	3.39	0.000766	0.09	0.15	Metabolite levels;	chr10:98411714	chr10:98395271~98395292:-
LGG	cis	rs17604090	0.877	rs57253003	MIMAT0004800	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29646940	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.877	rs57253003	MIMAT0004800_1	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29646940	chr7:32733002~32733024:+
LGG	cis	rs17604090	0.818	rs28390296	MIMAT0004800	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647475	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.818	rs28390296	MIMAT0004800_1	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647475	chr7:32733002~32733024:+
LGG	cis	rs17604090	0.536	rs112165062	MIMAT0004800	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647976	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.536	rs112165062	MIMAT0004800_1	hsa-miR-550a-5p	3.39	0.000767	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647976	chr7:32733002~32733024:+
LGG	cis	rs4073416	0.651	rs1958561	MIMAT0004808	hsa-miR-625-3p	3.39	0.00077	0.09	0.15	N-glycan levels;	chr14:65570043	chr14:65471153~65471174:+
LGG	cis	rs76886731	1	rs76886731	MIMAT0019927	hsa-miR-4772-3p	3.38	0.000774	0.16	0.15	Leprosy;	chr2:102328956	chr2:102432336~102432357:+
LGG	cis	rs1461503	0.966	rs10892936	MIMAT0000423	hsa-miR-125b-5p	3.38	0.000781	0.12	0.15	Menarche (age at onset);	chr11:122971012	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.966	rs10892936	MIMAT0000423_1	hsa-miR-125b-5p	3.38	0.000781	0.12	0.15	Menarche (age at onset);	chr11:122971012	chr21:16590253~16590274:+
LGG	cis	rs1950626	0.75	rs35683125	MIMAT0000736	hsa-miR-381-3p	-3.38	0.000781	-0.05	-0.15	Pelvic organ prolapse (moderate/severe);	chr14:100988413	chr14:101045968~101045989:+
LGG	cis	rs9426935	0.505	rs12033835	MIMAT0022491	hsa-miR-5698	3.38	0.000783	0.19	0.15	Lentiform nucleus volume;	chr1:153914397	chr1:154104562~154104583:-
LGG	cis	rs11678825	0.852	rs11676078	MIMAT0031175	hsa-miR-548ba	-3.38	0.000785	-0.26	-0.15	Reticulocyte fraction of red cells;	chr2:48443067	chr2:49059603~49059624:+
LGG	cis	rs7072216	0.922	rs4539242	MIMAT0005878	hsa-miR-1287-5p	3.38	0.000785	0.09	0.15	Metabolite levels;	chr10:98388301	chr10:98395271~98395292:-
LGG	cis	rs950880	0.56	rs974389	MIMAT0019927	hsa-miR-4772-3p	-3.38	0.00079	-0.15	-0.15	Serum protein levels (sST2);	chr2:102320521	chr2:102432336~102432357:+
LGG	cis	rs7072216	0.922	rs59667296	MIMAT0005878	hsa-miR-1287-5p	3.38	0.000791	0.09	0.15	Metabolite levels;	chr10:98386556	chr10:98395271~98395292:-
LGG	cis	rs56184018	0.709	rs7856642	MIMAT0000265	hsa-miR-204-5p	-3.38	0.000791	-0.13	-0.15	Mean platelet volume;	chr9:70491437	chr9:70810031~70810052:-
LGG	cis	rs9398586	0.803	rs4307179	MIMAT0009206	hsa-miR-2113	-3.38	0.000791	-0.23	-0.15	Neuroticism;	chr6:98036577	chr6:98024586~98024606:+
LGG	cis	rs10928112	0.649	rs16846518	MIMAT0028224	hsa-miR-7157-5p	-3.38	0.000792	-0.19	-0.15	Schizophrenia;	chr2:141579685	chr2:140586663~140586685:-
LGG	cis	rs10928112	0.649	rs74860605	MIMAT0028224	hsa-miR-7157-5p	-3.38	0.000792	-0.19	-0.15	Schizophrenia;	chr2:141579748	chr2:140586663~140586685:-
LGG	cis	rs10928112	0.611	rs16846521	MIMAT0028224	hsa-miR-7157-5p	-3.38	0.000792	-0.19	-0.15	Schizophrenia;	chr2:141580865	chr2:140586663~140586685:-
LGG	cis	rs10928112	0.622	rs16846522	MIMAT0028224	hsa-miR-7157-5p	-3.38	0.000792	-0.19	-0.15	Schizophrenia;	chr2:141581051	chr2:140586663~140586685:-
LGG	cis	rs12145833	1	rs61833916	MIMAT0019761	hsa-miR-4677-3p	3.38	0.000792	0.2	0.15	Obesity (early onset extreme);	chr1:243306644	chr1:243346225~243346246:+
LGG	cis	rs2205299	0.69	rs11088595	MIMAT0004603	hsa-miR-125b-2-3p	3.38	0.000793	0.08	0.15	Schizophrenia;	chr21:16791139	chr21:16590290~16590311:+
LGG	cis	rs728478	0.846	rs11079373	MIMAT0022696	hsa-miR-301a-5p	3.38	0.000793	0.09	0.15	QT interval;	chr17:59363223	chr17:59151187~59151208:-
LGG	cis	rs4725617	0.584	rs7792781	MIMAT0027684	hsa-miR-6892-5p	-3.38	0.000796	-0.23	-0.15	Blood protein levels;	chr7:143409933	chr7:143382686~143382706:+
LGG	cis	rs9398586	0.708	rs9375029	MIMAT0009206	hsa-miR-2113	-3.38	0.000797	-0.24	-0.15	Neuroticism;	chr6:97967304	chr6:98024586~98024606:+
LGG	cis	rs10908557	0.915	rs58095661	MIMAT0022491	hsa-miR-5698	3.38	0.000798	0.19	0.15	Age at first birth;	chr1:153935363	chr1:154104562~154104583:-
LGG	cis	rs6681460	0.549	rs7547857	MIMAT0014979	hsa-miR-3117-3p	3.37	8e-04	0.15	0.15	Presence of antiphospholipid antibodies;	chr1:66566207	chr1:66628485~66628505:+
LGG	cis	rs9329221	0.621	rs522483	MIMAT0019728	hsa-miR-4660	-3.37	0.000802	-0.18	-0.15	Neuroticism;	chr8:9955459	chr8:9048453~9048475:+
LGG	cis	rs9899728	0.706	rs7224300	MIMAT0017994	hsa-miR-3615	3.37	0.000802	0.29	0.15	Alzheimer's disease or small vessel stroke;	chr17:75033161	chr17:74748663~74748683:+
LGG	cis	rs7072216	0.881	rs2147896	MIMAT0005878	hsa-miR-1287-5p	3.37	0.000804	0.09	0.15	Metabolite levels;	chr10:98388419	chr10:98395271~98395292:-
LGG	cis	rs4553443	1	rs12369902	MIMAT0000759	hsa-miR-148b-3p	3.37	0.000805	0.1	0.15	Cancer;	chr12:54928983	chr12:54337278~54337299:+
LGG	cis	rs702485	0.967	rs836527	MIMAT0027648	hsa-miR-6874-5p	-3.37	0.000805	-0.19	-0.15	HDL cholesterol levels;HDL cholesterol;	chr7:6427040	chr7:5711883~5711905:-
LGG	cis	rs11603023	0.874	rs613243	MIMAT0025845	hsa-miR-6716-3p	-3.37	0.000807	-0.16	-0.15	Cholesterol, total;	chr11:118643304	chr11:118644048~118644069:+
LGG	cis	rs4919669	0.668	rs74558061	MIMAT0005951	hsa-miR-1307-3p	-3.37	0.000809	-0.15	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102624580	chr10:103394301~103394322:-
LGG	cis	rs950880	0.677	rs56224165	MIMAT0019927	hsa-miR-4772-3p	3.37	0.000811	0.18	0.15	Serum protein levels (sST2);	chr2:102308763	chr2:102432336~102432357:+
LGG	cis	rs9858542	0.953	rs35115732	MIMAT0003393	hsa-miR-425-5p	3.37	0.000813	0.11	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chr3:49020199~49020221:-
LGG	cis	rs4926298	0.89	rs1017180	MIMAT0004496	hsa-miR-23a-5p	-3.37	0.000815	-0.17	-0.15	Bipolar disorder;	chr19:13083958	chr19:13836630~13836651:-
LGG	cis	rs111803315	1	rs1273153	MIMAT0022287	hsa-miR-5586-5p	-3.37	0.000825	-0.27	-0.15	Schizophrenia;	chr14:59479741	chr14:59646999~59647020:-
LGG	cis	rs11678825	0.852	rs11692537	MIMAT0031175	hsa-miR-548ba	-3.37	0.000825	-0.26	-0.15	Reticulocyte fraction of red cells;	chr2:48443032	chr2:49059603~49059624:+
LGG	cis	rs11678825	0.852	rs76984715	MIMAT0031175	hsa-miR-548ba	-3.37	0.000825	-0.26	-0.15	Reticulocyte fraction of red cells;	chr2:48443863	chr2:49059603~49059624:+
LGG	cis	rs11678825	0.852	rs77961213	MIMAT0031175	hsa-miR-548ba	-3.37	0.000825	-0.26	-0.15	Reticulocyte fraction of red cells;	chr2:48445228	chr2:49059603~49059624:+
LGG	cis	rs11678825	0.852	rs75150625	MIMAT0031175	hsa-miR-548ba	-3.37	0.000825	-0.26	-0.15	Reticulocyte fraction of red cells;	chr2:48445234	chr2:49059603~49059624:+
LGG	cis	rs17604090	0.938	rs10253264	MIMAT0004800	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29652927	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.938	rs10253264	MIMAT0004800_1	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29652927	chr7:32733002~32733024:+
LGG	cis	rs17604090	1	rs17661896	MIMAT0004800	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653092	chr7:30289815~30289837:+
LGG	cis	rs17604090	1	rs17661896	MIMAT0004800_1	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653092	chr7:32733002~32733024:+
LGG	cis	rs17604090	1	rs17661938	MIMAT0004800	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653762	chr7:30289815~30289837:+
LGG	cis	rs17604090	1	rs17661938	MIMAT0004800_1	hsa-miR-550a-5p	3.37	0.000826	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29653762	chr7:32733002~32733024:+
LGG	cis	rs950880	0.56	rs12476925	MIMAT0019927	hsa-miR-4772-3p	3.36	0.000833	0.15	0.15	Serum protein levels (sST2);	chr2:102308089	chr2:102432336~102432357:+
LGG	cis	rs950880	0.56	rs12476968	MIMAT0019927	hsa-miR-4772-3p	3.36	0.000833	0.15	0.15	Serum protein levels (sST2);	chr2:102308202	chr2:102432336~102432357:+
LGG	cis	rs6088813	0.677	rs6087707	MIMAT0004772	hsa-miR-499a-3p	-3.36	0.000834	-0.19	-0.15	Height;	chr20:35418633	chr20:34990445~34990466:+
LGG	cis	rs7829975	0.514	rs2979151	MIMAT0019728	hsa-miR-4660	-3.36	0.000836	-0.17	-0.15	Mood instability;	chr8:8400509	chr8:9048453~9048475:+
LGG	cis	rs4073416	0.684	rs4581615	MIMAT0004808	hsa-miR-625-3p	3.36	0.000837	0.09	0.15	N-glycan levels;	chr14:65589225	chr14:65471153~65471174:+
LGG	cis	rs9426935	0.505	rs4845357	MIMAT0022491	hsa-miR-5698	3.36	0.000841	0.19	0.15	Lentiform nucleus volume;	chr1:153923736	chr1:154104562~154104583:-
LGG	cis	rs546131	0.642	rs10501136	MIMAT0019776	hsa-miR-1343-3p	3.36	0.000842	0.13	0.15	Lung disease severity in cystic fibrosis;	chr11:34824969	chr11:34941888~34941909:+
LGG	cis	rs4919669	0.719	rs17114803	MIMAT0005951	hsa-miR-1307-3p	-3.36	0.000843	-0.14	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102627177	chr10:103394301~103394322:-
LGG	cis	rs702485	0.811	rs836549	MIMAT0027648	hsa-miR-6874-5p	-3.36	0.000844	-0.18	-0.15	HDL cholesterol levels;HDL cholesterol;	chr7:6400314	chr7:5711883~5711905:-
LGG	cis	rs9858542	0.953	rs9841110	MIMAT0003393	hsa-miR-425-5p	3.36	0.000847	0.11	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chr3:49020199~49020221:-
LGG	cis	rs2494663	0.61	rs11264964	MIMAT0022491	hsa-miR-5698	3.36	0.000848	0.19	0.15	Mean platelet volume;	chr1:154056974	chr1:154104562~154104583:-
LGG	cis	rs7072216	0.922	rs10786415	MIMAT0005878	hsa-miR-1287-5p	3.36	0.000848	0.09	0.15	Metabolite levels;	chr10:98391509	chr10:98395271~98395292:-
LGG	cis	rs7072216	0.922	rs942814	MIMAT0005878	hsa-miR-1287-5p	3.36	0.000848	0.09	0.15	Metabolite levels;	chr10:98391548	chr10:98395271~98395292:-
LGG	cis	rs7172677	1	rs4886422	MIMAT0027665	hsa-miR-6882-3p	-3.36	0.000849	-0.19	-0.15	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75134382	chr15:74840642~74840665:-
LGG	cis	rs7172677	1	rs4243032	MIMAT0027665	hsa-miR-6882-3p	-3.36	0.000849	-0.19	-0.15	Systemic lupus erythematosus and Systemic sclerosis;	chr15:75134543	chr15:74840642~74840665:-
LGG	cis	rs11603023	1	rs11603023	MIMAT0025845	hsa-miR-6716-3p	-3.36	0.000852	-0.17	-0.15	Cholesterol, total;	chr11:118615352	chr11:118644048~118644069:+
LGG	cis	rs74233809	1	rs77860422	MIMAT0005951	hsa-miR-1307-3p	-3.36	0.000853	-0.18	-0.15	Birth weight;	chr10:102988252	chr10:103394301~103394322:-
LGG	cis	rs9502893	0.702	rs7746700	MIMAT0025851	hsa-miR-6720-3p	3.36	0.000853	0.18	0.15	Pancreatic cancer;	chr6:1323212	chr6:1390324~1390345:-
LGG	cis	rs4400599	0.586	rs6659053	MIMAT0022491	hsa-miR-5698	3.35	0.000858	0.18	0.15	Platelet distribution width;	chr1:154138445	chr1:154104562~154104583:-
LGG	cis	rs309064	0.964	rs309083	MIMAT0000429	hsa-miR-137-3p	-3.35	0.00086	-0.09	-0.15	Blood pressure;Blood pressure (anthropometric measures interaction);	chr1:98950546	chr1:98046091~98046113:-
LGG	cis	rs74233809	0.71	rs4147157	MIMAT0005951	hsa-miR-1307-3p	-3.35	0.00086	-0.16	-0.15	Birth weight;	chr10:102776603	chr10:103394301~103394322:-
LGG	cis	rs1461503	0.9	rs7119398	MIMAT0000062	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961784	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.9	rs7119398	MIMAT0000062_1	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961784	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.9	rs7119398	MIMAT0000062_2	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961784	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.934	rs7119533	MIMAT0000062	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961975	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs7119533	MIMAT0000062_1	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961975	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs7119533	MIMAT0000062_2	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122961975	chr9:94175962~94175983:+
LGG	cis	rs1461503	0.934	rs930982	MIMAT0000062	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122963670	chr11:122146568~122146589:-
LGG	cis	rs1461503	0.934	rs930982	MIMAT0000062_1	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122963670	chr22:46112752~46112773:+
LGG	cis	rs1461503	0.934	rs930982	MIMAT0000062_2	hsa-let-7a-5p	-3.35	0.000862	-0.11	-0.15	Menarche (age at onset);	chr11:122963670	chr9:94175962~94175983:+
LGG	cis	rs2980439	0.607	rs2980419	MIMAT0019728	hsa-miR-4660	3.35	0.000862	0.17	0.15	Neuroticism;	chr8:8256619	chr8:9048453~9048475:+
LGG	cis	rs74233809	1	rs11191607	MIMAT0005951	hsa-miR-1307-3p	-3.35	0.000864	-0.18	-0.15	Birth weight;	chr10:103199431	chr10:103394301~103394322:-
LGG	cis	rs1461503	0.934	rs7113330	MIMAT0000423	hsa-miR-125b-5p	3.35	0.000864	0.12	0.15	Menarche (age at onset);	chr11:122972650	chr11:122099809~122099830:-
LGG	cis	rs1461503	0.934	rs7113330	MIMAT0000423_1	hsa-miR-125b-5p	3.35	0.000864	0.12	0.15	Menarche (age at onset);	chr11:122972650	chr21:16590253~16590274:+
LGG	cis	rs1461503	1	rs1461499	MIMAT0000423	hsa-miR-125b-5p	3.35	0.000864	0.12	0.15	Menarche (age at onset);	chr11:122973279	chr11:122099809~122099830:-
LGG	cis	rs1461503	1	rs1461499	MIMAT0000423_1	hsa-miR-125b-5p	3.35	0.000864	0.12	0.15	Menarche (age at onset);	chr11:122973279	chr21:16590253~16590274:+
LGG	cis	rs546131	0.642	rs579926	MIMAT0019776	hsa-miR-1343-3p	3.35	0.000865	0.12	0.15	Lung disease severity in cystic fibrosis;	chr11:34831608	chr11:34941888~34941909:+
LGG	cis	rs503425	1	rs503425	MIMAT0025845	hsa-miR-6716-3p	-3.35	0.000865	-0.22	-0.15	Systemic lupus erythematosus;	chr11:118822018	chr11:118644048~118644069:+
LGG	cis	rs9858542	0.953	rs6446264	MIMAT0003393	hsa-miR-425-5p	3.35	0.000865	0.11	0.15	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chr3:49020199~49020221:-
LGG	cis	rs7829975	0.514	rs2976926	MIMAT0019728	hsa-miR-4660	3.35	0.000866	0.17	0.15	Mood instability;	chr8:8404114	chr8:9048453~9048475:+
LGG	cis	rs702485	0.84	rs836478	MIMAT0027648	hsa-miR-6874-5p	3.35	0.000866	0.18	0.15	HDL cholesterol levels;HDL cholesterol;	chr7:6392059	chr7:5711883~5711905:-
LGG	cis	rs10928112	0.649	rs72855428	MIMAT0028224	hsa-miR-7157-5p	-3.35	0.000867	-0.19	-0.15	Schizophrenia;	chr2:141581336	chr2:140586663~140586685:-
LGG	cis	rs5839475	1	rs5839475	MIMAT0021022	hsa-miR-5001-3p	3.35	0.000868	0.18	0.15	Strep throat;	chr2:233279369	chr2:232550493~232550514:-
LGG	cis	rs4919669	0.668	rs10883737	MIMAT0005951	hsa-miR-1307-3p	-3.35	0.000868	-0.15	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102561141	chr10:103394301~103394322:-
LGG	cis	rs4919669	0.546	rs4919644	MIMAT0005951	hsa-miR-1307-3p	-3.35	0.00087	-0.14	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102469831	chr10:103394301~103394322:-
LGG	cis	rs4919669	0.546	rs3740416	MIMAT0005951	hsa-miR-1307-3p	-3.35	0.00087	-0.14	-0.15	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);	chr10:102470680	chr10:103394301~103394322:-
LGG	cis	rs4917833	0.51	rs754586	MIMAT0005878	hsa-miR-1287-5p	-3.35	0.00087	-0.09	-0.15	Pediatric bone mineral density (femoral neck);	chr10:98464605	chr10:98395271~98395292:-
LGG	cis	rs60311166	1	rs934839	MIMAT0000414	hsa-let-7g-5p	-3.35	0.000871	-0.24	-0.15	CTACK levels;	chr3:52649882	chr3:52268336~52268357:-
LGG	cis	rs9398586	0.614	rs12528029	MIMAT0009206	hsa-miR-2113	-3.35	0.000873	-0.25	-0.15	Neuroticism;	chr6:97931898	chr6:98024586~98024606:+
LGG	cis	rs67601088	0.517	rs878902	MIMAT0003257	hsa-miR-550a-3p	3.35	0.000875	0.13	0.15	Pediatric bone mineral density (spine);	chr7:29876411	chr7:29680748~29680769:-
LGG	cis	rs67601088	0.517	rs878902	MIMAT0003257_1	hsa-miR-550a-3p	3.35	0.000875	0.13	0.15	Pediatric bone mineral density (spine);	chr7:29876411	chr7:30289854~30289875:+
LGG	cis	rs67601088	0.517	rs878902	MIMAT0003257_2	hsa-miR-550a-3p	3.35	0.000875	0.13	0.15	Pediatric bone mineral density (spine);	chr7:29876411	chr7:32733041~32733062:+
LGG	cis	rs7829975	0.742	rs12547493	MIMAT0019728	hsa-miR-4660	-3.35	0.000877	-0.17	-0.15	Mood instability;	chr8:8804024	chr8:9048453~9048475:+
LGG	cis	rs56184018	0.686	rs11792173	MIMAT0000265	hsa-miR-204-5p	-3.35	0.000879	-0.14	-0.15	Mean platelet volume;	chr9:70493435	chr9:70810031~70810052:-
LGG	cis	rs4073416	0.684	rs7161123	MIMAT0004808	hsa-miR-625-3p	3.35	0.000882	0.09	0.15	N-glycan levels;	chr14:65586183	chr14:65471153~65471174:+
LGG	cis	rs7072216	0.922	rs6584191	MIMAT0005878	hsa-miR-1287-5p	3.35	0.000882	0.09	0.15	Metabolite levels;	chr10:98392298	chr10:98395271~98395292:-
LGG	cis	rs4073416	0.712	rs6573624	MIMAT0004808	hsa-miR-625-3p	3.35	0.000883	0.09	0.15	N-glycan levels;	chr14:65760167	chr14:65471153~65471174:+
LGG	cis	rs9982086	0.557	rs1012947	MIMAT0000646	hsa-miR-155-5p	3.35	0.000887	0.19	0.15	Carboplatin disposition in epthelial ovarian cancer;	chr21:25494500	chr21:25573983~25574006:+
LGG	cis	rs9426935	0.505	rs11264620	MIMAT0022491	hsa-miR-5698	3.34	0.000889	0.19	0.15	Lentiform nucleus volume;	chr1:153932098	chr1:154104562~154104583:-
LGG	cis	rs56184018	0.686	rs6560138	MIMAT0000265	hsa-miR-204-5p	3.34	0.000889	0.14	0.15	Mean platelet volume;	chr9:70485172	chr9:70810031~70810052:-
LGG	cis	rs950880	0.56	rs11690443	MIMAT0019927	hsa-miR-4772-3p	3.34	0.00089	0.16	0.15	Serum protein levels (sST2);	chr2:102319671	chr2:102432336~102432357:+
LGG	cis	rs35489971	0.512	rs12944222	MIMAT0017994	hsa-miR-3615	-3.34	0.000891	-0.25	-0.15	Fibrinogen levels;Coronary artery disease;	chr17:74715497	chr17:74748663~74748683:+
LGG	cis	rs11743006	0.626	rs59351512	MIMAT0004911	hsa-miR-874-3p	-3.34	0.000892	-0.12	-0.15	Mathematical ability;	chr5:137141519	chr5:137647582~137647603:-
LGG	cis	rs17604090	0.938	rs28457783	MIMAT0004800	hsa-miR-550a-5p	3.34	0.000893	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647442	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.938	rs28457783	MIMAT0004800_1	hsa-miR-550a-5p	3.34	0.000893	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647442	chr7:32733002~32733024:+
LGG	cis	rs17604090	0.818	rs73090342	MIMAT0004800	hsa-miR-550a-5p	3.34	0.000893	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647924	chr7:30289815~30289837:+
LGG	cis	rs17604090	0.818	rs73090342	MIMAT0004800_1	hsa-miR-550a-5p	3.34	0.000893	0.19	0.15	Facial emotion recognition;Facial emotion recognition (sad faces);	chr7:29647924	chr7:32733002~32733024:+
LGG	cis	rs7162943	0.887	rs12438271	MIMAT0004554	hsa-miR-7-2-3p	-3.34	0.000896	-0.15	-0.15	Mean platelet volume;	chr15:89069996	chr15:88611896~88611917:+
LGG	trans	rs1891498	0.602	rs12408247	MIMAT0000727	hsa-miR-374a-5p	6.68	6.64e-11	0.27	0.29	Cognitive performance;	chr1:147772337	chrX:74287325~74287346:-
LGG	trans	rs4848143	0.864	rs2249979	MIMAT0000067	hsa-let-7f-5p	6.56	1.4e-10	0.24	0.29	Capecitabine sensitivity;	chr2:121050200	chr9:94176353~94176374:+
LGG	trans	rs4848143	0.864	rs2249979	MIMAT0000067_1	hsa-let-7f-5p	6.56	1.4e-10	0.24	0.29	Capecitabine sensitivity;	chr2:121050200	chrX:53557246~53557267:-
LGG	trans	rs66686620	1	rs6546473	MIMAT0000727	hsa-miR-374a-5p	6.48	2.31e-10	0.3	0.28	Breast cancer;	chr2:69033225	chrX:74287325~74287346:-
LGG	trans	rs982274	0.935	rs1491768	MIMAT0000449	hsa-miR-146a-5p	-6.48	2.35e-10	-0.27	-0.28	Amyotrophic lateral sclerosis (sporadic);	chr21:18103371	chr5:160485372~160485393:+
LGG	trans	rs10186876	0.542	rs6736282	MIMAT0000073	hsa-miR-19a-3p	-6.21	1.13e-09	-0.15	-0.27	Hand grip strength;	chr2:43977578	chr13:91350939~91350961:+
LGG	trans	rs4848143	0.864	rs2249979	MIMAT0000414	hsa-let-7g-5p	6.13	1.89e-09	0.2	0.27	Capecitabine sensitivity;	chr2:121050200	chr3:52268336~52268357:-
LGG	trans	rs10117734	0.632	rs10974525	MIMAT0000727	hsa-miR-374a-5p	6.1	2.19e-09	0.23	0.27	Parental extreme longevity (95 years and older);	chr9:4417406	chrX:74287325~74287346:-
LGG	trans	rs66686620	1	rs6546473	MIMAT0000414	hsa-let-7g-5p	-6.07	2.67e-09	-0.22	-0.27	Breast cancer;	chr2:69033225	chr3:52268336~52268357:-
LGG	trans	rs5015933	0.801	rs2416961	MIMAT0027684	hsa-miR-6892-5p	6.04	3.04e-09	0.22	0.27	Body mass index;	chr9:125378078	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs7357647	MIMAT0027684	hsa-miR-6892-5p	6.04	3.12e-09	0.23	0.27	Body mass index;	chr9:125374554	chr7:143382686~143382706:+
LGG	trans	rs736408	0.812	rs2071508	MIMAT0000067	hsa-let-7f-5p	-6.03	3.22e-09	-0.21	-0.27	Bipolar disorder;	chr3:52792830	chr9:94176353~94176374:+
LGG	trans	rs736408	0.812	rs2071508	MIMAT0000067_1	hsa-let-7f-5p	-6.03	3.22e-09	-0.21	-0.27	Bipolar disorder;	chr3:52792830	chrX:53557246~53557267:-
LGG	trans	rs5015933	0.767	rs12339434	MIMAT0027684	hsa-miR-6892-5p	6.02	3.47e-09	0.22	0.27	Body mass index;	chr9:125376602	chr7:143382686~143382706:+
LGG	trans	rs2847281	0.587	rs2542152	MIMAT0000727	hsa-miR-374a-5p	-5.99	4.06e-09	-0.24	-0.27	Esophageal cancer (squamous cell);C-reactive protein levels;	chr18:12782762	chrX:74287325~74287346:-
LGG	trans	rs5015933	0.801	rs7848571	MIMAT0027684	hsa-miR-6892-5p	5.99	4.1e-09	0.22	0.27	Body mass index;	chr9:125378927	chr7:143382686~143382706:+
LGG	trans	rs736408	0.812	rs2071508	MIMAT0000727	hsa-miR-374a-5p	5.98	4.39e-09	0.23	0.26	Bipolar disorder;	chr3:52792830	chrX:74287325~74287346:-
LGG	trans	rs5015933	0.801	rs4240490	MIMAT0027684	hsa-miR-6892-5p	5.96	4.89e-09	0.22	0.26	Body mass index;	chr9:125377728	chr7:143382686~143382706:+
LGG	trans	rs34638657	0.518	rs2288050	MIMAT0000727	hsa-miR-374a-5p	5.95	5.16e-09	0.22	0.26	Lung adenocarcinoma;	chr16:82149798	chrX:74287325~74287346:-
LGG	trans	rs5015933	0.864	rs10819049	MIMAT0027684	hsa-miR-6892-5p	5.94	5.55e-09	0.22	0.26	Body mass index;	chr9:125376805	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs3861866	MIMAT0027684	hsa-miR-6892-5p	5.91	6.65e-09	0.22	0.26	Body mass index;	chr9:125258595	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.966	rs10986724	MIMAT0027684	hsa-miR-6892-5p	-5.87	8.13e-09	-0.22	-0.26	Body mass index;	chr9:125369240	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs359597	MIMAT0027684	hsa-miR-6892-5p	5.87	8.23e-09	0.22	0.26	Body mass index;	chr9:125274312	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.734	rs4838261	MIMAT0027684	hsa-miR-6892-5p	5.87	8.26e-09	0.23	0.26	Body mass index;	chr9:125386970	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.801	rs6478703	MIMAT0027684	hsa-miR-6892-5p	-5.87	8.31e-09	-0.22	-0.26	Body mass index;	chr9:125379069	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs5015933	MIMAT0027684	hsa-miR-6892-5p	5.86	8.71e-09	0.22	0.26	Body mass index;	chr9:125375139	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.788	rs568409	MIMAT0027684	hsa-miR-6892-5p	5.82	1.11e-08	0.22	0.26	Body mass index;	chr9:125309994	chr7:143382686~143382706:+
LGG	trans	rs399593	1	rs399593	MIMAT0022705	hsa-miR-539-3p	5.8	1.2e-08	0.19	0.26	Dental caries;	chr10:30623101	chr14:101047369~101047390:+
LGG	trans	rs17635075	1	rs10212658	MIMAT0019805	hsa-miR-4705	5.8	1.23e-08	0.42	0.26	Obesity-related traits;	chr4:166429106	chr13:102045974~102045995:-
LGG	trans	rs5015933	0.815	rs10819043	MIMAT0027684	hsa-miR-6892-5p	5.79	1.31e-08	0.22	0.26	Body mass index;	chr9:125274966	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.832	rs2841332	MIMAT0027684	hsa-miR-6892-5p	5.77	1.4e-08	0.22	0.26	Body mass index;	chr9:125367578	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs11998746	MIMAT0027684	hsa-miR-6892-5p	5.77	1.45e-08	0.21	0.26	Body mass index;	chr9:125373083	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs4289914	MIMAT0027684	hsa-miR-6892-5p	5.77	1.45e-08	0.21	0.26	Body mass index;	chr9:125373526	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs10760395	MIMAT0027684	hsa-miR-6892-5p	5.76	1.49e-08	0.21	0.26	Body mass index;	chr9:125369582	chr7:143382686~143382706:+
LGG	trans	rs5015933	1	rs10760397	MIMAT0027684	hsa-miR-6892-5p	5.76	1.49e-08	0.21	0.26	Body mass index;	chr9:125370928	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.807	rs7043132	MIMAT0027684	hsa-miR-6892-5p	5.76	1.5e-08	0.22	0.26	Body mass index;	chr9:125255561	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.902	rs2291858	MIMAT0027684	hsa-miR-6892-5p	5.76	1.53e-08	0.21	0.26	Body mass index;	chr9:125366503	chr7:143382686~143382706:+
LGG	trans	rs10752961	0.868	rs2064790	MIMAT0000444	hsa-miR-126-5p	-5.73	1.83e-08	-0.12	-0.25	Lobe attachment (rater-scored or self-reported);	chr1:186068559	chr9:136670616~136670636:+
LGG	trans	rs5015933	0.788	rs13289976	MIMAT0027684	hsa-miR-6892-5p	5.72	1.87e-08	0.21	0.25	Body mass index;	chr9:125293178	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs1333055	MIMAT0027684	hsa-miR-6892-5p	5.71	1.94e-08	0.21	0.25	Body mass index;	chr9:125307948	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs12553785	MIMAT0027684	hsa-miR-6892-5p	5.71	2.01e-08	0.21	0.25	Body mass index;	chr9:125314262	chr7:143382686~143382706:+
LGG	trans	rs2288327	0.75	rs12693166	MIMAT0004808	hsa-miR-625-3p	-5.71	2.02e-08	-0.2	-0.25	Atrial fibrillation;	chr2:178722403	chr14:65471153~65471174:+
LGG	trans	rs5015933	0.902	rs7872015	MIMAT0027684	hsa-miR-6892-5p	5.69	2.19e-08	0.21	0.25	Body mass index;	chr9:125368854	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.801	rs4837016	MIMAT0027684	hsa-miR-6892-5p	-5.69	2.23e-08	-0.21	-0.25	Body mass index;	chr9:125379530	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.778	rs10819046	MIMAT0027684	hsa-miR-6892-5p	5.69	2.26e-08	0.21	0.25	Body mass index;	chr9:125349961	chr7:143382686~143382706:+
LGG	trans	rs736408	0.812	rs2071508	MIMAT0010133	hsa-miR-2110	-5.68	2.38e-08	-0.28	-0.25	Bipolar disorder;	chr3:52792830	chr10:114174151~114174172:-
LGG	trans	rs10117734	0.632	rs10974525	MIMAT0000424	hsa-miR-128-3p	5.67	2.48e-08	0.11	0.25	Parental extreme longevity (95 years and older);	chr9:4417406	chr2:135665446~135665466:+
LGG	trans	rs10117734	0.632	rs10974525	MIMAT0000424_1	hsa-miR-128-3p	5.67	2.48e-08	0.11	0.25	Parental extreme longevity (95 years and older);	chr9:4417406	chr3:35744527~35744547:+
LGG	trans	rs5015933	0.815	rs10114168	MIMAT0027684	hsa-miR-6892-5p	5.66	2.55e-08	0.21	0.25	Body mass index;	chr9:125273170	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.778	rs867547	MIMAT0027684	hsa-miR-6892-5p	5.64	2.85e-08	0.21	0.25	Body mass index;	chr9:125269184	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs10819041	MIMAT0027684	hsa-miR-6892-5p	5.63	3.15e-08	0.21	0.25	Body mass index;	chr9:125268558	chr7:143382686~143382706:+
LGG	trans	rs72632736	0.881	rs12032182	MIMAT0004673	hsa-miR-29c-5p	-5.63	3.16e-08	-0.22	-0.25	Systemic juvenile idiopathic arthritis;	chr1:4371255	chr1:207801903~207801924:-
LGG	trans	rs5015933	0.815	rs13291655	MIMAT0027684	hsa-miR-6892-5p	5.62	3.26e-08	0.21	0.25	Body mass index;	chr9:125348274	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs13291322	MIMAT0027684	hsa-miR-6892-5p	5.62	3.29e-08	0.21	0.25	Body mass index;	chr9:125348076	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.902	rs1969045	MIMAT0027684	hsa-miR-6892-5p	5.6	3.63e-08	0.21	0.25	Body mass index;	chr9:125368261	chr7:143382686~143382706:+
LGG	trans	rs4742903	0.509	rs1889285	MIMAT0000435	hsa-miR-143-3p	5.6	3.69e-08	0.13	0.25	Breast cancer;High-grade serous ovarian cancer;	chr9:104164412	chr5:149428978~149428998:+
LGG	trans	rs5015933	0.815	rs10819044	MIMAT0027684	hsa-miR-6892-5p	5.6	3.7e-08	0.21	0.25	Body mass index;	chr9:125278750	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.902	rs10819047	MIMAT0027684	hsa-miR-6892-5p	5.6	3.71e-08	0.21	0.25	Body mass index;	chr9:125365133	chr7:143382686~143382706:+
LGG	trans	rs7833787	0.86	rs6981676	MIMAT0019954	hsa-miR-4786-5p	5.59	3.86e-08	0.29	0.25	Obesity-related traits;	chr8:18821604	chr2:239943063~239943084:-
LGG	trans	rs7833787	1	rs17383616	MIMAT0019954	hsa-miR-4786-5p	5.59	3.91e-08	0.28	0.25	Obesity-related traits;	chr8:18847290	chr2:239943063~239943084:-
LGG	trans	rs728616	0.558	rs17616958	MIMAT0015024	hsa-miR-3151-5p	-5.58	3.97e-08	-0.43	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377705	chr8:103154623~103154643:+
LGG	trans	rs5015933	0.815	rs16928051	MIMAT0027684	hsa-miR-6892-5p	5.58	3.99e-08	0.21	0.25	Body mass index;	chr9:125308738	chr7:143382686~143382706:+
LGG	trans	rs34638657	0.518	rs2288050	MIMAT0002874	hsa-miR-503-5p	-5.58	4e-08	-0.22	-0.25	Lung adenocarcinoma;	chr16:82149798	chrX:134546371~134546393:-
LGG	trans	rs5015933	0.801	rs3104546	MIMAT0027684	hsa-miR-6892-5p	5.58	4.09e-08	0.21	0.25	Body mass index;	chr9:125375390	chr7:143382686~143382706:+
LGG	trans	rs10456847	0.789	rs2842411	MIMAT0000727	hsa-miR-374a-5p	5.57	4.21e-08	0.23	0.25	Chronic periodontitis (mean interproximal clinical attachment level);	chr6:19129447	chrX:74287325~74287346:-
LGG	trans	rs12715234	0.858	rs6763221	MIMAT0000270	hsa-miR-181a-3p	-5.57	4.22e-08	-0.2	-0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:33974126	chr1:198859069~198859090:-
LGG	trans	rs2288327	0.818	rs12618265	MIMAT0004808	hsa-miR-625-3p	5.57	4.24e-08	0.2	0.25	Atrial fibrillation;	chr2:178518082	chr14:65471153~65471174:+
LGG	trans	rs7833787	0.827	rs1022758	MIMAT0019954	hsa-miR-4786-5p	5.57	4.25e-08	0.29	0.25	Obesity-related traits;	chr8:18821195	chr2:239943063~239943084:-
LGG	trans	rs5015933	0.815	rs3896021	MIMAT0027684	hsa-miR-6892-5p	5.57	4.3e-08	0.21	0.25	Body mass index;	chr9:125262019	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs35216121	MIMAT0027684	hsa-miR-6892-5p	5.57	4.33e-08	0.21	0.25	Body mass index;	chr9:125263999	chr7:143382686~143382706:+
LGG	trans	rs72632736	1	rs12026935	MIMAT0004673	hsa-miR-29c-5p	-5.56	4.46e-08	-0.22	-0.25	Systemic juvenile idiopathic arthritis;	chr1:4370290	chr1:207801903~207801924:-
LGG	trans	rs5015933	0.815	rs10986718	MIMAT0027684	hsa-miR-6892-5p	5.56	4.5e-08	0.21	0.25	Body mass index;	chr9:125350617	chr7:143382686~143382706:+
LGG	trans	rs7335046	1	rs4238216	MIMAT0000437	hsa-miR-145-5p	5.56	4.6e-08	0.19	0.25	Basal cell carcinoma;	chr13:99412716	chr5:149430661~149430683:+
LGG	trans	rs7335046	1	rs4421856	MIMAT0000437	hsa-miR-145-5p	5.56	4.62e-08	0.19	0.25	Basal cell carcinoma;	chr13:99412793	chr5:149430661~149430683:+
LGG	trans	rs5015933	0.902	rs2270746	MIMAT0027684	hsa-miR-6892-5p	-5.55	4.72e-08	-0.21	-0.25	Body mass index;	chr9:125359313	chr7:143382686~143382706:+
LGG	trans	rs728616	0.558	rs17616964	MIMAT0015024	hsa-miR-3151-5p	-5.55	4.87e-08	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80377785	chr8:103154623~103154643:+
LGG	trans	rs5015933	0.902	rs1874943	MIMAT0027684	hsa-miR-6892-5p	5.55	4.88e-08	0.2	0.25	Body mass index;	chr9:125361055	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs4991998	MIMAT0027684	hsa-miR-6892-5p	5.54	4.92e-08	0.21	0.25	Body mass index;	chr9:125314702	chr7:143382686~143382706:+
LGG	trans	rs2847281	0.587	rs2542152	MIMAT0000449	hsa-miR-146a-5p	-5.53	5.25e-08	-0.24	-0.25	Esophageal cancer (squamous cell);C-reactive protein levels;	chr18:12782762	chr5:160485372~160485393:+
LGG	trans	rs2950163	0.796	rs12105544	MIMAT0022492	hsa-miR-5699-3p	5.53	5.42e-08	0.33	0.25	Response to metformin (IC50);	chr2:6049601	chr10:641699~641720:-
LGG	trans	rs5015933	0.966	rs1965342	MIMAT0027684	hsa-miR-6892-5p	5.52	5.5e-08	0.21	0.25	Body mass index;	chr9:125371382	chr7:143382686~143382706:+
LGG	trans	rs5015933	0.815	rs937482	MIMAT0027684	hsa-miR-6892-5p	5.52	5.64e-08	0.21	0.25	Body mass index;	chr9:125354538	chr7:143382686~143382706:+
LGG	trans	rs7833787	0.77	rs4921966	MIMAT0019954	hsa-miR-4786-5p	5.52	5.68e-08	0.28	0.25	Obesity-related traits;	chr8:18840908	chr2:239943063~239943084:-
LGG	trans	rs728616	0.614	rs61859199	MIMAT0015024	hsa-miR-3151-5p	-5.51	5.92e-08	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80358857	chr8:103154623~103154643:+
LGG	trans	rs728616	0.614	rs61859209	MIMAT0015024	hsa-miR-3151-5p	-5.51	5.92e-08	-0.42	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80368553	chr8:103154623~103154643:+